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Abstract  
 
One of the most important areas of intervention of Traditional Chinese Medicine is 
Phytotherapy. The repertoire of Chinese plants includes many well-known plants in the 
West, and their effectiveness has been tested, but there´s a lot of work to be done.  
Although many of the old Chinese formulas continue to be used in the East, many of its 
therapeutic properties remain little known by the Western scientific community. 
The Ephedra Decoction (Herba ephedrae, Semen armeniacae, Ramulus cassia, Radix 
Glycyrrhizae) is one of the oldest Chinese formulas, as described in the Shang Han Lun. 
In this master thesis I tried to search according to the sensitivity of Eastern and Western 
knowledge about each of the plants constituents of this formula and make the crossing 
information. It was concluded that most of the chemical constituents and pharmacological 
actions resulting from each individual plant explain its conduct traditional Chinese therapy 
behavior.  
 
 
Key words 
 
Traditional Chinese Medicine, traditional Chinese drugs, Ephedrae Decoctum (Ephedra 
Decoction), Herba ephedrae, Semen armeniacae, Ramulus cassia, Radix glycyrrhizae 
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Resumo 
 
Uma das áreas mais importantes de intervenção em Medicina Tradicional Chinesa é a 
Fitoterapia. O repertório de plantas Chinesas inclui muitas plantas bem conhecidas no 
Ocidente e a sua eficácia já foi testada. Apesar de muitas das antigas fórmulas chinesas 
continuarem a ser utilizadas no Oriente, muitas das suas propriedades terapêuticas 
persistem pouco conhecidas pela comunidade científica ocidental, à luz dos 
conhecimentos do Ocidente. 
A decocção de efedra (Herba ephedrae, Semen armeniacae, Ramulus cassia, Radix 
glycyrrhizae) é uma das mais antigas fórmulas chinesas, já descrita no Shang Han Lun. 
Nesta tese procurou-se pesquisar de acordo com a sensibilidade oriental e ocidental o 
conhecimento acerca de cada uma das plantas constituintes desta fórmula e proceder ao 
cruzamento da informação. Concluiu-se que muitos dos constituintes químicos e 
consequentes acções farmacológicas individuais de cada planta explicam o seu 
comportamento terapêutico tradicional chinês.  
 
 
Palavras - chave 
 
Medicina tradicional Chinesa, plantas tradicionais Chinesas, Ephedrae Decoctum 
(Decocção de Efedra), Herba ephedrae, Semen armeniacae, Ramulus cassia, Radix 
glycyrrhizae 
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1. Objectives 
 
One of the most important areas of intervention of Traditional Chinese Medicine is 
Phytotherapy. The repertoire of Chinese plants includes many well-known plants in the 
West, and their effectiveness has been tested, but there is still a lot of work to be done. 
The aim of this Master Thesis is to link the Chinese pathophysiological aspects of a 
Chinese standard formulation (Ephedrae Decoction) with the western pathophysiological, 
pharmacological and chemical aspects. 
 
2. Motivation 
 
When I began studying Chinese medicine 4 years ago, a new world opened before my 
eyes. I found great interest in Chinese Pharmacology once my scientific background being 
Pharmaceutical Sciences. With this master thesis I will try to bring Western and Chinese 
perspectives on the Chinese herbs pharmacology together, and to bridge two worlds with 
the example of the ancient formula Ephedra Decoction (Mahuang Tang). 
 
3. Research design and methods 
Search methodology 
 
To be included in this research, I conducted a systematic literature search of Medline/ 
PubMed, Scirus, Scopus, Proquest and Google Scholar, with no date or language 
restriction. I used the following medical subject headings and keywords: efedra, 
ephedra(e), mahuang, Mahuang, cinnamon, cinnamomum, cinnamomum cassia, 
cinnamomum zeylanicum, cinnamomum verum, cinnamomum aromaticum, cassia, 
ramulus cinnamomi, cortex cinnamomi, ramuli cinnamon, cortex cinnamon, cinnamon 
twig, cinnamon bark, guizhi, gui zhi, rougui, rou gui and other variations, semen 
armeniaca(e), apricot kernel, xingren, xing ren, radix glycyrrhiza(e), gancao, gan cao, 
licorice alone or in combination with: tradicional Chinese medicine, TCM, mao-to, ma-
huang tang, traditional Chinese herbs, Chinese herbology, alone or other variations. A 
manual search of retrieved articles was also performed. Reference lists and citations of 
included studies were also checked. In addition, the following additional databases were 
consulted: Chinese Herb Dictionary, Complementary and Alternative Healing University, 
eNatural Health Center, Sacred Lotus Arts-Traditional Chinese Medicine-TCM Herbs, 
Traditional Chinese Medicine and Acupuncture Health Information Organization, Natural 
Medicines Comprehensive Database.  
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4. Introduction 
 
Traditional Chinese medicine (TCM) has developed over more than 4000 years and is one 
of the most tested and applied sciences in mankind. Today, a tremendous amount of 
medical knowledge has been accumulated. For example, much knowledge of herbal 
drugs, such as sapor, nature, channel tropism, efficacy and compatibilities, has been 
discovered and verified. Each herbal drug has its own particular medical efficacy, and 
when combined with some others, we obtain a formula or decoction with more curative 
effects. Formulae that have proven medically effective have been treasured as part of the 
TCM legacy and recorded in text for future use or instruction (Cao et al., 2004). 
Traditional Chinese drugs (TCD), being natural materials, appeal to many people, 
because of their high activity, low toxicity, and rare complications. Building new TCM 
pharmacology theories relies heavily on thorough understanding of their chemical action. 
One of the most important tasks in revealing this is to analyze the composition of each 
TCD. It is well known that the determination of TCD is a rather complex problem 
compared with analysis of pharmaceutical medicine. For example, even a TCM for 
treating the common cold contains hundreds of chemical components. It is difficult to 
analyze such complex systems with a conventional single-wavelength detector unless 
demanding conditions are imposed to the chromatographic separation process. This calls 
for specific tools to handle these complicated systems. Fortunately, modern hyphenated 
chromatographic instruments, for example high performance liquid chromatography  
(HPLC) with diode array detection (HPLC–DAD) and gas chromatography mass 
spectrometry (GC–MS), and related chemometric methods, provide powerful tools to 
accomplish such an arduous job (Xu et al., 2001). Traditional Chinese pharmacology, 
pharmacology in the broad sense, is an integral part of TCM. It deals with the origin, 
collection, processing, actions and used of TCD, or Chinese Materia Medica, under the 
guidance of the basic theory of TCM (Ganzhong et al., 2003). 
There are very rich resources of TCD. According to a recent survey, the number of TCD is 
12.807. Among them, 11.146 are drugs of plant origin; the rest are of animal or mineral 
origin. Hence, traditional Chinese pharmacology is sometimes called traditional Chinese 
herbal pharmacology (Ganzhong et al., 2003). The theories that govern the prescription of 
medicinal plants are taken from traditional Chinese pharmacology, itself based on long 
centuries of clinical observation and practice (WHO, 1997). 
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5. The Development of Modern TCD Pharmacology 
 
The modern pharmacology of TCD started in China 70 years ago, when Dr. KK Chen 
(Chen Kehui) published a paper on ephedrine. There were around 30 TCD studied from 
the 1920s to the 1940s by phytochemists and pharmacologists, such as Radix Angelicae 
Sinensis (danggui), Rhizoma coptidis (huangglian), Radix Aconiti (chuanwu), Radix 
Dichroae (changshan), Radix Stephaniae Tetrandrae (fangji), Bulbus Fritillariae (beimu), 
Rhizoma Corydalis (yanhusuo), etc (Ganzhong et al., 2003). 
Beginning in the 1950s, the Chinese government has paid great attention to the 
development of TCM. TCM colleges have been established in every province and 
autonomous region, and TCM hospitals and research institutes at the national provincial, 
municipal and even county level have been set up. The development of TCM has thus 
entered a new era (Ganzhong et al., 2003). The trend of development of TCD is in two 
directions: One treats TCD as ordinary natural resources, plants and/or animals, and 
endeavors to extract new chemical ingredients from them. A number of compounds have 
been isolated and identified. Their actions have been studied and they have undergone 
clinical trial. Hence, a number of new drugs have been developed and marketed, such 
tetrandine, artemisinine and its derivatives, ferric acid, etc (Ganzhong et al., 2003). The 
other is the study of TCD under the guidance of TCM theory, mainly studying the actions 
of prescriptions experimentally and clinically. The traditional pharmaceutical preparations 
are also undergoing transformation. New forms of patent TCD are instant powders, 
tablets, injections and capsules. In order to elucidate the actions of prescriptions, both 
classical and contemporary, actions of drugs in the prescription individually and in 
combination have been studied and clarified. Chemical constituents in prescriptions are 
also being investigated. Hence there is both a need and the conditions to form a modern 
pharmacology of TCD which will include both the classical descriptions of actions and 
uses in TCM and the new information and data obtained from the study of TCD using 
modern technology and expertise. As a result, since the 1980s, the pharmacology of 
Chinese materia medica has been listed as a course in the curriculum of colleges of TCM, 
and textbooks have been published. Yet, TCM pharmacology is still at the infant stage, 
and there is still a lot of work to be done (Ganzhong et al., 2003). 
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6. Designing of a Chinese formula 
 
Westerners learning about Chinese herbs are often exposed to unusual concepts 
regarding the form of herbal administration.  
It is known that each formula is composed of certain herbs but it is more than a random 
group of herbs combined at one´s pleasure. Simple addition of the effects of some herbs 
does not entirely equate to the efficacy of a formula, in fact, is a process in which some 
proper herbs, guided by the principle of treatment based on syndrome differentiation, are 
chosen to constitute the formula in a certain formula-forming pattern. Among the herbs 
which constitute the formulas, there exists a certain formulating relationship such as the 
relationship of supplementing each other, relationship of both opposing and 
complementing each other, relationship of both opposing and complementing each other, 
etc. Generally the constitution of a formula has three purposes: 
 Adapting to the condition of the disease and increasing the therapeutic 
efficacy; 
 Harmonizing the partial property of the herbs and inhibiting their side-effects; 
 Reducing the toxicity (Gongwang, 2002). 
 
A formula consists of ruler/emperor, minister/medicamentum ministrale, assistant, and 
nuncio medication/signaling medication (Greten, 2007). Other authors use other terms like 
monarch (principal herb), minister, adjuvant and dispatcher, respectively. 
 
1. The most important is the ruler, or the emperor (principal herb): the herb which is 
aimed at producing the leading effects in treating the cause and main symptoms of 
a disease.  
2. The minister: the herb which helps the ruler to increase the effects of the principal 
herb, or treats the accompanying symptoms of a disease. 
3. The assistant: it can be divided into the following three types: 
a) The herb which helps to reinforce the actions of the principal and minister 
herbs, or the one which treats the minor accompanying symptoms of a 
disease. 
b) The herb which eliminates or restrains the drastic actions of the principal and 
minister herbs or the toxicity of these herbs. 
c) The herb which can reduce the overly potent action of the principal ingredients. 
For instance, adding one or two cool or cold-natured herbs to the formula 
dominated by the herbs of warm or heat nature can prevent the warm or heat 
property of the principal herbs from damaging the body fluid.  
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4. Signaling medication: the herb which mediates or coordinates the effects of 
various ingredients in the formula, or the herb which directs the actions of other 
herbs in the formula to the affected site. 
 
As a whole, the establishment of principal, assistant, adjuvant and dispatcher herbs in a 
formula should be based on their respective importance of efficacy, potency and dosage 
in the formula. Generally, there is only one principal herb in a formula though there may 
occur a case where there are two or three principal herbs in a complex formula. In a 
formula, the principal herb is absolutely necessary while the assistant, adjuvant and 
dispatcher herbs may be rejected according to the state of disease or herbal property. For 
some simple formulas, it is common that there are only the principal and assistant herbs, 
or the principal and adjuvant herbs (Gongwang, 2002). 
 
The example of Ephedrae Decoction 
 
 The the ruler, or the emperor is H. ephedrae. This part of a concoction acts as the 
principal medication representing the main direction of impact or main attack on 
disease. As this is the most important constituent, we take e.g. 4 once a day (the 
Chinese ounce is 3 grams), or about 60g per week. H. ephedrae is known to 
liberate the extima and to unfold the pulmonary orb. If it is taken roasted in honey it 
takes of pituita and humor thereby facilitating breathing and stopping cough. In 
other words, this medication works double-fold. The main action is to enhance the 
orb function. 
 A suitable medicamentum ministrale, suitable minister to this ruler should work in 
the same direction. Under the condition that we want to treat bronchitis with 
difficulties to breathe, such as is spastic bronchitis or asthma, we would to get rid 
of mucus and stop coughing. A suitable minister in this sense is Semem 
armeniacae. This medication belongs to Group XIII c) which removes pituita and 
stops coughing. So, in a way one could say that the minister acts dependent on 
the ruler and in a related direction of impact. It is the second main attack which 
complements the first, the principal impact. In this sense we add the effect on 
coughing and enhance ephedra´s liberation of airways. If you follow the idea of 
proportional dosage, we should have about 45g a week. The dosage therefore 
represents the hierarchy of the effects necessary. 
 The assistant drug also cannot work independently of the boss and the second 
boss of this prescription. It also must fit into the general direction of attack. If it 
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would contradict, e.g. by cooling, it would take away some of the effect of the ruler, 
thereby weakening the whole prescription instead of making it more effective. 
Ephedra, the ruler, is very hot. In so far it is directed against a cold attack. Its 
group is liberantia extimae acria et calida. Therefore we can assume that the 
concept is good for coughing as a result of cold as often seen in asthma. It is 
therefore a good complement to warm up the extima in order to get rid of the cold. 
For this propose we need a warming liberantium, a warming medication liberating 
the extima and to support the idea of H. ephedrae. Ramuli cassia does not only 
liberate the extima but also is warm in nature and therefore warms the pulmonary 
orb, as the extima is part of the pulmonary orb. 30g a week would correspond to its 
function as the assistant of this prescription. Now we have a medication which 
―opens‖ the airways and the pulmonary orb, gets rid of pituita, stops coughing and 
acts against cold which covers the main features of common cold, bronchitis and 
asthma. 
 The nuncio medication or signaling medication here is R. glycyrrhizae with itself is 
supplective in nature and belongs to the supplentia qi  group. This medication has 
a special effect not known by other. It distributes and guides the qi of the decoction 
not only in one conduit but in all 12 conduits at the same time. It is also sweet as a 
sapor and therefore harmonizes by strengthening the center. This is a desired 
effect within the overall purpose of the medication. If you want to get rid of pituita 
strengthening the center makes sense. The whole prescription actually is strongly 
guided to the pulmonary orb by the first three constituents already. This medication 
does not need to be directed to the pulmonary orb any more. On the contrary, it is 
necessary to soften this strong and very unilateral effect. Following the ideal of 
proportional usage, 15g per week is suitable. With this medication the much 
accentuated effect on the pulmonary orb is softened and spread over the whole 
medication has a genius double effect. You open the extima and all conduits, 
remove humor and pituita and warm it up tremendously, as especially ephedra and 
Ramuli cassia are warm liberanting substances. On the other hand, you also open 
and unfold the intima by Semen armeniacae and strengthening the center with R. 
glycyrrhizae (Greten, 2007). 
The example of this concoction shows that that the hierarchy within a concoction is 
extremely important for the effects in clinical usage. It shows that some of the herbs are 
not harmless and that we have to determine the primary objective of a concoction before 
composing it (Table 1) (Greten, 2007). 
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Table 1. Hierarchy in Ephedrae Decoction (adapted from Greten, 2007) 
I Herba ephedrae 
roasted in honey 
60g Opens the extima and unfolds the 
pulmonary orb, there by leading qi down, 
enhancing breathing, stopping anhelitus, 
and removes pituita 
II Sem. Armeniacae 
 
45g Removes pituita, warms and stops coughing 
III Ramuli cassiae 
 
30g Warms the extima and the pulmonary orb, 
thereby eliminating algor 
IV Radix glycyrrhizae 10g Softens and connects the 3 others by 
leading into 12 conduits, being sweet and 
strengthening the center 
 
In the literature we find several references to Ephedra Decoction where the usual quantity 
of its constituents can vary widely (Table 2). Some examples: 
 
Table 2. Examples of diferent constituent quantitys according diferents authors 
 (Liu et Tseng, 2005) (Gongwang, 2002) (Ling, 2005) 
H. ephedra  9 g 6g 6g 
Ramuli cassia 9 g 6g 4g 
Semen armeniacae 9 g 9g 9g 
Radix glycyrrhizae 3 g 6g 3g 
 
Of course we can play a little with the constituents. If we change the position within the 
hierarchy of the 4 constituents, we could e.g. give Ramuli cassiae the position of Sem. 
armeniacae. In this case we would happen between H. ephedrae and Ramuli cassiae 
whith both liberate the extima. This would be the classical usage of this concoction which 
is for the earliest phases of colds. We would maybe also not roast H. ephedrae in honey 
in order to enhance the extima liberanting effect and not the pituita dissolving effect. This 
little change would make this concoction useless for chroric asthma, as H. ephedrae, the 
ruler, would not anymore take away edema and mucus from the bronchi. We would rather 
promote sweating. Chronic asthma, however, is a condition which normally complies with 
stage IV of the ALT, an intimal event. Therefore, this second variation which is classical 
and older now is not as frequent as the alteration given as an example for a concoction 
(Greten, 2007). 
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Pulses for the original extima liberating form of this concoction should be superficial in the 
right policar, right clusal position and mostly intent, whereas superficiality is not seen in 
intimal disease. Also in the typical Stage IV (yin major), the intent pulses are often overlaid 
by slippery pulses (pulsus lubricus) indicating pituita and humor rather being effective than 
algor. The dosage of the concoctions varies a lot. One can say that a concoction is not a 
prescription but a therapeutic constellation that has to be adapted to the individual case. 
In those cases in which coughing and mucus are tremendous, Semem armeniacae can be 
enhanced, in other cases in which breathlessness, dyspnea, is the leading symptom, H. 
ephedrae can be augmented. In cases in which cold syndromes appear on the skin, in the 
muscles, etc. also Ramuli cassiae can be raised (Greten, 2007). 
Note: H. ephedrae can raise blood pressure, lead to palpitations and mydriosis. These 
effects are less common within the concoction as a whole. This may be due to roasting it 
in honey and by the beneficial effects of R. glycyrrhizae or other molecules in the 
concoction. H. ephedrae was the first substance to show genomic differences in the 
pharmacodynamics, as 9 out of 10 Chinese persons do not have mydriasis in a certain 
dosage, whereas 9 out of Caucasians respond sensitive with their sympathetic nervous 
system. Within the range of the dosage and in the combination given we have rarely seen 
this. Again it is necessary to start with one third of the daily dosage and then individually 
regulate the dosage required (Greten, 2007). 
 
7. Characterization of Ephedra Decoction (Ma-Huang Tang)  
麻黃湯 
 
Constituents 
Herba ephedrae, Semen armeniacae, Ramulus cassia, Radix glycyrrhizae 
 
Category 
Formulas that Release the Exterior (Anonymous, 2009a). 
 
Uses 
The main indications for Ephedra Decoction are absence of sweating and presence of 
wheezing which is a result of algor constricting the extima leading to Lung Qi rebellion. 
Thus, H. ephedrae is used as a chief herb to promote sweating and calm wheezing which 
follows the principle of using acrid warm herbs and promoting sweating (Liu et Tseng, 
2005). Exterior syndrome of excess due to wind-cold (Cold stroke syndrome of Taiyang 
channel) (Anonymous, 2009a; Anonymous, 2009c; Cheng, 2008; Gongwang, 2002) that 
causes chills and fever, headache body ache, absence of sweating (Anonymous, 2009a; 
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Gongwang, 2002; Ling, 2005; Liu et Tseng, 2005), wheezing, decreased taste sensitivity 
(Ling, 2005; Liu et Tseng, 2005), stuffy and running nose (Anonymous, 2009a; 
Gongwang, 2002), cough or asthma (Cheng, 2008; Gongwang, 2002), thin white tongue 
coat (Anonymous, 2009a; Gongwang, 2002), floating, and tight pulse (Anonymous, 
2009a; Gongwang, 2002; Ling, 2005; Liu et Tseng, 2005). 
 
Actions 
Releases the Exterior Cold and arrests wheezing. Opens the Lung Qi (Anonymous, 
2009c) and induces sweating (Anonymous, 2009a; Anonymous, 2009c; Cheng, 2008; 
Ling, 2005), relieving the exterior syndrome (Anonymous, 2009a; Cheng, 2008; Ling, 
2005), dispersing the lung to relive asthma (Gongwang, 2002), disperses algor, favors the 
dispersive action of the lung and eliminate asthma (Cheng, 2008). 
 
Western uses 
This medication is commonly used in asthma (Anonymous, 2009a; Cheng, 2008; Greten, 
2007), common cold (Anonymous, 2009a; Cheng, 2008), and chronic obstructive 
pulmonary disease (COPD) (Greten, 2007), influenza (Cheng, 2008; Chu, 2008), 
recommended for cases of flu accompanied by nasal congestion, sinusitis (Cheng, 2008) 
and cough (Anonymous, 2009a). Also used in rheumatoid arthritis, nocturia, cystitis and 
measles (Cheng, 2008). 
 
Originally Appeared In 
On Cold Damage (Shang Han Lun) (Discussion of Cold-induced Disorders) (Anonymous, 
2009a; Ling, 2005), Algor Leadens Theory (Greten, 2007). 
 
Brief description of the action of the constituents  
 
Herba ephedrae: pungent and slightly bitter, warm. Relieves the surface, disperse lung, 
and eliminates liquids and edema. Sweat to disperse syndrome superficial; encourages 
the dissemination and relaxes cough wheezing. Related to the pulmonary and vesical 
orbs. 
Semen armeniacae: bitter, slightly toxic; warm. Descends Lung Qi, relieves cough and 
asthma, and moistens intestines. Slow down wheezing cough. Related to the crass 
intestinal and pulmonary orbs.  
Ramulus cinnamomi: sweet, warm. Relieves the surface, warm the Yang and facilitates 
the flow channels, warms and unblocks channels to strengthen Yang, stimulates nutrient 
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layer and defensive, supports Herba ephedrae to strengthen diaphoretic and dispersive 
action. Related to the cardial, pulmonary and vesical orbs.  
Radix glycyrrhizae: sweet, neutral. Approximate the actions of the other ingredients, 
moderate the diaphoretic action of Herba ephedrae, and coordinate the other plants. 
Related to all the orbs.  
 
Action of associations in the formula 
 
Herba ephedrae + Ramulus cinnamomi 
When ephedra is combined with cassia twig, because of the pungent flavor and warm 
nature of the herbs, the formula has the effect of inducing perspiration and is applicable 
for the exterior syndrome of excess without presence of seat due to attack of Taiyang 
channel (Stage I of the ALT) by algor (Yanfu, 2002a). 
This association maximizes the diaphoretic effect and this combination very effective for 
reliving the exterior (Cheng, 2008). Both Ramulus cinnamomi and Herba ephedrae are 
diaphoretics for dispersing algor venti, whereas Ramulus Cinnamomi is moderate in 
action and weaker than H. ephedrae in inducing sweating. Since H. ephedrae is a 
medicinal herb mainly attributive to the lung and has the strong action of perspiration, it is 
often used for exterior syndrome with anidrosis due to ventus and algor and can disperse 
the lung and relieve asthma, promote diuresis to relieve edema (Yanfu, 2002a). 
Herba Ephedrae + Semen Armeniacae Amarum 
Ephedra is pungent in flavor and apricot kernel is bitter and when they two are combined, 
promotes the role of dispersive and descends Lung Qi, expelling the pathogen, relieving 
asthma, eliminate algor and relieve the surface (Cheng, 2008; Gongwang, 2002). Both 
apricot seed and ephedra belong to the pulmonary orb and can treat cough and asthma 
caused by algor venti attacking the lung co-operatively. Ephedra tends to disperse the 
algor venti to promote the flow of lung qi to allay asthma; apricot seed tends to lower the 
flow of qi to relieve cough. One for dispersing, the other for lowering, they can regulate the 
flow of qi to relieve cough and asthma. In addition ephedra can disperse lung qi to induce 
diuresis and reduce edema caused by attacking wind (Gongwang, 2001d). 
Plus Radix Glycyrrhizae 
The use of roasted licorice root has the action of preventing the ephedra and cassia twig 
from perspiring too much. It also has the effects of resolving phlegm and stopping cough 
(Gongwang, 2002). 
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Preparation 
Decoction. Take the warm decoction in three doses until mild sweating is induced (Liu et 
Tseng, 2005). 
 
Precautions and ontraindications 
 Used only in exterior excess Wind Cold, and its use is ceased once 
sweating occurs. 
 Not for exterior deficient Wind Cold patterns (Anonymous, 2009a). 
 Not for exterior Wind Heat patterns (Anonymous, 2009a; Gongwang, 
2002). 
 Not for patients that are prone to bleeding.  
 Use caution in patients with hypertension.  
 This formula contains one or more toxic substances (while some Chinese 
herbs are toxic, it must be noted that many come prepared, or are 
combined, to mitigate their toxicity) (Anonymous, 2009a).  
 This formula is not suitable for those with weak and fragile constitutions 
(Gongwang, 2002). 
 
Combined orbs of all herbs in this formula 
Pulmonary, Vesical, Cardial, Crass intestinal. 
 
The use of Ramulus cassia versus Cortex in Ephedra Decoction 
Mao-to (Ma-Huang-tang in Chinese) is traditionally used in Japan and China for treatment 
of influenza-like illness (high fever, headache, pain and cough) since ancient times. 
According to Shijie et al., 2008 in Japan the component herb names (botanical names) of 
Mao-to are as follows: H. ephedra (stem of Ephedra Sinica Stapf), Cinnamomi Cortex 
(bark of Cinnamomum cassia Blume), Armenicae Semen (semen of Prunus Armeniacae 
Linne) and Glycyrrhizae Radix (root of Glycyrrhizae uralensis Fisher).  
This exchange between the Cortex and he Ramulus of cinnamon is very pertinent. Is so 
important to use one or another part of this herb? I will try to answer this question later in 
this master thesis.  
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7.1. Herba Ephedrae 
 
Introduction 
Many members of the genus Ephedra have been used medically. The most common 
include E.sinica Satpf. (草麻黄 - cao Mahuang) (Fig. 1-2) (Bensky et al., 2004; Chen et 
Chen, 2004; Chu, 2008; CP, 2005 ; Ganzhong et al., 2003b; Soni et al., 2004; Yanfu, 
2002a), E. major Host. (Fig. 5), E. vulgaris, E.altissima, E.distachya (Fig. 4-5), E. 
helvetica, C.A. Meyer and  E. nevadensis Watson (Soni et al., 2004). E. equisetina Bunge, 
(木賊麻黄- mu zei Mahuang) (Chen et Chen, 2004; Chu, 2008; CP, 2005 ; Yanfu, 2002a) 
and E. intermedia Schrenk et Mey. (中麻黄 -zhong Mahuang) are also refered as standard 
species (Bensky et al., 2004; Chu, 2008; CP; 2005; Ganzhong et al., 2003b; WHO, 
1997a; Yanfu, 2002a). 
 
Fig. 1.  Ephedra sinica (adapted from Wu, 2005). 
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Fig.  2. Ephedra sinica (adapted from http://www.ktbotanicals.com/ephedra-sinica-Mahuang-p-6931.html) (visited 10-6-
2009). 
 
 
 
 
Fig. 3. Ephedra major Host (adapted from 
http://vanherbaryum.yyu.edu.tr/flora/famgenustur/ephedraceae/ephedra/emajor/index.htm) (visited 10-6-09) 
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Fig. 4. Ephedra distachya (adapted from http://commons.wikimedia.org/wiki/File:Illustration_Ephedra_distachya0.jpg) 
(visited 10-6-2009). 
 
 
Fig. 5. Ephedra distachya (adapted from http://www.hlasek.com/ephedra_distachya_6552.html) (visited 10-6-2009). 
 
By definition, Herba ephedrae consists of the dried stem or aerial part of Ephedra sinica 
Stapt or other ephedrine-containing Ephedra species (Lee et al., 2000; Soni et al., 2004; 
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WHO, 1999),  that belongs to the Family Efedraceae (Abourashed et al., 2003; Bensky et 
al., 2004; Ganzhong et al., 2003b; Lee et al., 2000; Leite, 2005a; Soni et al., 2004; WHO, 
1999; Yanfu, 2002a) or Gnetaceae (Lee et al., 2000; Soni et al., 2004; WHO, 1999). 
The Chinese term ‗Mahuang‘ may be loosely translated as ‗yellow astringent‘ 
(Abourashed et al., 2003; Andraws et al., 2005), ‗yellow horsetail‘ or ‗hemp yellow‘ (huang 
is yellow; ma has different meanings) and is more specific to the aerial parts of Ephedra 
sinica Stapf., E. equisietina Bunge., or E. intermedia Schrenk et Mey. Other species that 
are not official in the Chinese Pharmacopoeia but that are also considered as sources of 
Mahuang include E. minuta Florin, E. distachya L. and E. gerardiana Wall., as well as at 
least 6 more ephedrine-containing species (Abourashed et al., 2003). 
Other names commonly used are: ma hoàng, mao, maoh, mao-kon, môc tac ma hoàng, 
mu-tsi-Mahuang, san-Mahuang, phok (WHO, 1999), desert herb, Chinese ephedra 
(Anonymous, 2009i; WHO, 1999), horsetail, soma, amsania, budshur, chewa, hum, huma, 
khama (WHO, 1999), joint fir (Anonymous, 2009i; WHO, 1999), mormon tea (WHO, 1999; 
Soni et al., 2004), yellow horse (Anonymous, 2009i; WHO, 1999; Soni et al., 2004), sea 
grape, joint fir, squaw tea, teamster´s tea (Soni et al., 2004), popotillo, yellow astringent  
(Anonymous, 2009i; Soni et al., 2004), xin jiang xue lian hua (Chu, 2008), Cao Mahuang, 
Chinese Joint-Fir, Cao Ma-Huang, Ephedra Sinisa, Ephedrine, Ephedrine Alkaloid, Herbal 
Ecstasy, Indian Jointfir, Mahuang, Mahuanggen (Mahuang root), Mongolian Ephedra, 
Muzei Mahuang, Pakistani Ephedra, Sea Grape, Shuang Sui Mahuang, Teamster's Tea, 
Zhong Mahuang (Anonymous, 2009i). Mormon tea and ephedra are often confused. 
Mormon tea or American ephedra comes from Ephedra nevadensis, and ephedra or 
Mahuang comes primarily from Ephedra sinica. Mormon tea is alkaloid-free and lacks 
both the therapeutic effects and the toxicity of ephedrine (Anonymous, 2009i). 
 
Historical perspective 
One of the oldest medicinal herbs known to mankind is probably ephedra, or ―Mahuang‖, 
as it is known in TCM. Ephedra sinica is the primary species that has been used in China 
for more than 5000 years (Abourashed et al., 2003; Bent et al., 2003; Soni et al., 2004) 
and is still being used in ephedra preparations and extracts all around the world. Although 
originally examined by Emperor Shen Nung (ca. 3200 BC), the use of Mahuang as a 
stimulant and as an antiasthmatic was not documented until the time of the ancient 
Chinese Han Dynasty (ca. 207 BC–220 AD). Ephedra has a long story of use as a 
stimulant and for the management of bronquial disorders (Soni et al., 2004). Ephedra 
gerardiana has been similarly employed in Indian folk medicine since old times 
(Abourashed et al., 2003). Reports also indicate that the ancient Aryans discovered 
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ephedra or Soma plant as an energizer-cum-euphoriant. Use of ephedra juice for 
longevity was a part of ancient Indian Aryan custom mentioned in the Rigveda (the oldest 
of sacred Sanskrit Vedas) and followed even by ancient Romans. In Asian medicine, 
ephedra is recommended for colds and flu, fever, chills, headaches, edema, coughing, 
wheezing (Soni et al., 2004), and for the treatment of asthma (Bent et al., 2003; Soni et 
al., 2004). Even during the time of the Roman Empire, ephedra was well known and 
described until it was eventually dropped from medieval European literature. More 
recently, the importance of some ephedra species as potential cash crops in India and the 
United States (US) has been contemplated. In spite of its long history and its agronomic 
promise, the use of ephedra herb has declined throughout the years, but in the beginning 
of the 20th century, interest in the herb gradually revived, as demonstrated by its use in 
the US for weight loss and performance enhancement. Over the past decade, however, 
the use of ephedra in the US has been under increasing scrutiny due to the mounting 
evidence of possible hazards caused by misuse or abuse of the herb (Abourashed et al., 
2003). 
 
Geographical distribution 
The genus Ephedra includes ca. 40 species distributed throughout the temperate and 
subtropical zones of Europe, Americas and Asia (Abourashed et al., 2003; Andraws et al., 
2005; WHO, 1999 Soni et al., 2004) (China, India, Japan, and Southern Siberia) (Soni et 
al., 2004). In China, it is mainly produced in Liaoning Inner Mongolia, Hebei, Shanxi (Chu, 
2008; Wu, 2005; Ganzhong et al., 2003b; Yanfu, 2002a), Gansu (Ganzhong et al., 2003b; 
Wu, 2005; Yanfu, 2002a), Heilongjiang, Jilin, Shaanxi, Henan (Chu, 2008) and Sichuan 
provinces (Wu, 2005). Although China has been the main supplier of the herb, India and 
Pakistan are currently accepted as major suppliers as well (Abourashed et al., 2003). 
 
Description 
Ephedra is an erect postrate undershrub, 20-40 cm high but according to Abourashed et 
al. (2003) the plants are herbaceous perennials that can exceed 1 m in height. Branches 
erect, short, glaucous green, somewhat flat, 1.0-1.05 mm thick, with sparse longitudinal 
striae, fascinated at the nodes; internode 2.5-5.5 cm long by 2 mm, acute triangular. 
Flowers in summer, unisexual, dioecious; male flowers pedunculate or nearly sessile, 
grouped in catkins composed of 4-5 pairs of flowers with 8 anthers; female flowers 
biflorous, pedunculate with 3-4 pairs of bracts, the naked ovule with the outer coat 
produced into a styliform tube, fruiting with often freshy red succulent bracts, 2-seeded 
(WHO, 1997a). The medicinal parts of the plants are collected between August and 
October and dried in the shade. After being cut into pieces (segments) (Fig. 6), they are 
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left raw, or further prepared with honey, or made into fibers for clinical use (Wu, 2005; 
Ganzhong et al., 2003b). 
 
Fig. 6. Pieces from Ephedra sinica (adapted from http://tcm.health-info.org/Herbology.Materia.Medica/mahuang-
properties.htm) (visited 10-6-09). 
 
Plant material of interest 
Stem or arterial part (Cunha et al., 2003; Soni et al., 2004; WHO, 1997A; WHO, 1999). 
 
Organoleptic properties 
Odor, slight (WHO, 1999), with a strong pine odor (Abourashed et al., 2003); taste, slightly 
bitter (WHO, 1997A; WHO, 1999), and astringent (Abourashed et al., 2003; WHO, 1997A; 
WHO, 1999), giving a slight sensation of numbness on the tongue (WHO, 1999); colour: 
dark brown; solubility: partly soluble in water (Soni et al., 2004). 
 
General Identity Tests  
Macroscopic and microscopic examinations and microchemical tests for the presence of 
alkaloids with Mayer´s reagent (WHO, 1999). The VIII Portuguese Pharmacopoeia (2005) 
and the European Pharmacopoeia (2005) inscribes the monography of ephedrine 
(Ephedrinum anhydricum, Ephedrinum hemihydricum, Ephedrini hydrochloridum and 
Ephedrini racemici hydrochloridum), but not the ephedra monography. 
 
Purity Tests 
Microbiology 
The test for Salmonella spp. in Herba Ephedrae products should be negative. The 
maximum acceptable limits for other microorganisms are as follows. For preparation of 
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decoction: aerobic bacteria—not more than 107/g; fungi—not more than 105/g; Escherichia 
coli—not more than 102/g. Preparations for internal use: aerobic bacteria—not more than 
105/g or ml; fungi—not more than 104/g or ml; enterobacteria and certain Gram-negative 
bacteria—not more than 103/g or ml; Escherichia coli—0/g or ml (WHO, 1999). 
Foreign organic matter 
Woody stems, not more than 5% (CP, 2005; WHO, 1999). Does not contain stems of 
Equisetaceae or Gramineae plants, nor any other foreign matter (WHO, 1999). 
Total ash 
Not more than 9% (WHO, 1999) or according to Chinese Pharmacopoeia (2005) not more 
than 10%. 
Acid-insoluble ash 
Not more than 2% (WHO, 1999). 
Moisture 
Not more than 9% (CP, 2005; WHO, 1999). 
Pesticide residues 
To be established in accordance with national requirements. Normally, the maximum 
residue limit of aldrin and dieldrin for Herba Ephedrae is not more than 0.05 mg/kg (WHO, 
1999). 
Heavy metals 
Recommended lead and cadmium levels are no more than 10 and 0.3mg/kg, respectively, 
in the final dosage form of the plant material (WHO, 1999). 
Radioactive residues 
Analysis of strontium-90, iodine-131, caesium-134, caesium-137, and plutonium-239 
(WHO, 1999). 
Other purity tests 
Chemical, dilute ethanol-soluble extractive and water-soluble extractive tests to be 
established in accordance with national requirements (WHO, 1999). 
Chemical assays 
Contains not less than 0.7% total alkaloids, calculated as ephedrine by high performance 
liquid chromatography in the Japanese pharmacopoeia; or not less than 0.8% of total 
alkaloids, calculated as ephedrine in the Chinese pharmacopoeia. Thin-layer, gas–liquid 
or HPLC analysis for ephedrine and related alkaloids are available (WHO, 1999). 
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Chemical constituents  
The main active components are alkaloids (Ganzhong et al., 2003b). The yield of alkaloids 
of ephedra ranges from 0.5% to 2.5% (Soni et al., 2004; Zaacks et al, 1999), but 
according to Abourashed et al. (1993), the aerial parts of different ephedra species 
contain from 0.02% to 3.4% of 6 optically active alkaloids (Fig. 7) concentrated in the 
internodes. (-)-Ephedrine (EPH) is the major isomer (Cheng et al., 2004; Abourashed et 
al., 2003) comprising 30–90% of the total alkaloids. It was the first alkaloid isolated from 
ephedra by Nagai in 1887. (+)-Pseudoephedrine (PSE), the diastereomer of (-)-EPH, was 
subsequently isolated by Ladenburg and Ölschlägel in 1889 followed by the remaining 
isomers in the late 1920s (Abourashed et al., 2003). 
 
 
 
 
 
 
 
 
 
Fig.7. Naturally occurring ephedra alkaloids (adapted from Abourashed et al., 2003) 
 
The natural form of ephedrine is the L isomer (levorotatory), while the synthetic compound 
is generally a racemic mixture of L and D-isomer. The roots and fruits of the ephedra plant 
are generally devoid of alkaloids, while the woody basal stems are low in alkaloids (Soni 
et al., 2004). Other trace alkaloids in the alkaloid complex include (-)-norephedrine, (+)-
norpseudoephedrine, (-)-methylephedrine, (+)-methylpseudoephedrine (Andraws et al., 
2005; Bent et al., 2003; Soni et al., 2004; WHO, 1999) and phenylpropanolamine (a 
synthetic, racemic mixture of the stereoisomers of norephedrine) (Andraws et al., 2005). 
The Asian species (E. sinica, E. intermedia, and E. equisetina) have the highest alkaloid 
content and the greatest amount is found in the branches, the remainder of the shrub 
being devoid of the compounds. Extracts of the branches contain varying amounts of the 
different alkaloids and each alkaloid differs somewhat in its pharmacodynamic properties 
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(Andraws et al., 2005). It is to be noted that not all ephedra species contain ephedrine-
type alkaloids (Abourashed et al., 2003; WHO, 1999). Ephedra nevadensis, known as 
Mormon or desert tea, E. trifurca, and E. antisyphilitica, as well as most North and Central 
American species are believed to be devoid of these alkaloids. In addition to the 
ephedrine-type alkaloids, other alkaloids and amino compounds have been isolated from 
different species of ephedra. The macrocyclic spermine alkaloids, ephedradines A-D have 
been isolated from the roots E. sinica. Kynurenic acid derivatives have been found in the 
fresh stem extracts of E. foeminea and E. foliata. The fresh stems of E. foeminea and E. 
altissima have been reported to contain cyclopropylglycine and methanoproline 
aminoacids. Different types of secondary metabolites, such as flavones, flavanols, tannins 
carboxylic acids and volatile terpenes have also been reported (Abourashed et al., 2003). 
The tannins contribute to the adstringent taste of ephedra products (Soni et al., 2004), 
(ellagic and gallic tannins) (Cunha et al., 2003). Some other active components, such as 
volatile oil, are also present (Ganzhong et al., 2003b). A minor bioactive oxazolidone 
derivative of (-)-EPH, ephedroxane, has also been isolated from the aerial parts of E. 
intermedia and has been detected in at least 6 more species containing ephedrine 
alkaloids (Abourashed et al., 2003). Some of these constituents are shown in Fig. 8-9. 
 
Fig. 8.  Non-ephedrine alkaloids and amino compounds in ephedra 
species       
Fig. 9. Miscellaneous non-alkaloidal natural constituents of                 
ephedra species (adapted from Abourashed et al., 2003). 
 
 
 
 
Clinical pharmacology 
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The pharmacological action of ephedra is dependent upon its chemical composition. As 
the primary alkaloid found in most ephedra species is ephedrine, the effects of ephedrine 
can represent a surrogate for the expected pharmacological action of ephedra. Because 
other constituents of ephedra may alter the pharmacological action of ephedrine, 
understanding the effects of ephedrine may provide insight into the biological action of this 
herb. The profile of all alkaloids is also important, because although the individual 
alkaloids have similar pharmacological activity, they vary significantly in potency and thus 
alter the net effect. Recent studies suggest that the potency of the adrenergic activity and 
the cytotoxicity of ephedra extracts, correlate with the ephedrine content; however, the 
cytotoxicity of all ephedra extracts could not be completely accounted for their ephedrine 
content alone (Soni et al., 2004). 
The pharmacology of ephedra is complex, but for both traditional and more recent popular 
uses, the established pharmacological effects appear to be attributable to its ephedrine-
type alkaloids, mainly (-)-EPH and (+)-PSE. Current Western therapies utilize these two 
alkaloids (and until recently norephedrine, also known as phenylpropanolamine) in their 
optically pure forms or as their synthetic racemates. Due to their stability, they are often 
incorporated in oral dosage forms (Abourashed et al., 2003). Ephedrine and 
pseudoephedrine are potent sympathomimetic drugs that stimulate α, β1 and β2 
adrenoceptors (Abourashed et al., 2003; Maglione, 2005; Soni et al., 2004; WHO, 1999). 
Pseudoephedrine´s activity is similar to ephedrine, but its hypertensive effects and 
stimulation of the central nervous system (CNS) are somewhat weaker (WHO, 1999). Also 
has a weaker cardiac effect, but a greater diuretic activity (Soni et al., 2004). Part of 
ephedrine´s peripheral action is due to the releases of norepinephrine (Maglione, 2005; 
Soni et al., 2004; WHO, 1999) and dopamine (Maglione, 2005; Soni et al., 2004; WHO, 
1999), from neuronal storage sites in the symphathetic nerves (Soni et al., 2004) and 
direct action on α- and β-postsynaptic receptors at effector organs (Soni et al., 2004; 
WHO, 1999). This basic pharmacological mechanism seems to account for most of 
ephedrine‘s therapeutic efficacy, as well as its most prominent adverse effects. Hallmark 
effects of α- and β-adrenergic receptor stimulation include enhanced cardiac rate and 
contractility, peripheral vasoconstriction, bronchodilation, and CNS stimulation. The 
vasoconstrictor and bronchodilator effects explain the traditional use of ephedra as a 
nasal decongestant and anti-asthmatic. Ephedrine is metabolized to norephedrine 
(phenylpropanolamine) which may be responsible for the CNS stimulant effects. In current 
usage, the CNS stimulant and perhaps thermogenic effects are purported to afford 
enhanced weight loss in obesity, and improved performance in endurance training or 
body-building. Although ephedrine does suppress appetite, the main mechanism for 
promoting weight loss appears to be by increasing the metabolic rate of adipose tissue. 
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The actions of ephedrine and its congeners as sympathomimetics have been studied 
extensively, but variations in the compounds tested, species, target tissue, and study 
conditions vary sharply (Abourashed et al., 2003). 
Their molecular structures are isomers of one another or are closely related, substituted 
molecules that demonstrate significant similarity with amphetamines and other 
catecholamines (Fig. 10). It is not surprising, then, that these molecules possess 
significant α- and β-adrenergic agonist activity. In addition, they enhance the release of 
endogenous catecholamines. This latter effect, through depletion of endogenous 
catecholamine stores, is thought to explain the tachyphylaxis noted with repeated dosing 
(Andraws et al., 2005). Tachyphylaxis develops to its peripheral actions, and rapidly 
repeated doses become less effective owing to the depletion of norepinephrine stores 
(WHO, 1999). 
 
Fig. 10. Chemical structures of the ephedra alkaloids (left). The structures of epinephrine, amphetamine, and dobutamine (right) are shown 
for comparison (adapted from Andraws et al., 2005). 
 
In addition to the ephedrine alkaloids, some of the minor compounds isolated from 
Ephedra species exhibited other biological activities. Ephedroxane, was found to have 
anti-inflammatory activity; while others, such as ephedrannine A and maokonine (present 
in root) exhibited hypotensive activity in animals. It is interesting to notice that the reported 
hypotensive activity is exhibited by compounds present only in the roots of ephedra, which 
agrees with Chinese belief that the roots constitute a drug (Mahuang gen, or mao-kon in 
Japanese) that produces opposite effects to those of the aerial parts (Mahuang) 
(Abourashed et al., 2003). 
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Effects and uses 
Ephedra alkaloids have a long history as traditional folk remedies, particularly among the 
Chinese (Andraws et al., 2005). In Oriental medicine, the ephedra herb (Mahuang) is the 
chief medicine used in the treatment of asthma and bronchitis (Soni et al., 2004). Herbal 
ephedra has been used as part of Chinese traditional medicine for over 5,000 years 
(Morton, 2005) for asthma (Cunha et al., 2007; Kliger et Lee, 2004; Soni et al., 2004; 
Cunha et al., 2003; Abourashed et al., 2003; Ang-Lee et al., 200; Lee et al., 2000), 
common cold (Abourashed et al., 2003; Andraws et al., 2005; Cunha et al., 2003; Kliger et 
Lee, 2004; Lee et al., 2000; WHO, 1997 ; Soni et al., 2004), fever (Abourashed et al., 
2003; Lee et al., 2000 ; Soni et al., 2004), bronchitis (Ang-Lee et al., 2001) and cough 
(Abourashed et al., 2003; Andraws et al., 2005; Cunha et al., 2007; Lee et al., 2000; 
WHO, 1997 ). Other uses supported by clinical data include nasal congestion 
(Abourashed et al., 2003; Cheng et al., 2004; Cunha et al., 2003; Kliger et Lee, 2004; Lee 
et al., 2000 ; Soni et al., 2004), lung congestion (Lee et al., 2000), allergic rhinitis, (Cunha 
et al., 2007; Cunha et al., 2003 ; Kliger et Lee, 2004) acute coryza (Cunha et al., 2003 ; 
Kliger et Lee, 2004;), flu (Abourashed et al., 2003 ; Cunha et al., 2007; Soni et al., 2004), 
chills (Abourashed et al., 2003 ; Soni et al., 2004) lack of perspiration, (WHO, 1997 ; Soni 
et al., 2004) headache, aching joints and bones (Abourashed et al., 2003 ; Soni et al., 
2004), wheezing (Soni et al., 2004) and oedema (WHO, 1997A). 
In the West, ephedra preparations have been used, alone or with caffeine, as CNS 
stimulants and mood enhancers. Moreover, new uses for ephedra have recently emerged. 
Many ephedra-containing products are claimed to be effective for weight-loss, as 
energy/performance boosters (Abourashed et al., 2003; Ang-Lee et al., 2001), euphorics 
or aphrodisiacs, claims that are especially appealing to young adults. Such claims, 
however, have not been adequately substantiated and, in an attempt to probe their 
validity, the role of EPH in thermogenesis and cold tolerance in humans was investigated 
(Abourashed et al., 2003). Also, ephedrine acts on the hypothalamus reducind appetite, 
so it is often associated with caffeine in products for weight loss (Cunha et al., 2007). 
In Germany, ephedra is approved by the E Comission for respiratory problems with 
bhroncospasm in adults and children over 6 years of age (Cunha et al., 2007; Cunha et 
al., 2003; Soni et al., 2004). The Expanded Commision E monograph describes at length, 
dosage and administration (Soni et al., 2004). 
 
Pharmacological effects 
Ephedra causes dose-dependent increases in blood pressure and heart rate. Ephedrine, 
the predominant active compound, is a noncatecholamine sympathomimetic agent that 
exhibits α1, β1, and β2 activity by acting directly at adrenergic receptors and by indirectly 
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releasing endogenous norepinephrine (Abourashed et al., 2003; Ang-Lee et al., 2001; 
Maglione, 2005; Soni et al., 2004; WHO, 1999) and dopamine (Maglione, 2005; Soni et 
al., 2004; WHO, 1999). 
 
Cardiovascular actions 
The principle cardiovascular effects of ephedra alkaloids include increases in systolic and 
diastolic blood pressure (Andraws et al., 2005; Ang-Lee et al, 2001; Chen et Chen, 2004; 
Chu, 2008; Ganzhong et al., 2003b; WHO, 1999), heart rate (Andraws et al., 2005; Ang-
Lee et al, 2001; Ganzhong et al., 2003b; Soni et al., 2004; WHO, 1999) and indices of 
cardiac performance (Andraws et al., 2005; Ganzhong et al., 2003b). Like epinephrine 
(adrenaline), ephedrine excites the sympathetic nervous system, causing vasoconstriction 
and cardiac stimulation (Ganzhong et al., 2003b; WHO, 1999).The drug stimulates the 
cardiac output, and increases the peripheral resistance, thereby producing a lasting rise in 
the blood pressure (Soni et al., 2004; WHO, 1999). Ephedrine differs from epinephrine in 
that it is orally active, has a much longer duration of action, and has more pronounced 
activity in CNS, but is much less potent. The cardiovascular effects of ephedrine persist 
up to ten times as long as those of epinephrine. Renal and splanchnic blood flows are 
decreased, while coronary, cerebral, and muscle blood flow are increased (WHO, 1999). 
Reports of hypoglycemic activity were found about Ephedra distachya (Konno et al., 1985) 
 
Respiratory effects  
Ephedrine, like epinephrine, relaxes bronchial muscles and is a potent bronchodilatador 
(Chen et Chen, 2004; Soni et al., 2004; WHO, 1999) owing to its activation of the β-
adrenoreceptors in the lungs (Soni et al., 2004; WHO, 1999). Bronquial muscle relaxation 
is less pronounced but more sustained with ephedrine than with epinephrine (WHO, 
1999). Ephedrine has a more rapid onset of action, but its effectiveness may decrease if it 
is used repeatedly in a short period of time (Chen et Chen, 2004). The sympathomimetic 
action of ephedrine leads to an increase in respiratory rate and pulmonary ventilation and 
it is used to eliminate the cough also in non asthmatics subjects (Cunha et al., 2007). 
Ephedrine promote the release of noradrenaline and adrenaline and inhibit the release of 
sensitizing substances as histamine, resulting in the dilation of bronchial smooth muscle, 
the contraction of intra-mucosal blood vessels of the respiratory tract, and eventually, free 
movement in the air passage. Mahuang can relieve the respiratory system symptoms 
related to cough, sputum and asthma (Ganzhong et al., 2003b). Water extract of Mahuang 
administered via oral or intraperitoneal injection is also associated with an antitussive 
effect (Chen et Chen, 2004). 
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Nasal decongestant effect 
Ephedrine, like other sympathomimetics with α-receptor activity, causes vasoconstrition 
and blanching when applied topically to nasal and pharyngeal mucosal surfaces. Both 
ephedrine and pseudoephrine are useful orally as nasal decongestants in case of allergic 
rhinitis, but they may not be very effective for the treatment of nasal congestion due to 
colds (WHO, 1999). On the other hand, the most popular application of pseudoephedrine 
is in flu medications to relieve nasal decongestion and perhaps due to its anti-
inflammatory effect. Also ephedroxane was found to have anti-inflammatory activity 
(Abourashed et al., 2003). 
 
Central Nervous System actions 
Ephedrine is a potent stimulant of the central nervous system (Chen et Chen, 2004; 
Maglione, 2005; Soni et al., 2004; WHO, 1999), its immediate effects are attributable to 
stimulation of dopamine release (Maglione, 2005) and the effects may last for several 
hours after oral administration (WHO, 1999). The combination of adrenergic and 
dopaminergic effects of ephedrine leads, in the short therm, to improved mood and 
heightened alertness with decrease fatigue and lessened desire for sleep (Maglione, 
2005). 
 
Hypoglycemic effects 
The hypoglycemic effect of E. distachya has been investigated in Japan, in order to show 
that the hydroalcoholic extract produced long lasting hypoglycemia in mice following 
transient hyperglycemia. Activity-guided fractionation resulted in the isolation of five active 
glycans, ephedrans A, B, C, D and E which significantly reduced blood glucose levels in 
normal and alloxan-induced diabetic mice (Fig. 11). In a similar investigation of the 
hypoglycemic activity of selected plants growing in Egypt, the alcoholic extract of E. alata 
exhibited a persistent lowering of blood glucose one hour after administration to fasting 
rats. In alloxanized rats, however, the same extract failed to reduce blood glucose levels 
as compared to the positive control, glibenclamide (Abourashed et al., 2003; Konno et al., 
1985). 
 
 
Fig. 11. Chemical structure of alloxan (adapted from http://en.wikipedia.org/wiki/File:Alloxan.png) (visited 10-5-09) 
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Diaphoretic effect 
The diaphoretic components of mahuang are the volatile compounds and alkaloids. The 
decoction prepared from mahuang also shows a diaphoretic effect (Ganzhong et al., 
2003b). In humans, administration of ephedrine alkaloids is associated with increased 
perspiration, but only in subjects with elevated body temperature (Chen et Chen, 2004). 
 
Diuretic effect 
Pseudoephedrine has a diuretic function (Chen et Chen, 2004; Ganzhong et al., 2003b; 
Soni et al., 2004), greater than ephedrine (Soni et al., 2004), which exerts its diuretic 
effect possibly through dilating renal vessels, increasing renal blood flow, or inhibiting 
sodium ion reabsorption of renal tubes (Ganzhong et al., 2003b). 
 
Anti-infeccious effect 
Decoction of Mahuang “Mahuang Tang” has varying degrees of inhibitory effect in vitro 
against Staphylococcus aureus, α-streptococcus, β-streptococcus, Bacillus anthracis, 
Corynebacterium diphtheriae, Pseudomonas aeruginosa, Bacillus dysenteriae, and 
Salmonella typhi. The essential oil of Mahuang has an inhibitory effect against E. coli, 
Candida albicans and various types of influenza virus (Chen et Chen, 2004). Herba 
ephedra was reported to show the in vitro anti-influenza viral effects and augments the 
production of inflammatory cytokines including interleukin-6 and interleukin-1 (Shijie et al., 
2008). 
 
Effects on Weight Loss and Athletic Performance 
Dietary supplements containing ephedra have primarily been used in the United States, 
since the 1980‘s, to promote weight loss or to enhance athletic performance. 
Approximately three billion servings were consumed in the U.S. in 1999 according to a 
survey conducted by ephedra product manufacturers (Morton, 2005; Andraws et al., 
2005). Dietary supplements containing ephedra used as ‗‗herbal ecstasy‘‘ are widely 
available, and it is estimated that at least 1% of the adult population have taken these 
products (Cheng et al., 2004) and nearly one third of young, obese women have used a 
weight-loss supplement containing ephedra (Andraws et al., 2005). Several studies on 
these compounds (particularly ephedrine) have been undertaken to assess their efficacy 
and safety in humans for the treatment of obesity. Doses of ephedrine and related 
compounds ranged from 60 to 150 mg/d. Overall, studies have found statistically 
significant reductions in weight in obese patients treated with ephedra alkaloids versus 
those treated with placebo. Treatment with these carefully controlled doses resulted in a 
modest incidence of cardiovascular side effects, including increases in blood pressure 
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(both systolic and diastolic), heart rate, and palpitations that were often mild and transient. 
No clinical trial has reported major adverse cardiovascular events (stroke, myocardial 
infarction, or malignant arrhythmias) associated with the use of ephedra alkaloids for 
weight loss. However, several caveats must be noted. The studies to date have examined 
small cohorts for relatively short periods of time, usually 6 months or less. They have also 
suffered from high attrition rates (Andraws et al., 2005). In addition, most studies have 
looked at ephedrine in combination with caffeine (Andraws et al, 2005; Soni et al, 2004) 
and, in several cases, aspirin (the rationale for this combination is that it better stimulates 
increases in fat metabolism and energy expenditure) (Andraws et al., 2005). Perhaps the 
most sobering finding is that weight loss, although statistically significant, may not be 
clinically significant (<1 kg) with anywhere from a 2- to 4-fold increase in side effects 
compared to placebo. Moreover, side effect profiles may be quite different in cohorts with 
preexisting cardiovascular disease. Thus, it is difficult to generalize these results to the 
various ephedra products on the market that contain variable amounts of active 
compound and are sold to a variety of consumers with different risk factors who may 
consume higher doses than those studied (Andraws et al., 2005). According to Morton 
(2005), ephedra promotes modest short-term weight loss. The most rigorous review to 
date assessed studies with at least 8 weeks of follow-up and concluded that E. sinica and 
ephedrine promote a small short-term weight loss of about 0.9 kg per month more than 
placebo (Pittler et Ernst, 2005). 
Ephedrine is thought to cause thermogenesis and modest short-term weight loss, possibly 
by stimulating norepinephrine release. Some evidence suggests that aspirin and caffeine 
might act synergistically with ephedrine for weight loss by inhibiting prostaglandin, which 
increases norepinephrine release (Anonymous, 2009i). There is some evidence that 
ephedrine alone or in combination with caffeine can improve anaerobic exercise 
performance. Ephedrine causes catecholamine release and increases CNS stimulation, 
which may lead to better performance. Although ephedra is often included in muscle 
development products, preliminary research suggests ephedra does not affect muscle 
precursor cells called satellite cells, which are thought to cause muscular hypertrophy 
(Anonymous, 2009i). However, the intake is associated with an increased risk of 
psychiatric, autonomic or gastrointestinal symptoms and heart palpitations (Pittler et Ernst, 
2005). Again, studies tend to be small and contain young healthy individuals who may not 
reflect the general population. Thus, once more, the limited available safety assessments 
are difficult to extrapolate to the general population (Andraws et al., 2005). 
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Other effects 
Mydriasis occurs after local application of ephedrine to the eye, but the effect last only for 
only a few hours. Ephedrine is of little value as a mydriatic in the presence of inflammation 
(WHO, 1999). The activity of the smooth muscles of the uterus is usually reduced by 
ephedrine; consequently, the drug has been used to relieve pain of dysmenorrhoea. 
Ephedrine stimulates the α-adrenoreceptors of the smooth muscle cells of the bladder 
base, which increases the resistance to the outflow of urine (used in the treatment of 
urinary incontinence and nocturnal enuresis) (WHO, 1999). 
Pharmacokinetics 
Ephedrine is absorbed faster if it is consumed as the powdered extract. However, onset of 
action and extent of absorption does not differ greatly between the powdered extract and 
the powdered herb. Some sources claim ephedra is safer than pure ephedrine and 
pseudoephedrine because ephedrine from ephedra is absorbed more slowly. However, 
pharmacokinetic studies have found no differences in the pharmacokinetics of ephedrine 
from ephedra versus the purified form. The time to maximum concentration (t max) for 
ephedra is 2.4 hours. The half-life is 6.1 hours (Anonymous, 2009i). 
Ephedrine and pseudoephedrine are well-absorbed (Chen et Chen, 2004). Ephedrine is 
active when given orally, parenterally, and ophthalmically. Because of the rapid and 
complete absortion of ephedrine, the onset of pharmacological effects is generally evident 
within an hour of ingestion (Soni et al., 2004). Ephedrine is rapidly and completely 
absorbed from the gastrointestinal tract (Andraws et al., 2005; Soni et al., 2004). After oral 
administration, absorption of ephedrine is complete within 2-2.5h (Soni et al., 2004). 
According to Andraws et al. (2005), time to peak serum levels varies between 2 and 4 
hours and according to Chen et Chen (2004) peak plasma concentration is reached 1-2 
hours after oral ingestion of the herb. The pure alkaloid is absorbed most quickly; herbal 
alkaloid mixtures may retard the rate of absorption. The rate of absorption of ephedrine 
may be increased with heat stress. Additionally, elevations in blood pressure are 
significantly greater when ephedrine is taken during heat stress. The importance of this 
finding lays in the fact that ephedra extracts have been marketed as enhancers of athletic 
performance and are often taken prior to exercise in a warm environment (Andraws et al., 
2005). Thus, they may add to the cardiovascular stress already being experienced during 
physical activity. Once absorbed, ephedrine has a large volume of distribution and is not 
bound to plasma proteins (Andraws et al., 2005). Ephedrine and pseudoephedrine are 
distributed throughout the body, with higher concentrations found in the liver and kidneys, 
followed by the brain, spleen, fatty tissues, and saliva (Chen et Chen, 2004). Ephedrine 
and related alkaloids are lipophilic and cross the blood–brain barrier. It is this physical 
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property that accounts for their effects on the CNS, which include appetite suppression, 
anxiety, and changes in gastric motility (Andraws et al., 2005). The effects of ephedrine 
last for approximately 1 hour, but the serum half-life ranges from 3 to 11 hours (Andraws 
et al., 2005) (2.7-3.6h, according to Soni et al. (2004)). In humans, the primary route of 
ephedrine excretion is via the urine and within 24h of administration (Andraws et al., 2005; 
Soni et al., 2004). Approximately 95% of the ephedrine may be excreted unchanged (55-
75%) or as metabolites (Soni et al., 2004). According to Chen et Chen (2004) up to 75% 
of these compounds can be recovered unchanged in the urine.  
Because of the presence of ionizable groups, the urinary excretion of ephedrine is pH-
dependent, with excretion increasing in acidic urine and decreasing in alkaline urine 
(Andraws et al., 2005; Soni et al., 2004). It has been estimated that approximately 8-20% 
of the administered ephedrine is metabolized by N-demethylation to norephedrine, while 
4-13% undergoes oxidation deamination resulting in the formation of 1-phenylpropan-1,2-
diol and further side-chain oxidation to benzoic acid and hippuric acid. Studies in animals 
and humans suggests that the metabolism of ephedrine primarily takes place through 
aromatic hydroxylation, N-demethylation and oxidative deamination reactions. The extent 
of metabolism and the major metabolites formed, vary between species. Elimination from 
the plasma was reported to occur monoexponentially, with a half-life of 30.6minutes (Soni 
et al., 2004). According to Chen et Chen (2004) the half-lives of ephedrine and 
pseudoephedrine range from 4.73 to 7.1 or 13.4 hours (when the urinary pH is 5.2, 6, and 
7, respectively) and according to Ang-Lee et al. (2001) ephedrine has an elimination half-
life of 5.2h. In addition to renal excretion, ephedrine is also found to be excreted in breast 
milk and crosses the placenta, which poses concerns for younger women who may be 
using extracts for weight loss purposes while pregnant or after delivery (Andraws et al., 
2005). The pharmacokinetics of other alkaloids present in ephedra, including 
pseudoephedrine and phenylpropanolamine are similar to ephedrine (Soni et al., 2004). 
 
Precautions and contraindications  
Herba Ephedrae should not be used in patients with coronary thrombosis, impaired 
circulation of the cerebrum, (Soni et al., 2004; WHO, 1999),  diabetes (Abourashed et al., 
2003; Anonymous, 2009i; Cunha et al., 2003; Soni et al., 2004;  WHO, 1999) (ephedra 
might interfere with blood sugar control, and exacerbate high blood pressure and 
circulatory problems in people with diabetes) (Anonymous, 2009i),  glaucoma (Soni et al., 
2004; Abourashed et al., 2003; WHO, 1999),  heart disease (Soni et al., 2004; Cunha et 
al., 2003), arrhythmia (ephedra might exacerbate arrhythmia; has been linked to 
tachycardia and arrhythmias, due to its cardiac stimulant effects (Anonymous, 2009i), 
hepatitis (Charalampopoulos et al., 2007, Skoulidis et al., 2005), hypertension  
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(Anonymous, 2009i; Bensky et al., 2004; Soni et al., 2004; Abourashed et al., 2003; 
Cunha et al., 2003, WHO, 1999) (ephedra might exacerbate hypertension; contraindicated 
in uncontrolled hypertension) (Anonymous, 2009i) or other cardiovascular diseases 
(Abourashed et al., 2003), hyperthyroid, thyrotoxicosis (theoretically, ephedra might 
stimulate the thyroid and exacerbate hyperthyroid symptoms) (Anonymous, 2009i), mental 
health problems like anxiety  (Anonymous, 2009i; Soni et al., 2004) (large doses of 
ephedra might cause or exacerbate anxiety due to central nervous system (CNS) 
stimulant effects (Anonymous, 2009i), depression or psychosis (Soni et al., 2004), thyroid 
disease (Cunha et al., 2003; Soni et al., 2004; WHO, 1999), autonomic  insufficiency (Soni 
et al., 2004),  pheochromocytoma (Anonymous, 2009i; Soni et al., 2004; WHO, 1999), 
hyperthyroidism, (Abourashed et al., 2003; Anonymous, 2009i) (ephedra might 
exacerbate the symptoms of pheochromocytoma) (Anonymous, 2009i), prostate trouble 
(Soni et al., 2004; Cunha et al., 2003, WHO, 1999),  in people with angina (it might induce 
or exacerbate angina due its cardiac stimulant effects) (Anonymous, 2009i), essential 
tremor (ephedra might exacerbate essential tremor) (Anonymous, 2009i), kidney stones 
(nephrolithiasis) (ephedra and ephedrine can cause kidney stones) (Anonymous, 2009i), 
long QT interval syndrome (ephedra appears to prolong the QT interval; it might increase 
the risk of ventricular arrhythmias in patients with long QT interval syndrome (Anonymous, 
2009i), narrow-angle glaucoma (ephedra might exacerbate narrow-angle (angle-closure) 
glaucoma by causing mydriasis) (Anonymous, 2009i), seizure disorders (ephedra might 
cause an exacerbation or precipitation of a seizure in patients with an underlying seizure 
disorders) (Anonymous, 2009i). 
Pregnancy  
E. sinica did not have any teratogenic effects in vivo, and is not abortifacient in rats. 
Clinical studies in humans are not available (WHO, 1999); It is known that ephedrine 
crosses the placenta, therefore, use of the drug during pregnancy is not generally 
recommended (Andraws et al., 2005; Cunha et al., 2003; WHO, 1999). 
 
Nursing Mothers 
No reliable studies on this subject, breastfeeding is not generally recommended (WHO, 
1999). 
Other precautions 
Continued, prolonged use may cause dependency (WHO, 1999). Use not for children 
under 6 years of age (WHO, 1999). Patients suffering from renal insufficiency may be at 
an increased risk to ephedrine toxicity (Soni et al., 2004). Patients under surgery: although 
ephedrine is widely used as first-line therapy for intraoperative hypotension and 
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bradycardia, the unsupervised preoperative use of ephedra raises certain concerns. 
Vasoconstriction and, in some cases, vasospasm of coronary and cerebral arteries 
maycause myocardial infarction and thrombotic stroke. Do to the increased heart rate and 
blood pressure through direct and indirect sympathomimetic effects, the preoperative 
concerns are: Risk of myocardial ischemia and stroke from tachycardia and hypertension; 
ventricular arrhythmias with halothane (see Drugs Interactions); long-term use depletes 
endogenous catecholamines may cause intraoperative hemodynamic instability; life-
threatening interaction with monoamine oxidase inhibitors (see Drugs Interactions); Long-
term use results in tachyphylaxis from depletion of endogenous catecholamine stores and 
may contribute to perioperative hemodynamic instability. The preoperative discontinuation 
should be at least 24 hours before surgery (Ang-Lee et al., 2001). 
 
Drugs Interactions 
 
 Mahuang should not be combined with other sympathomimetic drugs, such as 
ephedrine, pseudoephedrine, theophylline, caffeine (Chen et Chen, 2004), 
monoamine oxidase inhibitors (MAOI) (Anonymous, 2009j; Beers, 2008; Chen et 
Chen, 2004), or substances with similar properties (Chen et Chen, 2004). 
 Concomitant use of ephedra and MAOI can result in life-threatening hyperpyrexia 
(Ang-Lee et al., 2001), hypertension (Anonymous, 2009j; Ang-Lee et al., 2001; 
Anonymous, 2009i; Soni et al., 2004; WHO, 1999) and coma (Ang-Lee et al., 
2001). Myocardial ischemia has also been reported with this association (also 
bupropion) (Andraws et al., 2005). 
 Oxytocin may increase the risk of high blood pressure (Beers, 2008; WHO, 1999). 
 Gaunethidine, which leads to the enhancement of the sympathomimetic effect 
(WHO, 1999). 
 Cardiac glycosides may cause heart rhythm disturbances (Chu, 2008; Bensky et 
al., 2004; Chen et Chen, 2004; WHO, 1999). 
 Halothane may cause heart rhythm disturbances (WHO, 1999). Patients who 
have consumed ephedra and are later anesthetized with halothane may be at risk 
of developing intraoperative ventricular arrhythmias because halothane sensitizes 
the myocardium to ventricular arrhythmias caused by exogenous catacholamines 
(Abourashed et al., 2003; Ang-Lee et al., 2001). (See Other Precautions) 
 Cautions with tea, cola, guarana, coffee (Anonymous, 2009i; Cunha et al., 2003; 
Soni et al., 2004) because caffeine enhances the ephedra action (Cunha et al., 
2003) and may lead to an increased heart rate and blood pressure (Soni et al., 
2004). 
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 Beta blockers: The effect may be reduced when combined with Mahuang 
because of increased levels of norepinephrine caused by the herb (Chen et Chen, 
2004). 
 Diuretics: Mahuang has a diuretic effect. Though this potential interaction has not 
been documented, concurrent use with diuretic drugs may lead to increased 
elimination of water and/or electrolytes (Chen et Chen, 2004). 
 Anticonvulsants: theoretically, concomitant use of ephedra might interfere with 
the effectiveness of anticonvulsant drugs. Ephedra is associated with seizure 
activity. Some anticonvulsant drugs include phenobarbital, primidone, valproic 
acid, gabapentin, carbamazepine, phenytoin, and others (Anonymous, 2009i). 
 Antidiabetes drugs: ephedra can raise blood glucose levels and might decrease 
the effectiveness of drug therapy (Anonymous, 2009i; Beers, 2008). Monitor blood 
glucose concentrations closely. Some antidiabetes drugs include glimepiride, 
glyburide, insulin, pioglitazone, rosiglitazone, and others (Anonymous, 2009i; 
Beers, 2008). 
 Dexamethasone: theoretically, concomitant use might reduce the effectiveness of 
dexamethasone, due to the ephedrine contained in ephedra. Ephedrine increases 
the clearance rate of dexamethasone (Anonymous, 2009i). 
 Ergot derivatives: theoretically, concomitant use of ephedra and ergot alkaloids 
might cause hypertension, due to the ephedrine contained in ephedra 
(Anonymous, 2009i). 
 Methylxanthines: the use of ephedra with caffeine or other methylxanthines such 
as theophylline might increase the risk of stimulatory adverse effects. There is also 
some evidence that using ephedra with caffeine might increase the risk of serious 
life-threatening or debilitating adverse effects such as hypertension, myocardial 
infarction, stroke, seizures, and death (Anonymous, 2009i; Beers, 2008). 
 QT interval-prolonging drugs: ephedra may have an additive effect with drugs 
that prolong the QT interval. This may increase the risk of ventricular arrhythmias. 
Drugs that prolong the QT interval include amiodarone, disopyramide, dofetilide, 
ibutilide, procainamide, quinidine, sotalol, thioridazine, and many others 
(Anonymous, 2009i). 
 Stimulant drugs: theoretically, drugs with CNS stimulant properties, such as 
phenylpropanolamine, pseudoephedrine, and diethylpropion, and many others 
might increase the risk of hypertension and adverse cardiovascular effects of 
ephedra due to its ephedra content (Anonymous, 2009i). 
 Amitriptiline: may decrease hypertensive effects of herb (Beers, 2008). 
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Interactions with Herbs & Supplements 
 
 Ergotamine: theoretically, concomitant use might cause excessive 
vasoconstriction and hypertension due to the ephedrine contained in ephedra 
(Anonymous, 2009i). 
 Herbs and supplements with stimulant properties: Use of ephedra and 
other stimulant herbs, such as those containing caffeine, can increase the risk 
of common side effects such as insomnia, jitteriness, tremulousness, 
dizziness, etc. Using ephedra with other stimulants might also increase the risk 
of more serious adverse effects such as hypertension, myocardial infarction, 
stroke, and death. There are several reports of serious life-threatening or 
debilitating adverse events in patients taking ephedra in combination with 
caffeine and other stimulants. Some herbs and supplements with significant 
caffeine content include black tea, coffee, cola nut, green tea, guarana, mate, 
and others, as referred before (Anonymous, 2009i). 
 Panax ginseng: Panax ginseng can cause prolonged QT interval with initial 
use. It might have an additive effect with ephedra on the QT interval, 
increasing the risk for arrhythmias (Anonymous, 2009i). 
 
Side effects 
The risk for an adverse reaction after the use of ephedra is substantially greater than with 
other herbal products (Anonymous, 2009i; Bent et al., 2003). The researchers reported 
that there was sufficient evidence to conclude that ephedrine and ephedra are associated 
with an increase of two to three times in the risk of psychiatric symptoms, autonomic 
symptoms, upper gastrointestinal symptoms and heart palpitations (Kliger et Lee, 2004). 
Adverse effects are consistent with catecholamine excess (Anonymous, 2009i).  Although 
ephedra products make up a modest amount of overall supplement sales (0.82%), they 
account for an inordinately large number of reported adverse events (64%) (Andraws et 
al., 2005). Because these products are not regulated as drugs, many of these ephedra 
dietary supplements have extreme variability in the content of ephedrine related to 
differences in ephedra species and place of origin (Chen et al., 2004). Insight into the 
potential toxicity of these agents may be obtained, by considering their pharmacologic 
properties and toxicity may not be limited to the pharmacologic effects of the alkaloids 
themselves (Andraws et al., 2005). 
By the year 2000, the Food and Drug Administration (FDA) had received more than 1000 
injury reports related to use of ephedra products. With the assumption that such reports 
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have been adequately substantiated, the causes can be attributed to at least one of the 
following practices linked to ephedra: 
(1) Misuse: [administration of overdoses of ephedra/ephedrine-containing products in an 
attempt to achieve better or faster response for the desired effect]. Overdosing may also 
result from regular administration of ephedra products spiked with ephedrine alkaloid(s). 
Even at sub-toxic levels, spiked products may result in alkaloid levels deemed illegal in 
many sporting events. (2) Abuse: [the use of illicit amphetamine derivatives (e.g. 
methylenedioxymethamphetamine-MDMA) chemically synthesized from ephedrine and 
used in illegal preparations or to spike ephedra products]. The conversion is relatively 
simple, cheap and high yielding.  
(3) Contraindication, hypersensitivity and/or drug interaction: [natural hypersensitivity to 
the pharmacological effects of ephedra alkaloids, or possible conditions in which ephedra 
administration may lead to serious side effects] (Abourashed et al., 2003). The 
unsupervised preoperative use of ephedra poses a risk to patients who are later 
anesthesized with halothane (Abourashed et al., 2003; Ang-Lee et al., 2001). Moreover, 
the concomittent use of ephedra with such drugs as antihypertensives or antidepressants 
may have a drastic influence on their intended effects. In view of the outlined information, 
it becomes clear why ephedra has arrived at its precarious situation in contrast to most 
other herbal supplements. It is mainly due to the specific nature of the pharmacological 
effects of ephedra alkaloids, aggravated by misuse and/or abuse that the damage has 
been so obvious and the reaction so intense. Other risks associated with herbal products 
in general may apply to ephedra, including problems of misidentification or adulteration 
with other toxic plants (Abourashed et al., 2003). 
 
Adverse Cardiac Events 
Ephedra alkaloids have been linked to myocarditis and myocardial infarction. This has 
been attributed to coronary artery vasoconstriction and possibly vasospasm caused by 
ephedra. Ephedra might also cause cardiac arrhythmia due to adrenergic effects that 
shorten the cardiac refractory period, causing re-entrant arrhythmias (Anonymous, 2009i). 
In addition to effects on blood pressure (which can lead to hypertensive 
urgencies/emergencies) and cardiac performance, they cause vasoconstriction and 
vasospasm, including coronary vasospasm. The latter effect may be more pronounced in 
individuals with higher vagal tone, a group which includes well-conditioned, athletic 
individuals. Moreover, there is some evidence that, along with spasm, ephedra alkaloids 
may induce hypercoagulable states, low flow, and oxygen supply–demand imbalance 
within the coronary circulation. This could account for reported cases of myocardial 
infarction in otherwise healthy young people without significant underlying coronary artery 
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disease. Catecholamines also decrease myocardial refractoriness, which can predispose 
the heart to arrhythmias, and indeed ventricular arrhythmias have been reported in 
pregnant women using over-the-counter decongestants as well as in others using ephedra 
alkaloids recreationally (Andraws et al., 2005). While cardiotoxicity is usually due to a 
dose-related α- and β- receptor activity, vasculitis due to ephedrine and other 
sympathomimetics has been primarily limited to the cerebral arteries (Zaacks et al., 1999). 
Sympathomimetics, including cocaine and amphetamine derivatives such as MDMA or 
―ecstasy‖ have been shown to induce cardiomyopathy, and it is reasonable to conclude 
that ephedra may also have this propensity, perhaps through the similar mechanism of 
repetitive sympathetic stimulation of myocardium and potential myocardium damage. 
Ephedra, combined with caffeine, also produces electrocardiographic abnormalities, 
specific QT prolongation, when given to healthy volunteers (Peters et al., 2005). 
Commercial preparations of ephedra alkaloids have been associated with adverse 
cardiovascular events, including hypertension (Anonymous, 2009i; Song et al., 2008; 
Simsek et al., 2006; Bensky et al., 2004; Soni et al., 2004; Srikanth et al., 2004; Chen et 
al., 2004; Woolf, 2003), cardiomyopathy  (Anonymous, 2009i),  palpitations (Anonymous, 
2009i; Inchiosa Jr, 2007, Soni et al., 2004; WHO, 1999), stroke (Simsek et al., 2006; Soni 
et al., 2004; Srikanth et al., 2004; Woolf, 2003), myocardial infarction (Anonymous, 2009i; 
Chen et al., 2004; Simsek et al., 2006; Song et al., 2008; Soni et al., 2004; Srikanth et al., 
2004), myocarditis (Ang-Lee et al., 2001; Anonymous, 2009i; Peters et al., 2005; Song et 
al., 2008; Srikanth et al., 2004, Zaacks et al., 1999), dysrhythmia (Simsek et al., 2006; 
Soni et al., 2004; Srikanth et al, 2004; Woolf, 2003, WHO, 1999), taquicardia 
(Anonymous, 2009i; Simsek et al., 2006; Soni et al., 2004; Srikanth et al, 2004; Woolf, 
2003, WHO, 1999), or lethal cardiac arrhythmia (Anonymous, 2009i; Song et al., 2008; 
Soni et al., 2004), chest tightness, cardiac arrest and sudden death (Anonymous, 2009i). 
 
Adverse Cerebrovascular Events 
Cerebrovascular events associated with ephedra use are another area of concern. Cases 
of stroke in connection with the use of ephedrine and related compounds have been 
reported (Andraws et al., 2005) as other several reports of adverse neurologic events 
including ischemic strokes, cerebral hemorrhages (Song et al., 2008; Chen et al., 2004) 
and seizures (Anonymous, 2009i; Chen et al., 2004; Soni et al., 2004; Srikanth et al., 
2004; Woolf, 2003). Cerebral hemorrhage associated with ephedra has been attributed 
primarily to hypertensive effects and possibly due to cerebral vasculitis, which has been 
reported with other adrenergic drugs. Ischemic stroke has been attributed to ephedra's 
vasoconstrictive effects on cerebral vasculature and possibly platelet aggregation effects 
due to adrenergic stimulation (Anonymous, 2009i). Ischemic strokes are presumably 
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related to vasoconstriction of large cerebral arteries leading to local thrombosis as a result 
of stasis and sympathomimetic-inducted platelet activation. Ephedrine-related cerebral 
infarcts occur in the distribution of large or small cerebral arteries. Arteriograms have 
shown extracranial or intracranial arterial occlusions, arterial beading, arterial narrowing, 
or normal vessels. Subarachnoid hemorrhage is thought to be a result of the hypertensive 
action of ephedrine, which can be short lived, or of cerebral vasculitis, which has been 
described in association with a variety of sympathomimetric drugs. Additionally, 
hemorrhagic strokes have also been hypothesized to be related to vasculitic changes that 
occur in the cerebral vessels after ephedrine use (Chen et al., 2004). There is some 
evidence that people who take doses greater than 32 mg per day, might have more than 
triple the risk of hemorrhagic stroke, including subarachnoid hemorrhage and intracerebral 
hemorrhage (Anonymous, 2009i) 
 
Adverse Psychiatric Events 
At higher doses, the release of norepinephrine causes anxiety, restlessness, and 
insomnia. Prolonged use of ephedra may lead to neurotoxicity, resulting in depletion of 
brain monoamines. Neurotoxicity may result in psychosis (Maglione, 2005; Simsek et al., 
2006), and the structural similarity of ephedrine to amphetamine raises concern about 
possible abuse (Maglione, 2005). Long-term use or use in high doses has also been 
associated with dependence and tolerance (Anonymous, 2009i). The most commonly 
serious psychiatric reported events are psychosis (Maglione, 2005; Miller, 2005; Simsek 
et al., 2006) (psychosis can occur in some people and in some cases it is prolonged for 
several months after discontinuation) (Anonymous, 2009i), severe depression, mania or 
agitation, desilutions, violent behavior, hallucinations, and suicidal ideation/ thoughts 
(Chen et al., 2004; Maglione, 2005;), anxiety, (Andraws et al., 2005; Anonymous, 2009i; 
Maglione, 2005; Srikanth et al., 2004) hostility, (Maglione, 2005) irritability (Anonymous, 
2009i; Chen et Chen, 2004; Maglione, 2005;), addiction (Miller, 2005), agitation or 
nervousness (Maglione, 2005, WHO, 1999), hyperactivity (Srikanth et al., 2004), 
restlessness (Anonymous, 2009i; Bensky et al., 2004; Chen et Chen, 2004; Maglione, 
2005), insomnia (Anonymous, 2009i; Bensky et al., 2004; Chen et Chen, 2004; Maglione, 
2005; WHO, 1999), personality changes, difficulty concentrating (Anonymous, 2009i), 
appetite suppression, changes in gastric motility (Andraws et al., 2005) and tremor (Chen 
et Chen, 2004; Srikanth et al., 2004, WHO, 1999). 
Other adverse events 
Other adverse effects include: dizziness (Anonymous, 2009i; WHO, 1999), visual 
impairment (Simsek et al., 2006), urine retention (WHO, 1999), vomiting (WHO, 1999), 
headache (Anonymous, 2009; WHO, 1999), nausea (Anonymous, 2009i; Srikanth et al., 
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2004; WHO, 1999), diarrhea (Srikanth et al., 2004), hepatitis (Charalampopoulos et al., 
2007, Skoulidis et al., 2005), skin flushing and tingling (Anonymous, 2009i; WHO, 1999), 
increased thirst, dry mouth, anorexia, vomiting, heartburn, difficulty urinating, 
hyperthermia (Anonymous, 2009i). Rebound effect on prolonged use of topical 
preparations (>3days) (nasal congestion and chronic rhinitis) (WHO, 1999). Allergic 
reactions in the form of cutaneous eruptions combined with slightly elevated temperature 
and measles-like erythema have been reported. Because ephedrine stimulates the 
sphincter muscle of the bladder, long-term administration may cause oliguria or anuresis 
(Bensky et al., 2004). Injury to the colon, especially ischemic colitis, in patients using 
Mahuang is presumably related to reduced splanchnic blood flow due to vasoconstrictions 
such as those seen in myocardial infarction and ischemic stroke (Song et al., 2008). 
Rhabdomyolysis, eosinophilia-myalgia syndrome, nephrolithiasis, and acute hepatitis 
(Anonymous, 2009i). Finally, heavy use of ephedra has been documented as a very rare 
cause of radiolucent kidney stones (Ang-Lee et al., 2001). 
 
Posology 
Ephedra is considered to be potentially safe by the FDA when used orally for a maximum 
of 7 days and in maximum doses of 24 mg/day of ephedrine equivalent (Cunha et al., 
2003; Song et al., 2008). 
The organs used in traditional medicine are the dried green stems, which are usually 
boiled in water and administered as a hot tea. The usual daily dose is 1.5–9 g of the 
decocted herb (Abourashed et al., 2003) or according to WHO (1999) 1-6g/day. Liquid 
extract (1:1 alcohol 45%): 1-3 ml/day. Tincture (1:4 alcohol 45%): 6-8 ml/day (WHO, 
1999). 
 
Storage 
Ephedra should be kept in a closed container (Soni et al., 2004; WHO, 1999), protect from 
light (FP, 2005; WHO, 1999). According to Chinese Pharmacopoeia (2005) it should be 
preserved in a ventilated and dry place, protected from moisture. 
Purity and toxicity 
Depending on species, parts used (aerial, stem, leaf or a combination of stem, and leaf), 
harvesting, and extraction techniques, the alkaloid content of the commercially available 
products varies considerably. As a result of this natural inconsistency in the contents of 
alkaloids in ephedra, significant inter-product and intra-product variability occurs in 
ephedra products (Soni et al., 2004). As ephedrine-type alkaloids (ETA) are the active 
principles, the quality of Mahuang is determined by the contents of total ETA, with higher 
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contents indicating better quality. However, this practice of grading using only the total 
ETA contents as sole parameter is inadequate. The profile of alkaloids is also important, 
because although individual ETA has similar pharmacological activity, they vary 
significantly in potency. Both the contents and the profile of ETA in Mahuang vary with 
plant species and varieties, plant parts, sex, seasons of harvest and geographical origins. 
In order to accurately evaluate the quality of the crude drug, the quantitative analysis of 
individual ETA in Mahuang is urgently needed. In addition to ETA, Mahuang also contains 
other phytoconstituents, which may modify its pharmacological and toxicological activities. 
Therefore, the toxicity of Mahuang cannot be totally accounted for by its ETA contents 
alone. A bioassay is needed to determine the total toxicity of Mahuang due to the 
combined effect of the alkaloids and other constituents. In all of the published studies 
reviewed, the Mahuang samples were ground before extraction. This preparation method 
is similar to that used in preparing the marketed forms of Mahuang as they are exported 
from China to foreign countries, either as power or as concentrated extract. However, the 
practices are different from the traditional use of Mahuang as documented in the Chinese 
literature. Traditionally, Mahuang was known to be used in whole-herb form and to be 
extracted for a longer period of time than other herbs in a prescription. Also, with 
reference to the Shang Han Lun, a classical Chinese pharmacopoeia, all herbs were only 
to be extracted once and then the extract was taken, without extracting the herbs any 
further. However, the current practice is that all herbs are extracted twice and pooled 
together before taking. There has been no information found regarding the effects of these 
different ways of preparation on the biological activities if Mahuang (Lee et al., 2000). 
 
Safety and regulatory actions in the United States 
Given the frequency of reports of adverse cardiovascular and cerebrovascular 
complications, the FDA recently moved to prohibit the sale of these supplements. 
However, it is likely these agents will remain available to the public through illicit channels 
and related compounds will be sold through legitimate vendors (Andraws et al., 2005). 
Products containing ephedra are classified by the FDA as dietary supplements and are 
regulated by the Dietary Supplement Health and Education Act (DSHEA) of 1994. This 
Act differs considerably from the regulations that govern the marketing of drugs. Dietary 
supplement manufacturers are not required to conduct clinical studies to establish the 
safety of their products. Manufacturers are forbidden from making disease treatment 
claims but they are also not required to demonstrate the efficacy of their products. DSHEA 
places the burden of proof for safety on the government. Specifically, the Act requires that 
the FDA monitor safety and ―grants the FDA the authority to take action against a dietary 
supplement under certain circumstances, including when the product presents a 
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significant risk, an unreasonable risk, or an imminent hazard, does not comply with good 
manufacturing practices, or makes an unsubstantiated structurefunction claim‖ (Morton, 
2005). In 1995, FDA convened a special working group on food products containing 
ephedrine alkaloids to evaluate the potential health effects associated with these 
alkaloids. The group recommended the establishment of single servings and daily total 
use limits for ephedrine alkaloids, requiring warning or cautionary statements on the labels 
of the products and the establishment of good manufacturing practices (Soni et al., 2004). 
Based on these recommendations and the reports of serious injury and death, on June 4, 
1997, the FDA proposed a rule to: (1) limit the daily intake of ephedrine alkaloids to a total 
of 24mg/day or 8mg/6-h period; (2) the label to state that the product shoud not be used 
for more than 7 days (Anonymous, 2009g; Cunha et al., 2007; Soni et al., 2004); (3) 
prohibit the use of ephedrine alkaloids with substances known to have a stimulant effect 
and (Anonymous, 2009; Cunha et al., 2007; Soni et al., 2004); (4) require a specific 
warning label (Anonymous, 2009; Soni et al., 2004). The FDA developed its proposed rule 
in response to what it termed ―serious illnesses and injuries, including multiples deaths, 
associated with the use of dietary supplement products that contain ephedrine alkaloids.‖ 
However, FDA withdrew this proposal because a lack of sound scientific evidence to 
support its position. Based on additional reports of adverse events, the FDA is being 
called on to enact stricter regulations and it has begun a new investigation into safety of 
ephedra. Some investigators have even claimed that these adverse events are an 
unintended consequence of the DSHEA of 1994 (Soni et al., 2004). A growing number of 
consumer complaints were made to the FDA and legal cases were filed against ephedra 
manufacturers in the 1990s. Several adverse events possibly associated with ephedra 
use, including deaths of highprofile athletes, were reported and focused attention on the 
safety and efficacy of ephedra. As a result, the nonprofit consumer group Public Citizen 
filed a petition with the FDA in 2001 asking for a ban on the production and sale of 
ephedra to protect public health (Morton, 2005). In February 2003, the FDA and 
Department of Health and Human Resources announced a series of actions to protect 
patients from the risks of ephedra containing products including: (1) gathering further 
evidence to support restrictions on ephedra use, (2) obtaining records of ‗‗signs of 
unreasonable risk of injury‘‘, (3) creating new warning labels, (4) minimizing 
unsubstantiated claims about the effects of ephedra. Even further, public health officials 
caution against the use of ephedra-containing supplements under strenuous exercise, in 
combination with other stimulants like caffeine, or by patients with underlying 
cardiovascular disease, hypertension, diabetes, thyroid disease, prostate problems, 
anxiety or glaucoma (Chen et al., 2004). Based on the evidence of adverse outcomes, 
professional sports leagues, college athletics associations, and the military were among 
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the first to prohibit the use of these supplements among its members (Andraws et al., 
2005). The action of the stimulant ephedrine explains the prohibition of the use of the 
plant and its alkaloids by athletes in sports competitions (Cunha et al., 2007). Several 
states passed legislation banning the sale of ephedra. The FDA was slower in announcing 
a national ban, likely because the DSHEA demanded such a high burden of proof. This 
formal ban was finally announced in December 2003 with implementation set for April 
2004 (Andraws et al., 2005; Anonymous, 2009). Yet, even after this long and winding road 
towards regulation, the threat from ephedra still exists. Recent commentaries have noted 
that the national ban has several loopholes. Extracts sold as dietary supplements and 
athletic enhancers are prohibited, but those marketed as herbal remedies are not. 
Moreover, compounds similar to phedra that technically do not fall into the ephedra family 
of alkaloids are not covered by the ban (Andraws et al., 2005). In April 2005, the dietary 
supplement industry successfully challenged the FDA Ban on ephedra. A year after the 
ban on ephedra began, a federal judge in Utah stuck down the FDA's action saying that 
FDA didn't prove that low doses of ephedra are harmful. In August 2006, an appeals court 
reversed the Utah judge's decision and upheld the FDA's ban of ephedra-containing 
dietary supplements. Ephedra use is banned by the National Collegiate Athletic 
Association, International Olympic Committee, and National Football League. Ephedra is 
sometimes marketed as a recreational drug "herbal ecstasy." The FDA has announced 
that ephedra products marketed as recreational drugs are unapproved and misbranded 
drugs subject to seizure and injunction (Anonymous, 2009). The current ruling does not 
apply to traditional Chinese herbal remedies, or to products such as herbal teas that are 
regulated as conventional foods (Nelson, 2004). Examples of ephedra containing products 
are in Fig. 12-16. 
In Portugal it is currently prohibited the marketing of efedra (Cunha et al., 2007a).  
 
 
Fig. 12. Example of ephedra containing products (adapted from http://www.buy-ephedrine.com/images/v.jpg) (visited 
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Fig. 13. Example of ephedra containing products (adapted from  http://www.dynapurenutrition.com/ephedra.html) (visited 
10-6-2009). 
 
Fig. 14. Example of ephedra containing products (adapted from http://www.ephedrafaqs.com/blog/2008/03/24/800-audition-
for-nbcs-the-biggest-loser/) (visited 10-6-2009). 
 
Fig. 15. Example of ephedra containing products (adapted from http://archives.starbulletin.com/97/03/27/news/story1.html) 
(visited 10-6-2009). 
 
Fig. 16. Example of ephedra containing products (adapted from 
http://www.cnn.com/HEALTH/9908/04/ephedra.safety/index.html)(visited 10-6-2009). 
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7.1.1. Herba Ephedrae (麻黃) according to Traditional Chinese Medicine 
 
In Oriental medicine, the ephedra herb (Mahuang) is the chief medicine used in the 
treatment of asthma and bronchitis (Soni et al., 2004). Alternate Chinese names are: Jing 
Mahuang, Mahuang Rong (Chen et Chen, 2004). 
Chinese ephedra is mainly produced in Chinese provinces of Hebei, Shanxi, Inner 
Mongolia, Gansu, etc., and are picked and gathered between the beginning of autumn 
and the First Frost. The herb is dried in the shade, cut into sections and used in raw, stir-
baked with honey (Anonymous, 2009l; Yanfu, 2002a) or pounded to fine hair 
(Anonymous, 2009l). According to the Chinese Pharmacopoeia (2005) the drug is 
collected in autumn, and dried in the sun. The text in which first appeared (Original 
Source) was The Divine Husbandman’s Classic of the Materia Medica, second century 
(Bensky et al., 2004; Chen et Chen, 2004). 
Common name 
Ephedra (CP, 2005; Gongwang, 2001a; Leite, 2005a; WHO, 1997a; Wu, 2005). 
 
Pharmaceutical name 
Herba Ephedrae (CP, 2005; Flaws, 1999d; Gongwang, 2001a; Greten, 2007; Wu, 2005; 
Yanfu, 2002a). 
 
Botanical name 
E. sinica Stapf., E equisitina Bge (Gongwang, 2001a).  
 
Pynin name 
Mahuang 
 
Part used 
Parts that grow above ground (Leite, 2005a; Tierra, 1997), stem (Anonymous, 2009g; 
Ganzhong et al., 2003b; Liu et Tseng, 2005a; Wu, 2005) or processed twigs (Anonymous, 
2009g; Ganzhong et al., 2003b).  
Classification 
Unfolds the lung and extima. Ephedra belongs to the group “Liberantia extimae acria et 
calida- I a)” (Greten, 2007) or by other words, ―Warm, acrid herbs that release the 
exterior‖ (Bensky et al., 2004). 
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Sapor & Temperature 
Pungent (acrid), slightly bitter and warm (Anonymous, 2009l; Bensky et al., 2004; Chen et 
Chen, 2004; Chu, 2008; Flws, 1999d; Ganzhong et al., 2003b;  Gongwang, 2001a; 
Greten, 2007; Leite, 2005a; Liu et Tseng, 2005a; Ni, 1991; Tierra, 1997; Wu, 2005; Yanfu, 
2002a). 
 
Orbs 
Pulmonar, Vesical (Anonymous, 2009l; Bensky et al., 2004; Chen et Chen, 2004; Chu, 
2008; Flws, 1999d; Ganzhong et al., 2003b; Gongwang, 2001a; Greten, 2007; Leite, 
2005a; Liu et Tseng, 2005a; Ni, 1991; Tierra, 1997; Wu, 2005; Yanfu, 2002a). 
Functions 
Induces sweating (Anonymous, 2009g; Anonymous, 2009l; Bensky et al., 2004; CP, 2005; 
Ganzhong et al., 2003b; Gongwang, 2001a), calms wheezing (Bensky et al., 2004) and 
unfolds the pulmonary orb and therefore has an opening effect on the extima which is 
enhanced by the orb which controls the extima, i.e. the pulmonary orb (Greten, 2007). 
Activates yang (Leite, 2005a). Expels wind–cold (Gongwang, 2001a; Leite, 2005a; Liu et 
Tseng, 2005a), circulates Lung Qi (Anonymous, 2009l; Leite, 2005a, Liu et Tseng, 2005a; 
Wu, 2005) and  promotes urination (Anonymous, 2009l; Bensky et al., 2004; CP, 2005; 
Gongwang, 2001a; Liu et Tseng, 2005a; Wu, 2005). As pungent and warm disperses cold 
(Anonymous, 2009l; Ganzhong et al., 2003b; Gongwang, 2001a) by exerting warming and 
dispersing functions (Ganzhong et al., 2003b; Gongwang, 2001a). 
Indications 
Common cold and influenza (Ganzhong et al., 2003b), asthma (Anonymous, 2009g; 
Anonymous, 2009l; Liu et Tseng, 2005a; Soni et al., 2004; Tierra, 1997; Wu, 2005), 
bronchitis (Leite, 2005a; Soni et al., 2004), cough, wheezing (Leite, 2005a; Liu et Tseng, 
2005a; Tierra, 1997). Ephedra is used to treat colds accompanied by chills, slight fever, 
headache, absence of sweating, and rheumatic complaints accompanied by water 
retention (Tierra, 1997). Used in upper tract respiratory tract infection, some infectious 
diseases in the early stages such measles, scarlet fever and parotiditis (Ganzhong et al., 
2003b), various kinds of oedema (Anonymous, 2009g; Anonymous, 2009l; Bensky et al., 
2004; Ganzhong et al., 2003b; Leite, 2005a; Liu et Tseng, 2005a) especially oedema 
complicated by an exterior syndrome (Anonymous, 2009g; Bensky et al., 2004; Ganzhong 
et al., 2003b). Also can be used in chronic cellulitis (ostemyelitis, bone tuberculosis), in 
the early stage of rheumatic arthritis and acute urticaria (Gongwang, 2001a). Mahuang 
can be prescribed, in company with other appropriate drugs, to treat arthralgia caused by 
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wind-damp and gangrene of yin type by dispelling pathogenic cold exerting warming and 
dispersing functions (Ganzhong et al., 2003b). Warms and disperses cold pathogens: 
useful for wind-damp painful obstruction and deep-rooted toxic sores without a head 
(Bensky et al., 2004). Clear nasal cavity, promoting eruption and relieving itching so it it is 
used to treat nasal obstruction, allergic rhinitis, rubella itch and measles without adequate 
eruption due to attack of pathogenic wind-cold (Anonymous, 2009l). On superficial 
(Bensky et al., 2004; Chen et Chen, 2004; Flws, 1999d; Gongwang, 2001a; Leite, 2005a) 
and tense pulse (Bensky et al., 2004; Chen et Chen, 2004; Flws, 1999d; Ganzhong et al., 
2003b; Gongwang, 2001a). H. ephedrae processed with honey is used in cough in 
common cold at the later stage when chill is absent, because moistens the lung and 
relieve cough (CP, 2005). 
 
Chinese therapeutic actions and examples of major combinations 
 
1. Liberates the Extima through Diaphoresis 
Extima-Repletio, algor venti condition: acrid and warm, Mahuang ventilates the ―lung‖ and 
is commonly used to treat exterior-excess, algor venti syndrome characterized by 
symptoms such as chills, fever, headache, nasal obstruction (Bensky et al., 2004; Chen et 
Chen, 2004; Ganzhong et al., 2003b; Wu, 2005), aversion to cold, absence of perspiration 
(Anonymous, 2009l; Bensky et al., 2004; Chen et Chen, 2004; Flws, 1999d; Ganzhong et 
al., 2003b; Gongwang, 2001a), body aches and pain (Bensky et al., 2004; Chen et Chen, 
2004; Flws, 1999d; Ganzhong et al., 2003b; Gongwang, 2001a). Induces sweating and 
releases the exterior (Anonymous, 2009g; Anonymous, 2009l; Bensky et al., 2004; 
Ganzhong et al., 2003b; Gongwang, 2001a) so it is used to halt asthmatic attacks by 
dispersing stagnated qi of the lungs (Ganzhong et al., 2003b) and its dispersing function 
also opens peripheral channels and collaterals (Chen et Chen, 2004). Facilities the flow of 
the lung-qi to relieve asthma (Anonymous, 2009l). 
 With Ramulus Cinnamomi (Guizhi) for patterns of wind-cold exterior excess 
presenting with fever and chills but no sweating,  plus Semen Pruni Armeniacae 
(Xingren), and Radix Glycyrrhizae Uralensis (Gancao) in ―The Ephedra Decoction‖ 
(Mahuang Tang) (Anonymous, 2009g; Bensky et al., 2004; Chen et Chen, 2004; 
Flws, 1999d; Wu, 2005; Yanfu, 2002a) in order to enhance its effect of relieving 
the exterior of the body by inducing sweat (Ganzhong et al., 2003b).  
2. Relieves Wheezing and Dyspnea, Stops Cough 
Wind-cold constriction of the Lung leading to Lung qi reversal: Mahuang disseminates and 
facilitates the Lung qi, calms wheezing, and stops coughing (Anonymous, 2009g; Bensky 
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et al., 2004; Chen et Chen, 2004; Yanfu, 2002a) and dyspnea and characterized by wind-
cold attacking the exterior that leads to abnormal rising of Lung qi (Chen et Chen, 2004; 
Yanfu, 2002a). The herb both encourages the Lung qi to flow more easily, and directs it 
downward (Bensky et al., 2004). It is important for treating either externally-contracted or 
internally-generated wheezing (Anonymous, 2009g; Bensky et al., 2004). 
 For treating asthmatic cough due to stagnation of the lung qi caused by exogenous 
wind-cold, mahuang is used together with Semen Armeniacae Amarum (Xingren, 
bitter apricot kernel) (Chen et Chen, 2004; Flws, 1999d; Ganzhong et al., 2003b; 
Wu, 2005; Yanfu, 2002a) and Radix Glycyrrhizae (Gancao, liquorice) in order to 
enhance its effect of halting asthmatic attacks, for example, the San-ao Decoction 
(Ganzhong et al., 2003b; Wu, 2005; Yanfu, 2002a) / Three Crude Drugs Decoction 
(Gongwang, 2002) / Three-Unbinding Decoction (Bensky et al., 2004) / (Three 
Rough & Ready [Ingredients] Decoction) (Flws, 1999d). Mahuang and Xing Ren 
work synergistically to treat cough, as the former herb disperses Lung qi and 
relieves stagnation while the latter herb sends qi downward (Chen et Chen, 2004). 
 For cough and asthma with profuse, thin, clear sputum that results from 
obstruction of the Lung by Cold Phlegm, it is used with Herba Asari (Xi Xin), 
Zingiberi Officinalis (Gan Jiang), and Rhizoma Pinelliae (Ban Xia) in ―The Minor 
Green Dragon Decoction‖ (Xiao Qing Long Tang) (Flws, 1999d; Ganzhong et al., 
2003b; Wu, 2005; Yanfu, 2002a). This formula is also used for wheezing or cough 
from wind-cold attack at the exterior and cold stagnation in the interior (Chen et 
Chen, 2004). 
 Wheezing or cough caused by Lung heat: combine it with Gypsum Fibrosum (Shi 
Gao) and Semen Armeniacae Amarum (Xing Ren). Mahuang and Xing Ren have 
synergistic functions in treating wheezing and dyspnea. Shi Gao clears Lung heat 
and neutralizes the warm property of Mahuang to prevent the possible side effect 
of excess perspiration (Chen et Chen, 2004). Ma Xing Gan Shi Tang (Ephedra, 
Apricot Kernel, Licorice, and Gypsum Decoction) is an exemplar formula (Bensky 
et al., 2004; Chen et Chen, 2004; Flws, 1999d; Ganzhong et al., 2003b; Wu, 2005; 
Yanfu, 2002a). 
 Wheezing and dyspnea caused by stagnation of qi and phlegm: combine it with 
Semen Armeniacae Amarum (Xing Ren), Pericarpium Citri Reticulatae (Chen Pi) 
and Cortex Magnoliae Officinalis (Hou Po). Shen Mi Tang (Mysterious Decoction) 
is an exemplar formula (Chen et Chen, 2004). 
 With Ginseng Radix (Renshen) for wind-cold where there is underlying primal qi 
deficiency (Bensky et al., 2004). 
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3. Regulates Water Circulation and Relieves Edema 
Edema with exterior syndrome: Mahuang enters the Lung and Urinary Bladder channels 
to regulate water circulation and eliminate oedema. Excess water is generally eliminated 
through perspiration, increased urination, or both (Chen et Chen, 2004). 
 Promotes urination and reduces oedema (Anonymous, 2009g; Anonymous, 2009l; 
Bensky et al., 2004; Ganzhong et al., 2003b; Leite, 2005a; Liu et Tseng, 2005a): 
especially for oedema that accompanies an exterior condition (Anonymous, 2009g; 
Bensky et al., 2004; Ganzhong et al., 2003b) by promoting water metabolism 
(Ganzhong et al., 2003b). Used to treat edema with obvious or wind-cold type 
external symptoms on the upper body (Anonymous, 2009l). 
 Edema with exterior wind-cold signs or symptoms: use Mahuang with Rhizoma 
Zingiberis Recens (Sheng Jiang), Rhizoma Atractylodis Macrocephalae (Bai Zhu) 
and Radix Glycyrrhizae (Gan Cao), etc. to dispel the exterior condition and 
eliminate water accumulation. Yue Bi Jia Zhu Tang (Maidservant from Yue 
Decoction plus Atractylodes) is an exemplar formula (Bensky et al., 2004; Chen et 
Chen, 2004; Ganzhong et al., 2003b; Yanfu, 2002a). 
 For edema with fever, it is used with Gypsum fibrosum (Flws, 1999d; Gongwang, 
2001a; Wu, 2005). The ratio of dosage of gypsum and ephedra is used with a 
ration of approximately 3 to 1 (Gongwang, 2001a). 
 For edema with deep pulse and cold, it is used with Radix Aconiti Carmichaeli 
Preparata (Zhi Fu Zi) and Radix Glycyrrhizae Uralensis (Gan Cao) in ―The 
Ephedra Aconiti Licorice Decoction‖ (Mahuang Fu Zi Gan Cao Tang) (Flws, 1999d; 
Wu, 2005). 
 
4. Disperses Cold 
Bi zheng (painful obstruction syndrome): warm and dispersing in nature, Mahuang 
disperses and eliminates cold and damp from the exterior parts of the body (Chen et 
Chen, 2004). Also for wind-cold-damp painful obstruction (Bensky et al., 2004). 
 
 Bi zheng caused by wind-damp: use it with Semen Coicis (Yi Yi Ren), Semen 
Armeniacae Amarum (Xing Ren) and Radix Glycyrrhizae (Gan Cao) to treat 
muscle aches and pain of the extremities caused by wind-damp (Chen et Chen, 
2004).  
 Yin sores: use Mahuang with Radix Rehmanniae Preparata (Shu Di Huang), 
Semen Sinapis (Bai Jie Zi) or Gelatinum Cornu Cervi (Lu Jiao Jiao) (Chen et 
Chen, 2004). This condition is characterized by localized, painful swellings without 
heads that blend into the surrounding tissues. They often appear to be the same 
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color as the skin and are not hot to the touch. The underlying cause of this 
problem is blood deficiency with stagnation of cold and phlegm (Bensky et al., 
2004; Chen et Chen, 2004). 
 Arthritis obliterans, obliterating phlebitis or Raynaud‘s disease: use it with Radix 
Rehmanniae Preparata (Shu Di Huang), Semen Sinapis (Bai Jie Zi), Gelatinum 
Cornu Cervi (Lu Jiao Jiao), Cortex Cinnamomi (Rou Gui) and Radix Glycyrrhizae 
(Gan Cao) (Chen et Chen, 2004). 
 With Aconiti Radix lateralis preparata (zhì fù zî) for wind-cold painful obstruction, or 
exterior cold conditions and edema associated with yang deficiency (Bensky et al., 
2004). 
 With Rehmanniae Radix preparata (Shu Di Huang). This combination is also used 
for cough and wheezing associated with Kidney yin deficiency, as in Yang-
Heartening Decoction (Yang He Tang) (Bensky et al., 2004). 
Note: If heat is generated from the use of Herba Ephedrae, Gypsum fibrosum and Radix 
Scutellariae may be added for their cooling effect (Bensky et al., 2004). 
Dosage and method of use 
 Decoction: 3-9g (Anonymous, 2009g; Greten, 2007; Leite, 2005a; Liu et Tseng, 2005a; 
Tierra, 1997; Yanfu, 2002a), 2-9g (Bensky et al., 2004; CP, 2005), 3-10g (Ni, 1991), 1.5 to 
10 g (Anonymous, 2009l;  Chen et Chen, 2004; Flaws, 1999d; Ganzhong et al., 2003b), 
1.5-9 g (Gongwang, 2001a; Wu, 2005), 2.5 g to 6 g. Use of Mahuang in treating edema 
requires dosage between 10 and 15 grams (Chen et Chen, 2004) or 9-15g according to 
Gongwang (2001a). To relieve exterior, use fresh, to control asthma, the herb is fried with 
honey (Gongwang, 2001a). 
The maximum dosage of Mahuang is 20 to 25 grams (Chen et Chen, 2004). According to 
Chu (2008) the large amount is up to 15 g. 
When used properly, the warming dispersal of Mahuang can be a powerful and versatile 
agent, but its use requires familiarity with the qualities of the local environment and 
population. A dosage appropriate in one place may be excessive in another and Chinese 
physicians have been debating the relationship between locality and dosage of this herb 
for a long time (Bensky et al., 2004). 
The proper method for preparing Mahuang is to predecoct it (Anonymous, 2009g; Chen et 
Chen, 2004; Ganzhong et al., 2003b; Leite, 2005a) and remove the resultant foam from 
the solution prior to the addition of other herbs (Anonymous, 2009g; Chen et Chen, 2004). 
Classic texts state that the foam is the component more likely to cause irritability. To 
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minimize diaphoresis and neutralize the warm nature of Mahuang, Shigao (Gypsum 
Fibrosum) is frequently used with Mahuang in a three-to-one ratio (Shigao 3: Mahuang 1). 
Different types of Mahuang have slightly different therapeutic functions: unprocessed 
Mahuang has a stronger function to induce perspiration and is commonly used to treat 
wind-cold conditions (Anonymous, 2009l; Chen et Chen, 2004; Leite, 2005a; Yanfu, 
2002a); honey-fried Mahuang is weaker in inducing perspiration but more strongly 
moistens the Lung and relieves wheezing, dyspnea and cough (Anonymous, 2009l; Chen 
et Chen, 2004; Yanfu, 2002a) and asthma (Anonymous, 2009g; Anonymous, 2009l); and 
crushed Mahuang Rong is milder in inducing perspiration and is generally pediatric 
medicine to relieve exterior syndromes (Chen et Chen, 2004). To promote diaphoresis 
and induce diuresis, Herba Ephedrae is usually used unprepared; for relieving cough and 
dyspnea, it is stir-baked (Wu, 2005). According to Flaws (1999) decoct in water and 
administer internally. For effusing sweat and resolving the exterior, disinhibiting water and 
dispersing swelling, mostly use uncooked.  For stopping cough and leveling panting use 
mix-fried (Flaws, 1999d). 
 
Nomenclature & Preparation 
➢ Cleaned Ephedra (淨麻黃 jìng má huáng) 
This has the nodes on the stalks removed, as well as the roots, as both are generally 
considered to reduce the herb‘s diaphoretic effect. The nodes can be left if the herb is not 
to be used to induce sweating. For example, the formula Three-Unbinding Decoction (sän 
âo täng) specifically calls for Herba Ephedrae without the nodes removed, since the 
desired effect is to disseminate the Lung qi and calm wheezing, rather than sweating 
(Bensky et al., 2004). 
➢ Ephedra Cotton (麻黃絨 má huáng róng) 
Cleaned ephedra is brought to a boil until it ‗rolls over‘ in the water ten times, or simply 
infused in boiling water until froth rises; it is then removed and dried. Once dried, it is 
ground until the fibbers become soft. It is then called ephedra cotton. Usually, when 
cleaned ephedra is used to promote sweating, the patient first boils it, and then removes 
the froth, as it can cause agitation. Ephedra cotton saves this trouble. The diaphoretic 
effect, however, is slightly less than cleaned ephedra, while stronger than prepared 
ephedra (Bensky et al., 2004). 
➢ Prepared Ephedra (炙麻黃 zhì má huáng) 
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Cleaned ephedra is stir-fried with water. This method of preparation reduces the herb‘s 
diaphoretic action, but strengthens its effect in calming the Lungs. Discussion of Cold 
Damage says to remove the froth after boiling. According to Materia Medica of 
Combinations, this is because the froth ―makes one irritable‖; however, ―frying with honey 
before use will also work‖ (Bensky et al., 2004). 
➢ Honey-prepared Ephedra (蜜炙麻黃 mì zhì má huáng) 
Honey is first brought to a boil slowly, and the froth and any residual wax or extraneous 
material scraped from the surface. The honey is then poured through a filter. It is returned 
to the wok, and again brought to a boil, which is maintained at 116-118°C until the whole 
wok bubbles and the honey no longer stretches between the fingers. Boiling water is then 
added to thin the honey, which is then poured slowly over cleaned ephedra and left 
covered briefly. The amount of cooked honey should be approximately one-fifth the 
amount of herb, while the amount of water should be approximately one-third the quantity 
of honey; too much water and the herb will become overly damp and difficult to dry after 
preparation. The herb is then dry-fried at a low temperature until deep yellow and no 
longer sticky to the touch. When ephedra is prepared with honey, the diaphoresis is 
modified by the sweetness of the honey. Not only is the intensity of its acrid, dispersing 
qualities moderated, but the duration of its action is lengthened in a kind of ‗timerelease‘ 
manner. Sweetness pertains to the earth phase and thus brings harmony. Honey 
preparation also moistens the Lungs and protects it from the drying effects of the acrid, 
warm qualities of the unprepared herb (Bensky et al., 2004). 
 
Precautions and Contraindications 
Because Mahuang strongly functions to induce diaphoresis and ventilate the lungs, 
chronic or repetitive use is not recommended. Inappropriate use may damage qi, yin and 
body fluids (Bensky et al., 2004; Chen et Chen, 2004). Also the dosage should not be too 
large (Bensky et al., 2004; Flaws, 1999d; Wu, 2005). Other herbs can be added to 
harmonize its strong effects (Chen et Chen, 2004). It should be used with caution in 
patients with weak constitutions (Bensky et al., 2004; Chen et Chen, 2004), or those with 
wheezing associated with the failure of the kidneys to accept qi (Wu, 2005; Bensky et al., 
2004).  Precaution in spontaneous perspiration arising from qi deficiency (Wu, 2005; Chen 
et Chen, 2004; Gongwang, 2001a), sweating due to exterior deficiency (Bensky et al., 
2004; Ganzhong et al., 2003b), night perspiration due to yin deficiency (Wu, 2005; Bensky 
et al., 2004; Chen et Chen, 2004; Ganzhong et al., 2003b) or qi deficiency (Gongwang, 
2001a), wheezing or dyspnea caused by kidney deficiency (manifesting in long exhalation 
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and short inhalation), edema due to spleen deficiency (Chen et Chen, 2004). Ingesting 
Mahuang is not recommended in patients with Liver yang rising or yin-deficient fire, as its 
use may lead to vertigo, epistaxis, or hematemesis (Chen et Chen, 2004). Mahuang has a 
stimulating effect on the sympathetic nervous system (Chen et Chen, 2004). Thus, it 
should be used with caution in patients with such medical conditions as convulsions, 
epilepsy and seizure disorders, diabetes mellitus (Chen et Chen, 2004), hypertension 
(Anonymous, 2009g; Chen et Chen, 2004; Gongwang, 2001a; Wu, 2005; Tierra, 1997; 
Yanfu, 2002a), tachycardia (Gongwang, 2001a), hyperthyroidism and prostatic 
enlargement (Chen et Chen, 2004). Use with caution during pregnancy because of its 
stimulating effect on the uterus (Chen et Chen, 2004). This herb should cease to be taken 
as soon as the sweat comes out and the disease is cured; it is not suitable for 
administration over a long period (Anonymous, 2009l). 
 
Overdosage 
Overdose of Mahuang is characterized by stimulation of the sympathetic nervous system 
by the numerous ephedrine alkaloids in the herb (Chen et Chen, 2004). The toxic dose is 
approximately 30-45g (Bensky et al., 2004). Symptoms of acute toxic reaction include 
insomnia, restlessness, perspiration, tremor (Bensky et al., 2004; Chen et Chen, 2004), 
excitation, irritability, hypersensitivity, tinnitus, nausea, vomiting, red face, upper 
abdominal discomfort, poor appetite, thirst, increased blood pressure, dizziness, elevated 
blood glucose levels, chest pain (Chen et Chen, 2004), palpitations, chest pain, elevated 
temperature (Bensky et al., 2004). Extreme overdoses can lead to blurred vision, dilated 
pupils, coma, dyspnea, dysuria, (Bensky et al., 2004) convulsions, (Bensky et al., 2004; 
Chen et Chen, 2004) respiratory arrest, cardiac failure, bradycardia, ventricular fibrillation 
(Bensky et al., 2004), cardiac arrhythmia, increased blood pressure, and possibly 
epilepsy. Adverse reactions generally occur between one-half and two hours following 
ingestion of an excessive quantity of the herb (Chen et Chen, 2004). 
 
Chinese Treatment of Overdosage 
Overdose of Mahuang may be treated with either of two herbal formulas: 
• Formula one contains Radix et Rhizoma Rhei (Da Huang) 9g, Cortex Magnoliae 
Officinalis (Hou Po) 9g, Radix Aucklandiae (Mu Xiang) 9g, Natrii Sulfas (Mang Xiao) 15g, 
and Radix Glycyrrhizae (Gan Cao) 6g. The decoction is to be taken once every four hours 
until toxic symptoms are alleviated. 
• Formula two contains Semen Phaseoli Radiati (Lu Dou) 15g and Radix Glycyrrhizae 
(Gan Cao) 30g cooked in water to yield 300 ml of decoction. Patients are instructed to 
take 150 ml per dose, every two hours, for 3 to 5 doses (Chen et Chen, 2004). 
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7.2. Semen armeniacae 
 
Introduction 
By definition Semen armeniacae is the seed of Prunus armeniaca Linne var. ansu 
Maximowicz (Fig.17) (Chang et al., 2005; Hwang et al., 2008; Koo et al., 2005; WHO, 
1998a; WHO, 2001), which belongs to the Rosaceae Family (Anonymous, 2009d; Chang 
et al., 2005; DerMarderosian et Beutler, 2002; Ganzhong et al., 2003a; Hwang et al., 
2008; Koo et al., 2005; Newall et al., 1996; WHO, 1998a; WHO, 2001; Wu, 2005a) or 
allied species (WHO, 2001). Semen armeniacae is a traditional drug with many benefits, 
including the provision of antipyretic, antitussive, thirst-quenching (Chang et al., 2006 et 
2005; Hwang et al., 2008; Koo et al., 2005) and anticancer effects (Hwang et al., 2008). In 
traditional oriental medicine, Semen armeniacae has been used for the treatment of 
asthma (Chang et al., 2006 et 2005; Hwang et al., 2008; Koo et al., 2005), bronchitis, 
emphysema (Chang et al., 2006 et 2005; Hwang et al., 2008), nausea, leprosy, 
leucoderma (Chang et al., 2006 et 2005; Hwang et al., 2008), constipation, nausea 
(Chang et al., 2005; Hwang et al., 2008), aplastic anemia, tumors (Koo et al., 2005), pain 
(Chang et al., 2005 et 2006) and inflammation (Chang et al., 2005). 
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Fig. 17. Prunus armeniaca Linne var. ansu Maxim. (adapted from Wu, 2005a) 
 
 
Historical perspective 
In India and China, the apricot has been used for over 2000 years. During the 2nd century 
AD, a physician, Dong Feng, is said to have received his payment in apricot trees. There 
are also biblical references to the plant.  The Greeks wrongly assumed the apricot to have 
originated in Armenia, hence the botanical name “Prunus armeniaca”. The Romans 
termed the fruit ―praecocium‖ meaning ―precocious,‖ referring to the fruit´s early ripenleg. 
From this, the name ―apricot‖ evolved (DerMarderosian et Beutler, 2002). Amygdalin is 
considered the major constituent of Semen armeniacae, a cyanogenic glycoside (WHO, 
2001). When apricot is ground up, the enzyme emulsin breaks down amygdalin, releasing 
benzaldehyde and hydrogen cyanide, HCN, which is a deadly poison. So, this preparation 
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was used by the ancient Egyptians and Romans in making various poisons (Anonymous, 
2009g). 
 
Synonyms 
Armeniaca vulgaris Lam. (Barnes et al, 2007; WHO, 2001) var. vulgaris, Ku Xing Ren 
(seed/kernel), Prunus armeniaca L., Prunus tiliifolia Salisb (Barnes et al., 2007). 
 
Selected vernacular names 
Apricot (DerMarderosian et Beutler, 2002; WHO, 2001, 1998, 1997), abricotier, anzu, 
aprikose, aprikosenbaum, barqouq, bitter apricot, chuli, cuari, culu, elk mesmas, haeng-in, 
Himalayan wild apricot, hsing, ku-xinggren, kurbani, mao, michmich, mouchmouch, o mai, 
touffah armani, wild apricot, xing ren, zardalou, zardalu (WHO, 2001), sal-goo (WHO, 
2001, 1998), Chinese almond (DerMarderosian et Beutler, 2002). 
 
Geographical distribution  
Semen armeniacae is indigenous to the Korean peninsula and to China, India and Japan 
(WHO, 2001, 1997).  Cultivated in Asia, North Africa and United States of America (WHO, 
2001). Is produced mainly in the Chinese provinces of Inner Mongolia (Ganzhong et al., 
2003a; WHO, 1997B), growing in Northeast, North and Northwest China, Inner Mongolia, 
Xiajiang and Chinese provinces along the Yangtzi River (Ganzhong et al., 2003a), Hebei, 
Shanxi, and Shandong (Wu, 2005a). Is mostly cultivated in Korea (WHO, 1998a, 1997). 
The apricot is native to China and Japan but is also cultivated in warmer temperate areas 
of the world, mainly the regions including Turkey through Iran, Southern Europe, South 
Africa, Australia and California (DerMarderosian et Beutler, 2002). 
 
Description 
Apricots grow on trees up to 30 feet in height (DerMarderosian et Beutler, 2002). It is a 
medium-sized, deciduous tree (WHO, 2001, 1997), with reddish bark (WHO, 2001) and 
glabrous twigs (WHO, 2001, 1998, 1997). Leaves convoluted in bud, blade broadly ovate, 
5–7 cm long, 4–5 cm wide, acuminate, crenate-glandular, hairy on the veins of the 
underside when young (WHO, 2001, 1997), glabrous when mature, except for the axils of 
the underside veins (WHO, 2001). Petiole approximately 2.5 cm long, glandular; stipules, 
lanceolate, glandular on the margins (WHO, 2001, 1997). Flowers appearing before the 
leaves, bisexual, pinkish to white (WHO, 2001, 1998, 1997), solitary or fascicled, pedicels 
very short; calyx-tube campanulate, puberulent, 5 mm long; surrounding lobes, 
pubescent, half the length of the tube (WHO, 2001, 1997).; petals suborbicular, 7–13 mm 
long (WHO, 2001).; stamens inserted with the petals at the mouth of the calyx-tube 
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(WHO, 2001, 1998, 1997); ovary and base of the style hairy (WHO, 2001, 1997). Fruit a 
downy or glabrous, yellow-tinged, red drupe (WHO, 2001, 1997) with a fleshy outer layer 
surrounding a hard stone containing the seed (WHO, 2001, 1998). 
There are many varieties and species of apricot, differing in flavor, color and size. Fruits 
vary in color from yellows and oranges to deep purples. They ripen in late summer 
(DerMarderosian et Beutler, 2002). Then the seed is dried in sunlight, and crushed before 
use (Wu, 2005a). 
 
Plant material of interest 
Kernel (seed) (Fig. 18) (Barnes et al., 2007; WHO, 2001, 1998, 1997; Newall et al., 1996), 
expressed oil (Barnes et al., 2007; Newall et al., 1996; WHO, 2001). 
 
 
 
 
Fig. 18. Apricot kernels (adapted from 
http://www.cancerchoices.com/Merchant2/merchant.mvc?Screen=PROD&Store_Code=001&Product_Code=ApricotKernels 
(visited 9-6-2009) 
 
General appearance of the dried ripe seeds 
The apricot seeds are flattened, cordate, 1.1–1.9 cm long, 0.8–1.5 cm wide, 0.4–0.8 cm 
thick (WHO, 2001, 1997), acute at one end, plump, unsymmetrical, rounded at the other. 
Seed coat yellowish-brown to deep brown; short linear hilum situated at the acute end; 
chalaza at the rounded end, with numerous, deep-brown veins radiating upwards. Testa, 
thin (WHO, 2001); two cotyledons (WHO, 2001, 1997). 
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Organoleptic properties 
Odourless; taste: bitter (WHO, 2001, 1997). 
 
Microscopic characteristics 
Epidermal surface has stone cells, 60–90 μm in diameter, on veins protruded by vascular 
bundles, which appear as angular circles–ellipses, approximately uniform in shape, with 
uniformly thickened walls. In lateral view, stone cells appear obtusely triangular, walls 
extremely thickened at the apex (WHO, 2001). 
 
General identity tests 
Macroscopic and microscopic examinations and microchemical tests (WHO, 2001). 
 
Purity tests 
Microbiological 
Tests for specific microorganisms and microbial contamination have different limits are set 
according to the use of the material and the material itself.  
• For contamination of "crude" plant material intended for further processing (including 
additional decontamination by a physical or chemical process) the limits are given for 
untreated plant material harvested under acceptable hygienic conditions:  
- Escherichia coli, maximum 10
4 
per gram;  
- Mould propagules, maximum 10
5 
per gram.  
• For plant materials that have been pretreated (e.g. with boiling water as used for herbal 
teas and infusions) or that are used as topical dosage forms:  
- Aerobic bacteria, maximum 10
7 
per gram;  
- Yeasts and moulds, maximum 10
4 
per gram;  
- Escherichia coli, maximum 10
2 
per gram;  
- Other enterobacteria, maximum 10
4 
per gram;  
- Salmonellae, none.  
• For other plant materials for internal use:  
- Aerobic bacteria, maximum 10
5 
per gram;  
- Yeasts and moulds, maximum 10
3 
per gram;  
- Escherichia coli, maximum 10 per gram;  
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- Other enterobacteria, maximum 10
3
, per gram;  
- Salmonellae, none (WHO, 1998b). 
 
Pesticide residues 
The recommended maximum limit of aldrin and dieldrin is not more than 0.05 mg/kg 
(WHO, 2001). 
Heavy metals 
For maximum limits and analysis of heavy metals, according the WHO guidelines on 
quality control methods for medicinal plants the following maximum amounts in dried plant 
materials, are proposed:  
- Lead, 10 mg/kg;  
- Cadmium, 0.3 mg/kg (WHO, 1998b). 
Radioactive residues 
Even at maximum observed levels of radioactive contamination with the more dangerous 
radionuclides, significant risk is associated only with consumption of quantities of over 20 
kg of plant material per year so that a risk to health is most unlikely to be encountered 
given the amount of medicinal plant materials that would need to be ingested. Additionally, 
the level of contamination might be reduced during the manufacturing process. Therefore, 
no limits for radioactive contamination are proposed (WHO, 1998b). 
Other purity tests 
Chemical, foreign organic matter, total ash, acid-insoluble ash, sulfated ash, alcohol-
soluble extractive, water-soluble extractive and loss on drying tests to be established in 
accordance with national requirements (WHO, 2001). 
Chemical assays 
Contains not less than 3.0% amygdalin determined by titrimetric assay with silver nitrate. 
A high-performance liquid chromatography method is also available (WHO, 2001). 
Amygdalin also has been determined from seeds, using gas chromatography 
(DerMarderosian et Beutler, 2002). 
 
The VIII Portuguese Pharmacopoeia (2005) doens´t inscribe the monography of Semen 
armeniacae. 
 
Chemical constituents 
Semen armeniacae is divided into the outer husk and an inner part that contains 
glycoside, amygdaline, starch, and fatty acids (Chang et al., 2005). Amygdalin occurs in 
the seeds of Rosaceae, principally in the fruit of Semen Armeniacae (bitter almonds) 
(Yang et al., 2007; Du et al., 2005) and Semen Persicae (sweet almond) (Yang et al., 
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2007). Amygdalin (Fig. 19) is considered the major constituent of Semen armeniacae (up 
to 4.9%), a cyanogenic glycoside (a plant compound that contains sugar and produces 
cyanide) (WHO, 2001). According to DerMarderosian et Beutler (2002) kernels contain up 
to 8% amygdalin cyanide content in kernels varies from 2 to 200mg/100g (Barnes et al., 
2007; DerMarderosian et Beutler, 2002; Newall et al., 1996). Other cyanogenic 
compounds present are prunasin and mandelonitrile (Fig. 20). Also present are the 
amygdalin-hydrolysing enzyme, emulsin, and fatty acids and sitosterols (WHO, 2001). 
 
 
 
 
 
Fig. 19. Chemical structure of amygdalin (adapted from 
http://www.angelo.edu/faculty/kboudrea/molecule_gallery/04_aromatics/00_aromatics.htm) (visited 9-6-09) 
 
 
 
 
 
 
Fig. 20. Chemical structure of mandelonitrile (adapted from http://en.wikipedia.org/wiki/File:Racemic-mandelonitrile-2D-
skeletal.png) (visited 9-6-09) 
 
Amygdalin is a disaccharide consisting of two glucose molecules in which a carbon 
bearing a cyano (CN) group and a benzene ring is attached to one of the oxygen atoms 
on a glucose.  The combination of a cyano group with a OH or OR group on a single 
carbon is called a cyanohydrin; cyanohydrins easily break down to release the cyanide 
ion, CN-. When apricot are ground up, the enzyme emulsin breaks down amygdalin, 
releasing benzaldehyde and hydrogen cyanide, HCN, which is a deadly poison (Fig. 21) 
(Anonymous, 2009g).  
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Fig. 21. Hydrolisis of amygdalin (adapted from http://commons.wikimedia.org/wiki/File:Amygdalin-benzaldehyd.png (visited 
9-6-09) 
 
Amigdalin Epimerization 
Semen armeniacae contains not only amygdalin but also emulsin, which is an enzyme 
that hydrolyzes amygdalin. It was reported that d-amygdalin in Semen armeniacae 
undergoes hydrolytic reaction by emulsin when using water, and it is almost decomposed 
when extracting from powder type. In addition, it was reported that d-amygdalin in boiling 
water is epimerized to neoamygdalin (L-mandelonitrile-β-D-gentiobioside) (Fig. 22). Since 
amygdalin has been referred as an antitumor drug and neoamygdalin has no antitumor 
activity, it is important to prevent D-amygdalin from being converted into neoamygdalin by 
epimerization in water (Koo et al., 2005). Therefore, the quantitative measurement of the 
amygdalin epimers in the crude drugs is a very important step to evaluate the quality of 
such drugs (Isozaki et al., 2001). 
 
 
Fig. 22.  Chemical structures of d-amygdalin and neoamygdalin (adapted from Koo et al., 2005). 
 
 
Effects and uses 
Among his traditional uses are cough (WHO, 1998a, 1997), phlegm and common cold 
(WHO, 1998a). Used internally as a decoction, after processing by dipping in boiling water 
and stir-frying until yellow, for symptomatic treatment of asthma, cough with profuse 
expectoration and fever. The seed oil is used for treatment of constipation (WHO, 2001).  
Used in traditional medicine for the treatment of gynaecological disorders, skin 
hyperpigmentation, headache and rheumatic pain. The seed oil is used in the form of 
eardrops for inflammation and tinnitus, and for treatment of skin diseases (WHO, 2001). 
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In very small amounts, the toxic prussic acid (hydrogen cyanide) present in apricot kernels 
is prescribed in Chinese Medicine for asthma treatment, cough and constipation. 
Decoction of the plant´s bark serves as an astringent to soothe irritated skin. Other folk 
medicine uses of apricot include treatment of hemorrhage, infertility, eye inflammation and 
spasm. Apricot kernel paste may help eliminate vaginal infections (DerMarderosian et 
Beutler, 2002). Semen armeniacae is known to have antidiarroheic, antipyretic, 
antiemetic, and anthelmintic effects (Chang et al., 2005). 
 
Food Use 
Apricots are usually eaten as a fruit, either fresh or dried, made into jams and jellies or 
alcoholic beverages. The seeds are used like almonds by Chinese and Afghan cultures. 
The oil (apricot kernel oil) (Fig. 23) is also used. Its used in food, flavorings, confection, 
juices, jams, etc. is common. Some cultures use certain varieties of apricot kernels as 
almonds (DerMarderosian et Beutler, 2002). Apricot is listed by the Council of Europe as a 
natural source of food flavourings (categories N1 and N2). These categories limit the total 
amount of hydrocyanic acid permitted in the final product to 1mg/kg. Exceptions to this are 
25mg/kg for confectionery, 50mg/kg for marzipan and 5mg/kg for fruit juices. Previously, 
apricot kernel extract has been listed as GRAS (Generally Recognised As Safe) (Barnes 
et al., 2007). 
 
 
Fig. 23. Apricot kernel oil (adapted from http://www.apricotkerneloil.com/) visited (10/1/2010) 
 
Other Uses 
Traditionally, the oil has been incorporated into cosmetic and perfumery products such as 
soaps and creams (Fig. 24-26) (Barnes et al., 2007). The oil is used in cosmetics or as a 
pharmaceutical vehicle (DerMarderosian et Beutler, 2002). 
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Fig. 24. Example of cosmetic containg apricot kernel oil (adapted from 
http://store.bluemountainorganics.com/index.php?cPath=21_22) visited (10/1/2010) 
 
 
 
 
 
Fig. 25. Example of cosmetic containg apricot kernel oil (adapted from 
http://www.stendersshop.com/en/shop/Body/?id=2923) visited (10/1/2010) 
 
Fig. 26. Example of cosmetic containing apricot kernel oil (adapted from 
http://www.akomaskincare.co.uk/product.php/71/apricot_kernel_oil_certified_organic) visited (10/1/2010) 
 
Pharmacological Effects 
 
Antitumor effects 
Laetrile, a semi-synthetic derivative of the naturally occurring ―amygdalin,‖ has been used 
(during late ´70s, early ´80s) in a highly controversial treatment for cancer (Barnes et al., 
2007; DerMarderosian et Beutler, 2002; Newall et al., 1996). Although it was advocated 
as a new cancer cure or preventative and examined clinically in the late 1970s and early 
1980s, it was not approved by the FDA for cancer treatment due to insufficient clinical 
evidence of its efficacy and potential toxicity. Despite the failure of clinical tests to 
demonstrate the anticancer effects of amygdalin in the US and in Europe, amygdalin 
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continues to be manufactured and administered as an anticancer therapy in northern 
Europe and Mexico, and few studies have examined other pharmacological activities of 
amygdalin (Hwang et al., 2008). It has been reported that D-amygdalin selectively kills 
cancer cells at the tumor site without systemic toxicity, which is the usual problem when 
using general chemotherapeutic agents (Koo et al., 2005). A theory claimed that laetrile, 
when metabolized by the enzyme β-glucosidase, released toxic cyanide. The enzyme was 
said to be most prevalent in tumor tissue (as opposed to normal tissue). As a result, this 
reaction was believed to destroy mainly cancer cells. It was later proven that both 
cancerous and normal cells contained only traces amounts of this enzyme. Although the 
treatment may have slight activity in some cases, it was not as valuable as once thought. 
A report in 1980 concluded laetrile to be ineffective in cancer treatment (DerMarderosian 
et Beutler, 2002). One suggestion is that amygdalin enhances the functions of pancreatic 
enzymes, which may prevent transformation of cancer primordial germ cells (Chang et al., 
2006). Other theory claimed that cancerous cells contained abundant quantities of β-
glucosidases and high concentrations of rhodanese, an enzyme which converts cyanide 
to the less toxic thicyanate. However, this theory was disproved when it was shown that 
both cancerous and normal cells contain only traces amounts of β-glucosidases, and 
similar amounts of rhodanese. In addition, it was thought that amygdalin was not 
absorbed intact from the gastrointestinal tract (Barnes et al., 2007; Newall et al., 1996). 
Another theory proposed that following ingestion, amygdalin was hydrolysed to 
mandelonitrile, transported intact to the liver and converted to a β-glucuronide complex. 
This complex was then carried to the cancerous cells, hydrolysed by β-glucosidases to 
release mandelonitrile and subsequently hydrogen cyanide. This theory was considered to 
be untenable (Barnes et al., 2007; Newall et al., 1996). Another theory proposed that 
laetrile is vitamin B17, (Barnes et al., 2007; Yang et al., 2007; Chang et al., 2006 et 2005; 
Newall et al., 1996) that cancer is a result of a deficiency of this vitamin, and that chronic 
administration of laetrile would prevent cancer (Barnes et al., 2007; Newall et al., 1996) 
and restores the vitamin deficiency that could lead to metabolic disorders in cancer 
patients (Chang et al., 2006). Again this was not substantiated by any scientific evidence. 
Furthermore, it was claimed that patients taking laetrile reduced their life expectancy as a 
result of lack of proper medical care and chronic cyanide poisoning (Barnes et al., 2007; 
Newall et al., 1996). Taking apricot kernel or the amygdalin constituent orally is not 
effective for treating cancer (Anonymous, 2009d). A recent review concluded that there is 
no evidence from controlled clinical trials to support the alleged beneficial effects of laetrile 
as an anticancer agent, or as an adjunctive agent in cancer chemotherapy (Barnes et al., 
2007). 
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Respiratory effects 
Amygdalin (D-mandelonitrile-b-D-gentiobioside) is a natural compound with the antitussive 
activitie. It is decomposed by the action of b-D-glucosidase to yield hydrocyanic highacid 
(Isozaki et al., 2001) which stimulates the respiratory center reflexively and produces a 
kind of antitussive and antiasthmatic effects (Ganzhong et al., 2003a; Isozaki et al., 2001).  
 
Antiinflammatory and analgesic activities 
Recently, it was reported that Semen armeniacae containing abundant amygdalin exhibits 
analgesic and anti-inflammatory effects, showing that low doses of amygdalin may relieve 
pain (Yang et al., 2007; Chang et al., 2006, Chang et al., 2005).  
Amygdalin extract inhibited the LPS-stimulated enhancement of the COX-1 mRNA 
expression, the COX-2 mRNA expression and the PGE2 synthesis in the mouse BV2 
microglial cells. Amygdalin suppressed the COX-2 mRNA expression more potently 
compared to the COX-1 mRNA expression. The elevation of COX-2 activity was 
suggested to be closely associated with the occurrence of cancers, arthritis and several 
types of neurodegenerative disorders. PGE2 is a major metabolite of the COX-2 pathway, 
and it has emerged as an important lipid mediator of the inflammatory and 
immunoregulatory processes. PGE2 has been implicated in the pathogenesis of acute and 
chronic inflammatory disease states, and specific COX-2 inhibitors are known to attenuate 
the symptoms of inflammation. In a recent study, amygdalin extract inhibited the LPS-
stimulated enhancement of iNOS mRNA expression and NO production in the mouse BV2 
microglial cells. The COX activity and the subsequent production of PGE2 are closely 
related to the generation of the NO. It has been reported that NO modulates the activity of 
COX-2 in a cGMP-independent manner, and NO plays a critical role in the release of 
PGE2 by the direct activation of COX-2. NO production has been shown to be a key 
regulator of homeostasis and an important mediator of inflammation in several animal 
models. Especially, the generation of NO by iNOS plays an important role in inflammation, 
in the host-defense responses and for tissue repair. After cells are exposed to 
endogenous and exogenous stimulators such as LPS and viral infections, iNOS is 
quantitatively induced in a variety of cells, and it triggers several deleterious cellular 
responses inducing inflammation, sepsis and stroke. Inhibition of the iNOS expression in 
murine macrophages has been suggested as another possible underlying mechanism of 
the non-steroidal anti-inflammatory drugs (Yang et al., 2007).  
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Actions on the gastrointestinal tract 
Fatty oil in apricot kernel can lubrificate the intestines and promote defecation. Amygdalin 
can be dissociated by enzymes to produce benzaldeyde, which can inhibit the activity of 
pepsine and prevent the development of peptic ulcers (Ganzhong et al., 2003a). 
 
Antihelmintic action 
Fatty oil of apricot kernel can inhibit and kill ascaris, ancylostomi (Anonymous, 2009f; 
Ganzhong et al., 2003a) and pinworm, and it can also produce a bactericidal effect to 
inhibit some pathogenic bacteria (Ganzhong et al., 2003a) including typhoid bacillus and 
paratyphoid bacillus (Anonymous, 2009f). 
 
Pharmacokinetics 
After ingestion, amygdalin is metabolized in the gastrointestinal tract to produce prunasin 
and mandelonitrile, which are further broken down to benzaldehyde and hydrocyanic acid, 
the latter of which is highly toxic (WHO, 2001). 
After intragastric administration of 30.0 mg of amygdalin or prunasin to rats, capacity for 
hydrolysing these compounds was greatest in the organs of 15-day-old animals, most of 
the activity being concentrated in the tissues of the small and large intestines. The activity 
decreased with age. In adult rats, hydrolysis of prunasin was greater than that of 
amygdalin and was concentrated in the spleen, large intestine and kidney (35.0 μg, 15.0 
μg and 8.9 μg of prunasin hydrolysed per hour per gram of tissue, respectively). Minced 
liver, spleen, kidney and stomach tissue had a greater hydrolytic capability than the 
homogenate of these organs, while the reverse was the case with the small and large 
intestines. Following oral administration of 30.0 mg of amygdalin to adult rats, distribution 
after the first hour was as follows: stomach 0.89 mg, small intestine 0.78 mg, spleen 0.36 
mg, large intestine 0.30 mg, kidney 0.19 mg, liver 0.10 mg and serum 5.6 μg/ml. At the 
end of the second hour, the highest amygdalin content, 0.79 mg, was found in the large 
intestine (WHO, 2001).  
 
Toxicology 
 
Acute poisoning 
Apricot kernel ingestion is a common source of cyanide poisoning (Fig. 27) (Barnes et al., 
2007; DerMarderosian et Beutler, 2002; Newall et al., 1996). The lethal dose is reported to 
be 7–10 kernels in children and 50–60 kernels (approximately 30 g) in adults (WHO, 
2001) but deaths are reported from as little as ingesting two kernels (DerMarderosian et 
Beutler, 2002). There may be considerable variation in the number of kernels required to 
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be toxic, depending on the concentration of amygdalin and β-glucosidases present in the 
kernels, the timespan of ingestion, the degree of maceration of the kernels, individual 
variation in hydrolysing, and detoxifying abilities (Barnes et al., 2007; Newall et al., 1996). 
Apricot kernels are toxic because of their amydaline content. Hydrolysis of the amygdaline 
molecule by β-glucosidases, heat, mineral acids or high doses of ascorbic acid (vitamin C) 
yields hydrogen cyanide (HCN), benzaldehyde, and glucose. β-glucosidases are not 
generally abundant in the gastro-intestinal tract, but they are present in the kernels 
themselves as well certain foods including beansprots, carrots, celery, green peppers, 
lettuce, mushrooms, and sweet almonds (Newall et al., 1996). 
 
 
Fig. 27. Typical illustration of cyanide = poison in http://northerndoctor.com/2009/03/08/apricot-kernels-theyve-still-got-
cyanide-in-them/) (visited in 23-6-2009) 
 
Extract of amygdalin and water extract of apricot kernel produced sedation, convulsion, 
hyperventilation and death in mice. Amygdalin content in apricot pits varies and can be up 
to 8%. Wild varieties may contain 20 times the amount of cultivated apricot varieties 
(DerMarderosian et Beutler, 2002). Hydrolysis of amygdalin yielding the toxic hydrogen 
cyanide (HCN) is more rapid in alkaline pH (than acidic, in the GI tract), which can delay 
symptoms of poisoning (Barnes et al., 2007; DerMarderosian et Beutler, 2002; Newall et 
al., 1996). Symptoms of cyanide toxicity include: dizziness, headheache, nausea/vomiting; 
and quickly progress to palpitations, hypotension, convulsion, paralysis, coma and death, 
from 1 to 15 minutes after ingestion (Barnes et al., 2007; DerMarderosian et Beutler, 
2002; Newall et al., 1996). Cyanide is rapidly absorbed from the upper gastrointestinal 
tract, diffuses readily throughout the body and promptly causes respiratory failures if 
untreated (Barnes et al., 2007; Newall et al., 1996).  
 
Chronic poisoning 
Principal symptoms include increased blood thyocyanate, goitre, thyroid cancer, lesions of 
the optic nerve, blindness, ataxia, hypertonia, cretinism and mental retardation. These 
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symptoms may develop as a result of ingesting significant amounts of cyanide, 
cyanogenetic precursors in the diet, or cyanogenetic drugs such laetrile. Demyelinating 
lesions and other neuromyophaties reportedly occur secondary to choric cyanide 
exposure, including long-term therapy with laetrile. Agranulocytosis has also been 
attributed to long-term laetrile therapy (Barnes et al., 2007; Newall et al., 1996). 
Normally, low concentrations of ingested cyanide are controlled naturally by exhalation or 
by rapid conversion to the less toxic thiocyanate by the enzyme rhodanese. Oral doses of 
50mg of hydrogen cyanide (HCN) can be fatal. This is equivalent to approximately 30g 
kernels which represents about 50-60 kernels, and approximately 2mg HCN/g kernel. 
Apricot seed has also been reported to contain 2.92mg HCN/g. A 500-mg laetrile tablet 
was found to contain 5-51mg HCN/g (Barnes et al., 2007; Newall et al., 1996).  
Systemic concentrations of β-glucosidases are low and therefore toxicity following 
parenteral absorption of amygdalin is low. However, cyanide poisoning has been reported 
in rats following intraperitoneal administration of laetrile, suggesting another mechanism of 
hydrolysis has ocorred (Barnes et al, 2007; Newall et al., 1996). 
It is thought that cyanogenetic glycosides may possess carcinogenic properties. 
Mandelonitrile (amygdalin= mandelonitrile diglucoside) is mutagenic and stimulates 
guanylate cyclase (Barnes et al, 2007; Newall et al., 1996).  
Antidotes to cyanide poisoning include nitrite, thiosulfate, hydroxocobalamin and 
aminophenol (Barnes et al., 2007; DerMarderosian et Beutler, 2002; Newall et al., 1996) 
and cobalt edetate (Newall et al., 1996). 
 
Adverse reactions 
The side-effects associated with amygdalin treatment are the same as the symptoms of 
cyanide poisoning (WHO, 2001). Cyanide is a neurotoxin that initially causes nausea and 
vomiting headache and dizziness (Anonymous, 2009d; WHO, 2001), rapidly progressing 
to cyanosis (bluish discoloration of the skin due to oxygen-deprived haemoglobin in the 
blood) (WHO, 2001), drowsiness, dyspnea, palpitations (Anonymous, 2009d), liver 
damage, ptosis (droopy upper eyelid), ataxic neuropathies (difficulty in walking due to 
damaged nerves), fever, mental confusion (WHO, 2001), marked hypotension, 
convulsions, coma and death (Anonymous, 2009d; WHO, 2001). These side-effects can 
be potentiated by the concurrent administration of raw almonds or crushed fruit pits, 
eating fruits and vegetables that contain β-glucosidase, such as celery, peaches, bean 
sprouts and carrots, or high doses of vitamin C. Overdose causes dizziness, nausea, 
vomiting and headache, which may progress to dyspnoea, spasms, dilated pupils, 
arrhythmias and coma (WHO, 2001). Apricot can also cause chronic poisoning, with 
symptoms of increased blood thiocyanate, goiter, thyroid cancer, optic nerve lesions, 
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blindness, ataxia, hypertonia, cretinism, and mental retardation. Demyelinating lesions 
and neuromyopathies reportedly occur secondary to chronic exposure, including long-
term therapy (Anonymous, 2009d).  Contact dermatitis has been reported from apricot 
kernels (DerMarderosian et Beutler, 2002; Newall et al., 1996). Kernel ingestion may be 
teratogenic as well (DerMarderosian et Beutler, 2002). Contact dermatitis has been 
reported following contact with apricot kernels (Barnes et al., 2007; Newall et al., 1996). 
 
Precautions and contraindications 
 
Carcinogenesis, mutagenesis, impairment of fertility 
No effects on fertility were observed in rats fed a diet containing 10% Semen armeniacae 
for 5 weeks. An aqueous extract of the seeds was not mutagenic in the 
Salmonella/microsome assay using S. typhimurium strains TA98 and TA100, or in the 
Bacillus subtilis H-17 recombinant assay at concentrations of up to 100.0 mg/ml. 
However, a hot aqueous extract of the seeds was mutagenic in the Salmonella/microsome 
assay in S. typhimurium strains TA98 and TA100 at a concentration of 12.5 mg/plate 
(WHO, 2001). 
 
Pregnancy and Breastfeeding 
Intragastric administration of amygdalin (dose not specified) to pregnant hamsters induced 
skeletal malformations in the offspring, and intravenous administration resulted in 
embryopathic effects (WHO, 2001). The ingestion of cyanogenetic substances may result 
in teratogenic effects (Barnes et al., 2007). 
Semen armeniacae should not be administered during pregnancy or nursing, or to 
children (WHO, 2001).  
 
Interactions  
No information available concerning drug interactions (Barnes et al., 2007; Werneke et al., 
2004; WHO, 2001) or drug and laboratory test interactions (WHO, 2001). 
 
Storage 
This dosage forms should be store in a cool, dry place, protected from moths (CP, 2005a; 
WHO, 2001).  
 
Posology 
Average daily dose: 3–9g (Greten, 2007; WHO, 2001) of dried ripe seeds processed by 
breaking into pieces, rinsing in boiling water and stir-frying until yellow, then adding to a 
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decoction when nearly finished (WHO, 2001). According to Chinese Pharmacopoeia 
(2005a): 4.5-9g, decocted later. 
 
Safety and regulatory actions in the United States 
In 1984, amygdalin was classified as POM (prescription-only medicine) in an effort to 
protect the general public (Anonymous, 2009d; Newall et al., 1996). In 1987, it was ruled 
to be an unapproved drug and its importation into the USA under an affidavit system 
created in 1977 ended. The FDA has sought a permanent injunction against three 
corporations for unlawfully promoting and marketing laetrile and apricot seeds or kernels 
for treating cancer on their Internet websites (Anonymous, 2009d). 
 
7.2.1. Semen armeniacae (杏仁 ) according to Traditional Chinese 
Medicine 
 
The source is from the mature seed of Prunus armeniacae L., or P. armeniacae L. var. 
ansu Maxim, family Rosasea. The medicinal material is produced in the areas of 
Northeast, North and Northwest China, Xinjiang, and the reaches of the Yangtze River of 
China (Yanfu, 2002b). The seeds are collected after the fruits ripen in summer, and they 
are then dried in the sun (CP., 2005a; Ganzhong et al., 2003a; Yanfu, 2002b). The raw 
kernels are also pounded to prepare a paste for clinical application (Ganzhong et al., 
2003a). 
Common name 
(Bitter) apricot seed (Chu, 2009; Gongwang, 2001d; Greten, 2007; Wu, 2005a), apricot 
seed or kernel (Anonymous, 2009e). 
Pharmaceutical name 
Semen Pruni Armeniacae (Chu, 2009; Flaws, 1999db; Gongwang, 2001d; Greten, 2007;  
Wu, 2005a), Semen Armeniacae Amarum (Anonymous, 2009h; Yanfu, 2002b), Semen 
Armeniacae Amarae (Greten, 2007). 
Botanical name 
Prunus armeniaca L.var. ansu Maxim. or P. armeniaca L. (Gongwang, 2001d). 
Pinyin name 
Xing Ren (Anonymous, 2009e; Flaws, 1999db; Ganzhong et al., 2003a; Greten, 2007; Liu 
et Tseng, 2005b; Ni, 1991a) (Ku XingRen) (Bei Xing Ren) (Liu et Tseng, 2005b), Xingren 
(Gongwang, 2001d; Yanfu, 2002b). 
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Other names 
Xing ren (杏仁) (Chu, 2009), ku xing ren (苦杏仁) (Anonymous, 2009e; Chu, 2009), kuang 
xing ren (光杏仁), ku he ren (杏核仁，炒杏仁), jian xing ren (尖杏仁), xing ren xiang (杏仁
霜) (Chu, 2009). 
 
Part used 
Seed (Greten, 2007; Liu et Tseng, 2005b; Tierra, 1997a; Wu, 2005a), dried ripe seed (Fig. 
28) (Wu, 2005a) 
 
Fig. 28. Dried ripe seed (adapted from http://tcm.health-info.org/Herbology.Materia.Medica/xingren-properties.htm) (visited 
9-6-2009) 
 
Classification 
In cough, pieira and for moistoring. Belongs to the group “Tussostatica- XIII c)” (Greten, 
2007) i.e. ―Herbs that Relieve Coughing and Wheezing‖ (Anonymous, 2009e). 
 
Sapor & Temperature 
Neutral (Greten, 2007), slightly warm (Anonymous, 2009f; Chu, 2009; Flaws, 1999db; 
Ganzhong et al., 2003a; Gongwang, 2001d; Greten, 2007; Leite, 2005d; Liu et Tseng, 
2005b; Ni, 1991a; Tierra, 1997a; Yanfu, 2002b), bitter, (Anonymous, 2009f; Chu, 2009; 
Flaws, 1999db; Ganzhong et al., 2003a; Gongwang, 2001d; Greten, 2007; Leite, 2005d; 
Liu et Tseng, 2005b; Ni, 1991a; Tierra, 1997a; Wu, 2005a; Yanfu, 2002b), acrid (Flaws, 
1999db), slightly toxic (Anonymous, 2009f; Anonymous, 2009h; Chu, 2009; Wu, 2005a; 
Ganzhong et al., 2003a; Gongwang, 2001d; Leite, 2005d; Ni, 1991a; Tierra, 1997a; 
Yanfu, 2002b), (sweet) (Greten, 2007). 
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Orbs 
Crass intestinal, pulmonar (Anonymous, 2009f; Anonymous, 2009h; Chu, 2009; Flaws, 
1999db; Ganzhong et al., 2003a; Gongwang, 2001d; Greten, 2007; Wu, 2005a; Leite, 
2005d; Liu et Tseng, 2005b; Ni, 1991a; Tierra, 1997a; Yanfu, 2002b). 
 
Functions 
Its bitterness can send down rebellious qi to relieve cough and asthma (Anonymous, 
2009h; Wu, 2005a); moisturizes the lung (Anonymous, 2009f). The warmness can 
disperse algor venti in the lung channel. Its action is rather slow and uniform. It is 
applicable in compound prescriptions for treatment of cough and asthma caused by 
exopathogen and internal injury, cold and heat, depletio and repletio. It is especially 
effective in treatment of cough with abundant expectoration due to algor venti invasion of 
lung (Anonymous, 2009h).  
 
It is rich in oil, which acts on the large intestine channel to lubricate the bowel to relieve 
constipation (Anonymous, 2009h, Wu, 2005a), moistens intestine (Flaws, 1999db; 
Gongwang, 2001d; Leite, 2005d; Liu et Tseng, 2005b; Yanfu, 2002b), relax the bowels 
(CP, 2005a; Yanfu, 2002b), helping bowel movements (Chu, 2009; Gongwang, 2001d; 
Leite, 2005d) and promoting defecation (Ganzhong et al., 2003a; Gongwang, 2001d; 
Tierra, 1997a). 
 
Indications 
Against coughing (Anonymous, 2009f; Chu, 2009; Ganzhong et al., 2003a; Gongwang, 
2001d; Leite, 2005d; Liu et Tseng, 2005b; Tierra, 1997a; Yanfu, 2002b), and wheezing 
(Liu et Tseng, 2005b; Tierra, 1997a), for arresting asthma (Anonymous, 2009f; Chu, 2009; 
Ganzhong et al., 2003a; Gongwang, 2001d; Tierra, 1997a), bronchitis (Tierra, 1997a), 
expelling phlegm (Chu, 2009). It is particularly effective in counteracting dry coughs 
(Tierra, 1997a). Used in chronic bronchitis manifesting coughing, profuse sputum and 
short breath (Anonymous, 2009f). Chronic coughing due to deficient lungs and kidneys 
(Anonymous, 2009f). For short breath and edema (abnormally large amounts of fluid in 
the intercellular tissue spaces of the body) (Anonymous, 2009f). 
 
Used to treat constipation due to dryness in the intestines (Anonymous, 2009h; Ganzhong 
et al., 2003a), dry stools (Gongwang, 2001d; Leite, 2005d; Liu et Tseng, 2005b). 
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Chinese therapeutic actions and examples of major combinations 
1-Treats coughs and dyspnea (shortness of breath): entering the lung channel, being so 
bitter as to be lowering and with its dredging, lubricating, opening and clearing properties, 
almond can ventilate the lungs while sending down adversely rising lung-qi to such an 
extent as to arrest coughing and relieve dyspnea, so it is a major herb for the treatment of 
coughs and dyspnea. It can be used for a large variety of ailments with coughs and 
dyspnea when it is used in combination with other herbs according to each case 
(Anonymous, 2009f). 
 for coughs and dyspnea due to algor venti, it can be used in combination with 
Herba Ephedrae (Mahuang) and Radix Glycyrrhizae (Gancao), i.e., San Ao Tang  
(Anonymous, 2009f; Ganzhong et al., 2003a; Gongwang, 2001d; Yanfu, 2002b), in 
order to dispel pathogenic wind-cold, ventilate the lungs and relieve dyspnea 
(Anonymous, 2009f). 
 For algor venti common cold with cough and qi panting, mostly it is combined with 
Folium Perillae Frutescentis (Su Ye) as in Xing Su San (Armeniaca & Perilla 
Powder) (Flaws, 1999db).  
 For coughs and dyspnea due to wind-heat, it can be used in combination with 
Folium Mori (Sangye) (mulberry leaves) and Flos Chrysanthemi (Juhua) 
(chrysanthemum) (Anonymous, 2009f; Flaws, 1999db; Ganzhong et al., 2003a; 
Gongwang, 2001d; Wu, 2005a; Yanfu, 2002b), e.g., Sang Ju Yin, in order to dispel 
pathogenic wind-heat, ventilate the lungs and arrest coughing (Anonymous, 
2009f). This decoction is also called ―The Decoction of Folium Mori and Flos 
Chrysanthemi‖ (Morus & Chrysanthemum Drink) (Flaws, 1999db; Wu, 2005a). 
 For treatment of cough due to exopathogenic wind-heat, it can be used together 
with Fructus Arctti, Folium Mori, Bulbus Fritillariae, Radix Platycodi, Radix 
Glycyrrhizae (Ganzhong et al., 2003a). 
 Coughs due to dryness-heat, it can be used in combination with Folium Mori 
(Sangye), Bulbus Fritillariae (Beimu) (thunberg fritillary bulb) and Radix 
Adenophorae Strictae (straight ladybell) (Anonymous, 2009f; Flaws, 1999db; 
Ganzhong et al., 2003a; Gongwang, 2001d; Wu, 2005a; Yanfu, 2002b), e.g., Sang 
Xing Tang, in order to clear heat away from the lungs, remove dampness by 
moistening and arrest coughing (Anonymous, 2009f; Ganzhong et al., 2003a). This 
decoction is also called ―The Decoction of Folium Mori and Semen Pruni 
Armeniacae‖ (Wu, 2005a) or Morus & Armeniaca Decoction (Flaws, 1999db). 
 Coughs due to the lung-heat it is used in combination with Herba Ephedrae 
(Mahuang), Gypsum Fibrosum (Shegshigao) and Radix Glycyrrhizae, e.g., Ma 
Xing Shi Gan Tang (Anonymous, 2009f; Anonymous, 2009h; Flaws, 1999db; 
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Ganzhong et al., 2003a; Gongwang, 2001d; Yanfu, 2002b), in order to clear heat 
away from the lungs, purge away heat, ventilate the lungs and relieve dyspnea 
(Anonymous, 2009f; Anonymous, 2009h). This decoction is also called Ephedra, 
Armeniaca, Gypsum & Licorice Decoction (Flaws, 1999db). 
2. Treats constipation due to dryness in the intestines (Anonymous, 2009f; Yanfu, 2002b): 
containing oil and grease, almond is lubricating in quality, and being so bitter in taste to 
keep adverse qi flowing downward, this herb can relax the bowels to relieve constipation 
(Anonymous, 2009f).  
 For treatment of constipation due to bowel dryness, it is commonly used in 
combination with Radix Angelicae Sinensis, Radix Paeoniae Alba, Fructus 
Cannabis, and so on to nourish Yin and supplement blood, lubricate the bowel to 
relieve constipation (Anonymous, 2009h). 
 For constipation due to dryness of the intestine, it is used with Semen Cannabis 
Sativae (Huo Ma Ren) (Flaws, 1999db; Wu, 2005a), Radix Angelicae Sinensis 
(Dang Gui), and Fructus Aurantii (Zhi Qiao) (Wu, 2005a) and Semen Pruni 
Persicae (Tao Ren) in ―The Intestine-Moistening Pill‖ (Run Chang Wan) (Flaws, 
1999db; Wu, 2005a; Yanfu, 2002b). 
 
Dosage and method of use 
Decoct in water and administer internally (Flaws, 1999db). Decoct almond for oral 
administration and it should be pounded finely for decoction. It could also be eaten raw 
(Anonymous, 2009f). The dosage varies according to different authors: 3-10 g 
(Anonymous, 2009f; Wu, 2005a; Ganzhong et al., 2003a; Ni, 1991a; Yanfu, 2002b), 
decocted in water for an oral dose (Wu, 2005a). According to Flaws (1999b) the referred 
dosage is 6-10g. It should be decocted after other herbs (Wu, 2005a; Ganzhong et al., 
2003a). Fried apricot kernel is used to treat coughing and asthma in weak patients with 
deficiency of the spleen; and apricot kernel frost (de-oiled apricot kernel) is used for 
patients with diarrhea (Ganzhong et al., 2003a).Use 3 to 9g (Gongwang, 2001d; Greten, 
2007; Leite, 2005d; Liu et Tseng, 2005b; Tierra, 1997a). Should be coarsely crushed for 
cooking (Liu et Tseng, 2005b) and decoct for 10 minutes only (Tierra, 1997a).  
 
Precautions and contraindications 
Use with caution in children due to its toxicity (Flaws, 1999db; Wu, 2005a; Ganzhong et 
al., 2003a; Gongwang, 2001d; Tierra, 1997a; Yanfu, 2002b). This drug is contraindicated 
for treatment for coughing due to yin deficiency (Ganzhong et al., 2003a). Should not be 
prescribed for patients with diarrhea (Ganzhong et al., 2003a; Tierra, 1997a). Should not 
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be prescribed in a large dose, because of its toxicity (Flaws, 1999db; Ganzhong et al., 
2003a; Gongwang, 2001d). 
 
Herb interactions 
Do not use this herb with astragalus (Huang Qi - Radix Astragali membranacei), pueraria 
(Ge Gen – Radix Pueraria) or scutelaria (Huang Qin – Radix Scutellaria baicalensis) 
(Leite, 2005d; Tierra, 1997a). 
 
Sweet and bitter apricot kernel 
 There are differences in the functions between bitter apricot seed (Kuxingren) and sweet 
apricot seed (Tianxingren) (Gongwang, 2001d). Bitter apricot seed, also called Bei xin 
ren (northern xing ren, Prunus armeniaca) (Chu, 2009) is characterized by bitterness in 
its flavor and tends to lower the flow of adverse qi, which is good for treating cough and 
asthma (Gongwang, 2001d); while sweet apricot seed, also called Nan xin (southern xin 
ren, Prunus dulcis) (Chu, 2009), tends to moisten and treats mostly chronic cough due to 
lung qi deficiency. Both of them can treat constipation due to loss of body fluid 
(Gongwang, 2001d). Sweet apricot seed is milder and is suitable for older people with 
weaker bodies and with cough and asthma. Bitter apricot seed is stronger in property and 
it is suitable for stronger and younger people and in strong syndromes (Chu, 2009). 
For treatment of cough due to exopathogen, bitter Semen armeniacae is mostly used, 
while of cough due to consumption, the sweet one is mostly used (Anonymous, 2009h). 
Sweet apricot kernel (Semen Armeniacae Dulce) is the sweet seed of some species of 
apricot trees cultivated in Hebei and Shandong provinces, and Beijing. It is also called 
large apricot kernel because its size is bigger than that of the bitter apricot kernel. Sweet 
apricot kernel is sweet is taste and neutral in nature, with a similar therapeutic effect to 
bitter apricot kernel, but it is less drastic in nature. Sweet apricot kernel can produce a 
better nourishing and moistening effect to enrich lung qi, but is does not have any effect 
on dispersing qi. Therefore, it is useful to treat chronic coughing due to deficiency of the 
lungs and constipation due to exhaustion of jin (body fluid) (Ganzhong et al., 2003a). 
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7.3. Ramuli Cinnamomi / Cortex Cinnamomi  
 
Introduction 
In western literature, including monographs and scientific papers, most references to 
cinnamon are related to the bark, not the twigs. Would not expect too many difference in 
the ingredients, as bark is part of stems and twigs. This is pertinent for this study, because 
Ramuli Cinnamomi ―Guizi‖ (twigs) and Cortex Cinnamomi ―Rougui” (bark) have different 
uses in Traditional Chinese Medicine (TCM).  
Yet whereas in the Chinese Pharmacopoeia (CP) Guizhi is defined as the Cinnamomi 
Ramulus (the whole twig), in the Japanese Pharmacopoeia (JP) it is defined as the 
Cinnamomi Cortex (the bark). Until the Han period, the drug name Gui was commonly 
used for products made from the bark (the cork from the bark being removed) of 
cinnamomic plant. Such products have been excavated from a tomb where they were 
interred in the second century B.C., and the drug name Guixin was commonly used for 
them until the Tang period. The terms Gui, Qin, Mugui, Guirou, Rougui, Guixin, and Guizhi 
found in medical texts up to the tenth century were all used for the products made from 
the bark. The Tang government's pharmacopoeia of 659, the Xinxiu Bencao, designates 
their material plant as either C. cassia or C. obtusifolium. This product primarily 
corresponds to Cinnamomi cortex, being Keihi in JP or Rougui in CP. The term Jungui 
was used from the third century B.C. for products in the shape of a bamboo pipe which 
was made from the bark of cinnamomic plant twig that had been repeatedly rolled up, and 
which were used as dietary foods or spices. The Xinxiu Bencao designates the material 
plant as C. burmanni, and the product corresponds to the cinnamon sticks now in use 
(Mayanagi, 1995). In Ephedra Decoction (mahuang tang), cinnamon twigs are used. 
Mahuang tang is correspondent to the Japanese mao-to, equal to the Chinese formula, 
except that uses the cinnamon bark (Kainuma et al., 2004; Shijie et al., 2008). Although 
the Chinese Pharmacopoeia refers to the twigs and bark of cinnamon, the Japanese 
Pharmacopoeia only refers to the cortex. Based on these findings, the author decided to 
refer in this master thesis both parts of the plant (Ramuli Cinnamomi and Cortex 
Cinnamomi). 
7.3.a. Cortex Cinnamomi 
 
According to Barnes et al. (2007a) the sources of Cortex Cinnamomi include 
Cinnamomum cassia (cassia) and Cinnamomum verum (cinnamon). The systematic 
classifications and correct taxonomic names of species and/or related sub-species to the 
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officinal specie are currently being discussed, because there are various commercial 
varieties, which differ by their quantitative and qualitative composition of essential oil 
(Wichtl et Anton, 1999). 
By definition, cinnamon is the bark of the Cinnamomi cassiae (Fig. 29) (Kim et al., 2006; 
Tabak et al, 1999; Newall et al., 1996a), Family Lauraceae (Anonymous, 2009m; Barnes 
et al, 2007a; Duke, 2003; Ganzhong et al., 2003c; Kim et al., 2006; Newall et al., 1996a; 
WHO, 1999, 1997) or according to WHO (1999) Cortex Cinnamomi consists of the dried 
inner bark of the shoots grown on cut stock of Cinnamomum verum J.S. Presl. or of the 
trunk bark, freed of cork, of Cinnamomum cassia Blume. The Chinese cinnamon is 
obtained from the bark of the branches of Cinnamomum cassia Blume (C. cassia Nees) 
with similar smell to the Ceylon cinnamon (C. verum), with characteristics of a fineness 
less appreciated (Wichtl et Anton, 1999), less attractive, and therefore more for local 
consumption or for the acquisition of essential oil (Cunha, 2005). Cassia from China is 
less aromatic than that from Vietnam and Indonesia. Cassia from all three countries has a 
sweet, aromatic, and pungent flavor. Vietnamese, or Saigon, cassia is particularly highly 
esteemed. Cassia buds, the dried, unripe fruits of Cinnamomum cassia and Cinnamomum 
loureirii, have a cinnamon-like aroma and a warm, sweet, pungent taste akin to that of 
cassia bark. The whole buds are added to foods for flavouring (Anonymous, 2009f). 
Other species of cinnamon include: Cinnamomum loureirii Nees (Cinnamomum 
obtusifolium Nees var. loureirii Perr. & Eb., Saigon Cassia, Saigon Cinnamon), 
Cinnamomum burmanii (Ness) Bl. (Batavia Cassia, Batavia Cinnamon, Padang-Cassia, 
Panang Cinnamon) (Barnes et al., 2007b). Falsifications occur occasionally with Saigon 
cinnamon bark (Cinnamomum loureirii Ness) (Wichtl et Anton, 1999). 
 
77 
 
 
Fig. 29. Cinnamomum cassia Blume (adapted from Wu, 2005b) 
 
Other names for Chinese cinnamon 
Cassia Bark (Barnes et al., 2007a; Duke, 2003; WHO, 1999a; Newall et al., 1996a; PDR, 
1998), Cinnamomum aromaticum Nees (Barnes et al., 2007a; WHO, 1999a; Newall et al., 
1996a; PDR, 1998), Cassia Lignea (Barnes et al., 2007a; Duke, 2003; Newall et al., 
1996a; PDR, 1998), False Cinnamon (Barnes et al., 2007a; Newall et al., 1996a; PDR, 
1998), Cassia (Duke, 2003; PDR, 1998), Bastard Cinnamon, Cassia aromaticum, Canton 
Cassia (PDR, 1998), China Junk Cassia, Chinese Cassia, Saigon Cinnamon (Duke, 
2003), Cinnamomum pseudomelastoma auct. Non Liao (Barnes et al., 2007a) and 
Cinnamomum cassia Blume (Newall et al., 1996a; WHO, 1999a; Wu, 2005b).  
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Other names for Ceylon Cinnamon 
Cinnamomum zeylanicum Bl. (Barnes et al., 2007b; Duke, 2003; Cunha et al., 2003a; 
WHO, 1999a), Cinnamomum verum J.S. Presl. (Barnes et al., 2007b; Cunha et al., 2003a; 
WHO, 1999a), True Cinnamon (Barnes et al., 2007b), Laurus cinnamomum L. (Duke, 
2003; Ooi et al., 2006; WHO, 1999a), C. zeylanicum Nees (Ooi et al., 2006). 
Cinnamomum verum J.S. Presl. is the correct botanical name according to the 
International Rules of Botanical Nomenclature (WHO, 1999a).  
 
Selected vernacular names 
Cinnamomum verum J.S. Presl. 
Abdalasini, blood-giving drops, canela, canela en raja, cannalavanga pattai, cannelle de 
ceylan, cannelle dite de Ceylan, cannelier, Ceylon celonzimi cinnamon, Ceylon cinnamon, 
cinnamon, cinnamon bark, cinnamon tree, cortex cinnamomi ceylanici, dalchini, dalochini, 
dar sini quirfa, darchini, daruchini, darusila, ecorce de cannelier de Ceylan, echter Kanel, 
gujerati-dalchini, kannel, kuei-pi, kurundu, kurundu-potu, kulit kayumanis, ob choei, 
tamalpatra, wild cinnamon, zimtrinde (WHO, 1999a). 
Cinnamomum cassia Blume 
Annan cinnamon, cassia, cassia bark, cassia bark tree, cassia lignea, chinazimt, Chinese 
cassia, Chinese cinnamon, ching hua yu-kuei, cinnamomi cassiae cortex, cinnamon, 
cinnamon bark, dalchini, guipi, guizhi, kannan keihi, keihi, keishi, kuei-chíi, lavanga-pattai, 
lavanga-patti, lurundu, macrophyllos cassia bark tree, rou gui, róugì, Saigon cinnamon, 
saleekha, taj, toko keihi, Viet Nam cinnamon (WHO, 1999a). 
 
Description 
Cinnamomum verum J.S. Presl. 
A moderate-sized evergreen tree (Fig. 30-32); bark rather thick, smooth, pale; twigs often 
compressed; young parts glabrous except the buds which are finely silky. Leaves opposite 
or subopposite (rarely alternate), hard and coriaceous, 7.5–20 by 3.8–7.5 cm, ovate or 
ovate-lanceolate, subacute or shortly acuminate, glabrous and shining above, slightly 
paler beneath, base acute or rounded; main nerves 3–5 from the base or nearly so, 
strong, with fine reticulate venation between; petioles 1.3–2.5 cm long, flattened above. 
Flowers numerous, in silky pubescent, lax panicles usually longer than the leaves; 
peduncles long, often clustered, glabrous or pubescent; pedicels long. Perianth 5–6mm 
long; tube 2.5 mm long; segments pubescent on both sides, oblong or somewhat obovate, 
usually obtuse. Fruit 1.3–1.7 cm long, oblong or ovoid-oblong, minutely apiculate, dry or 
slightly fleshy, dark purple, surrounded by the enlarged campanulate perianth that is 8 mm 
in diameter (WHO, 1999a). 
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Fig. 30. Cinnamomum zeylanicum. Ceylon Cinnamon twig, showing leaf venation (adapted from 
http://chestofbooks.com/health/materia-medica-drugs/Manual-Pharmacology/Cinnamomum-Cinnamon.html) (visited on 
8/5/2009). 
 
 
Fig. 31. Cinnamomum zeylanicum (adapted from http://www.gaiaherbs.com/herb_of_the_week.php?id=1 (visited on 
8/5/2009). 
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Fig. 32. Cinnamomum verum, from Koehler's Medicinal-Plants (1887) (adapted from http://en.wikipedia.org/wiki/Cinnamon) 
(visited on 6/12/2009). 
 
Cinnamomum cassia Blume 
An evergreen tree, up to 10 m high (Fig. 33). Leaves alternate, coriaceous, petiolate, 
oblong, elliptical-oval or oblong-lanceolate, 8–15cm long by 3–4cm wide, tip acuminate, 
base rounded, entire, 3-nerved; glabrous or underside lightly pubescent; petiole 10 mm 
long, lightly pubescent. Inflorescence a densely hairy panicle as long as the leaves; 
panicles cymose, terminal and axillary. Flowers yellowish white, small, in cymes of 2–5. 
Perianth 6-lobed. No petals. Stamens 6, pubescent. Ovary free, 1-celled. Fruit a globular 
drupe, 8mm long, red. The bark is used in either channelled pieces or simple quills, 30–
40cm long by 3–10cm wide and 0.2–0.8 cm in thickness. The surface is grayish brown, 
slightly coarse, with irregularly fine wrinkles and transverse lenticels. There are found 
scars of holes, indicating the insertion of leaves or lateral shoots; the inner surface is 
rather darker than the outer, with fine longitudinal striate. The fracture is short, the section 
of the thicker pieces showing a faint white line (pericyclic sclerenchyma) sometimes near 
the centre, sometimes near and parallel to the outer margin (WHO, 1999a).  
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Fig. 33. Cassia tree (adapted from http://acupuntura.blogas-pt.com/gui-zhi-ramulus-cinnamomi/ ) (visited on 14/9/9) 
 
General appearance of the bark 
Cinnamomum verum J.S. Presl. 
The bark (Fig. 34) is about 0.2–0.8 mm thick and occurs in closely packed compound 
quills made up of single or double quills. The outer surface is smooth, yellowish brown 
with faint scars marking the positions of leaves and axillaries buds and has fine, whitish, 
and wavy longitudinal striations. The inner surface is slightly darker and longitudinally 
striated. The fracture is short and fibrous (WHO, 1999a). 
 
 
 
 
 
 
 
 
 
 
Fig. 34.  Cinnamon bark (adapted from http://www.ancientway.com/Pages/MartialArtsHerbs.html ) (visited on 8/5/2009). 
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Cinnamomum cassia Blume 
The drug is channeled or quilted, 30–40cm long, 3–10cm in diameter, 2–8mm thick. Outer 
surface grayish brown, slightly rough, with irregular fine wrinkles and transverse raised 
lenticels, some showing grayish white streaks; inner surface reddish brown, with fine 
longitudinal striations and exhibiting oily trace on scratching. Texture hard and fragile, 
easily broken, fracture uneven, outer layer brown and relatively rough, inner layer reddish 
brown and oily and showing a yellowish brown line between two layers (WHO, 1999a). 
Chinese cinnamon consists of the completely or partly peeled, dried stem bark from the 
above ground axis. The drug comes from 2 to 3 cm thick branches; it is peeled with horn 
knives and freed from cork and outer rind and dried in the sun within 24 hours (PDR, 
1998). Cassia bark is peeled from stems and branches and set aside to dry. Some 
varieties are scraped. While drying, the bark curls into quills. The color varies from light 
reddish brown for the thin, scraped bark to gray for the thick, unscraped bark. Ground 
cassia is reddish brown in color (Anonymous, 2009f).  
 
Geographical distribution 
Cinnamomum verum J.S. Presl. 
The tree of Cinnamomum zeylanicum originates in India (Cunha et al., 2003a; Dugoua et 
al., 2007; Ooi et al., 2006; WHO, 1999a) and Ceylon (Cunha et al., 2003a). Also is native 
to Sri Lanka (Dugoua et al., 2007; WHO, 1999a) and cultivated in parts of Africa, the 
Seychelles, Indonesia, South America, and the West Indies (WHO, 1999a). It was 
introduced in the islands of the Pacific Ocean and the southwest of India and Asia. Sri 
Lanka remains the largest exporter (Cunha et al., 2003a). 
 
Cinnamomum cassia Blume 
The bark of Chinese cinnamon is mainly cultivated in China (Ooi et al., 2006; PDR, 1998; 
WHO, 1999a; WHO, 1997C; Wichtl et Anton, 1999) (provinces of Guangxi, Guangdong, 
Yunnan (Chu, 2009; Ganzhong et al., 2003c), Fujian (Chu, 2009) and Malabar (Wichtl et 
Anton, 1999). Also found in Indonesia, the Lao People‘s Democratic Republic (Ooi et al., 
2006; WHO, 1999a; WHO, 1997C), Burna (PDR, 1998) and Viet Nam (Ooi et al., 2006; 
PDR, 1998; WHO, 1999a; WHO, 1997C).  
 
Historical perspective 
Cinnamon is among the world's oldest and most frequently consumed spices and is often 
used as an herbal remedy (Qin et al., 2008). There are reports of cinnamon being 
imported to Egypt from China as early as 2000 BC (Dugoua et al., 2007). Cinnamon is 
mentioned in the Bible (Exodus and Proverbs) (Dugoua et al., 2007; Ravindran et al., 
83 
 
2004) and in Chinese texts written 4000 years ago (Dugoua et al., 2007; Qin et al., 2008). 
The name cinnamon comes from the Greek kinnámōmon, ultimately from the Malaysian 
and Indonesian kayu manis, which means ‗‗sweet wood‘‘ (Anonymous, 2009f; Ravindran 
et al., 2004). Common cinnamon correctly refers to ‗‗true cinnamon,‘‘ or its synonym 
Ceylon cinnamon (Cinnamomum verum, C. zeylanicum). In addition, the related species 
cassia cinnamon (C. aromaticum), also known as Chinese cinnamon, is sometimes sold 
labeled as cinnamon (Dugoua et al., 2007). Cinnamon was once more valuable than gold 
(Anonymous, 2009f). In Egypt it was sought for embalming (Anonymous, 2009f; 
Ravindran et al., 2004) and witchcraft; in medieval Europe for religious rites and as a 
flavoring (Anonymous, 2009f).  
The south Arabians held a virtual monopoly on the spice trade for a very long time, but 
historical evidence is quite insufficient to come to a conclusion on the relative roles played 
by the Arabians and Phoenicians in the ancient spice trade. The Arab domination of the 
spice trade was broken by the rise of the Roman Empire. By the thirteenth century, the 
East Indies became a busy trading centre in spices. China emerged as a major trader of 
spices during this period, trading in cassia and ginger and procuring large quantities of 
pepper and other spices from the Malabar Coast and the East Indies. At this time cassia 
and cassia buds became popular spices in Europe and England. Of course, spices were 
beyond the reach of common folk, as they were so costly, mainly because no direct trade 
links existed between Europe and the eastern spice-producing countries. The Arabs 
monopolized the trade in the east, and Venice controlled the trade in the Mediterranean.  
The modern chapter in the saga of spices begins with the discovery of the sea route to 
India and the landing of Vasco da Gama on the Malabar Coast. This indeed was the 
beginning of the history of modern India too. The West European countries were 
compelled to establish a sea route to the eastern spice lands following the conquest of the 
Roman Empire and the closure of Constantinople for trade by the Ottoman Turks in 1453. 
The quest for spices opened up the era of great expeditions; Columbus discovered 
America and Vasco da Gama sailed eastwards round the Cape of Good Hope and arrived 
in India. In the decades that followed the Portuguese gradually established their hold on 
spice trading (Ravindran et al., 2004). Later it was the most profitable spice in the Dutch 
East India Company trade (Anonymous, 2009f; Ravindran et al., 2004). The seventeenth 
century saw the rise of British naval supremacy. Yet another chapter in the saga of 
cinnamon starts with the British occupation of Ceylon in 1796, and the monopoly of 
cinnamon trade changed hands once more. Even today, cinnamon is associated with the 
lives of people of Sri Lanka, emotionally, socially and economically. For them it is the 
spice of life (Ravindran et al., 2004). In modern times, cinnamon is used to flavor a variety 
of foods, from confections to curries; in Europe and the United States it is especially 
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popular in bakery goods. In China, it is used as a decongestant herb to relieve exterior 
syndromes (Anonymous, 2009f). 
 
Organoleptic properties  
Odour, characteristic and aromatic; taste, characteristic, slightly sweet and fragrant 
(WHO, 1999a). 
 
General identity tests 
Macroscopic and microscopic examinations; and thin-layer chromatographic analysis for 
the presence of cinnamaldehyde (WHO, 1999a). 
 
Purity tests 
Microbiology 
The test for Salmonella spp. in Cortex cinnamomi products should be negative. The 
maximum acceptable limits of other microorganisms are as follows. For preparation of 
decoction: aerobic bacteria—not more than 107/g; fungi—not more than 105/g; Escherichia 
coli—not more than 102/g. Preparations for internal use: aerobic bacteria—not more than 
105/g or ml; fungi—not more than 104/g or ml; enterobacteria and certain Gram-negative 
bacteria—not more than 103/g or ml; Escherichia coli—0/g or ml (WHO, 1999a). 
Foreign organic matter 
C. verum: not more than 2%. C. cassia: not more than 1% (WHO, 1999a). 
Total ash 
C. verum: not more than 6% (WHO, 1999a). C. cassia: not more than 5% (CP, 2005b; 
WHO, 1999a). 
Acid-insoluble ash 
C. verum: not more than 4%. C. cassia: not more than 2% (WHO, 1999a). 
Sulfated ash 
C. verum: not more than 6%. C. cassia: to be established in accordance with national 
requirements (WHO, 1999a). 
Moisture 
Not more than 15% (CP, 2005b). 
Volatile oil 
It contains not less  than 1.2% (ml/g) (CP, 2005b). 
Alcohol (90%)-soluble extractive 
C. verum: 14–16%. C. cassia: to be established in accordance with national requirements 
(WHO, 1999a). 
Pesticide residues 
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To be established in accordance with national requirements. Normally, the maximum 
residue limit of aldrin and dieldrin for Cortex Cinnamomi is not more than 0.05 mg/kg 
(WHO, 1999a). 
Arsenic and heavy metals 
Recommended lead and cadmium levels are not more than 10mg/kg and 0.3 mg/kg, 
respectively, in the final dosage form of the plant material (WHO, 1999a). 
Radioactive residues 
Analysis of strontium-90, iodine-131, caesium-134, caesium-137, and plutonium-239 
(WHO, 1999a). 
Other tests 
Chemical tests to be established in accordance with national requirements (WHO, 1999a). 
Chemical assays 
Not less than 1.2% v/w of volatile oil derived from C. verum or C. cassia, containing 60–
80% w/w aldehydes calculated as cinnamaldehyde. Assay for cinnamaldehyde content by 
means of thin-layer or highperformance liquid chromatographic methods (WHO, 1999a). 
 
Chemical constituents  
According to Dugoua et al. (2007) common and cassia cinnamon contain 1%–4% of 
volatile oils and the major constituent is cinnamaldehyde (Fig. 35-36), at concentrations of 
60-80%, or 65–80% (Anonymous, 2002; WHO, 1999a) or 67% to 83% (Anonymous, 
2009m). 
 
 
 
 
Fig.  35. Chemical structure of cinnamaldehyde (adapted from 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=637511&loc=ec_rcs) (visited on 6/12/09). 
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Fig. 36. Cinnamaldehyde (adapted from http://www.made-in-china.com/showroom/queena689/product-
detailAoqQvsWPfLcZ/China-Cinnamaldehyde.html) (visited on 20/5/09) 
 
 
Also contains trans-cinnamic acid (5-10%); phenolic compounds (4-10%) such as 
catechins and proanthocyanidins (Fig. 37); monoterpenes and sesquiterpenes; calcium-
monoterpenes oxalate; gum; mucilage; resin; starch; sugars; and coumarin (Dugoua et 
al., 2007). 
 
Fig.  37. Chemical structure of proanthocyanidin (adapted from 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=108065&loc=ec_rcs) (visited on 6/12/09) 
 
 
C. verum differs considerably from C. cassia in its eugenol (phenolic compound) (Fig. 38) 
and coumarin (Fig. 39) contents. Coumarin is present in C. cassia, but not in C. verum 
(WHO, 1999a). According to Anonymous (2009), Cassia cinnamon contains a wide range 
of coumarin concentrations from 0.004% to 1.2%. So, the presence of coumarin and other 
compounds can be used to distinguish C. cassia from C. verum. 
 
 
Fig. 38. Chemical structure of eugenol (adapted from 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3314&loc=ec_rcs) (visited on 6/12/09) 
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Fig. 39. Chemical structure of coumarin (adapted from 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=323&loc=ec_rcs) (visited on 6/12/09).  
 
Of the various types of cinnamon bark the oil of C. verum is stated to contain the highest 
amount of eugenol (Barnes et al., 2007b), 10% according to WHO (1999) whereas in C. 
cassia, only a trace quantity of this compound is found (Barnes et al., 2007b; WHO, 
1999a). Cinnamon oil also differs from the closely related cassia oil in that the latter is 
reported to be devoid of monoterpenoids and sesquiterpenoids (Barnes et al., 2007b). 
 
Cinnamomum cassia bark 
The main components are cinnamaldehyde (Kim et al., 2006), cinnamic acid (Fig. 40) 
(Kim et al., 2006; PDR, 1998), tannin and methylhydroxychalcone polymer (Kim et al., 
2006). Cinnamic acid has preservative properties (Sweetman, 2009a). 
 
 
 
Fig. 40. Chemical structure of cinnamic acid (adapted from 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=444539&loc=ec_rcs) (visited on 6/12/09). 
 
Contains 1-2 % of volatile oils (Barnes et al., 2007a; Newall et al., 1996a; Ooi et al., 2006; 
Van Hellemont, 1986a.). The main constituents of C. cassia bark oil are cinnamaldehyde 
(Kim et al., 2006; Chang et al., 2001; Ooi et al., 2006; PDR, 1998), about 75-90% (Barnes 
et al., 2007a; Sweetman, 2009b; Van Hellemont, 1986a), 60–80% (Ooi et al., 2006) and 
coumarin (Barnes et al., 2007a; Chang et al., 2001; Ooi et al., 2006; PDR, 1998; Newall et 
al., 1996a). Other major components include salylaldehyde, methylsalicyladehyde, 
methyleugenol (Barnes et al., 2007a; Newall et al., 1996a), cinnamylacetate, cinnamyl 
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alcohol, o-methoxycinnamaldehyde (Fig. 41), diterpenes, tannins, oligomere 
proanthocyanidins (PDR, 1998), mucilages (Barnes et al., 2007a; PDR, 1998; Newall et 
al., 1996a) (higher content compared to cinnamon) (Barnes et al., 2007a; Newall et al., 
1996a), about 11.5% according to Van Hellemont (1986a). Eugenol is reported to be 
absent. Although cassia oil contains no monoterpenoids or sesquiterpenoids, complex 
diterpenoids have been isolated (Barnes et al., 2007a; Newall et al., 1996a). Also contains 
calcium oxalate (Barnes et al., 2007a; Newall et al., 1996a), resins, sugars, condensed 
tannins (Barnes et al., 2007a; Newall et al., 1996a), about 2-3% (Van Hellemont, 1986b). 
 
 
 
Fig. 41. Chemical structure of o-methoxycinnamaldehyde (adapted from 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=641298&loc=ec_rcs) (visited on 28/11/09). 
 
Cinnamomum verum bark  
The cinnamon bark contains volatile oils up to 4% (Barnes et al., 2007b; Van Hellemont, 
1986), 0.5 to 2.5% according to Wichtl et Anton (1999), 1.2-2.5% according to Cunha et 
al., (2003a) or 1.2-2% according to Fitoterapia (1998). The dry plant has to contain at 
least 12ml/kg of essential oil (Fitoterapia, 1998). The bark also contains condensed 
tannins (Anonymous, 2002; Barnes et al, 2007; Wichtl et Anton, 1999) and according to 
Van Hellemont (1986) also contains starch, and methylamilketone that gives finesse to the 
essence. Other constituents are calcium oxalate (Barnes et al, 2007; Van Hellemont, 
1986), cinnzeylanin, cinnzeylanol (Barnes et al, 2007), mannitol, L-arabino-D-xylan, β-
sitosterol (Wichtl et Anton, 1999), coumarin (Anonymous, 2002; Barnes et al, 2007; 
Fitoterapia, 1998), gum (Barnes et al, 2007), mucilages (Barnes et al, 2007; Cunha et al., 
2003a; Wichtl et Anton, 1999; Fitoterapia, 1998), resins and sugars (Barnes et al, 2007).  
Cinnamaldehyde was the predominant active compound found in cinnamon oil 
(Prabuseenivasan et al., 2006), 60-75% according to Barnes et al. (2007), 65-75% 
according to Wichtl et Anton (1999), 65-80% according to Cunha et al. (2003a), WHO 
(1999) and Ooi et al. (2006) and 50-75% according to Fitoterapia (1998). Contains 
benzaldehyde and cuminaldehyde; phenols (4-10%) including eugenol (Anonymous, 
2002; Barnes et al., 2007b; Ooi et al., 2006) (about 5% according to Wichtl et Anton 
(1999), 4-10% according to Cunha et al. (2003a), Fitoterapia (1998) and Van Hellemont 
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(1986) and trans-cinnamic acid (Anonymous, 2002; Ooi et al., 2006), about 5–10% (Ooi et 
al., 2006). Also contains methyleugenol, -pinene, phellandrene, cymeme and 
caryophyllene (hydrocarbons), cinnamyl acetate and benzyl benzoate (esters), linalool 
(Barnes et al., 2007b). The essential oil also contains procyanidic oligomers (Anonymous, 
2002; Cunha et al., 2003a; Wichtl et Anton, 1999) (less than 2%, otherwise too much 
primary bark is present) (Wichtl et Anton, 1999) and o-methoxycinnamaldehyde 
(Anonymous, 2002; WHO, 1999a; Wichtl et Anton, 1999). Also contains cinnamic alcohol 
(Fig. 42) (Anonymous, 2002; Wichtl et Anton, 1999) and its acetate (Anonymous, 2002; 
Cunha et al., 2003a; Wichtl et Anton, 1999); mono- and sesquiterpenes in small 
quantities, pentacyclic diterpenes with insecticidal activity (cincassiols, cinnzeylanine), 
phenolic acids (protocatechic acid, hydroxycinnamic acids...) (Wichtl et Anton, 1999), 
cineol, linalool, β-caryophyllene (about 2% each), limonene, α-terpineol (Anonymous, 
2002), carbohydrates, tannins (Anonymous, 2002; Cunha et al., 2003a; Fitoterapia, 1998; 
Van Hellemont, 1986). The cinnamon oil also contains traces of terpenic compounds ( -
pineno, cineol, phellandrene, linalool) and methylketone (Fitoterapia, 1998). 
 
 
Fig. 42. Chemical structure of cinnamic alcohol (adapted from 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5315892&loc=ec_rcs) (visited on 6/12/09) 
 
Essential Oil 
According to the Portuguese Pharmacopoeia (2005) and Sweetman (2009b) by definition 
C. cassia essential oil (Cinnamomi cassiae aetheroleum) is the essential oil obtained by 
the steam distillation of leaves and young branches of Cinnamomum cassia Blume (C. 
aromaticum Nees.) and C. verum essential oil (Cinnamomi zeylanicii corticis aetheroleum) 
is the essential oil obtained by the steam distillation of the bark of young branches of 
Cinnamomum zeylanicum Nees (C. verum JS Presl). In some countries cassia oil is 
known as cinnamon oil (Sweetman, 2009b).  
 
Oil Appearance 
The cassia and cinnamon essential oil should be: liquid fluid, clear, the characteristic odor 
resembling that of cinnamaldehyde (FP, 2005). The color of cassia essential oil should be 
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yellow to brown – reddish and the color of cinnamon essential oil should be light yellow, 
becoming reddish with age (FP, 2005, Sweetman, 2009b, 2009c). 
Oil Identification 
C. cassia and C. verum: Thin-layer chromatography. Chromatographic profile. Gas 
chromatography. 
Relative density: C. cassia: 1.052 to 1.070. C. verum: 1.000 to 1.030.  
Refractive index: C. cassia: 1.600 to 1.614. C. verum: 1.572 to 1.591.  
Angle of optical rotation: C. cassia:-1 ° to +1 °. C. verum: -2 ° to +1 °. 
 
The levels are between the following values:  
- trans-cinnamaldehyde: C. cassia: 70.0 - 90.0 %,  
- Cinnamyl acetate: C. cassia: 1.0- 6.0 %,  
- Eugenol: C. cassia: less than 0.5 %, C. verum: less than 7.5 %, 
- Coumarin: C. cassia: 1.5-4.0 %, C. verum: less than 0.5 %, 
- trans-2-methoxy cinnamaldehyde: C. cassia: 0.3-1.5 % C. verum:  0.1 - 1.0%, 
- Cineole: C. verum: less than 3.0 %, 
- Linalool: C. verum: 1.0-6.0 %, 
- β-Caryophyllene: C. verum: 1.0-4.0 %,  
- Safrole: C. verum: less than 0.5 %,  
- Aldehyde trans-cinnamic: C. cassia: 70.0-90.0 % C. verum:  55.0-75.0 %,  
- Benzyl benzoate: less than 1.0 % (FP, 2005).  
 
Effects and uses  
Cortex Cinnamomi is used in the symptomatic treatment of gastrointestinal disorders 
(PDR, 1998), including the treatment of dyspeptic conditions such as mild spastic 
conditions (PDR, 1998; WHO, 1999a). Cortex Cinnamomi is stated to possess 
antispasmodic properties (Barnes et al., 2007b; Barnes et al., 2007a; Cunha et al., 2003a; 
Fitoterapia, 1998 Newall et al., 1996a) and is used in intestinal spasms (Barnes et al., 
2007b; Cunha et al., 2003a; Fitoterapia, 1998; Wichtl et Anton, 1999), stomachache (Van 
Hellemont, 1986b; WHO, 1997C) and possess orexigenic (Barnes et al., 2007b; Cunha et 
al., 2003a; Fitoterapia, 1998), antidiarrheic, antimicrobial (Barnes et al., 2007b; Barnes et 
al, 2007a; Cunha et al., 2003a; Fitoterapia, 1998; Lirussi et al., 2004; Newall et al., 1996a) 
and antihelmintic properties. It has been used for anorexia (Barnes et al., 2007b; Barnes 
et al., 2007a; Cunha et al., 2003a; Fitoterapia, 1998; Newall et al., 1996a), as appetite 
stimulating (Cunha et al., 2003a; Fitoterapia, 1998; PDR, 1998; WHO, 1999a; Wichtl et 
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Anton, 1999), for diarrhea (Barnes et al., 2007a; Newall et al., 1996a) including infantile 
diarrhea (Barnes et al., 2007b; Cunha et al., 2003a), flatulence (Cunha et al., 2003a; 
PDR, 1998; Wichtl et Anton, 1999; WHO, 1999a) and bloating (Cunha et al., 2003a; PDR, 
1998; Wichtl et Anton, 1999). The plant is occasionally used as an eupeptic (Cunha et al., 
2003a; Fitoterapia, 1998; Van Hellemont, 1986; Wichtl et Anton, 1999), carminative 
(Barnes et al., 2007b; Barnes et al., 2007a; Cunha et al., 2003a; Fitoterapia, 1998; Newall 
et al., 1996a; Van Hellemont, 1986; Wichtl et Anton, 1999) and antiemetic (Barnes et al., 
2007a; Newall et al., 1996a). Used for hiposecretic dispepsys, meteorism (Fitoterapia, 
1998), gastritis (Fitoterapia, 1998), stimulant of digestive secretions (Cunha et al., 2003a), 
flatulent colic (Barnes et al., 2007b; Barnes et al., 2007a; Newall et al., 1996a) and 
dyspepsia with nausea (Barnes et al., 2007b). The German Commission E indicates its 
use for loss of appetite, flatulence and bloating (Cunha et al., 2003a). It has antibacterial, 
fungistatic properties, improves immunity in animal tests, promotes motility and inhibits 
ulcers (PDR, 1998). Also used to treat abdominal pain (WHO, 1999a), with diarrhea and 
pain associated with amenorrhoea and dysmenorrhoea (WHO, 1999a; WHO, 1997C). 
Used in shock, clammy extremities, cough and wheezing, pain in the lower part of the 
body a knees, low blood pressure, frost bite (WHO, 1997C). Cinnamon is used as a tonic 
on convalescence state consecutively on infectious diseases (Van Hellemont, 1986b), in 
temporary states of exhaustion and to increase weight (PDR, 1998).  Used to treat 
common cold (Barnes et al., 2007b; Barnes et al, 2007a; Fitoterapia, 1998; Newall et al., 
1996a; PDR, 1998; WHO, 1997C), influenza (Cunha et al., 2003a; Barnes et al., 2007b), 
coryza accompanied by inflammation of the oropharynx (Cunha et al., 2003a; Fitoterapia, 
1998) and respiratory tract (Cunha et al., 2003a). Used to treat cough and bronchitis, 
emphysema, bronquiectasias, fevers (Fitoterapia, 1998), asthma (Cunha et al., 2003a; 
Fitoterapia, 1998) as a respiratory stimulant (Cunha et al., 2003a). Cortex cinnamomi is 
also stated to be astringent (Barnes et al., 2007b; Barnes et al., 2007a; Newall et al., 
1996a) due to tannins (Barnes et al., 2007b). Used in the treatment of amenorrhea 
(Fitoterapia, 1998) and dysmenorrhoea (Cunha et al., 2003, Fitoterapia, 1998). Possesses 
emenagogue (Fitoterapia, 1998; Van Hellemont, 1986), even abortive properties (Van 
Hellemont, 1986b). In animals shows estrogen action (Cunha et al., 2003a). C. cassia is 
anticarcinogenic, insecticide, antipyretic, and stimulant of human linfocitary activity in vitro 
(Lirussi et al., 2004). The cinnamon oil is a muscletropic of papaverine type which has a 
cardiac positive inotropic and chronotropic effects (Wichtl et Anton, 1999).  
C. cassia is one of the traditional folk herbs used in Korea, China and Russia for diabetes 
mellitus (Kim et al., 2006). Used in Chinese medicine for impotence, diarrhea, enuresis, 
rheumatic conditions, testicle hernia, menopause syndrome, amenorrhoea, abortion and 
to stabilize immunity (PDR, 1998). In TCM is prescribed in decoction alone or together 
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with the other herbs to relieve stomachache, and to improve general blood circulation, 
especially in the lower part of the body, such as loin, knee joints, legs and extremities. It is 
also used to promote sweating and expel the ―weakness‖ inside the internal organs of the 
body, thus, to reach the balance of ―Yin and Yang‖ in Chinese traditional medical terms. 
All these actions are due to the Yang quality of the volatile aroma and the medicinal 
characteristics of this bark (Ooi, et al., 2006). 
According to the WHO (1999), Cortex Cinnamomi is used for the treatment of impotence, 
frigidity, dyspnea, inflammation of the eye, leucorrhoea, vaginitis, rheumatism, neuralgia, 
wounds, and toothache, but this uses are described in folk medicine and not supported by 
experimental or clinical data (WHO, 1999a). 
In folk medicine, the cinnamon essential oil is used in dysmenorrhoea (Wichtl et Anton, 
1999). The cinnamon oil is used externally in stomatitis, cutaneous mycosis (Cunha et al., 
2003a), parodontophathys, dermatomicosis, otitis and vulvovaginitis (Fitoterapia, 1998), 
possesses tonic and antihelmintic properties (Van Hellemont, 1986a) and it´s slight 
astringent and rubefacient (Fitoterapia, 1998). 
Food use of the bark 
Cinnamon has a certain value as a flavoring agent (Van Hellemont, 1986a), also the 
correspondent oil (Barnes et al., 2007a; Newall et al., 1996a). Cinnamaldehyde and 
coumarin from C. cassia oil have been used as food additives (Chang et al., 2001). 
Cinnamon is listed by the Council of Europe as a natural source of food flavoring 
(category N2). This category indicates that cinnamon can be added to foodstuffs in small 
quantities (Barnes et al., 2007b; Barnes et al., 2007a; Newall et al., 1996a). In the food 
industry and home cookery, when cinnamon is added to bakery items or food 
preparations, it functions as an additive flavor and aroma with the bonus of microbial 
inhibition (Ooi et al., 2006). According to the United States Food and Drug Administration 
(USFDA), Cinnamomum spp., including common and cassia cinnamon, are generally 
recognized as safe (GRAS) (Anonymous, 2009m; Barnes et al., 2007b; Barnes et al., 
2007a; Dugoua et al., 2007; Newall et al., 1996a; Ziengefuss et al., 2006) when used in 
amounts commonly found in food (Dugoua et al., 2007). Cinnamon is commonly used as 
a spice in cooking (Barnes et al., 2007b; Barnes et al., 2007a; Newall et al., 1996a; Wichtl 
et Anton, 1999; Van Hellemont, 1986), sometimes also in liquor preparation (Anonymous, 
2009f; Wichtl et Anton, 1999; Van Hellemont, 1986), although at levels much less than the 
stated therapeutic doses. The acceptable daily intake of cinnamaldehyde has been 
temporarily estimated as 700µg/kg body weight (Barnes et al., 2007b; Barnes et al., 
2007a; Newall et al., 1996a) and the accepted daily intake of eugenol is up to 2.5mg/kg 
(Barnes et al., 2007b). 
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Other uses 
The oil is used also in perfumes (Anonymous, 2009f). 
 
Pharmacological Activities 
Activities documented for cinnamaldehyde include CNS stimulation (low dose), sedation 
(high dose) (Barnes et al., 2007a; Duke, 2003), hypothermic and antipyretic actions 
(Anonymous, 2009f; Barnes et al., 2007a); antibacterial and antifungal activity, 
acceleration of catecholamine (mainly adrenaline) release from the adrenal glands, weak 
papaverine-like action, increase in peripheral blood flow, hypotension and  bradycardia 
have also been reported (Barnes et al., 2007a) Cinnamaldehyde has the analgesic effect 
(Anonymous, 2009f; Shen et al., 2002), has the effect for sedation, relieve fever, is used 
against eclampsia, stimulates peristalsis of stomach and intestine, has cholagogue (Shen 
et al., 2002) and antitumor properties (Anonymous, 2009m; Shen et al., 2002). Also has 
convulsion-resistant properties and injecting cinnamaldehyde into the abdominal cavity of 
a mouse can alleviate the body sprain reaction caused by acetic acid. The use of the 
dosage of 500 mg/kg can resist tonic convulsions caused by strychnine. Also relieves 
coughing and induces diuresis (Anonymous, 2009f). Cinnamaldehyde may also have 
immunomodulating activity (Anonymous, 2009m). 
Much of the cinnamaldehyde content of cassia is thought to be lost by evaporation and 
auto-oxidation during decoction of the crude drug, so the contribution of cinnamaldehyde 
to the overall therapeutic efficacy of cassia has, therefore, been questioned (Barnes et al., 
2007a). That`s why it´s so important to add the drug at the end of the decoction 
preparation. 
Anti-infectious effects 
Antifungal, antiviral, bactericidal (Dugoua et al., 2007) and larvicidal actions have been 
reported for the volatile oil (Barnes et al., 2007b; Dugoua et al., 2007).  The essential oil is 
active in vitro against the following bacteria: Escherichia coli, Staphylococcus aureus 
(Barnes et al., 2007b; WHO, 1999a), Salmonella typhimurium, Bacillus subtilis and 
Pseudomonas aeruginosa (WHO, 1999a). The essential oil, per os, at a dose of 0.1ml, is 
active in cystitis caused by E. coli (Cunha et al., 2003a). It was also active in vitro against 
the following fungi: Aspergillus spp., Cladosporium werneckii, Geotrichum candidum, 
Kloeckera apivulata, Candida lipolytica (WHO, 1999a) and C. albicans (WHO, 1999a; 
Barnes et al., 2007b). The antibacterial and fungicidal effects have been attributed to o-
methoxycinnamaldehyde (Ooi et al., 2006; WHO, 1999a), but according to Tabak et al. 
(1999) cinnamaldehyde seems to be the main inhibitory component of cinnamon. 
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According to Senhaji et al. (2007) the major antimicrobial components of cinnamon and 
the essential oil are cinnamaldehyde and eugenol. Cinnamaldehyde has broad spectrum 
gram-positive and gram-negative antibacterial activity (Dugoua et al., 2007; Liu et al., 
2007) in which it was shown to inhibit the growth of Clostridium perfringens, Bacteroides 
fragilis, Bifidobacterium bifidum, Staphylococcus aureus, Listeria monocytogenes, 
Escherichia coli, Enterobacter aerogenes, Proteus vulgaris (Dugoua et al., 2007), Vibrio 
cholerae, V. parahaemolyticus, and Salmonella typhimurium as well as broad-spectrum 
vaginal microflora. One mechanism that has been explored for this antibacterial activity is 
that cinnamaldehyde destroys the cytoplasmic membrane of both gram-positive and 
gram-negative bacteria and induces depletion of the intracellular ATP concentration 
(Dugoua et al., 2007). Cinnamaldehyde also exhibits antibacterial activity against clinical 
P. aeruginosa (Dugoua et al., 2007; Liu et al., 2007) and has a synergistic effect with 
tetracycline, gentamycin, and streptomycin (Liu et al., 2007). In addition, (–)-epicatechin; 
1,8-cineole; -pinene; -terpineol; benzaldehyde; benzoic acid; cinnamic acid; 
cuminaldehyde; eugenol; geranial; guaiacol; limonene; linalool; methyleugenol; OPC; p-
cymene; procyanidins; safrole; salicylic acid; terpinen-4-ol are referred to have 
antibacterial effects (Duke, 2003). 
Cinnamaldehyde was previously found inhibited the Mycobacterium tuberculosis and 
influenza virus effectively, and could regulate the immunological function (Ma et al., 2008). 
A low concentration of trans-cinnamaldehyde elevates the antimicrobial action of 
clindamycin, and suggests a possible clinical benefit for utilizing these natural products for 
combination therapy against C. difficile (Shahverdi et al., 2006). Cinnamaldehyde has also 
been shown to inhibit growth of fungi (Dugoua et al., 2007) including yeasts (4 species of 
Candida: C. albicans, C. tropicalis, C. glabrata, and C. krusei), filamentous molds (3 
Aspergillus spp. and 1 Fusarium sp.), and dermatophytes (Microsporum gypseum, 
Trichophyton rubrum, and T. mentagrophytes), as well as the eggs and adult females of 
human head louse Pediculus humanus capitis (Dugoua et al., 2007). The mechanism of 
antimicrobial activity has been partially revealed in a study on yeast cells (Saccharomyces 
cerevisiae). The inhibitory effect of trans-cinnamaldehyde was due to its ability to inhibit 
yeast cell wall-synthesizing enzymes, β-(1,3)-glucan synthase and chitin synthase I (Ooi 
et al., 2006). ο-Methoxycinnamaldehyde was shown to inhibit the growth and toxin 
production of mycotoxinproducing fungi. Inhibits the growth of Aspergillus parasiticus, A. 
flavus, A. ochraceus and A. versicolor. It also inhibits the production of aflatoxin, 
ochratoxin A and sterigmatocystin. ο-Methoxycinnamaldehyde is also effective against S. 
aureus and C. botulinum (Morozumi, 1978). In addition, 2-methoxycinnamaldehyde has 
been reported to inhibit the growth of Aspergillus parasiticus and A. sterigmatocystin (Guo 
et al., 2006b). Aqueous and alcohol extracts of cinnamon have demonstrated antibacterial 
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effects against H. pylori (Dugoua et al., 2007). A recent study indicates that trans-
cinnamaldehyde could potentially be used to kill Enterobacter sakazakii in reconstituted 
infant formula (Amalaradjou et al., 2008).  C. cassia bark also shows activity against 
Tryponosoma cruzi (Lirussi et al., 2004) and Salmonella enteritidis (Dugoua et al., 2007). 
The use of commercial cinnamon preparation produced an improvement of oral 
candidiasis of HIV infected patients. Cinnamon bark essential oil exhibited high activity 
against Listeria monocytogenes at low doses and might be useful as a food preservative 
because of its possible low sensory impact (Cava et al., 2007). It can be incorporated into 
creams, lotions, drops, etc. which are applied externally on the body to treat diseases 
caused by Aspergillus niger. In a recent study comparing different antibacterial oils 
(cinnamon, clove, geranium, lemon, lime, orange and rosemary) cinnamon oil has the 
most potential bactericidal properties. It can be used as antibacterial supplement in the 
developing countries towards the development of new therapeutic agents. Additional in 
vivo studies and clinical trials would be needed to justify and further evaluate the potential 
of this oil as an antibacterial agent in topical or oral applications (Prabuseenivasan et al., 
2006). Antiviral properties has been attributed to several constituents of cinnamon, 
including: (–)-epicatechin; -pinene; cinnamaldehyde; geranial; limonene; linalool; 
oligomeric procyanidin (OPC); p-cymene; procyanidins. In addition: -pinene; limonene; p-
cymene are referred to have antiflu effects (Duke, 2003).  
 
Gastrointestinal effects 
The essential oil of C. verum has carminative activity and decreases smooth muscle 
contractions in guinea-pig trachea and ileum, and in dog ileum, colon and stomach. The 
active antispasmodic constituent of the drug is cinnamaldehyde. A reduction of stomach 
motility in rats and dogs and intestinal motility in mice and a decrease in the number of 
stress- and serotonin induced ulcers in mice have been described. An ethanol extract of 
the drug inhibits histamine- and barium-induced contractions in guinea-pig ileum but the 
hot-water extract was not active (WHO, 1999a). Animal studies suggest that an extract of 
cinnamon bark taken orally may help prevent stomach ulcer. Cinnamaldehyde was 
completely inhibiting both sensitive and resistant strain of Helicobacter pylori 
(Prabuseenivasan et al., 2006). Eugenol and cavracol also exert varying inhibitory effects 
on H. pylori (Tabak et al., 1999). Anti-ulcerogenic properties have been described for two 
propionic derivatives identified as 3-(2-hydroxyphenyl)-propanoic acid and its O-glucoside 
isolated from cassia (Tanaka et al., 1989). An in vivo study using rats reported activity 
against a variety of ulcerogens including serotonin, phenylbutazone, ethanol, water 
immersion, and stress. The compounds where thought to act by improving gastric blood 
flow rather than by inhibiting gastric secretion (Barnes et al., 2007a; Newall et al., 1996a; 
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Tanaka et al., 1989). These results suggest that the antiulcerogenic effect is probably 
attributable to the potentiation of defensive factors through the improvement of the 
circulatory disorder and gastric cytoprotection (Tanaka et al., 1989). Several constituents 
has been referred has antiulcer compounds such as (+)-catechin, cinnamaldehyde and 
eugenol. Also procyanidins have reported to be antigastritic compounds (Duke, 2003). 
Water and ether extract of C. cassia bark have shown antidiarrheic effects in laboratory 
mice. Choleretic and analgesic effects have been seen in anesthetized laboratory rats. 
The effects are due to the ―warming‖ and analgesic effects of the stomach and spleen 
(Anonymous, 2002). In addition, its constituent‘s eugenol, eugenol acetate, and methyl 
eugenol have been reported to enhance trypsin activity in vitro (Dugoua et al., 2007). The 
mucilage present in cinnamon has demulcent properties and 1,8-cineole is secretagogue. 
Eugenol; methyl-salicylate and safrole possess carminative effects (Duke, 2003).   
 
Cytotoxic effects 
Antitumor activity has been described to cinnamon and the activity depends on the plant 
source used (Barnes et al., 2007a). Weak tumor-promoting activity on the mouse skin and 
weak cytotoxic activity against HeLa cells has been documented for eugenol (Barnes et 
al., 2007b). Anti-tumor properties has been attributed to several constituents of cinnamon, 
including: (+)-catechin; (–)-epicatechin; -pinene; -terpineol; benzaldehyde; 
cinnamaldehyde; cinnamic acid; coumarin; eugenol; isoeugenol; limonene; linalool; 
methyl-eugenol; methyl-salicylate; mucilage; OPC; safrole; salicylic acid; trans-
cinnamaldehyde (Duke, 2003). 
 
Anti-inflammatory effects 
Previous studies have found that C. cassia has anti-inflammatory effects on various soft 
tissue conditions. Some recent studies have suggested that the anti-inflammatory effects 
of C. cassia were attributed to the scavenging of nitric oxide free radicals by this herb in 
the tissues (Fung et Ng, 2005). Cinnamaldeyde is also a potent anti-inflammatory 
compound through its inhibitory action on nuclear factor kB (NF-kB), nitric oxide (NO) 
synthase or cicloxigenase 2 (COX2) activities (Boudry et Perrier, 2008). 
In vivo inhibitory activity against complement formation has been documented and 
attributed to the diterpenoid and condensed tannin constituents. Anti-inflammatory activity 
exhibited by the Japanese plant Cinnamomum sieboldii Meisn (also used as a source of 
cassia bark), has been attributed to a series of condensed tannins constituents (Barnes et 
al., 2007a).  2-methoxycinnamaldehyde can affect the PGE2 release in rat cerebral 
microvascular endothelial cells (rCMEC) induced by IL-1, which might be related with its 
inhibition on the activity of COX-2 (Guo et al., 2006c). Anti-inflammatory properties has 
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been attributed to several constituents of cinnamon, including: (+)-catechin; (–)-
epicatechin; alpha-pinene; beta-pinene; cinnamaldehyde; cinnamic acid; coumarin; 
eugenol; methyl-salicylate; OPC; salicylic-acid. In addition, (+)-catechin; eugenol; salicylic-
acid are referred as COX-2-inhibitors (Duke, 2003). 
 
Antipyretical and analgesic effects 
Prostaglandin E2 (PGE2), a COX-derived metabolite of arachidonic acid, is a well-defined 
mediator of fever. IL-1b is a principle component of endogenous pyrogens, and it has 
been generally recognized that IL-1b released from cells peripherally produces fever by 
signaling the brain via various routes (Guo et al., 2006b). Recently, Guo et al. (2006b) 
showed that 2-methoxycinnamaldehyde dose-dependently inhibits IL-1b -induced PGE2 
production through the inhibition of COX-2 protein and COX-2 activity in rat cerebral 
endothelial cells (CECs), while 2-methoxycinnamic acid (Fig. 43) does not influence the 
PGE2 production in CECs with IL-1b inducement. Cinnamaldehyde was previously found 
that relieved fever and pain and could regulate the immunological function. Recent 
research also showed that it could reduce the amount of cyclooxygenase (COX)-1, COX-2 
and prostaglandin E2 (PGE2) and perhaps this is the mechanism of its relieving-fever 
effect (Ma et al., 2008). In addition, analgesic effects are attributed to: coumarin; eugenol; 
methyl-salicylate; p-cymene; salicylic-acid (Duke, 2003). 
 
 
 
 
Fig. 43. Chemical structure of 2-methoxycinnamic acid (adapted from 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=734154&loc=ec_rcs) (visited on 28/11/09). 
 
 
Antithrombotic effects 
Antiplatelet aggregation and antithrombotic actions have also been reported for C.cassia. 
These actions, together with the documented anti-inflammatory activity, are thought to 
contribute to the suppression of thrombus formation in certain diseases (Barnes et al., 
2007a). 
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Anti-diabetic and anti-dislipidemic effects 
Recently was reported that cinnamon extract (C. cassia) decreases blood glucose in 
Wistar rats. It was shown that cinnamon increases the insulin sensitivity and glucose 
uptake in adipocytes.  Cinnamon extract has a regulatory role in blood glucose level and 
lipids and it may also exert a blood glucose-suppressing effect by improving insulin 
sensitivity or slowing absorption of carbohydrates in the small intestine, in db/db mice. The 
cassia extract does not have any role in the alteration of the body weight, food intake and 
food efficiency ratio (FER); However, it was observed that cinnamon extract significantly 
reduces blood glucose levels in db/db mice after 2 weeks of treatment, which also 
demonstrates that there is significantly higher rate of glucose disposal. There was also a 
significant increase in the levels of serum insulin after administration of a cinnamon 
extract to db/db. So, the possible mechanism by which cinnamon extract brings about its 
hypoglycemic action in diabetic mice may be by potentiating the effect of insulin in serum 
or by increasing either the pancreatic secretion of insulin from the existing beta cells or its 
release from the bound form. There was significant decrease in triglyceride and total 
cholesterol level whereas increase in HDL–cholesterol and HTR (total cholesterol ratio) 
(%) levels in cinnamon-treated mice. It was reported that triglyceride and total cholesterol 
were decreased by administration of cinnamon extract in rats treated with streptozotocin 
for 3 weeks. The mechanism is explained by the AMPK-enhanced triacylglycerol lipase 
activity that increases glycogen synthesis in the liver and enhances glucose uptake in 
skeletal muscle and adipocytes. However, in insulin-deficient diabetics, free fatty acid 
concentration in the serum is elevated as a result of increased free fatty acid outflow from 
fat depots, where the balance of the free fatty acid esterification–triglyceride lipolysis cycle 
is displaced in favor of lipolysis. Another possible mechanism of cinnamon extract in anti-
hyperglycemic effect may be due to decreased activity of small intestinal α-glycosidase 
activity that converts carbohydrates into glucose preventing the rapid upward swing of 
PB2 (postprandial 2h blood glucose levels) level and slow absorption of carbohydrate in 
the small intestine (Kim et al., 2006). Polyphenolic polymers such as hydroxychalcone 
found in cassia cinnamon seem to potentiate insulin action. These compounds seem to 
increase phosphorylation of the insulin receptor, which increases insulin sensitivity. 
Increased insulin sensitivity may improve blood glucose control and lipid levels 
(Anonymous, 2009m). In vitro studies have shown that cinnamon enhances glucose 
uptake by activating insulin receptor (IR) kinase activity, autophosphorylation of IR, 
glycogen synthesis and glycogen synthase activity (Baker et al., 2008; Mang et al., 
2006a). According to Baker et al., 2008 these activities have been also seen in vivo 
studies. In vivo, cinnamon extract enhances glucose utilization in rats in a dose dependent 
fashion by potentiating insulin-stimulated tyrosine phosphorylation of (IR)- R substrate 
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(IRS)-1 and the IRS-1 association with phosphatidylinositol (PI) 3-kinase  (Mang et al., 
2006a).  It has been assumed that the methylhydroxychalcone polymer (MHCP) (Fig. 44) 
is the active substance (Mang et al., 2006a) and it was found to be an effective mimetic of 
insulin (Dugoua et al., 2007; Jarvill- Taylor et al., 2001; Pham et al., 2007).  
 
 
 
Fig. 44. Chemical structure of 3'-methyl-3-hydroxychalcone (adapted from 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6440383&loc=ec_rcs) (visited on 7/12/09). 
 
Combining MHCP and insulin provided synergistic effects on both glucose uptake and 
glycogen production in vitro (Jarvill- Taylor et al., 2001; Pham et al., 2007).  However, 
other findings suggested that the previously identified MHCP in cinnamon may have 
actually been water-soluble polyphenolic type-A polymers. Thus, the biologically active 
insulin-like substance in cinnamon remains unidentified. In vivo, oral administration of 
cinnamon extract has enhanced glucose utilization in rats by increasing the glucose 
infusion rate into skeletal muscle (Pham et al., 2007). In addition to improving cellular 
glucose metabolism, cinnamon may provide additional benefits for persons with diabetes 
through its antioxidant activity (Anderson et al., 2004).  The polyphenolic polymers have 
antioxidant effects, which may provide synergistic benefits for the treatment of diabetes. 
Botanical antioxidants may play a role in helping maintain the integrity of cell membranes 
by preventing polyunsaturated fatty acid peroxidation. The lipid composition of muscle 
membrane phospholipids reflects the combined influences of diet and 
desaturase/elongase activity, and in turn, the phospholipid composition affects the binding 
and action of insulin. In general, the more unsaturated the membrane, the better glucose 
is utilized. The more saturated the membrane, the more deleterious the effects on insulin 
efficiency. Lipid peroxidation and damage by reactive oxygen metabolites are also major 
problems in terms of diabetic complications. Clinical studies have shown that 
supplementation of both nutrient and phytochemical antioxidants can reduce or slow the 
progression of various complications of diabetes. It was reported that the major 
procyanidin oligomers in the ethanolic and aqueous extracts of cinnamon are doubly 
linked type-A (Anderson et al., 2004). It was demonstrated that water-soluble polymeric 
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compounds isolated from cinnamon have insulin-enhancing biological activity in the in 
vitro assay measuring the insulindependent effects on glucose metabolism and also 
function as antioxidants. These same compounds have been shown to inhibit 
phosphotyrosine phosphatase in the insulin-receptor domain and to activate insulin 
receptor kinase and function as a mimetic for insulin in 3T3-L1 adipocytes (Anderson et 
al., 2004). It was suggested that used various aqueous cinnamon extracts and showed 
insulin-enhancing properties in vitro in adipocytes, suggesting that isolated A-type doubly 
linked procyanidin oligomers of the catechins and/or epicatechins from cinnamon may be 
responsible for the observed effect (Mang et al., 2006a).  In a recent study made by Khan 
et al. (2003) supplementation of 1, 3, or 6 g of cinnamon for 40 days caused positive 
effects on fasting serum glucose and blood lipids. However, the results of this study, 
which was performed in Pakistan, may not be valid for Western populations (Mang et al., 
2006a). Mang et al. (2006a) evaluated the effect of an aqueous cinnamon extract on 
fasting plasma glucose, HbA1c and serum lipids in Western type 2 diabetics. This study 
showed that in Western type 2 diabetics treated in accordance with the current guidelines, 
the intake of an aqueous cinnamon extract leads to a moderate effect on fasting plasma 
glucose, but not on HbA1c, serum lipids or blood coagulation parameters (Mang et al., 
2006a). Another recent study showed that ingestion cinnamon reduces postprandial blood 
glucose concentrations and gastric emptying rate (GER) in healthy subjects. This finding 
could indicate that the reduction in the postprandial blood glucose response seen after the 
ingestion of cinnamon could be partly explained by an accompanying reduction in gastric 
emptying, because the rate of gastric emptying acts as a major factor in blood glucose 
homeostasis in normal subjects by controlling the delivery of carbohydrate to the small 
intestine. However, the reduction in the blood glucose concentrations, unexpectedly, was 
much more noticeable and pronounced in the present study than was the lowering of the 
GER. Therefore, it should be assumed that the change in GER itself could not be the only 
reason for the lower blood glucose response after the addition of cinnamon to the meal. In 
fact, cinnamon has been shown to improve insulin receptor function by activating insulin 
receptor phosphoinositide 3-kinase (PI 3-kinase) and inhibiting tyrosine phosphates. 
Cinnamon has also been shown to stimulate the insulin receptor activity by increasing the 
concentrations of the phosphorylated intracellular protein insulin receptor substrate-1 
(IRS-1) and increasing the binding to PI 3-kinase, which leads to enhanced cellular 
glucose uptake. It has been shown that cinnamon prevents the development of insulin 
resistance in rats fed a high-fructose diet by enhancing the insulin signaling, possibly via 
the nitric oxide pathway in skeletal muscle. A new study shows that rats given cinnamon 
and then administered a glucose tolerance test had decreased blood glucose 
concentrations. The same study shows that cinnamon has a direct antidiabetic effect by 
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increasing insulin concentrations in plasma. A recent study shows that the presence of 
cinnamon in a semisolid meal reduces postprandial glucose responses in healthy subjects 
and that the cause of this reduction could at least partly be a delayed GER (Hlebowicz et 
al., 2007). However, studies show that cinnamon might also have a direct role in lipid 
metabolism. For example, cinnamon bark powder at different doses 1, 3 and 6 g/day 
prevents hypercholesterolaemia and hypertriglyceridaemia and lowers the levels of free 
fatty acids and triglycerides in plasma of type 2 diabetic subjects by its strong lipolytic 
activity. Cinnamate, a phenolic compound found in cinnamon bark and other plant 
materials, lowers cholesterol levels in high fat-fed rats by inhibiting hepatic 5-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase activity. Research findings clearly show 
that cinnamon triggers the insulin cascade system (Kannappan et al., 2006). Although the 
physiological basis of metabolic dyslipidaemia appears to be hepatic overproduction of 
apolipoprotein (apo)B-containing very low-density lipoprotein (VLDL) particles, emerging 
evidence suggests that intestinal overproduction of apoB-containing lipoproteins, in 
insulin- resistant states, may be an important contributor to the elevation of circulating 
triglyceride (TG)-rich lipoproteins (TRLs). ApoB-48 is an essential structural component of 
intestinally derived chylomicrons and its remnants, and a marker of TRLs of intestinal 
origin. Recent studies suggest that the accumulation of postprandial apoB48-TRLs not 
only leads to the enhanced delivery of exogenous lipids to liver, which will result in an 
increased production of hepatic lipoproteins, but also delays in the clearance of hepatic-
derived TRLs. Consequently, apoB-48 TRL and remnants may play a disproportionally 
more important role in postprandial lipoprotein metabolism, even if the absolute plasma 
concentrations of chylomicrons are low compared with levels of hepatic-derived VLDL 
particles. Recent results suggest that acute oral aqueous cinnamon extracts treatment 
inhibits the increase in postprandial triglycerides and the overproduction of apoB48-
containing lipoproteins in fructose-fed, insulin-resistant rats (Qin et al., 2008). 
Peroxisome proliferator-activated receptors (PPARs) are transcriptional factors involved in 
the regulation of insulin resistance and adipogenesis. Cinnamon is found to activate 
PPARγ and α, resulting in improved insulin resistance, reduced fasted glucose, free fatty 
acids (FFA), LDL-c, and AST levels in high-caloric diet-induced obesity (DIO) and db/db 
mice in its water extract form. In vitro studies demonstrate that cinnamon increases the 
expression of peroxisome proliferator-activated receptors γ and α (PPARγ/α) and their 
target genes such as Lipoprotein lipase (LPL), fatty acid transporter (CD36), glucose 
transporting protein 4 (GLUT4), and Acyl-CoA oxidase (ACO) in 3T3-L1 adipocyte. The 
transactivities of both full length and ligand-binding domain (LBD) of PPARγ and PPARα 
are activated by cinnamon as evidenced by reporter gene assays. These data suggest 
that cinnamon in its water extract form can act as a dual activator of PPARγ and α, and 
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may be an alternative to PPARγ activator in managing obesity-related diabetes and 
hyperlipidemia (Shen et al., 2008). 
It was showed that cinnamon oils can improve insulin sensitivity and cinnamon water 
extract (CE) increases glucose uptake in 3T3-L1 adipocyte. However, the separated 
compounds derived from cinnamon displayed little insulinlike or insulin-enhancing activity. 
In a recent report, it was demonstrated that cinnamon water extract can elevate the 
expression of both PPARγ, α and their target genes in 3T3-L1 adipocyte possibly through 
stimulation of the transactivities of both full length and LBD of PPARγ and PPARα. In vivo 
study reveals that cinnamon water extract improves insulin resistance and lipid 
metabolism in both high-calorie dietinduced obesity (DIO) mice and db/db mice. This 
study demonstrated that CE had several beneficial effects on type 2 diabetes possibly 
through the activation of both PPARγ and PPARα resulting in improved insulin resistance, 
lowered blood glucose, and serum lipid level without weight gain and the structure change 
of the white adipose tissue. In addition, CE improved the liver function of obese mice. CE 
may have potential use in management of obesity-related type 2 diabetes and 
hyperlipidemia (Shen et al., 2008). 
Furthermore, cinnamon may inhibit hepatic 3-hydroxy-3-methylglutaryl (HMG)-CoA 
reductase activity and lower blood lipids in animals and humans. However, a cholesterol-
increasing effect has also been shown in rats in a previous study (Mang et al., 2006a). A 
recent study made by Altshuler et al. (2007) evaluates the effect of cinnamon on glycemic 
control in type 1 diabetic adolescents. The results did not demonstrate any benefit of 
cinnamon in this patient population. There were no significant differences in final A1C, 
change in A1C, total daily insulin intake, or number of hypoglycemic episodes between 
the cinnamon and placebo arms (Altshuler et al., 2007). Recently, Baker et al. (2008) 
performed a meta-analysis of five randomized placebo controlled trials with patients with 
type 1 or type 2 diabetes receiving cinnamon. It was not demonstrated statistically or 
clinically significant changes in A1C, FBG, or lipid parameters in comparison with subjects 
receiving placebo. Concerning this matter, human studies are needed, of better 
methodological quality, referring to exercise control or patients‘ diet, drug therapy diabetes 
control or other metabolic factors, as blood pressure or lipid values (Luis et Haler, 2008). 
However, it seems promising that if these data will be validated in the future clinical trials. 
Antioxidant effects 
The polyphenolic polymers found in C. verum and C. aromaticum have antioxidant activity 
and have been shown to reduce oxidative stress in a dose-dependant manner through 
inhibition of 5-lipooxygenase enzyme (Dugoua et al., 2007). Specific antioxidant 
phytochemicals that have been identified in cinnamon include epicatechin, camphene, 
eugenol, -terpinene, phenol, salicylic acid, and tannins (Anderson et al., 2004). A water-
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soluble polyphenol typ-A polymer from cinnamon showed in vitro to have an antioxidant 
effect (Hlebowicz et al., 2007). The beneficial effect of these compounds has been 
approached in the ―Anti-diabetic and anti-dislipidemic effects‖ concerning the insulin-
mimetic activity. 
Antioxidant  properties has been attributed to several constituents of cinnamon, including: 
(+)-catechin; (–)-epicatechin; camphene; eugenol; -terpinene; isoeugenol;methyl-
eugenol; OPC; procyanidins; salicylic acid (Duke, 2003). Also cinnamaldehyde reveals 
antioxidant properties (Anonymous, 2009m; Prabuseenivasan et al., 2006). 
 
Respiratory effects 
According to Duke (2003) expectorant properties has been attributed to several 
constituents of cinnamon, including: 1,8-cineole; -pinene; benzoic-acid; camphene; 
guaiacol; limonene; linalool. Antitussive effects are attributed to: 1,8-cineole; terpinen-4-ol. 
Antibronchitic effects to1,8-cineole. Also linalool is referred as bronchorelaxant (Duke, 
2003). 
 
Neurological and neuroprotective effects 
As for the effect of cinnamaldehyde on the CNS, it is known that an action is concentration 
dependent: the administration of low doses stimulates this system, while high doses 
cause sedation (Barnes et al., 2007a, Duke, 2003). The cinnamaldehyde accelerates the 
release of catecholamines, primarily adrenaline, from adrenergic glands into the 
bloodstream (Duke, 2003). Increases peripheral blood flow, slows heart rate, reduces 
blood pressure, and has antipyretic and hypothermic effects (Dugoua et al., 2007). 
Cinnamaldehyde is a circulostimulant and it accelerates release of catecholamines 
(mainly adrenaline) from the adrenal glands into the blood (Duke, 2003). Common 
cinnamon bark reduces the amplitude of penile somatosensory-evoked potentials in a 
mechanism that is not clearly understood, but may be useful in the treatment of premature 
ejaculation (Dugoua et al., 2007). Several constituents such as 1,8-cineole, -pinene, -
terpineol, benzaldehyde, cinnamaldehyde, coumarin, eugenol, farnesol, isoeugenol, 
limonene, linalool, methyl-eugenol and p-cymene have been referred to have sedative 
properties (Duke, 2003). 
In traditional Japanese Oriental (Kampo) medicine, the bark of C. cassia Blume, 
Cinnamomi cortex, is one of the medicinal plants that have been used for improving 
various diseases caused by insufficient blood microcirculation. This medicinal plant has 
also been often administered to patients suffering from ischemic brain diseases. It was 
found that a water extract from the bark of C. cassia (CC) provided a marked protective 
effect against glutamate-induced neuronal death and also an inhibitory effect on Ca2+ 
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influx in vitro. Antithrombotic and endothelium-dependent vasodilator actions of CC have 
been reported. These actions may contribute to improvement of cerebral blood flow. 
Further, these findings suggest that CC may be a potential medicinal plant with protective 
activity against ischemic brain injury (Shimada et al., 2000). 
 
Activation of the olfactory cortex of the brain 
A recent study conducted an observational study on 23 human subjects to determine the 
effect of abstract linking of linguistic and odor information in the brain using functional 
magnetic resonance imaging (fMRI). Odour-related terms, such as reading the word 
‗‗cinnamon‘‘, elicited activation in the primary olfactory cortex, which include the piriform 
cortex and the amygdale (Dugoua et al., 2007). 
 
Other effects 
Cinnamon oil is locally applied with much benefit in neuralgia and headache 
(Prabuseenivasan et al., 2006). Antiseptic and anesthetic properties have been 
documented for eugenol (Barnes et al., 2007b). 
There is a lack of clinical research assessing the effects of cinnamon and cassia rigorous 
randomized controlled clinical trials are required (Barnes et al., 2007b; Barnes et al., 
2007a). 
 
Non Medical Effects 
Constituents of the Cinnamomum bark, as trans-cinnamaldehyde, eugenol and 
salicylaldehyde revealed insecticidal activity (Park et al., 2000). Other two insecticidal 
compounds, cinnzeylanin and cinnzeylanol, have been isolated (Barnes et al., 2007b). 
 
Adverse reactions 
 Cinnamon bark absorbed in large quantities (as well as cinnamon oil at moderate doses) 
leads to tachycardia, intestinal peristaltisme stimulation an increase in respiratory rate and 
sweating, and this phase of the vasomotor centers excitation is followed by a state of 
sedation with drowsiness and depression (Anonymous, 2002; Wichtl et Anton, 1999). 
Allergic reactions, mainly contact sensitivity, to cassia oil and bark have been reported 
(Barnes et al., 2007a; WHO, 1999a). The irritant and sensitizing properties of cassia oil 
have been attributed to cinnamaldehyde (Barnes et al., 2007a; Newall et al., 1996a). The 
dermal LD50 of the C.verum oil is reported to be 690mg/kg body weight (Barnes et al., 
2007b) and for cassia oil is stated as 320mg/kg body weight (Barnes et al., 2007a; Newall 
et al., 1996a). The consumption of flavored gum with cinnamon causes perioral dermatitis 
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(Cunha et al., 2003a; Fitoterapia, 1998) and stomatitis (Tremblay et Avon, 2007). 
Topically, allergic skin reactions and stomatitis from toothpaste flavored with cassia 
cinnamon have been reported (Anonymous, 2009m). Cassia oil is stated to be one of the 
most hazardous oils and should not be used on the skin in concentrations of more than 
0.2% (Barnes et al., 2007a; Newall et al., 1996a). The essential oil of C. verum can cause 
contact dermatitis, irritation of mucous membranes or allergic reactions (bronchospasm). 
Internally, in high doses, it can produce nervous changes (Cunha et al., 2003a). 
Cinnamaldehyde in toothpastes and perfumes has also been reported to cause contact 
sensitivity (Barnes et al., 2007a; Newall et al., 1996a).  Examples of adverse reactions 
include the following:  contact dermatitis, stomatitis, oral lichen planus, oral leukoplakia, 
mouth-burning syndrome, sunscreen dermatitis, urticaria, perioral dermatitis, oral 
erythema multiform-like sensitivity reaction (Dugoua et al., 2007). There is one case 
wherein squamous cell carcinoma was reported after long-term cinnamon-gum chewing. 
Although cinnamon has not been specifically implicated as a carcinogenic agent given 
that its ethanolic extract was shown to be no mutagenic, caustic chemical irritants acting 
through cytotoxic mechanisms can have carcinogenic activity when excessive doses 
exceed threshold levels. Of some concern is the case in which first- and second-degree 
burns were convincingly linked to cinnamon oil exposure (Dugoua et al., 2007).  No health 
hazards or side effects are known as conjunction the proper administration of designated 
therapeutic dosages (Wichtl et Anton, 1999; PDR, 1998; Van Hellemont, 1986). Orally, 
cassia cinnamon appears to be well-tolerated. No significant side effects have been 
reported in clinical trials (Anonymous, 2009m; Barnes et al., 2007b; PDR, 1998). 
Additionally, there is some concern about the safety of ingesting large amounts of cassia 
cinnamon due to its coumarin content. Coumarin can cause hepatotoxicity in animal 
models. In humans, very high doses of coumarin from 50-7000 mg/day can result in 
hepatotoxicity that resolves when coumarin is discontinued. In most cases, ingestion of 
cassia cinnamon won't provide a high enough amount of coumarin to cause significant 
toxicity; however, in especially sensitive people, such as those with liver disease, 
prolonged ingestion of large amounts of cassia cinnamon might exacerbate the condition 
(Anonymous, 2009m). 
 
Contraindications and warnings 
Do not administer orally or topically, the essential oil (C. verum) to people with respiratory 
allergies or with known hypersensitivity to this or other aromatic products. Do not use with 
vanilla (Cunha et al., 2003a; Fitoterapia, 1998) neither Peru balsam (Cunha et al., 2003a; 
Fitoterapia, 1998; WHO, 1999a) because they may have cross-reaction (Fitoterapia, 
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1998). Preparations with cinnamon should not use it in case of gastric ulcer or intestinal 
ulcer (Cunha et al., 2003a; Fitoterapia, 1998; WHO, 1999a; Wichtl et Anton, 1999). Do not 
use in case of gastritis, syndrome bowel disease, ulcerous, colitis, Crohn disease, 
hepatopathys, epilepsy, Parkinson and other neurologic diseases (Fitoterapia, 1998). The 
drug is contraindicated in cases of fever of unknown origin (Ooi et al., 2006; WHO, 1999a) 
and in patients with an allergy to cinnamon (WHO, 1999a). However, clinical safety data 
and toxicity data for cinnamon and cassia are limited and further investigation of these 
aspects is required (Barnes et al., 2007b; Barnes et al., 2007a; PDR, 1998).  
Beware of the alcohol content in fluid extract, tincture and syrup (Fitoterapia, 1998). 
 
Pregnancy and lactation 
Available data are not sufficient for an adequate benefit/risk assessment (Anonymous, 
2009m; WHO, 1999a; PDR, 1998). Therefore, Cortex Cinnamomi should not be used 
during pregnancy (Anonymous, 2009m; Cunha et al., 2003a; Fitoterapia, 1998; Ooi, et al., 
2006; WHO, 1999a; Wichtl et Anton, 1999; PDR, 1998). According to Barnes (2007) there 
are no known problems with the use of cinnamon during pregnancy and lactation, 
provided that doses do not greatly exceed the amounts used in foods (Newall et al., 
1996a; WHO, 1999a). There is one report of teratogenicity of cinnamaldehyde in chick 
embryos, but studies of teratogenicity in chick embryos are of limited usefulness when 
evaluating the teratogenic potential for humans. A methanol extract of the drug given by 
gastric intubation was not teratogenic in rats. Concerning nursing mothers available data 
are not sufficient for an adequate benefit/risk assessment (WHO, 1999a). It is not known 
whether the constituents of cassia are secreted into breast milk (Barnes et al., 2007a). 
Therefore, Cortex Cinnamomi should not be used during lactation (WHO, 1999a).  
Pediatric use 
The safety and efficacy of Cortex cinnamomi in children have not been established (WHO, 
1999a). Do not administer orally or topically, the essential oil (C. verum) to children under 
6 years-old (Cunha et al., 2003a; Fitoterapia, 1998).  
 
Interactions with Diseases or Conditions 
Diabetes: Cassia cinnamon might lower blood glucose in patients with type 2 diabetes. 
Tell patients with diabetes to use cassia cinnamon products cautiously and monitor blood 
glucose levels very closely (Anonymous, 2009m). 
Liver disease: There is some concern that ingesting large amounts of cassia cinnamon 
might cause hepatotoxicity in susceptible people. Cassia cinnamon contains coumarin 
which can cause hepatotoxicity in animal models. In otherwise healthy humans, very high 
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doses of coumarin from 50-7000 mg/day can result in hepatotoxicity that resolves when 
coumarin is discontinued. Lower amounts cassia cinnamon might exacerbate liver 
function in people with existing liver disease (Anonymous, 2009m). 
Surgery: Cassia cinnamon might affect blood glucose levels. Theoretically, cassia 
cinnamon might interfere with blood glucose control during and after surgical procedures. 
Tell patients to discontinue cassia cinnamon at least 2 weeks before elective surgical 
procedures (Anonymous, 2009m). 
 
Drug interactions  
Antidiabetic drugs 
Although theoretical, the antidiabetic effect of common and cassia cinnamon may have an 
additive effect with antidiabetic medication and insulin (Dugoua et al., 2007). Patients 
taking antidiabetic medication or insulin should be monitored by their health care provider 
when taking common or cassia cinnamon (Anonymous, 2009m; Dugoua et al., 2007). 
Some antidiabetic drugs include glimepiride, glyburide, insulin, metformin, pioglitazone, 
rosiglitazone and others (Anonymous, 2009m). 
Tetracycline 
C. cassia bark extract (2 g in 100 ml) markedly decreased the in vitro dissolution of 
tetracycline hydrochloride. In the presence of C. cassia bark, only 20% of tetracycline was 
in solution after 30 minutes, in contrast to 97% when only water was used. However, the 
clinical significance of this interaction has not been established (WHO, 1999a).  
 
Interactions with Herbs & Supplements 
Hepatotoxic herbs and supplements: There is some concern that ingesting large 
amounts of cassia cinnamon might cause hepatotoxicity in some people. Theoretically, 
concomitant use with other potentially hepatotoxic products might increase the risk of 
developing liver damage. Some of these products include androstenedione, chaparral, 
comfrey, dehydroepiandrosterone (DHEA), germander, kava, niacin, pennyroyal oil, red 
yeast and others (Anonymous, 2009m). 
Herbs and supplements with hypoglycemic potential: Cassia cinnamon might lower 
blood glucose levels. Theoretically, it might have additive effects when used with other 
herbs and supplements that also lower glucose levels. This might increase the risk of 
hypoglycemia in some patients. Some herbs and supplements with hypoglycemic effects 
include alpha-lipoic acid, bitter melon, chromium, devil's claw, fenugreek, garlic, guar gum, 
horse chestnut, Panax ginseng, psyllium, Siberian ginseng and others (Anonymous, 
2009m). 
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Other interactions 
Cortex Cinnamomi Cassiae (Rou Gui) antagonizes Halloysirum Rubrum (Chi Shi Zhi) (CP, 
2005b; WHO, 1999a; Wu, 2005b). Chinese cassia bark is averse to red kaoline 
(Anonymous, 2009f). 
 
Interactions with Laboratory Tests 
Blood glucose 
Cassia cinnamon might lower blood glucose levels and test results in some patients 
(Anonymous, 2009m). 
Liver function tests 
There is some concern that ingesting large amounts of cassia cinnamon might increase 
liver enzymes and cause hepatotoxicity in some people due to coumarin content 
(Anonymous, 2009m). 
 
Dosage forms 
Crude plant material, powder, volatile oil and other galenic preparations (WHO, 1999a). 
Mode of administration: comminuted bark for infusions, essential oil, as well as other 
galenic preparations for internal use (PDR, 1998). 
Posology 
Crude drug 
Average daily dose: 2-4g (Cunha et al., 2003a; PDR, 1998; WHO, 1999a). 
Infusion 
1-3g per cup, boil for 2 minutes and infusion for 10 min. (Fitoterapia, 1998) 3 cups a day, 
before meals (Cunha et al., 2003a; Fitoterapia, 1998) or 0.5-1.0g as an infusion three 
times daily (Barnes et al., 2007a; Cunha et al, 2003; Newall et al., 1996a; Van Hellemont, 
1986). 
Fluid extract 
 30-50 drops, 1-3 times/day (Fitoterapia, 1998). 
Essential oil 
2 or 3 drops, on a lump of sugar, or in capsules with 25-50mg, 1-2 times/day (Cunha et 
al., 2003a) or 3 times/day (Fitoterapia, 1998), before meals (Cunha et al., 2003a; 
Fitoterapia, 1998). 0.05-0.2mL three times daily (Barnes et al, 2007a; Newall et al., 
1996a). Average daily dose, 0.05–0.2g (Cunha et al., 2003a; WHO, 1999a; PDR, 1998). 
Syrup (10% of tincture 
1-3 tablespoon/day (Fitoterapia, 1998). 
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Tincture (1:5) 
Produced from 1 part of the drug and 5 parts of ethanol (70 per cent V/V) by an 
appropriate procedure (EP, 2005), 50-100 drops, 1-2 times/day (Cunha et al., 2003a) or 
XX to XL drops several times a day (Van Hellemont, 1986b), 2-4ml (Barnes et al., 2007b). 
Pulvis cinnamomi 
500mg to 1g (Van Hellemont, 1986a), or 250-500mg per capsule (Cunha et al., 2003a), 3-
5 times/day (Van Hellemont, 1986a), 1-2 times/day (Cunha et al., 2003a) or 1-3 times/day 
(Fitoterapia, 1998). 
Infusion for external use 
5g/cup (Cunha et al., 2003a). Boil 10 min, applied with compressing pad, collutory, 
irrigation or instillation (Fitoterapia, 1998). 
Tincture for external use (1:10) 
Apply locally (Cunha et al., 2003a; Fitoterapia, 1998). 
Essential oil for external use 
Diluted to 5% in almond oil: 2-3 applications per day (Cunha et al., 2003a; Fitoterapia, 
1998). 
Aqua cinnamomi 
1 tablespoon per shot (Van Hellemont, 1986b). 
 
Storage 
Cool, dry conditions in well-sealed (PDR, 1998), well-filled airtight containers (Sweetman, 
2009b). Use glass or metal container (do not use plastic). Keep away from light (FP, 2005; 
Sweetman, 2009b; WHO, 1999a; Wichtl et Anton, 1999), humidity (FP, 2005; WHO, 
1999a; Wichtl et Anton, 1999) and heat (Sweetman, 2009b). According to Chinese 
Pharmacopoeia (2005b) should be preserved in a cool and dry place. 
7.3.b. Ramuli Cinnamomi cassia  
 
Cinnamon twig (Guizhi) is the tender twigs of the bushy evergreen tree Cinnamomum 
cassia Presl. (Fig. 45) (Anonymous, 2009f; Ganzhong et al., 2003d), of the Lauraceae 
family. Native to Sri Lanka (Ceylon cinnamon--Cinnamomum zeylanicum Bl.), the 
neighboring Malabar Coast of India and Myanmar (Burma), it is also cultivated in South 
America and the West Indies for the spice consisting of its dried inner bark.  The Chinese 
herb cinnamon twigs are mainly produced in the Chinese provinces Guangdong, Guangxi 
and Yunnan (Anonymous, 2009f; Yanfu, 2002c). The spice is light brown in color and has 
a delicately fragrant aroma and warm, sweet flavor (Anonymous, 2009f). 
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The medicinal parts of the plant are collected in spring and summer, and dried in the sun 
(Anonymous, 2009f; Ganzhong et al., 2003d; Yanfu, 2002) or in the shade after the leaves 
have been removed. Before clinical use, they are further processed into slices or small 
pieces by soaking, softening, cutting, and drying in the shade or in the sun (Fig. 46) 
(Ganzhong et al., 2003d; Yanfu, 2002). 
 
Fig. 45. Cinnamon twigs 
 (adapted from http://www.asante-academy.com/ke-explains/medicinesa-z/cassiatwig.htm) (visited on 8/5/2009). 
 
Fig.  46. Cinnamon processed twigs 
 (adapted from http://www.nmbm.com.cn/www/nmbm/en/cp/productDetail.jsp?productId=1470 (visited on 8/5/09) 
 
Chemical constituents  
Cinnamic oil is the active component of guizhi. It consists of cinnamaldehyde, cinnamic 
acid, and a small amount of cinnamyl acetate and phenylpropyl acetate (Ganzhong et al., 
2003d). In a recent study performed by Kaul et al. (2003) different parts of the C. verum 
plant were analyzed by gas chromatography (GC) and GC/mass spectrometry (GC/MS). 
The essential oil yield was 0.40% for the tender twigs. This oil was richer in -
phellandrene, limonene and (E)-cinnamaldehyde comparing to the oil of other different 
parts of the plant as pedicels of buds and flowers, from buds and flowers, from pedicels of 
fruits and from fruits. 
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In 2001, Xu et al. performed a gas chromatography on an essential oil from cinnamon 
cassia twigs prepared in accordance with to the standard method of extraction in the 
Chinese Pharmacopoeia. All the qualitative results are shown in Table 3. The components 
identified account for 89.55% of the total content of the sample. Unfortunately, 31 
components remain unidentified, because of the low signal-to-noise ratio or the absence 
of the compound from the mass spectra database. The compound present in largest 
amount is E- 3-Phenyl-2-propenal (cinnamaldehyde) (50.43%). Other referring 
compounds are: benzaldehyde (Fig. 47) (2.90%), 1-ethenyl-4-methoxybenzene (Fig. 48) 
(3.77%), 3-(2-methoxyphenyl) 2-propenal (2-methoxycinnamaldehyde) (4.72%), 
hexadecanoic acid   (Fig. 49) (4.31%) (Xu et al., 2001). 
 
 
 
Fig. 47. Chemical structure of benzaldehyde (adapted from 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=11528246&loc=es_rss) (visited on 7/12/09) 
 
 
 
Fig. 48. Chemical structure of 1-ethenyl-4-methoxybenzene (adapted from 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=80512878&loc=es_rss) (visited on 7/12/09)  
 
 
 
 
Fig. 49. Chemical structure of hexadecanoic acid (palmitic acid) (adapted from 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=85088443&loc=es_rss) (visited on 7/12/09)  
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Table 3.  Composition of the essential oil from Ramulus cinnamomi (adapted from Xu et al., 2001)  
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Pharmacological actions 
 
Vasodilator and diaphoretic effects 
Guizhi itself only has a weak diaphoretic effect (Ganzhong et al., 2003d). Cinnamic oil can 
expand blood vessels, regulate blood circulation, and make the blood flow toward the 
superficial part of the body (Ganzhong et al., 2003d).  
Anti-infectious effects 
Tests in vitro have shown that water decoction of Guizhi and alcohol extract solution of 
guizhi can inhibit certain kinds of pathogenic bacteria; cinnamic oil and cinnamaldehyde 
can inhibit Mycobacterium tuberculosis. In addition, Guizhi has been proven to have an 
inhibitory effect on influenza virus and orphan virus (Ganzhong et al., 2003d). 
Antipyretic and analgesic effects 
The active components cinnamaldehyde and cinnamic acid of Guizhi, and the Guizhi 
Decoction can lower increased body temperature of animals. This is related to the effects 
of expanding blood vessels in the skin, and promoting diaphoresis and heat dispersal. 
Guizhi can also increase the pain threshold, and the drug may produce a better analgesic 
effect when is included in a recipe (Ganzhong et al., 2003d). 
Sedative and anticonvulsive effects 
The active component cinnamaldehyde can reduce the autonomic activities of mice and 
prolong the survival time of mice with titanic convulsions caused by strychnine (Ganzhong 
et al., 2003d). 
Antiallergic effect 
Guizhi may inhibit the release of sensitizer from mastocytes caused by IgE (Ganzhong et 
al., 2003d). 
Storage 
According to Chinese Pharmacopoeia (2005c) cinnamon twigs should be preserved in a 
cool and dry place. 
 
Ramuli versus Cortex 
Many pharmacological investigations have been carried out on Cinnamomi Cortex. These 
studies have either looked at the volatile oil, in particular the major constituent 
cinnamaldehyde, or at parts excluding the oil (Newall et al., 1996a). Actions observed for 
essential oil-free aquous extracts have been reported to be weak (Barnes et al, 2007a; 
Newall et al., 1996a). This is suggestive that essential oil contributes to the 
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pharmacological effects (Barnes et al, 2007a). Shen et al. (2002) performed a comparison 
study on the two different essential oils. Essential oil from Ramulus Cinnamomi and 
Cortex Cinnamomi (Cinammomum cassia Prels.) were obtained by steam distillation. The 
chemical components of the oil were examined and compared by means of gas 
chromatography- mass spectrometry (Table 4). 
Table 4. Chemical components of the oil (GC- MS) (adapted from Shen et al., 2002) 
   
Relative amount of % Relative amount of % 
Number Compound name 
Retention 
time 
Ramuli cinnamomi 
cassiae oil 
Cortex cinnamomi oil 
1 α-pinene 2.5 - 0.07 
2 phenylethylene 2.81 - 0.1 
3 β-pinene 3.1 - 0.03 
4 limonene 3.62 - 0.06 
5 p-cymene 3.99 - 0.07 
6 benzaldehyde 4.37 1.1 0.59 
7 2-hydroxy-phenylaldehyde 5.87 0.17 - 
8 phenylacetaldehyde 6.05 0.06 0.02 
9 acetophenone 6.47 0.21 0.04 
10 2-methoxyphenol 6.81 0.03 - 
11 4-acetyl-1-methylcyclohexene 6.91 0.04 0.04 
12 camphol 7.26 0.62 0.66 
13 phenethyl alcohol 7.52 0.24 - 
14 α-terpineol 7.63 0.21 0.27 
15 2-methyl-benzofuran 8.02 - 0.03 
16 2'-hydroxy-acetophenone 8.82 0.03 - 
17 phenylpropyl aldehyde 9.05 1.7 1.23 
18 3-methyl acetophenone 9.16 0.09 0.04 
19 citral 10.01 0.06 - 
20 phenylpropanol 10.55 0.41 - 
21 Not translated 10.58 - 0.48 
22 trans-cinnamaldehyde 10.8 3.19 3.44 
23 2-methoxybenzaldehyde 11.53 0.48 - 
24 α-cedrene 12.23 0.03 - 
25 cinnamaldehyde 13.33 64.57 83.1 
26 cinnamyl alcohol 13.66 0.82 1.04 
27 caryophyllic acid (eugenol) 14.14 0.54 - 
28 γ-cadinene 14.62 0.29 0.16 
29 β-bisabolene 15.07 0.22 0.11 
30 curcumene 15.31 0.24 0.09 
31 α-muurolene 15.54 0.21 0.29 
32 1,5-dimethyl-naphthalene 16.69 0.11 - 
33 δ-cadinene 16.86 0.21 0.3 
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Fifty four of the separated constituents were identified. Ten components of these were not 
observed in the oil of Ramulus Cinnamomi, and sixteen components of these were not 
observed in the oil Cortex Cinnamomi. Cinnamaldehyde was the main component for both 
herbs, followed by benzaldehyde, trans-camphol, phenylpropyl aldehyde, trans-
cinnamaldehyde, 2-methoxy-cinnamaldehyde, trans-cinnamyl acetate, and others (Shen 
et al., 2002). The minor different components found in both of oils have no significant 
expression, as they commonly exist in nature, and they relative amount (%) is not 
relevant. What is interesting is the difference between the content of cinnamaldehyde 
64.57 % for Ramuli cinnamomi cassiae oil and 83.1% for the Cortex. Also relevant is the 
difference between the content of 2-methoxy-cinnamaldehyde (12.72 % for Ramuli 
cinnamomi cassiae oil and 2.61 % for the Cortex cinnamomi oil).  
 
7.3.1. Cortex cinnamomi cassiae ( 肉桂 ) according to Traditional 
Chinese Medicine 
 
The source is from the bark of C. cassia Presl., family Lauraceae. In China, the medicinal 
material is mainly produced in the areas of Guangdong, Guangxi, and Yunnan, etc. 
(Yanfu, 2002d). The bark is cut in situ before mid-summer, and peeled in early autumn. 
34 cadinene 17.25 - 0.08 
35 cinnamic acid 17.71 0.1 0.08 
36 trans-cinnamyl acetate 18.37 1.31 0.92 
37 myristic aldehyde 19.67 0.05 - 
38 paeonol 20.03 - 0.63 
39 calacorene 20.29 0.11 0.09 
40 methoxy cinnamaldehyde 21.19 0.4 0.13 
41 spathulenol 22.2 1.12 0.15 
42 oxy-caryophyllene 22.62 0.38 - 
43 benzofuran 23.48 - 0.32 
44 coumarin 23.54 0.94 - 
45 aromadendrene 23.93 0.1 - 
46 
1,2,3,4,4a,7-hexahydro-1,6-dimethyl-
naphthaline 
24.54 0.22 0.32 
47 calamene;calarene 24.97 0.37 0.06 
48 cadinol 26.48 0.3 0.5 
49 bisabolol 26.86 0.23 - 
50 2-methoxy-cinnamaldehyde 28.28 12.72 2.61 
51 cis-farnesol 31.81 0.16 - 
52 
1,4-dimethyl-7-(1-Methylethyl)-
anthracene 
32.36 0.38 0.24 
53 hexadecanoic acid 39.73 0.15 0.12 
54 benzyl benzenecarboxylate 40.03 0.27 0.1 
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After the cork is removed, the bark is dried in the shade, and sliced or ground to prepare a 
powder as a raw product for clinical application. The dry bark with the cuticle removed is 
called Rouguixin, and the bark peeled from a thick branch of an old tree or from the thin 
stem of a young tree is called Guangui (Ganzhong et al., 2003c). 
 
Common name 
Cassia bark (CP, 2005b; Gongwang, 2001b). 
Pharmaceutical name 
Cortex cinnamomi cassiae (Gongwang, 2001b). 
Botanical name 
Cinnamomum cassia Presl. (Gongwang, 2001b). 
 
Pynin name 
Rou Gui (Chu, 2009; Flaws, 1999e; Leite, 2005b), Rougui (Ganzhong et al., 2003c; 
Gongwang, 2001b; Greten, 2007; Yanfu, 2002d). 
 
Part used 
Inner bark of the tree (Tierra, 1997b). Rougui is the thick bark of the trees (Chu, 2009), or 
the bark of the trunk or thick branches of C. cassia (Ganzhong et al., 2003c).  
 
Classification 
Warms the kidney and conduits. Belongs to the group ―Tepefacientia intimae-IX)‖ (Greten, 
2007), i.e.  ―Herbs that Warm the Interior and Expel Cold‖ (Anonymous, 2009n). 
 
Sapor & Temperature 
 Pungent  (Anonymous, 2009f; Chu, 2009; Flaws, 1999d; Ganzhong et al., 2003c; 
Gongwang, 2001b; Leite, 2005b; Greten, 2007; Tierra, 1997b; Yanfu, 2002d), sweet 
(Anonymous, 2009f; Chu, 2009; Flaws, 1999d; Ganzhong et al., 2003c; Gongwang, 
2001b; Greten, 2007; Leite, 2005b; Tierra, 1997b; Yanfu, 2002d) warm (Flaws, 1999d; 
Ganzhong et al., 2003c; Leite, 2005b; Tierra, 1997b), hot (Anonymous, 2009f; Chu, 2009; 
Flaws, 1999d; Ganzhong et al., 2003c; Gongwang, 2001b; Greten, 2007; Yanfu, 2002d).  
 
Orbs 
Cardial, lienal, renal, hepatic (Anonymous, 2009f; Flaws, 1999d; Ganzhong et al., 2003c; 
Gongwang, 2001b; Greten, 2007; Leite, 2005b; Tierra, 1997b).   
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Functions 
Supplements fire and restores yang (Anonymous, 2009f; CP., 2005b; Gongwang, 2001b; 
Yanfu, 2002d), dispels cold and kills pain (Anonymous, 2009f; CP., 2005b;  Gongwang, 
2001b; Yanfu, 2002d)as well as warms the channels (Anonymous, 2009f; Gongwang, 
2001b; Yanfu, 2002d) and removes obstruction in the collaterals. The addition of cassia 
bark into a recipe to nourish qi and replenish xue, can stimulate the growth of qi and xue 
(Anonymous, 2009f) and promotes the xue circulation (Yanfu, 2002d). 
 
Indications 
Cinnamon bark alleviates an aversion to cold, cold limbs (CP, 2005b; Gongwang, 2001b; 
Tierra, 1997b); weak back; impotence; frequent urination; abdominal pain and spasms 
caused by algor; weak appetite, diarrhea, wheezing, and rheumatism caused by algor. 
Also improves digestion and warms the interior (Tierra, 1997b). Used in arthralgia due to 
cold and dampness pathogens, and lumbago (Ganzhong et al., 2003c). Used for sores 
and welling abcesses in the external medicine department categorized as qi and blood 
vacuity cold (Flaws, 1999d). Can be used to treat all pains due to accumulation of cold 
and stagnation of qi or xue stasis (Yanfu, 2002d). It´s used to treat impotence and 
retention of cold in the uterus due to the deficiency of spleen-yang, palpitations with 
asthma of the insufficiency type, etc. (Anonymous, 2009f), to treat cold pain in the chest 
and abdomen and cold hernia with pain, in cold pain in the abdomen due to invasion of 
cold into the interior or deficiency-cold in the spleen and stomach, vomiting with 
abdominal pain, cold limbs and loose stools (Anonymous, 2009f), cold pain in the 
epigastrium, poor appetite (Gongwang, 2001b) due to yang deficiency of the spleen and 
kidneys, cold hernia (Anonymous, 2009f). To treat lumbago with arthralgia due to cold, 
obstruction of qi in the chest and deep-rooted carbuncles, lumbago with arthralgia due to 
cold, epigastric pain due to obstruction of qi in the chest as a result of suppression of 
chest yang and invasion of pathogenic cold into the interior, deep-rooted carbuncles due 
to deficiency of yang and stagnation of cold (Anonymous, 2009f). To treat xue stasis due 
to accumulation of cold (Gongwang, 2001b), amenorrhea and dysmenorrhea 
(Anonymous, 2009f; Gongwang, 2001b). To treat weakness due to prolonged illness and 
insufficiency of qi and blood (Anonymous, 2009f). 
 
Chinese therapeutic actions and examples of major combinations 
 
 Cassia bark can replenish fire and yang, expel cold pathogens, relieve pain and 
warm channels and blood vessels to treat deficiency of kidney yang and 
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declination of fire in the life gate when the drug is prescribed with aconite side root, 
prepared rehmannia root and dogwood fruit (Fructus Corni) (Shanzhuyu) in the Pill 
of Eight Drugs Including Cassia Bark and Aconite Root (Gulf Bowie Wan) 
(Ganzhong et al., 2003c). 
 In the Pill of Cassia Bark and Aconite Root for Adjusting the Middle Energizer 
(Guifi Lizhong Wan), cassia bark is prescribed with aconite side root, dry ginger, 
and bighead atractylodes tuber to treat deficiency of spleen and kidney yang 
(Ganzhong et al., 2003c). 
 For insufficiency of kidney-yang with impotence, chilliness, soreness and coldness 
of loins and knees, frequent micturition, seminal emission, and enuresis, etc., it is 
usually used in combination with Radix Aconiti Lateralis Praeparata (Fuzi), 
Rhizoma Rehmanniae Preaparatae (Shoudihuang) (Gongwang, 2001b; Yanfu, 
2002d), and Fructus Corni (Shanzhuyu), etc., such as Shenqi Wan (Pill) (Yanfu, 
2002d). 
 For syndrome with deficiency and weakness of kidney-yang and up-floating of 
deficiency-yang, the herbal medicine can be used in combination with Radix 
Aconiti Lateralis Praeparata (Fuzi) so as to direct fire to its source (Yanfu, 2002d). 
 With Radix Aconiti Lateralis Praeparata (Fuzi), Lagerhead Atractylodes Rhizome 
(Baizhu) for deficiency of spleen and kidney yang (Gongwang, 2001b). 
 With Prepared Rhizome of Adhesive Rehmania (Shoudihuang), Chinese Angelica 
Root (Danggui) for xue stasis due to accumulation of cold, abdominal pain of 
amenorrhea (Gongwang, 2001b). 
 With Argy Wormwood Leaf (Aiye), Chinese Angelica Root (Danggui) for deficiency 
cold of qi and xue, dysmenorrhea (Gongwang, 2001b). 
 With Chinese Taxillus Twig (Sangjisheng), Eucommia Bark (Duzhong) for pain in 
the loins due to cold arthralgia (Gongwang, 2001b). 
 With Mulberry Leaf (Sangye), Doubleteeth Pulbescent Angelica Root (Duhuo) for 
arthralgia (Gongwang, 2001b). 
 With Common Anemarrhea Rhizome (Zhimu), Chinese Corktree Bark (Huangbai) 
for diabetes and urine retention, uroschesis due to deficiency of the kidney 
(Gongwang, 2001b). 
 With Prepared Rhizome of Adhesive Rehmania (Shoudihuang), Ginseng 
(Renshen) for palpitation, shortness of breath due to deficiency of both qi and 
blood (Gongwang, 2001b). 
 With Prepared Rhizome of Adhesive Rehmania (Shoudihuang), Antler Glue 
(Lujiaijiao) for chronic carbuncle of yin type, un-rupted swelling abcess or slow-
healing carbuncles (Gongwang, 2001b). 
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 With Tuber Fleeceflower Root (Heshouwu), Ass-hide Glue (Ejiao) for anemia 
(Gongwang, 2001b). 
 Add Yanhusuo, Chinese Angelica Root (Danggui) for cold pain of the lower 
abdomen (Gongwang, 2001b). 
 Add Coptidis Rhizome (Huanglian) for irritability, insomnia, soreness of loin and 
knees due to failure of the heart and kidney to integrate, and it is also used to treat 
choric diarrhea (Gongwang, 2001b). 
 With White Peony Root (Baishaoyao) to suppress the liver yang (Gongwang, 
2001b). 
 For deficiency and coldness of the spleen and stomach marked by cold pain in 
epigastric abdomen, it can be used alone or together with Rhizoma Zinziberis 
(Ganjiang) and Rhizoma Alpiniae Officinarum (Gaoliagjiang) (Yanfu, 2002d). 
 For colic of cold type with abdominal pain, usually combined Radix Angelicae 
Sinensis (Danggui) and Rhizoma Chuanxiong (Chuanxiong), etc. (Yanfu, 2002d). 
 Powder of cassia bark or combined Chinese angelica root (Radix Angelica 
Sinensis, Danggui) and Sichuan lovage (Rhizoma Ligustici, Chuanxiong) can be 
taken by mouth to treat algor and pain in the epigastric region (Ganzhong et al., 
2003c). 
 In the Yang Activating Decoction (Yanghe Tang), cassia bark is combined with 
prepared rehmannia root, deer horn glue and ephedra to treat cellulitis of yin type 
(Ganzhong et al., 2003c). 
 Cassia bark can be prescribed with milk vetch root (Radix Astragali seu Hedysari, 
Huangqui) and angelica root to treat deficiency of qi (Ganzhong et al., 2003c). 
 For yin flat abscesses and chronic swellings with no head which are not red or hot, 
Cortex Cinnamomi Cassiae is commonly combined with uncooked Radix 
Rehmanniae (Shu Di), Gelatinum Cornu Cervi (Lu Jiao Jiao), and Herba Ephedrae 
(Mahuang) as in Yang He Tang (Yang Harmonizing Decoction) (Flaws, 1999d). 
 For pudendal carbuncle and pyocutaneous disease of deficient-cold type that has 
not been healed for a long time, it is combined with Colla Cornus Cervi (Lujiaojiao), 
Rhizoma Zinziberis Preparata (Paojiang), and Herba Ephedrae (Mahuang), etc. 
Such as Yanghe Tang (Yanfu, 2002d). 
 Combined with Radix Astragali (Huangqi), Radix Angelicae Sinensis (Danggui), 
etc., such as Tuoli Huagqi San (Powder) (Yanfu, 2002d). 
 For welling abscesses and swellings which have produced pus but have not 
ruptured or, if after rupturing, endure without restraining and constraining, i.e., 
closing, Cortex Cinnamomi Cassiae is commonly combined with Radix Astragali 
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Membranacei (Huang Qi) and Radix Angelicae Sinensis (Dang Gui) as in Tuo Li 
Huang Qi Tang (Out-thrust the Interior Astragalus Decoction) (Flaws, 1999d). 
 To treat impotence and retention of cold in the uterus due to the deficiency of 
spleen-yang, palpitations with asthma of the insufficiency type, etc. Chinese cassia 
bark is mostly used together with Radix Aconiti Praeparata (monkshood root), 
prepared rehmannia, shelled medicinal cornel fruit (Fructus Corni), etc., e.g., 
Shenqi Wan, You Gui Yin (Anonymous, 2009f). 
 Cold pain in the abdomen due to invasion of cold into the interior or deficiency-cold 
in the spleen and stomach: Chinese cassia bark can be ground alone into powder 
and decocted with wine for oral administration or used together with dried ginger, 
lesser galangal (Rhizoma Alpiniae Officinarum), long pepper (Fructus Piperis 
Longi), etc. (Anonymous, 2009f). 
 Vomiting with abdominal pain, cold limbs and loose stools due to yang deficiency 
of the spleen and kidneys: Chinese cassia bark is often used together with 
monkshood root (Radix Aconiti Praeparata), ginseng, dried ginger, etc., e.g., Gui 
Fu Lizhong Wan (Anonymous, 2009f). 
 Lumbago with arthralgia due to algor: this herb is mostly used together with 
angelica root (Radix Angelicae Pubescentis), parasitic loranthus, eucommia bark, 
etc., e.g., Duhuo Jisheng Tang (Anonymous, 2009f). 
 Epigastric pain due to obstruction of qi in the chest as a result of suppression of 
chest yang and invasion of pathogenic cold into the interior: Chinese cassia bark 
can be used together with monkshood root (Radix Aconiti Praeparata), dried 
ginger, zanthoxylum, etc. (Anonymous, 2009f). 
 Deep-rooted carbuncles due to deficiency of yang and stagnation of cold: Chinese 
cassia bark can be used together with deerhorn glue, blast-fried ginger, ephedra, 
etc., e.g., Yang He Tang (Anonymous, 2009f). 
 To treat amenorrhea and dysmenorrhea: Chinese cassia bark can be used 
together with Chinese angelica, chuanxiong (Rhizoma Ligustici Chuanxiong), 
fennel, etc., e.g. as Shaofu Zhuyu Tang (Anonymous, 2009f). 
 
Dosage and method of use 
Cinnamon bark is usually taken by powder or pill, since decoction causes a loss of volatile 
oils. If this herb is decocted, prepare it for 5 minutes (maximum); crushed it into small 
pieces (Leite, 2005b; Tierra, 1997b). According to Flaws (1999d), when decocted, add 
later. It may also be ground into powder and washed down with the rest of the decocted 
prescription, taking 1-2g each time. 
The dosage varies between 0.9 to 5g according to different authors: 
121 
 
- Use 1.5-4.5 g (Leite, 2005b; Gongwang, 2001b; Tierra, 1997b); 
- 1-5g (Chu, 2009; Flaws, 1999d) used as powder form or added to the decoction when 
they are ready for use (Chu, 2009);  
- 2-5g. It should be decocted later or administered separately. Grind it into powder for oral 
administration with boiled water (Anonymous, 2009f);  
- 2-5g is used in decoction for oral use and decocted later or soaked in water for taking;  
- 1-2g of the powder is taken after it is mixed with water (Yanfu, 2002d); 
- 1-1.5g each time with water (Gongwang, 2001b); 
- 0.9-3g decocted (Greten, 2007). 
-1-4.5g (CP, 2005b). 
 
Precautions and contraindications 
Because this medicinal is acrid and hot and stirs the blood, it is contraindicated in those 
with yin vacuity fire effulgence, those with interior replete heat (Flaws, 1999d; Leite, 
2005b), and in pregnant women (CP, 2005b; Flaws, 1999d; Gongwang, 2001b; Leite, 
2005b; Tierra, 1997b; Yanfu, 2002d). Do not use this herb in the presence of deficient 
heat (Tierra, 1997b), excessive heat (Gongwang, 2001b; Tierra, 1997b). Contraindicated 
for bleeding due to blood heat (Gongwang, 2001b; Tierra, 1997b; Yanfu, 2002d), and 
used with caution for hypermenorrhea (Yanfu, 2002d). Contraindicated in patients with 
hyperactivity of fire caused by yin deficiency (Gongwang, 2001b). 
 
7.3.2. Ramuli cinnamomi cassiae ( 桂枝 ) according to Traditional 
Chinese Medicine 
 
The source is from the tender branch of C. cassia Presl, family Lauraceae. Its producing 
areas are mainly the provinces of Guangdong, Guangxi, and Yunnan. The medicinal 
material is collected in spring and summer, and dried in shade or in the sun, then is cut 
into pieces or segments for use (Ganzhong et al., 2003c; Yanfu, 2002c).  
 
Common Name 
Cassia twig (Anonymous, 2009n; Ganzhong et al., 2003d; Gongwang, 2001c), cinnamon 
twig (Anonymous, 2009n; Chu, 2009; Liu et Tseng, 2005c; Ganzhong et al., 2003d; Tierra, 
1997b).  
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Pharmaceutical Name 
Ramulus Cinnamomi (Ganzhong et al., 2003d; Gongwang, 2001c; Yanfu, 2002c), Ramuli 
cassiae (Greten, 2007), Ramulus Cinnamomi Cassiae (Anonymous, 2009n; Chu, 2009; 
Flaws, 1999e).  
 
Pynin name 
Gui Zhi (Anonymous, 2009m; Anonymous, 2009n; Chu, 2009; Liu et Tseng, 2005c; Ni, 
1991b; Ody, 2004b; Tierra, 1997b), Guizi (Gongwang, 2001c; Greten, 2007). 
 
Part used 
Twig (Anonymous, 2009n; Greten, 2007; Ganzhong et al., 2003d; Gongwang, 2001c; 
Ody, 2004b; Tierra, 1997b).  
 
Classification 
Causes sweat and dispels repletion in flesh and extima. Belongs to the group ―Liberantia 
extimae acria et calida- I a)‖ (Greten, 2007), i.e. ―Warm, Spicy Herbs that Release the 
Exterior‖ (Anonymous, 2009n). 
 
Sapor &Temperature  
Pungent (Anonymous, 2009m; Anonymous, 2009f; Chu, 2009; Ganzhong et al., 2003d; 
Gongwang, 2001c; Greten, 2007; Liu et Tseng, 2005c; Ni, 1991b; Ody, 2004b; Tierra, 
1997b; Yanfu, 2002c), sweet (Anonymous, 2009n; Anonymous, 2009f; Chu, 2009; Ni, 
1991b; Gongwang, 2001c; Greten, 2007; Ody, 2004b; Yanfu, 2002c), warm (Anonymous, 
2009m; Anonymous, 2009n; Anonymous, 2009f; Chu, 2009; Ni, 1991b; Ganzhong et al., 
2003d; Gongwang, 2001c; Greten, 2007; Liu et Tseng, 2005c; Ody, 2004b; Tierra, 1997b; 
Yanfu, 2002c). 
 
Orbs 
Pulmonal, Cardial, Vesical (Anonymous, 2009m; Anonymous, 2009n; Anonymous, 2009f; 
Chu, 2009; Ganzhong et al., 2003d; Gongwang, 2001c; Greten, 2007; Leite, 2005c; Liu 
et Tseng, 2005c; Ni, 1991b; Ody, 2004b; Tierra, 1997b; Yanfu, 2002c).  
 
Functions 
Induces diaphoresis to dispel pathogenic factors from the exterior of the body 
(Anonymous, 2009f; CP, 2005c; Flaws, 1999e; Ganzhong et al., 2003d), warms the 
channels to relieve pain, stimulates menstruation, and reinforces Yang to promote the flow 
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of Qi (Flaws, 1999e; Ganzhong et al., 2003d). Balances Ying/Wei Qi, warms channel, 
disperses wind–cold–damp, circulates Yang Qi, strengthens Heart Yang, warms uterus 
(Liu et Tseng, 2005c). Warms the channels to ensure the flow of the yang-qi (Anonymous, 
2009f). Induces sweating to relieve superficies and activate yang and circulate qi by 
warming channel (Gongwang, 2001c; Yanfu, 2002c). To get better Yang Qi (Ody, 2004b). 
To dispel algor (Leite, 2005c; Gongwang, 2001c; Ody, 2004b). 
Indications 
Cinnamon twigs are used to treat common colds due to pathogenic algor venti 
(Anonymous, 2009f; Gongwang, 2001c). For algor venti for sligth fever, aversion to cold, 
headeache, stiff neck (Gongwang, 2001c). Reumathic arthritis for excessive algor-humor, 
pain and heavy sensation of the joints, especially the shoulders (Gongwang, 2001c). For 
the treatment of arthralgia due to wind-cold-dampness (Anonymous, 2009f). Warms the 
channels and collaterals (Anonymous, 2009n; Ody, 2004b), for wind-cold damp bi pain, 
arthritic complaints, especially in the shoulders (Anonymous, 2009n). Unblocks the Yang 
Qi of the Chest (Anonymous, 2009n; Ody, 2004b), for chest pain, palpitations, edema, 
dysuria, and abdominal fullness (Anonymous, 2009n).  Algor in the stomach and 
abdominal pain for cold pain in the epigastric regions relieved by pressure and warmth, 
pale or sallow complexion (Gongwang, 2001c). Congested fluids syndrome for fullness, 
stuffiness and discomfort in the chest and hypochondriac regions, vertigo, palpitation, 
cough due to shortness of breath, etc. due to deficiency of the heart and the spleen yang, 
poor circulation of yang qi and water retention (Gongwang, 2001c). Water retention 
syndrome from urine retention, edema, headache, fever, irritability and thirst, vomiting 
right after drinking, a white and greasy coating of the tongue or a white and thick coating 
(Gongwang, 2001c). Obstruction in the chest due to hyperactivity of the heart yang 
accompanied by chest congestion, shortness of breath and radiating precardialgia 
(Gongwang, 2001c). Cinnamon twigs alleviate colds, flu, fever, joint, shoulder, limb and 
abdominal pain, edema, weakness of the heart and muscular contractions. It also warms 
the hands (Tierra, 1997b). Used for exterior cold with underlying deficiency, painful 
shoulder joints, palpitations, connects heart fire and kidney water, painful menses due to 
cold (Liu et Tseng, 2005c). Used in external contraction wind cold with symptoms of 
headache, aversion to cold, etc. (Flaws, 1999e; Gongwang, 2001c). For arthralgia due to 
wind cold dampness with pain in the shoulder, back, limbs, and joints (Ganzhong et al., 
2003d). It is used for pains due to xue stasis due to stagnation of cold (Yanfu, 2002c). For 
cold obstructing the flow of xue in dysmenorrhea and other gynecological conditions 
(Anonymous, 2009n; Ganzhong et al., 2003d; Gongwang, 2001c) like menostasis and 
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dysuria, amenorrhea, irregular menstruation, climacteric syndrome (Ganzhong et al., 
2003d) and edema due to the loss of control of the bladder-qi (Anonymous, 2009f).  
 
Chinese therapeutic actions and examples of major combinations 
 Combination with White Peony Root (Baishayao) and Cassia Twig (Guizi) can be 
used for influenza with sweating, while combination with Ephedra (Mahuang) can 
be used to treat influenza without sweating (Gongwang, 2001c). 
 For headache, fever, and aversion to cold due to algor venti, it is used with Radix 
Paeoniae Alba (Bai Shao), uncooked Rhizoma Zingiberis (Sheng Jiang), Fructus 
Zizyphi Jujubae (Da Zao), and Radix Glycyrrhizae (Gan Cao) in ―The Cinnamon 
Twig Decoction‖ (Gui Zhi Tang) (Ganzhong et al., 2003d). 
 It is often used together with Mahuang for algor venti, headache, pain all over the 
body, pain in the joints, aversion to cold and absence of sweating (Gongwang, 
2001c), to produce a stronger diaphoresis (ex: Mahuang Decoction) (Ganzhong et 
al., 2003d). 
 Add Licorice Root (Gancao) for deficiency of the heart yang, palpitation 
(Gongwang, 2001c). 
 Add Twotooth Achyrantes Root (Niuxi) for pain of the back, lumbar and legs due to 
algor, amenorrhea and dysmenorrhea due to algor and stasis of qi and xue 
(Gongwang, 2001c). 
 Add Fresh Ginger (Shengjiang) for pain in the epigastrium, vomiting of watery fluid, 
nausea, vomiting, and hiccups caused by cold in the stomach or water retention in 
the stomach (Gongwang, 2001c). 
 Add White Peony Root (Baishaoyao) for aversion to cold, fever, spontaneous 
perspiration, aversion to wind, superficial and slow pulse (The Taiyang channel is 
affected by ventus) when externally contracted with algor venti and disharmony of 
the qi nutritivum and qi defensivum (Gongwang, 2001c). 
 Add Tuckahoe (Fuling) for water retention, palpitation and shortness of breath due 
to heart yang deficiency (Gongwang, 2001c). 
 Add Medicinal Evodia Root (Wuzhuyu) for irregular menstruation and cold pain in 
the lower abdomen due to deficiency cold of Impedimental and Respondens 
channels (Gongwang, 2001c). 
 Add Peach Seed (Taoren), Tree Peony Bark (Mudanpi) for hysteromyoma 
(Gongwang, 2001c). 
 Add Chinese Angelica Root (Danggui), Manchurian Wildginger Herb (Xixin) for 
cold stagnation in the channel, extremely cold hands and feet, pain in the lumbar 
region and knees (Gongwang, 2001c). 
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 Add Tuckahoe (Fuling), Lagerhead Atractylodes Rhizome (Baizhu) for urine 
retention (Gongwang, 2001c). 
 Add Apricot Seed (Xingren), Oficinal Magnolia Bark (Houpo) for cough and asthma 
due to a reversal upward flow of qi (Gongwang, 2001c). 
 Add Snakegourd Fruit (Gualou), Longstament Oion Bulb (Xiebai) for radiating 
precardialgia, palpitation, knotty and regularly-intemittent pulse caused by 
hyperactivity of the heart yang (Gongwang, 2001c). 
 Add White Peony Root (Baishayao), Malt Sugar (Yitang) for pain in the 
epigastrium due to insufficiency and coldness in the spleen and stomach 
(Gongwang, 2001c). 
 In terms of its effects of regulating qi nutritivum and promoting the flow of yang qi, 
Guizhi is used together with Mahuang for the treatment of excessive exterior 
syndromes of ventus-algor-humor; in this case, Guizhi assists Mahuang in exerting 
a diaphoretic effect, for example the Mahuang Decoction (Ganzhong et al., 
2003d).  
 For exterior repletion lack of sweating, one can combine Ramulus Cinnamomi 
Cassiae with Herba Ephedrae (Mahuang), etc. as in Mahuang Tang (Ephedra 
Decoction) (Flaws, 1999e; Ganzhong et al., 2003d).  
 Based on its effects of dispelling wind, cold and damp, and relieving by warming 
and activating conduits, guizhi is usually used together with Fuzi (Radix Aconiti 
Lateralis Praeparata) to treat wind-cold-damp arthralgic syndrome, for example the 
Guizhifuzi Decoction (Ganzhong et al., 2003d). 
 Because of its effect of warming, and removing water retention, Guizhi is usually 
employed in association with Fuling (Poria), Baizhu, and so on, to produce 
associate effects of warming and circulating splenic yang, resolving dampness and 
discharging water, for the treatment of diseases caused by humor and phlegmy 
fluid. Based on its effects of warming visceral qi, guizhi is often in conjunction with 
Fuling and Zexie (Rhizoma Alismatis) to produce associate effects of discharging 
water and excreting humor for treatment of oedema and difficult urination, for 
example the Wuling Decoction (Ganzhong et al., 2003d). 
 It is combined with Poria alba (Fuling), Rhizoma Atractylodis Macrocephalae 
(Baizhu), etc. such as Ling Gui Zhu Gan Tang for the treatment of palpitation, 
dizziness and fullness in the chest due to retention of fluids (Yanfu, 2002c). 
 Combined with Polyporus (Zhuling), Rhizoma Alismatis (Zexie), etc., such as 
Wuling San (Powder) for dysuria and edema (Yanfu, 2002c). 
 In  terms of its effect of warming and circulating yang qi in the chest, Guizhi is 
frequently used in company with Fructus Auratii Immaturus (Zhishi), Fructus 
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Trichosanthis (Gualou), Bulbus Alli Macrostemonis (Xiebai), and so on, for the 
treatment of palpitations due to blockage of qi in the chest, for example, the Zhishi-
xiebai-guizhi Decoction (Ganzhong et al., 2003d). 
 In the line with its effect of assisting yang and normalizing the pulse, guizhi is often 
used jointly with Radix Glycyrrhizae (Gancao) baked with honey, ginseg, Colla 
Corri Asini (Ejiao), and so on, for the treatment of knotty and intermittent pulse, for 
example the Zhigancao Decoction (Ganzhong et al., 2003d). 
 Combined with Semen Persicae (Taoren), Cortex Moutan (Mudanpi) etc. such as 
Guizhi Fuling Wan (Pill) for the treatment of irregular menstruation, dysmenorrhea, 
amenorrhea or abdominal mass due to blood stagnation caused by invasion of 
cold (Yanfu, 2002c). 
 Combined with Radix Aconiti Lateralis Praeparata (Fuzi) as in Guizhi Fuzi Tang for 
the treatment of arthralgia due to stagnation of wind-cold-damp (Yanfu, 2002c). 
 If there is an insufficiency of qi constructivum and defensivum with xue impediment 
stubborn numbness, one can combine Ramulus Cinnamomi Cassiae with Radix 
Astragali Membranacei (Huang Qi) and Radix Paeoniae Lactiflorae (Shao Yao) as 
in Huang Qi Gui Zhi Wu Wu Tang (Astragalus & Cinnamon Twig Five Materials 
Decoction) (Flaws, 1999e). 
 Used for women‘s blood cold stasis and stagnation with menstrual irregu larity, 
blocked menstruation, abdominal pain, and concretions and conglomerations, 
Ramulus Cinnamomi Cassiae is commonly combined with Radix Angelicae 
Sinensis (Dang Gui), Radix Paeoniae (Shao Yao), Radix Ligustici Wallichii (Chuan 
Xiong), Semen Pruni Persicae (Tao Ren), Cortex Radicis Moutan (Dan Pi), and 
other such blood-quickening, freeing the flow of the channels medicinals as in Wen 
Jing Tang (Warm the Channels Decoction) or Gui Zhi Fu Ling Wan (Cinnamon 
Twigs & Poria Pills) (Flaws, 1999e).  
 To warm and circulate the xue for dispelling cold and xue stasis, Guizhi is 
employed together with Radix Angelicae Sinensis (Danggui) and Rhizoma 
Chuanxiong (Chuanxiong), for example the Wenjing Decoction (Ganzhong et al., 
2003d). 
 Used for middle burner vacuity cold with stomach and venter insidious pain with a 
liking for obtaining warmth and pressure. In that case, Ramulus Cinnamomi 
Cassiae is commonly combined with Radix Albus Paeoniae Lactiflorae (Bai Shao), 
Maltose (Yi Tang), and Radix Astragali Membranacei (Huang Qi) as in Huang Qi 
Jian Zhong Tang (Astragalus Fortify the Center Decoction) (Flaws, 1999e). 
 Used for heart-spleen yang vacuity, yang qi not moving, with water dampness 
gathering internally. The symptoms of this are upper back pain and rib-side 
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distention, cough counterflow, and dizziness. In that case, Ramulus Cinnamomi 
Cassiae is commonly combined with Sclerotium Poriae Cocos (Fu Ling) and 
Rhizoma Atractylodis Macrocephalae (Bai Zhu) as in Ling Gui Zhu Gan Tang 
(Poria, Cinnamon Twig, Atractylodes & Licorice Decoction).  
 If there is urinary bladder qi transformation not moving inhibited urination and 
water swelling, Ramulus Cinnamomi Cassiae is commonly combined with 
Sclerotium Poriae Cocos (Fu Ling) and Sclerotium Polypori Umbellati (Zhu Ling) 
as in Wu Ling San (Five [Ingredients] Poria Powder) (Flaws, 1999e). 
 Used for chest impediment and chest pain or heart stirring palpitations and a 
bound, regularly intermittent pulse. For the former, Ramulus Cinnamomi Cassiae 
is commonly combined with Fructus Immaturus Citri Aurantii (Zhi Shi), Fructus 
Trichosanthis Kirlowii (Gua Lou), and Bulbus Allii (Xie Bai) as in Zhi Shi Xie Bai 
Gui Zhi Tang (Immature Aurantium, Allium & Cinnamon Twig Decoction) (Flaws, 
1999e). 
 For the latter, Ramulus Cinnamomi Cassiae is commonly combined with mix-fried 
Radix Glycyrrhizae (Gan Cao), Radix Panacis Ginseng (Ren Shen), and 
Gelatinum Corii Asini (E Jiao) as in Zhi Gan Cao Tang (Mix-fried Licorice 
Decoction) (Flaws, 1999e). 
 For Yang Stagnation and retention of water in the body due to Deficiency of the 
Heart Yang and Spleen Yang, which presents as a cold feeling in the back, 
hypochondriac distension, cough, dyspnea, hiccups, vertigo, difficulty in urination, 
and edema, it is used with Sclerotium Poriae Cocos (Fu Ling), Sclerotium Polypori 
Umbellati (Zhu Ling), and Rhizoma Alismatis (Ze Xie) in ―Wu Ling Powder‖ (Wu 
Ling San) (Ganzhong et al., 2003d). 
 For chest pain due to Qi obstruction, it is used with Fructus Trichosanthis (Gua 
Lou), Bulbus Allii Macrostemi (Xie Bai), and Fructus Aurantii Immaturus (Zhi Shi) 
(Ganzhong et al., 2003d). 
 For palpitations or slow pulse with irregular intervals, it is used with honey-
processed licorice root (Gan Cao), ginseng (Ren Shen), and Colla Corii Asini (A 
Jiao) in ―The Processed Licorice Decoction‖ (Zhi Gan Cao Tang) (Ganzhong et al., 
2003d). 
 For irregular menstruation, amenorrhea, dysmenorrhea, and masses in the 
abdomen caused by Cold in the Blood, it is used with herbs that promote the 
circulation of Blood and restore regular menstrual flow, such as Radix Angelicae 
Sinensis (Dang Gui), Rhizoma Ligustici Chuanxiong (Chuan Xiong), Cortex 
Moutan (Mu Dan Pi), and Semen Persicae (Tao Ren) in ―The Warming Channels 
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Decoction‖ (Wen Jing Tang) or ―The Cinnamon Twig and Sclerotium Poriae Cocos 
Pill‖ (Gu Zhi Fu LingWan) (Ganzhong et al., 2003d). 
 
Precautions and contraindications 
As a drug with a pungent taste and a warm nature, the use of Guizhi is prohibited in the 
treatment of diseases and syndromes involving yin deficiency (Flaws, 1999e; Ganzhong 
et al., 2003d; Gongwang, 2001c; Wu, 2005b) and excessive yang, and bleeding due to 
heat in blood (Ganzhong et al., 2003d; Gongwang, 2001c). Contraindicated in warm 
febrile diseases (Anonymous, 2009n; Flaws, 1999e; Gongwang, 2001c; Ody, 2004b; Wu, 
2005b). Caution should be taken when this drug is used for treating pregnant women 
(Anonymous, 2009n; Flaws, 1999e; Ganzhong et al., 2003d; Gongwang, 2001c; Ody, 
2004b; Wu, 2005b; Yanfu, 2002c) or patients with menorrhagia (Anonymous, 2009n; 
Flaws, 1999e; Ganzhong et al., 2003d; Wu, 2005b). Contraindicated for the syndromes 
such as exuberant heat impairing yin in seasonal febrile diseases, hyperactivity of yang 
due to yin deficiency in miscellaneous diseases and bleeding due to blood-heat (Yanfu, 
2002c). Use cautiously in women with excessive menses (Gongwang, 2001c). 
 
Dosage and method of use 
According to Liu et Tseng (2005) and Tierra (1997) cinnamon twigs should be prepared as 
an infusion: use 3-9g to treat exterior conditions and 9-15g to treat pain (Anonymous, 
2009n; Leite, 2005c; Tierra, 1997b). Use 3–10 g, decocted (Anonymous, 2009f; Chu, 
2009; Flaws, 1999e; Ni, 1991b; Wu, 2005b) or 3-9g (CP, 2005c; Gongwang, 2001c; 
Greten, 2007; Ody, 2004b; Yanfu, 2002c). According to Ganzhong et al. (2003c) an oral 
dose of Guizhi is 5-10g, in the form of decoction, pills or powder.  
 
Ramuli versus Cortex  
The both medicines can expel cold and strengthen yang, Ramuli cinnamomi cassiae 
dominates going up to be a bit on the side of expelling cold to relieve exterior syndrome 
while Cortex Cinnamomi cassiae;  dominates warming the interior to enter the lower 
energizer, being a bit on the side of warming kidney-yang (Yanfu, 2002d). Cassia bark 
and cassia twigs have the functions of warming blood, supporting the transformation of qi 
and dispelling the accumulation of algor. Cassia twig, being light, tends to go upwards and 
has the functions of invigorating yang and transforming qi, relieving the exterior syndrome 
and expelling algor. Cassia twig also acts in the limbs and has the functions of warming 
and dredging the channels, and invigorating qi and xue. While cassia bark tends to go 
downwards and has the functions of invigorating kidney yang and letting the fire back to 
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the gate of life. Thus it is applied to cases due to excessive yin and algor in the intima and 
kidney yang deficiency (Gongwang, 2001b). 
Ramuli is hot, sweet, warm, belongs to Cardial, Pulmonal and Vesical conduit. It induces 
sweat, opens muscle, warms and opens the conduits, helps yang, transforms qi, has the 
function of against heteropathy and is a common used as a ―Liberantia extima calida” 
herb. Cortex tastes hot, sweet and belongs to Renal, Lienal, Cardial and Hepatical 
conduit, has the function of strength ardor, helps yang, leads ardor to the origin, leads out 
algor, stops pain, moves xue and opens the conduits, which is a common used group ―IX 
Tepefacientia intimae” herb. Both herbs have the essential oil content, which the main 
ingredient is cinnamaldehyde (Shen et al., 2002). Cortex is considered warmer than 
Ramuli, affecting the interior of the body, whereas Ramuli is used for the exterior (Ody, 
2004b). According to Chu (2009) usually Cortex is used in tonic while Ramuli is used for 
expelling wind and dampness but they can be used interchangeably. 
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7.4. Radix Glycyrrhizae 
 
Introduction 
Glycyrrhiza has been described as ―the grandfather of herbs‖ (Asl et Hosseinzadeh, 
2008). The genus Glycyrrhiza, belongs to the Family Leguminosae (Anonymous, 2009; 
Anonymous, 2009l; Asl et Hosseinzadeh, 2008; Isbrucker et Burdock, 2006; Leite, 2005e; 
Newall et al., 1996b; Shin et al., 2008)/Fabaceae (Anonymous, 2009; Anonymous, 2009l; 
Dhingra et Sharma, 2006; Gupta et al., 2008; WHO, 1999b; Visavadiya et 
Narasimhasharya, 2006) or Papilionaceae (Gupta et al., 2008; Visavadiya et 
Narasimhasharya, 2006). Glycyrrhiza genus includes about 30 species including G. 
glabra, G.uralensis, G.inflata (Anonymous, 2009l; Asl et Hosseinzadeh, 2008), G.aspera, 
G.korshinsky and G.eurycarpa (Asl et Hosseinzadeh, 2008). But according to Isbrucker et 
Burdock (2006) there are only about 14 species known.  
G glabra (Fig. 50) also includes 3 varieties: Persian and Turkish licorices are assigned to 
G. glabra var. violacea, Russian licorice is G. glabra var. gladulifera, and Spanish and 
Italian licorices are G. glabra var. typica (Asl et Hosseinzadeh, 2008). Glycyrrhiza 
uralensis Fish is a well-known Chinese herbal medicine used for the treatment of various 
diseases (Cheng et al., 2008; Ma et al., 2005) as well as a tonic medicine for thousands of 
years (Cheng et al., 2008). 
 
 
Fig. 50. Glycyrrhiza glabra (adapted from Shen et al., 2007). 
 
Chinese licorice roots can be obtained from the three species of Glycyrrhiza genus, G. 
glabra, G. uralensis or G. inflata (Anonymous, 2009l; Asl et Hosseinzadeh, 2008; 
Blumenthal, 2003; WHO, 1999b). By definition, Radix Glycyrrhizae consists of the dried 
roots and rhizomes of Glycyrrhiza glabra L. (Blumenthal, 2003; Sweetman, 2009d; WHO, 
1999b) and its varieties or of Glycyrrhiza uralensis Fisch (Fig.51-52), (Blumenthal, 2003; 
WHO, 1999b) or other varieties of Glycyrrhizae, and contains no less than 4% glycyrhhizic 
acid (glycyrrhizin). The roots of Glycyrrhiza glabra L. are popularly known as liquorice 
(Dhingra et Sharma, 2006; Newall et al., 1996b), Liquiritiae radix (FP, 2005) or Liquiratae 
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officinalis Moench (WHO, 1999b) and are used as a folk medicine both in Europe and in 
Eastern countries (Visavadiya et Narasimhasharya, 2006).  
 
Fig. 51. Glycyrriza uralensis Fisch (adapted from Wu, 2005c). 
 
Historical perspective 
The licorice (liquorice) plant has a long and storied history of use in both Eastern and 
Western cultures pre-dating the Babylonian and Egyptian empires (Isbrucker et Burdock, 
2006). Historically, the dried rhizome and root of this plant were employed medicinally by 
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the Egyptian, Chinese, Greek, Indian, and Roman civilizations (Anonymous, 2005; Fiore 
et al., 2008) as an expectorant and carminative (Anonymous, 2005). The genus name 
Glycyrrhiza is derived from the ancient Greek word for ‗sweet root‘ (Gr. glykos (sweet) + 
rhiza (root)) (Anonymous, 2005; Anonymous, 2009l; Isbrucker et Burdock, 2006), which 
was later Latinized to liquiritia and eventually to licorice. The two principal forms in 
commerce are licorice root (Liquiriti radix) and the extract (Glycyrrhizae extractum crudum 
or Succus liquiritiae). The ancient Greeks and Romans are known to have cultivated the 
plants in the third century (Isbrucker et Burdock, 2006; Verma et Thuluvath, 2007). The 
first report of medicinal use comes from Greeks, who recommended it for the treatment of 
gastric and peptic ulcers (Gupta et al., 2008). Licorice was a prescriptive agent of 
Hippocrates in the treatment for asthma, dry cough, and other ―pectoral diseases‖ and 
was also thought to be effective in preventing thirst (Isbrucker et Burdock, 2006; Verma et 
Thuluvath, 2007). Furthermore, Alexander the Great distributed the root to his soldiers to 
alleviate thirst (Huang, 1999). Licorice was used in Arabic medicine during the middle 
Ages, as documented by the Canone of Ibn Sina (980–1037 AD), a summary of 
Hippocrates and Galen‘s medicine (Fiore et al., 2008).  The use of liquorice (Gan Cao) is 
documented in the oldest source on remedies in China, the Shennong bengao created 
200 B.C. According to legend this work is based on sources dating back to the Emperor 
Shennong (ca. 2700 B.C.) (Fiore et al., 2005). In Chinese traditional medicine, licorice 
(Gan Cao) remains one of the oldest and most commonly prescribed herbs and has been 
used in the treatment of numerous ailments ranging from tuberculosis to peptic ulcers 
(Isbrucker et Burdock, 2006; Verma et Thuluvath, 2007). Licorice is one of the oldest and 
widely used herbs from the ancient medical history of Ayurveda, both as a medicine and a 
flavoring herb to disguise the unpleasant flavor of other medications. Licorice is used to 
relieve ‗Vata‘ and ‗Kapha‘ inflammations, eye diseases, throat infections, peptic ulcers, 
arthritic conditions, and liver diseases in Indian Ayurveda system (Gupta et al., 2008). The 
uses of Glycyrrhiza glabra (in Sanskrit: klitaka, madhuka, yasti or yastimadhuka) reported 
here apart from its use in antidote mixtures for a variety of acute and chronic poisonings, 
include improvement of the voice, an indication mentioned in the context of viral 
respiratory tract infections, wound infections, operation wounds of the ear, excessively 
bleeding punctures from bloodletting and acute and chronic liver diseases like hepatitis 
(Fiore et al., 2005). European, Indian and Chinese traditions all contain references to 
antiviral effects in the context of viral induced voice changes in laryngitis, pharyngitis, 
most likely viral induced cough, viral hepatitis and viral skin diseases like condyloma and 
ulcers (Fiore et al., 2005). The reported indications for licorice include some which were 
common in Europe like: pharyngitis, cough, palpitations, gastric pain, ulcers in the 
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intestinal tract and sores. In addition to this, an area of application not found in Europe is 
intoxication by drugs and poisoned food (Fiore et al., 2005). 
In modern medicine, licorice extracts are often used as a flavoring agent to mask bitter 
taste in preparations, and as an expectorant in cough and cold preparations. Licorice 
extracts have been used for more than 60 years in Japan to treat chronic hepatitis, and 
also have therapeutic benefit against other viruses, including human immunodeficiency 
virus (HIV), cytomegalovirus (CMV), and Herpes simplex. Deglycyrrhizinated licorice 
(DGL) preparations are useful in treating various types of ulcers, while topical licorice 
preparations have been used to sooth and heal skin eruptions, such as psoriasis and 
herpetic lesions (Anonymous, 2005). 
 
Geographical Distribution 
Licorice species are perennial herbs native to the Mediterranean Region (Anonymous, 
2005; Asl et Hosseinzadeh, 2008; Fiore et al., 2008), central to southern Russia, and Asia 
Minor to Iran, now widely cultivated throughout Europe, the Middle East and Asia (Asl et 
Hosseinzadeh, 2008, Fiore et al., 2008). Commercially important sources are Spain, Iraq, 
Iran, Turkey, Russia and China, and although there are no known prohibitions against use 
of any species, variety or country of origin, some types are not sweet enough to have 
commercial value (Isbrucker et Burdock, 2006). Chinese licorice (G. uralensis and G. 
pallidiflora) are somewhat smaller, related plants, regarded as separate species of 
Glycyrrhiza (Isbrucker et Burdock, 2006). Glycyrrhiza uralensis is native to Northern 
China, Mongolia, and Siberia (WHO, 1999b). Glycyrrhiza glabra is native to central and 
south-western Asia (Fiore et al., 2008; WHO, 1999b) and the Mediterranean region (Fiore 
et al., 2008; Isbrucker et Burdock, 2006; WHO, 1999b). It is cultived in the Mediterranean 
basin of Africa, in southern Europe, and in India (WHO, 1999b). Glycyrrhiza glabra is a 
hardy herb or under shrub, erect grows to about 2m height. The roots are long, cylindrical 
(Gupta et al., 2008; WHO, 1997d), fibrous, flexible 20-22cm long and 15mm in diameter, 
with or without corks, corks reddish, furrowed, ligth-yellow inside, sweet taste (WHO, 
1997d) thick and multibranched (Gupta et al., 2008). It has oval leaflets, white to purplish 
flower clusters, and flat pods. Below ground, the licorice plant has an extensive root 
system with a main taproot and numerous runners. The main taproot, which is harvested 
for medicinal use, is soft, fibrous, and has a bright yellow interior (Anonymous, 2005). 
Licorice also grows in the United States (var. lepidota) and England (var. typica) but 
neither represents a significant contribution to world production (Isbrucker et Burdock, 
2006). The harvesting of licorice root occurs in the autumn of its third or fourth year of 
growth. The roots are dug up, washed and transported to warehouses for bailing, sorting 
and drying. The dried roots are crushed by millstones and the pulp is boiled to make the 
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extract. After removal of the solids, the extract is vacuum dried to a dark paste, which is 
cast into blocks or short sticks, or may be dried to a powder. Licorice paste is the 
preferred form for flavoring tobacco whereas licorice powder is preferred for confectionery 
and pharmaceuticals (Isbrucker et Burdock, 2006).  
 
Selected vernacular names 
Glycyrrhiza glabra L. and its varieties 
Adimaduram, akarmanis, asloosoos, aslussos, athimaduram, athimaduramu, 
athimathuram, bekh-e-mahak, bois doux, cha en thet, estameee, gancao, glycyrrhiza, 
herbe aux tanneurs, hsi-pan-ya-kan-tsao, irk al hiel, irk al hilou, irksos, jakyakgamcho-
tang, jashtimadhu, jethimadh, jethimadha, kanpo, kanzo, kan-ts´ao, kum cho, 
Lakritzenwurzel, licorice, licorice root, liquiritae radix, liquorice, liquorice root, 
madhuyashti, madhuyasthi rasayama, mulathee, muleti, mulhatti, neekhiiyu, Persian 
licorice, racine de reglisse, racine douce, reglisse, reglisse, oficinalis, rhizoma 
glycyrrhizae, Russian licorice, Russisches Sussholz, si-pei, sinkiang licorice, Spanish 
licorice, Spanish liquorice, Spanisches Sussholz, Susshlzwurzel, sweet root, sweet wood, 
ud al sus, velmi, walmee, welmi, xi-bei, yashti, yashtimadhu, yashtimadhukam, 
yashtomadhu (WHO, 1999b). 
Glycyrrhiza uralensis Fisch. 
Chinese licorice, Chinese liquorice, gancao, kan-ts´ao, kanso, kansoh, licorice root, 
liquiritae radix, north-eastern Chinese licorice, saihokukanzoh, tohoku kanzo, tongpei 
licorice, tung-pei-kan-tsao. Ural loquorice, uraru, kanzo (WHO, 1999b). 
 
 
Fig. 52. Glycyrrhiza uralensis Fisch (adapted from Shen et al., 2007). 
Other names  
Alcacuz, Alcazuz, Deglycyrrhized Licorice, Gan Cao, Gan Zao, Glabra, Glycyrrhiza, 
Glycyrrhiza radix, Glycyrrhizae, Glycyrrhizic Acid, Glycyrrhizinic Acid, Isoflavone, Jethi-
Madh, Lakritze, Liquiritiae radix, Liquirizia, Liquorice, Mulhathi, Orozuz, Phytoestrogen, 
135 
 
Radix Glycyrrhizae, Regliz, Russian Licorice, Spanish Licorice, Subholz, Sussholz, Sweet 
Root, Yashti-Madhu, Yashti-Madhuka, Zhi Gan Cao (Anonymous, 2009). 
 
Plant material of interest 
Dried root and rhizome (Anonymous, 2005; WHO, 1999b; WHO, 1997d). 
 
Organoleptic properties 
Odour slight characteristic; taste, very sweet (WHO, 1999b). 
 
General identity tests 
Macroscopic, microscopic, and microchemical examinations; thin layer chromatographic 
analysis for the presence of glycyrrhizin (FP, 2005; WHO, 1999b) and isoliquirritin (FP, 
2005). 
 
Purity tests 
Microbiology 
The test for Salmonella spp. in Radix Glycyrrhizae products should be negative. The 
maximum acceptable limits of other microorganisms are as follows. For preparation of 
decoction: aerobic bacteria—not more than 107/g; fungi—not more than 105/g; 
Escherichia coli—not more than 102/g. Preparations for internal use: aerobic bacteria—
not more than 105/g or ml; fungi—not more than 104/g or ml; enterobacteria and certain 
Gram-negative bacteria—not more than 103/g or ml; Escherichia coli—0/g or ml (WHO, 
1999B). 
Total ash 
Not more than 7% (WHO, 1999b), not more than, 10,0 % on uncruded drug and not more 
than, 6,0 % on crude drug (FP, 2005). 
Acid-insoluble ash 
Not more than 2% (WHO, 1999b), not more than, 2.0 % on uncruded drug and not more 
than, 0.5 % on crude drug (FP, 2005). 
Sulfated ash 
Not more than 10% (WHO, 1999b). 
Water-soluble extractive 
Not less than 20% (WHO, 1999b). 
Dilute alcohol-soluble extractive 
Not less than 25% (WHO, 1999b). 
Pesticide residues 
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To be established in accordance with national requirements. Normally, the maximum 
residue limit of aldrin and dieldrin for Radix Glycyrrhizae is not more than 0.05 mg/kg 
(WHO, 1999b). 
Heavy metals 
Recommended lead and cadmium levels are no more than 10 and 0.3mg/kg, respectively, 
in the final dosage form of the plant material (WHO, 1999b). 
Radioactive residues 
Analysis of strontium-90, iodine-131, caesium-134, caesium-137, and plutonium-239 
(WHO, 1999b). 
Other purity tests 
Alcohol-soluble extractive, chemical, and foreign organic matter tests to be established in 
accordance with national requirements (WHO, 1999b). 
Loss on drying not more than 10%, in 10,0 g of pulverised sample determined in 
greenhouse in 100-105°C, for 2 h (FP, 2005). 
Chemical assays 
Assay for glycyrrhizin (glycyrrhizic acid, glycyrrhizinic acid) content (at least 4%) by means 
of spectrophotometric, thin layer chromatographic densitometric or high performance 
liquid chromatographic methods (WHO, 1999b). Determination by liquid chromatography 
to determine the content in glycyrrhizic acid: at least 4.0 % of glycyrrhizic acid (C42H62O16, 
Mr 823) (dried plant) (FP, 2005). 
 
Chemicals constituents 
As with most plant extracts, the number of chemical constituents is potentially vast and 
greatly influenced by a constellation of genetic, environmental, and processing factors; 
licorice root extract is no exception (Isbrucker et Burdock, 2006). A number of 
components have been isolated from licorice, including a water-soluble, biologically active 
complex that accounts for 40-50 % of total dry material weight. This complex is composed 
of triterpene saponins, flavonoids, polysaccharides, pectins, simple sugars, amino acids, 
mineral salts, and various other substances (Anonymous, 2005). The main components 
are the triterpene saponin glycyrrhizin (also known as glycyrrhizic or glycyrrhizinic acid) 
and the respective aglycone, the glycyrrhetic acid or glycyrrhetinic acid (Shin et al., 2008; 
Visavadiya et Narasimhasharya, 2006), which are believed to be partly responsible for 
anti-ulcer, anti-inflammatory, anti-diuretic, anti-epileptic anti-allergic and antioxidant 
properties of the plant as well as their ability to ―fight‖ low blood pressure (Visavadiya et 
Narasimhasharya, 2006). 
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Saponins 
The major constituents are triterpene saponins, 4-20% (Asl et Hosseinzadeh, 2008; WHO, 
1999b), 3-15% according to Cunha et al., 2007 (mostly glycyrrhizin,  (Fig.53), the major 
component, about 2-9%, 5-9% according to Cunha et al., 2007, is  glycyrrhizin, a 
glycoside of glycyrrhetinic acid  (Fig.54) (Asl et Hosseinzadeh, 2008; WHO, 1999b). 
According to Isbrucker et Burdock (2006) glycyrrhizin constitutes 10–25% of licorice root 
extract and is considered the primary active ingredient.  
Glycyrrhizin or glycyrrhizic acid or glycyrrhizinic acid 
 Aglycone = glycyrrhetic acid or glycyrrhetinic acid 
Fig. 53. Chemical structure of glycyrrhizin and its aglycone (adapted from WHO, 1999b) 
 
Glycyrrhizin is a monodesmoside, which on hydrolysis releases two molecules of D-
glucuronic acid (Cunha et al., 2007; Fiore et al., 2008, WHO, 1999b) and the aglycone 
glycyrrhetic (glycyrrhetinic) acid (enoxolone) (Fig.) (WHO, 1999b). 
 
 
 
Fig. 54. Structure of glycyrrhetinic acid (adapted from http://www.glabridin.com/glab.htm ) (visited 9-6-2009). 
 
By other words, glycyrrhizin is a saponin compound comprised of a triterpenoid aglycone, 
glycyrrhetic acid (glycyrrhetinic acid; enoxolone) conjugated to a disaccharide of 
glucuronic acid. Both glycyrrhizin and glycyrrhetic acid can exist in the 18α- and 18β-
stereoisomers. As a tribasic acid, glycyrrhizin can form a variety of salts and occurs 
naturally in licorice root as the calcium and potassium salts. Carbenoxolone (18β-
glycyrrhetinic acid hydrogen succinate), an analog of glycyrrhetic acid (Fig.55), is used in 
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the treatment of some alimentary tract ulcerative conditions, such as peptic ulcers 
(Isbrucker et Burdock, 2006).  
 
 
Fig. 55. Chemical structure of glycyrrhizin (A) and carbenoxolone (B) (adapted from Isbrucker et Burdock, 2006). 
 
Other triterpenes present are liquiritic acid, glycyrretol, glabrolide, isoglaborlide and 
licorice acid (Asl et Hosseinzadeh, 2008). 
Flavonoids  
Other constituents include flavanones such as liquiritigenin and liquiritin (Asl et 
Hosseinzadeh, 2008; WHO, 1999b) (Fig. 56) rhamnoliquiritin, and chalcones such as 
isoliquiritigenin and isoliquiritin (Asl et Hosseinzadeh, 2008; Newall et al., 1996b; WHO, 
1999b) (Fig. 56), chalcones isoliquiritin, neoisoliquiritin, licuraside and licoflavonol (Asl et 
Hosseinzadeh, 2008). Other chalcones includes licuraside, echinatin, licochalcones A and 
B and neolicuroside (Newall et al., 1996b). The bright yellow color of licorice root is 
provided by flavonoids, particularly liquiritin, isoliquiritin and their corresponding 
aglycones, which typically comprise 1-1.5% of the water soluble extract (Isbrucker et 
Burdock, 2006).  
 
Fig. 56. Chemical structure of liquiritin, isoliquiritin, isoliquiritigenin, liquiritigenin (adapted from WHO, 1999b) 
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Licorice include flavonols and isoflavones including formononetin, glabrin, glabrol, 
glabrone, glyzarin, glycyrol, glabridin (Fig. 57) and derivatives, kumatakenin, licoflavonol, 
licoisoflavones A and B, licoisoflavanone, licoricone, liquiritin and derivatives, 
phaseollinisoflavan (Newall et al., 1996b). 
 
 
Fig. 57. Chemical structure of glabidrin (adapted from http://www.glabridin.com/glab.htm)  (visited 9-6-2009) 
 
Other isoflavonoid derivatives present in licorice include glabrene, glabrone, 
shinpterocarpin, licoisoflavones A and B, formononetin, glyzarin, kumatakenin. More 
recently, hispagladribin A, hispaglabidrin B, 4´- O-methylgladridin and 3´-hydroxy-4´-O-
methylgladribin and glabroisoflavanone A and B have been found (Asl et Hosseinzadeh, 
2008). 
Recently 5,8-dihydroxy-flavone-7-O-β -D-glucuronide, glychionide B were isolated from 
the roots of G. inflata and the minor flavonoids, isotrifoliol and glisoflavanone, from the 
underground part of G. uralensis (Asl et Hosseinzadeh, 2008).  
Besides, the isolates from Glycyrrhiza glabra roots, glabridin (an isoflavan) and 
isoliquiritigenin (a chalcone), are known to be pharmacologically active compounds. 
Glabridin is reported to be potent antioxidant towards LDL oxidation whereas 
isoliquiritigenin is known to exert vasorelaxant effect, anti-platelet, anti-viral, estrogenic 
activities and has the protective potential against cerebral ischemic injury (Visavadiya et 
Narasimhasharya, 2006). The isoflavones glabridin and hispaglabridins A and B have 
significant antioxidant activity, and both glabridin and glabrene possess estrogen-like 
activity (Anonymous, 2005). 
 
Coumarins  
Coumarins present in G. glabra include glabrocoumarone A and B (Asl et Hosseinzadeh, 
2008), umbelliferone, liqcoumarin, herniarin, glycyrin (Asl et Hosseinzadeh, 2008, Newall 
et al., 1996b), glycocoumarin, licofuranocoumarin, licopyranocoumarin, glabrocoumarin 
(Asl et Hosseinzadeh, 2008) and GU-7 (a-arylcoumarine derivative (Newall et al., 1996b) 
Although glycycoumarin (Fig. 58) is a minor ingredient in the hot water extracts of licorice 
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(approximately 0.10%), it is an important species-specific ingredient of G. uralensis (Nagai 
et al., 2006). 
 
 
Fig. 58. Chemical structure of glycycoumarin (adapted from Nagai et al., 2006) 
 
Glycyrol (Fig.59) is a benzofuran coumarin isolated from Radix Glycyrrhizae (Shin et al., 
2008a). Whereas the anti-inflammatory activity of glycyrol has not been well known, 
glycyrol has been reported to have antibacterial activity against upper-airway respiratory 
tract bacteria such as Streptococcus pyogenes, Haemophilus influenzae and Moraxella 
catarrhalis. In order to investigate the anti-inflammatory activity of glycyrol in LPS-
stimulated RAW264.7 macrophages, several important inflammation mediators were 
examined. Glycyrol showed dose-dependent inhibitory effects on NO production, iNOS 
mRNA and protein expression. In addition, glycyrol dose dependently down-regulated 
LPS-induced COX-2 production, both on mRNA and protein level. Furthermore, glycyrol 
was tested at different times against LPS stimulations, and showed dose-dependent 
inhibitory effects on NO, iNOS and COX-2 production, regardless of pre or post-
administration. Additionally, glycyrol showed the pronounced inhibitory effect on IL-1β 
mRNA expression in the LPS-stimulated RAW264.7 macrophages. However, glycyrol was 
revealed to have no inhibitory effect on the mRNA of TNF-α, due to its competitive dose-
dependent TNF-α producing activity (Shin et al., 2008).  
 
Fig. 59. Chemical structure of glycyrol (adapted from Shin et al., 2008) 
Stilbenoids 
Four new dihydrostilbenes, dihydro-3, 5-dihydroxy-4´-acetoxy-5´-isopentenylstilbene, 
dihydro-3,3´,4´-trihydroxy-5-O-isopentenyl-6-isopentenylstilbene, dihydro-3,5,3´-
thrihydroxy-4´-methoxystilbene and dihydro-3,3´-dihydroxy-5-β-d-O-glucopyranosyloxy-4´-
methoxystilbene were isolated from the leaves of G. glabra grown in Sicily (Asl et 
Hosseinzadeh, 2008). 
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Licochalcone 
Licochalcone A (LicA) (Fig. 60), a major phenolic constituent of the licorice species 
Glycyrrhiza inflata, has recently been reported to have anti-inflammatory as well as anti-
microbial effects. These anti-inflammatory properties might be exploited for topical 
applications of LicA. Topical LicA causes a highly significant reduction in erythema relative 
to the vehicle control in both the shave- and UV-induced erythema tests, demonstrating 
the anti-irritative properties of LicA. Furthermore, LicA is a potent inhibitor of pro-
inflammatory in vitro responses, including N-formyl-MET-LEU-PHE (fMLP)- or zymosan-
induced oxidative burst of granulocytes, UVB-induced PGE2 release by keratinocytes, 
lipopolysaccharide (LPS)-induced PGE2 release by adult dermal fibroblasts, fMLP-induced 
LTB4 release by granulocytes, and LPS-induced IL-6/TNF-a secretion by monocyte-
derived dendritic cells. The reported data suggest therapeutic skin care benefits from LicA 
when applied to sensitive or irritated skin. Licochalcone A, a reversely constructed 
chalcone or ‗‗retrochalcone‘‘ extracted from the licorice species. Glycyrrhiza inflata, has 
drawn pharmacological attention in the recent past due to its anti-bacterial, anti-protozoan, 
and anti-tumor properties. Besides these properties, suppressive effects of LicA on 
phorbol-ester-driven processes, like the mouse ear edema formation induced by 
arachidonic acid and tetradecanoylphorbol acetate (TPA), have been described. 
Furthermore, direct immunosuppressive effects of LicA on mitogen-induced T cell 
proliferation and IFN-c production, as well as on LPS-induced cytokine production by 
monocytes, have been reported (Kolbe et al., 2006). 
 
 
Fig. 60.  Chemical structure of licochalcone A (adapted from Kolbe et al., 2006). 
 
Even though LicA‘s mode of action is still not resolved on a molecular level, the results 
suggest therapeutic skin care benefits from LicA when applied to sensitive or irritated skin 
(Kolbe et al., 2006). 
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Polysaccharide 
Glycyrrhiza polysaccharide (GP), one of the main active ingredients of Glycyrrhiza is 
attributed to many healing properties of the herb. Recently, it has been reported that GP 
had many functions such as immunity regulation, phagocytosis, anti-virus, anti-tumor, anti-
complement, and it has low cellular toxicity. The aqueous extracts from Glycyrrhiza and 
the structure of their oligo and polysaccharides have been described. Studies indicate that 
GP at least includes three core structures: firstly, a backbone chain composed of β-1,3-
linked D-galactosyl residues,  three-fifth of the galactose units glycosidic units in the 
backbone carry side chains composed of β-1,3- and β-1,6-linked D-galactosyl residues at 
position 6; secondly, glycosidic units in the backbone carry side chains composed mainly 
α-1,5- linked L-arabino-β-1,6- or 1,3-linked D-galactosyl residues at position 6,; thirdly, 
glycosidic units were composed of α (1→4) linked D-glucan (Cheng et al., 2008).  
Miscellaneous compounds 
Minor components occur in proportion that varies depending on the species and 
geographical location (WHO, 1999b). Licorice extract also contains reducing and 
nonreducing sugars, starch (Asl et Hosseinzadeh, 2008; Isbrucker et Burdock, 2006), 
plant gums, resins, essential oils, inorganic salts and low levels of nitrogenous 
constituents such as proteins, individual amino acids, and nucleic acids (Isbrucker et 
Burdock, 2006). G. glabra extract also contains fatty acids (C2-C16) and phenols (phenol, 
guaiacol), together with common saturated linear γ-lactones (C6-C14). A series of new 4-
methyl- γ-lactones and 4-ethyl- γ-lactones in trace amounts also has been found. 
Asparagines, polysaccharides (arabinogalactants), sterols (β-sitosterol, 
dihydrostigmasterol) are also present (Asl et Hosseinzadeh, 2008). It also contains trace 
elements, including zinc and manganese (Ganzhong et al., 2003e). 
 
Mechanism of Action 
 Glycyrrhizin is metabolized to its aglycone 18-β-glycyrrhetinic acid in the intestine 
by human intestinal bacteria (Anonymous, 2009; Blumenthal, 2003; Isbrucker et 
Burdock, 2006; Newall et al., 1996b; Shin et al., 2007), which is then absorbed into 
the blood (Blumenthal, 2003; Isbrucker et Burdock, 2006; Shin et al., 2007);  
 Protects liver through 18-β-glycyrrhetinic acid and glycyrrhizin (Anonymous, 2005; 
Asl et Hosseinzadeh, 2008; Blumenthal, 2003; Fiore et al., 2008; Isbrucker et 
Burdock, 2006; Newall et al., 1996b; WHO, 1999b);  
 Relieves gastric inflammation, possibly by inhibiting prostaglandin synthesis and 
lipoxygenase (Blumenthal, 2003); 
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 Antigastric ulcer activity is due to the FM 100 fraction (licorione), which lowers 
gastric acidity, reduces pepsin activity and inhibits gastric secretion (Blumenthal, 
2003; Borrelli et Izzo, 2000; Takagi et al., 1971); 
 Glycyrrhetinic acid inhibits 11-β-hydroxysteroid dehydrogenase (11-β-OHSD), the 
enzyme that deactivates cortisol (Asl et Hosseinzadeh, 2008; Anonymous, 2005; 
Anonymous, 2009; Blumenthal, 2003; Chan et Kritchley, 1996; Cunha et al., 2007; 
Fiore et al., 2008; Newall et al., 1996b; WHO, 1999b) and bacterial 3-α, 20-β-
hydroxysteroid dehydrogenase (Blumenthal, 2003);  
 Inhibits human 11- β-hydroxysteroid dehydrogenase (Asl et Hosseinzadeh, 2008; 
Anonymous, 2005; Anonymous, 2009; Blumenthal, 2003; Breidthardt et al., 2006; 
Chan et Kritchley, 1996; Cunha et al., 2007; Fiore et al., 2008; Newall et al., 
1996b; Newall et al., 1996b; WHO, 1999b), which minimizes the binding of cortisol 
to mineralocorticoid receptors, creating a miniralocorticoid-like effect (Asl et 
Hosseinzadeh, 2008; Blumenthal, 2003; Chan et Kritchley, 1996; Fiore et al., 
2008); 
 Inhibits peripheral metabolism of cortisol, which binds mineralocorticoid receptors 
in the same way that aldosterone (Blumenthal, 2003; Cunha et al., 2007b); 
 May also inhibit 17- β-hydroxysteroid dehydrogenase  and 17, 20-lyase, which 
catalyzes conversion of 17-hydroxyprogesterone to androstenedione (Blumenthal, 
2003); 
 Modulates the cell- mediated immune system, which may be due to glycyrrhizin 
stimulating the induction of contrasuppressor cells (Blumenthal, 2003); 
 Demulcent and expectorant actions due to stimulating tracheal mucous secretion 
(Blumenthal, 2003; Ganzhong et al., 2003e; WHO, 1999b); 
 Antioxidant action may be related to absorption and binding of licorice´s flavonoids 
(e.g. glabridin) to the LDL particle from oxidation (Blumenthal, 2003). 
 
Effects and uses 
Licorice is one of the most widely used medicinal plants, found in traditional formulas 
since antiquity (Fiore et al., 2008). Liquorice approved its use by the German Commission 
E for the treatment of cough, bronchitis and gastritis (Cunha et al., 2007b). This herb has 
long been valued to relieve respiratory ailments (Cheng et al., 2008; Gupta et al., 2008; 
Verma et Thuluvath, 2007), as an expectorant (Dhingra et Sharma, 2006; Fiore et al., 
2005; Isbrucker et Burdock, 2006; WHO, 1999b), as antitussive (Anonymous, 2009; 
Cheng et al., 2008; Fiore et al., 2005; Gupta et al., 2008; Isbrucker et Burdock, 2006; 
Verma et Thuluvath, 2007; WHO, 1999b), as an anti-inflammatory agent (Cheng et al., 
2008; Dhingra et Sharma, 2006; Shin et al., 2008; WHO, 1999b), antipyretic (Dhingra et 
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Sharma, 2006; Isbrucker et Burdock, 2006; Ma et al., 2005; Shin et al., 2008; Verma et 
Thuluvath, 2007). It is been used to treat sore throats (Anonymous, 2009; Fiore et al., 
2005; Ganzhong et al., 2003e; Isbrucker et Burdock, 2006; WHO, 1999b), asthma 
(Ganzhong et al., 2003e; Isbrucker et Burdock, 2006), bronchitis (Anonymous, 2009; 
Ganzhong et al., 2003e; Isbrucker et Burdock, 2006; Ma et al., 2005) and tuberculosis 
(Anonymous, 2009; Ganzhong et al., 2003e; Gupta et al., 2008; WHO, 1999b). 
The most consistent use is as a demulcent for the digestive system (Cheng et al., 2008; 
Isbrucker et Burdock, 2006). Licorice has antacid activities (Dhingra et Sharma, 2006), 
used in dyspepsia (Anonymous, 2009; Fiore et al., 2005; Isbrucker et Burdock, 2006; 
WHO, 1999b), and  among its traditional uses licorice is felt to be effective in the 
treatment of ulcer disease (Anonymous, 2009; Cheng et al., 2008; Cunha et al., 2007; 
Dhingra et Sharma, 2006; Ganzhong et al., 2003e; Gupta et al., 2008; Isbrucker et 
Burdock, 2006; Ma et al., 2005; WHO, 1999b), stomachache (Anonymous, 2009; 
Ganzhong et al., 2003e; Gupta et al., 2008; WHO, 1999b), gastritis (Anonymous, 2005; 
Cheng et al., 2008; Verma et Thuluvath, 2007). It also has been used as a laxative 
(Anonymous, 2009; Asl et Hosseinzadeh, 2008; Cheng et al., 2008; Fiore et al., 2005; 
Gupta et al., 2008; Isbrucker et Burdock, 2006; Verma et Thuluvath, 2007; WHO, 1999b). 
Also used as an anti-inflammatory agent (Cheng et al., 2008; Dhingra et Sharma, 2006; 
Shin et al., 2008; WHO, 1999b), in the treatment of allergic reactions (Cheng et al., 2008; 
WHO, 1999b; Shin et al., 2008), contact dermatitis (Anonymous, 2009; Ganzhong et al., 
2003e), alergic dermatitis and eczema (Ganzhong et al., 2003e), urticaria (Ganzhong et 
al., 2003e), and other  skin diseases (Cheng et al., 2008; Ganzhong et al., 2003e). 
Studies also show licorice constituents to be effective in the treatment of eczema and 
melasma (Anonymous, 2005).  
Other uses of the plant include the treatment of sex-hormone imbalances and 
menopausal symptoms in women (Gupta et al., 2008). Licorice has held claim for 
therapeutic use for liver ailments (Cheng et al., 2008; Gupta et al., 2008; Isbrucker et 
Burdock, 2006; Shin et al., 2008; Verma et Thuluvath, 2007; WHO, 1999b), hepatitis 
(Ganzhong et al., 2003e; Ma et al., 2005; Shin et al., 2008), Addison´s disease 
(adrenocortical insufficiency) (Anonymous, 2009; Asl et Hosseinzadeh, 2008; Ganzhong 
et al., 2003e; Isbrucker et Burdock, 2006; WHO, 1999b), and rheumatoid arthritis 
(Isbrucker et Burdock, 2006; WHO, 1999b). Its hypocholesterolaemic and hypoglycemic 
activities have been reported (Ragesh et Latha, 2004). Furthermore, Glycyrrhiza glabra 
extracts have been shown to possess antidepressant-like, and produce antithrombotic 
effects. On the other hand, the root extracts are reported to exhibit antiangiogenic, 
antitumor activity and radio-protective effects (Visavadiya et Narasimhasharya, 2006), 
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anticonvulsant activities (Dhingra et Sharma, 2006) and memory enhancing activities 
(Dhingra et Sharma, 2006; Visavadiya et Narasimhasharya, 2006). 
Orally, licorice is used for colic, osteoarthritis, systemic lupus erythematosus (SLE), and 
for bacterial and viral infections. It is also used orally for cholestatic liver disorders, 
hypokalemia, hypertonia (Anonymous, 2009; Ganzhong et al., 2003e), malaria 
(Anonymous, 2009; Ganzhong et al., 2003e), Leishmania (Anonymous, 2005), abscesses, 
food poisoning, diabetes insipidus (Anonymous, 2009; Ganzhong et al., 2003e), chronic 
fatigue syndrome (CFS) (Anonymous, 2009). Licorice can be used to treat 
thrombocytopenic purpura, hypercholesterolemia, herpetic keratitis, scleritis and acute 
iridocyclitis (Ganzhong et al., 2003e), eosinophilic peritonitis, postural hypotension 
(Anonymous, 2005), used as a diuretic (Asl et Hosseinzadeh, 2008; Dhingra et Sharma, 
2006; Gupta et al., 2008), antimicrobial, anxiolytic (Dhingra et Sharma, 2006), and in other 
diseases as: treatment for wounds, cystitis, diabetes, kidney stones (Gupta et al., 2008), 
as a anabolic and to improve the voice (Asl et Hosseinzadeh, 2008; Gupta et al., 2008), 
as a contraceptive and to improve male sexual function (Asl et Hosseinzadeh, 2008). 
 
Other uses 
Licorice root is not only used in Chinese traditional medicine and pharmaceutics, but also 
used in cosmetic, food, ink and cigarette industries (Shen et al., 2007). Licorice is used as 
a as a flavoring agent (Anonymous, 2009; Isbrucker et Burdock, 2006) in foods, 
beverages, and tobacco (Anonymous, 2009). Glycyrrhizin (one of the major components) 
is responsible for the sweetness of licorice, which is 50 times that of sucrose (Asl et 
Hosseinzadeh, 2008; Isbrucker et Burdock, 2006; WHO, 1999b). Although glycyrrhizin is 
considered much sweeter than sucrose, the associated licorice flavor makes direct 
comparison difficult and affords it little commercial value as a sweetener. Because 
glycyrrhizin also imparts an undesirable brownish color to foods and the sweetness is lost 
in acidic solutions, as occurs in most beverages, glycyrrhizin remains of little value to the 
food and beverage industries. The primary use for licorice products and glycyrrhizin is 
limited to flavoring tobacco and candy. The tobacco industry is the primary user of licorice 
derivatives in the United States, with the remainder equally divided among the food and 
pharmaceutical industries. Some minor consumer use for licorice root extract and 
glycyrrhizin has been in beer and ales, where they provide good surfactant (foaming) 
properties and take the edge off these potentially bitter-tasting beverages. Similarly, 
licorice root extract and glycyrrhizin may be used to alleviate the bitter after taste in some 
saccharinated products and pharmaceutical preparations. Industrial uses for glycyrrhizin 
include an adhesive agent in insecticides and a wetting agent (surfactant) for various 
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industrial processes (Isbrucker et Burdock, 2006). Licorice has Generally Recognized as 
Safe (GRAS) status in the US (Anonymous, 2009). 
 
Pharmacological activities 
 
Anti-inflammatory activities 
Pharmacological studies showed a marked anti-inflammatory action by licorice (Cunha et 
al., 2007b). The similarity in structure of glycyrrhetic acid to the structure of hormones 
secreted by the adrenal cortex accounts for the mineralocorticoid and glucocorticoid 
activity of glycyrrhizic acid. Licorice constituents also exhibit steroid-like anti-inflammatory 
activity, similar to the action of hydrocortisone. This is due, in part, to inhibition of 
phospholipase A2 activity, an enzyme critical to numerous inflammatory processes 
(Anonymous, 2005).  In vitro research has also demonstrated that glycyrrhizic acid inhibits 
cyclooxygenase activity and prostaglandin formation (specifically prostaglandin E2), as 
well as indirectly inhibiting platelet aggregation, all factors in the inflammatory process 
(Anonymous, 2005; Cunha et al., 2007b). This action has been put in evidence that there 
is a strong inhibition of the enzyme 11β-hydroxysteroid dehydrogenase involved in the 
conversion of cortisol (hydrocortisone) and cortisone in enzymes involved in the 
metabolism of sterols (5-β-reductase and 3-β- hydroxysteroid dehydrogenase). Thus, at 
the adrenal level there is an increase in cortisol content with activation of mineralocorticoid 
receptors, with reabsorption of sodium and depletion of potassium, in addition to the 
reduction in the metabolism of aldosterone, desoxicorticosterone and glucocorticoids. The 
subsequent accumulation of these compounds leads to a pseudo-hyperaldosteronism 
syndrome (Cunha et al., 2007b). Glycyrrhizin and glycyrrhetic acid (enoxolone) act 
indirectly by potentiating the activity of corticosteroids. In vitro, glycyrrhetic acid inhibits 
∆4β-reductase, an enzyme that competitively inactivates steroid hormones besides 11β-
hydroxysteroid dehydrogenase, the enzyme that deactivates cortisol (WHO, 1999b). 
Newall et al. (1996) refer that 18-α-glycyrrhetinic acid exhibited stronger anti-inflammatory 
action compared to its stereoisomer 18-β-glycyrrhetinic acid. 
Glycyrrhizin has been found to significantly and dose-dependently decrease neutrophil-
generated −O2 •, −H2O2 • and −OH•. These reactive oxygen species (ROS) are 
considered to be the most potent inflammatory mediators at the site of inflammation (Shin 
et al., 2008). It was thought that one of its anti-inflammatory effects was due to this 
inhibitory effect (Asl et Hosseinzadeh, 2008). Also, the generation of reactive species was 
also suppressed by glabridin treatment in RAW 264.7 cells (Asl et Hosseinzadeh, 2008). 
Glycyrrhetinic acid did not inhibit either cyclo-oxigenase 1 or 2 catalysed prostaglandin 
biosynthesis with an IC50 value of 425µm in an in vitro study. However, in another study 
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G.radix was believed to be involved in COX-2 inhibition. Also, glycyrrhizin and 
glycyrrhetinic acid have shown their inhibitory activity against interleukin-1b (IL-1b)-
induced prostaglandin E2 (PGE2) production in normal human dermal fibroblasts (Asl et 
Hosseinzadeh, 2008). 
Chalcones isolated from G.inflata Bat. have been reported to inhibit leukotriene production 
and increase cyclic AMP concentrations in human polymorphonucleares neutrophils in 
vitro. Glycyrrhetinic acid derivatives, but not glycyrrhetinic acid, have exhibited inhibitory 
effects on writhing and vascular permeability tests and on type IV allergy in mice (Newall 
et al., 1996b). Also significant anti-inflammatory action is exhibited by glycyrrhetinic acid 
against UV eritema (Newall et al., 1996b). 
 
The extract of radix Glycyrrhizae equivalent to 100, 200 or 500 mg/kg of glycyrrhizin, or 
the same doses of glycyrrhizin and glycyrrhetinic acid were used to treat induced 
inflammation by subcutaneous injection of carrageenan into the palm of the hind paw of 
rats. It was found that carraheen induced edema was not affeted by 100 mg/kg, 
attenuated by 200 mg/kg, and potentated by 500 mg/kg of these the tested drug. 
Glycyrrhhizin inhibited to some extent prostaglandin E2 biosynthesis by the activated rat 
peritoneal macrophage, whereas in the cell-free experiment glycyrrhizin and glycyrrhetinic 
acid showed little effect on the inhibition of cyclooxygenase. The anti-inflammatory 
principles were found to be glycyrrhizic acid and glycyrrhitic acid. Glycyrrhizic acid 25 or 
50 mg/kg given by IV injection to mice inhibited passive cultaneous anaphytazoxis 
response. Glycyrrhizic acid antagonized the contraction of isolated rabbit illum and guinea 
pig trachea induced by histamine acetylcholine or slow reacting substance of anaphytaxis 
in a concentration dependent fashion. The anti-inflammatory effects of glycyrrhetinic acid 
and its derivatives on TPA-induced mouse ear edema were studied. Glycyrrhetinic acid 
derivatives examined strongly inhibited ear edema. The mechanism of the anti-
inflammatory effect was to a certain degree related to the adrenal cortex, suppression of 
vascular permeability and antagonism to inflammation as well. Sodium glycyrrhinic acid 
(SGA) inhibited significantly paw edema of rats with ajuvant arthritis (AA), reduced 
proliferation of synovial cells and pannus formation, and eleminated the destruction of 
articular cartilage in inflammed joints of AA rat. T-lymphocyte ratio was increased in 
normal mice and decreased in rats with ajuvant arthris by SGA. The result showed that 
SGA possesses two-way regulating activity for immune functions (Shen et al., 2007). 
 
Antiallergic effects 
Glycyrrhizin showed an anti-allergic activity. It inhibited the passive cultaneous 
anaphylaxis (PCA) response in rats. It inhibited the contraction of rabbit ileum and guinea 
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pig trached induced by histamine, acetylcholine or slow-reacting substances of 
anaphylaxis. Glycyrrhizin has clinically been employed as an anti-allergic agent. Thus it 
can be as a lead compound, and modified its molecule to study the anti-allergic actions of 
the modified compunds on Type I, II and IV allergy in experimental animals. The effect of 
deoxoglycyrrhetol and its derivatives against the type IV allergy in mice was studied in the 
PCA test. The preventing effective dose is 25-200 mg/kg (Shen et al., 2007). Glycyrrhizin 
and 18-β-glycyrrhetinic acid administered orally exhibited the most potent inhibition 
against the PCA reaction. However, this effect was not observed with the intraperitoneally 
administered glycyrrhizin. This suggests that the inhibitory effect of glycyrrhizin against the 
PCA reaction might be due to the metabolism of 18-β-glycyrrhetinic acid by the intestinal 
microflora. This suggestion is supported by previous reports showing that the intestinal 
microflora hydrolyze glycyrrhizin to 18-β-glycyrrhetinic acid (Shin et al., 2007). In other 
hand, liquiritigen most potently inhibited the degranulation of peritoneal mast cells and 
RBL-2H3 cells, followed by 18-β-glycyrrhetinic acid (Shin et al., 2007). Liquiritigenin and 
18-β-glycyrrhetinic acid exhibited antiscratching behavioral effects. These effects were in 
proportion to their inhibitory effects against the vascular permeability. This suggests that 
antischatching behavioral effect of licorice might be due to the inhibition of vascular 
permeability. Glycyrrhizin and 18-β-glycyrrhetinic acid reduced the IgE level in the blood of 
the mice induced by ovalbumin (OVA). In addition, many studies have reported that 
glycyrrhizin inhibits the production of nitric oxide and cytokines in RAW264.7 cells as well 
as in an in vivo test. Glycyrrhizin, that seems to be transformed to 18-β-glycyrrhetinic acid 
in the digestive tract, may be absorbed with liquiritigenin into the blood, and regulate the 
degranulation and cytokine biosynthesis in mast cells and basophils, which cause allergic 
diseases. Overall, it is believed that orally administered licorice can treat IgE-induced 
allergic diseases such anaphylaxix, rhinitis and asthma. Its effect might be due to its main 
constituents, glycyrrhizin, 18-β-glycyrrhetinic acid and liquiritigenin (Shin et al., 2007). 
Liquiritigenin and isoliquiritigenin have been shown to have an inhibition of xanthine 
oxidase activity in vitro and dose-related anti-allergic activities (Ma et al., 2005). 
 
Antibacterial activities 
The methanol extract of aerial parts of G. glabra showed antibacterial activity against 
several kinds of bacteria. Several flavonoids with C5 aliphatic residues were isolated as 
the effective constituents of licorice against methicillin-resistant Staphylococus aureus 
(MRSA) and restore the effects of oxacillin and β-lactam antibiotic against MRSA. 
Glabridin, glabren and lincochalcone A exhibited antimicrobial activity against 
Helicobacter pylori in vitro. The ether-water extracts of G. glabra were found to have 
effective antibacterial activity against all the five bacteria, E.coli, B. subtilis, E. aerogenes, 
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K. pneumonia and S. aureus (Asl et Hosseinzadeh, 2008). In vitro, the drug inhibits the 
growth of Bacillus subtilis, Mycobacterium tuberculosis, Aspergilus spp. (WHO, 1999b), 
Staphylococcus aureus, Mycobacterium smegmatis, and Candida albicans (Newall et al., 
1996b; WHO, 1999b) and this antimicrobial activity is attributed to the isoflavonoid 
constituents (grabidrin, glabrol and their derivatives) (Newall et al., 1996b). 
The antitubercular phenolic compounds from Glycyrrhiza glabra and Glycyrrhiza inflata 
were previously identified as licoisoflavone and licochalcone A. Additionally, glabridin was 
more active against Gram-positive strains than Gram-negative. Glabridin has been 
reported to exhibit multiple pharmacological activities such as antimicrobial activity against 
Helicobacter pylori, MRSA, effect on adenosine 3´,5´-cyclic monophosphate 
phosphodiesterase, melanogenesis, inflammation, low-density lipoprotein oxidation, 
inhibition of human cytochrome P450s 3A4, 2B6 and 2C9 activities and protection of 
mitochondrial functions from oxidative stresses. Having the structural similarity in glabridin 
and hispaglabridin B, the study provides some insight to structure and activity relationship 
to some extent. Glabridin was active against Mycobacterium while hispaglabridin was 
inactive (Fig. 61). There are two free phenolic hydroxyls in glabridin at 1,3-positions which 
might be crucial in inducing the activity. The inactivity of hispaglabridin might be due to 
one of the hydroxyl in protected form by an isoprenyl group as benzopyrene ring (Gupta et 
al., 2008). 
1 2 
Fig. 61. Chemical structures of glabridin (1) and hispaglabridin B (2) (adapted from Gupta et al., 2008). 
 
This findings support ethnomedical uses of Glycyrrhiza glabra to cure coughs and chest 
related ailments with the establishment of glabridin as a potent lead molecule for 
antimycobacterial activity (Gupta et al., 2008).  
 
Anti-cariogenic studies  
Ammonium glycyrrhizate (from licorice root) is used in toothpastes, mouth rinses and 
other products for the control of periodontal disease (Asl et Hosseinzadeh, 2008). Several 
studies have been conducted on the effects of licorice and glycyrrhizin on the growth and 
acid production of oral bacteria associated with the development of dental caries. It was 
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reported that glycyrrhizin could significantly reduce the growth and acid production of 
Streptococcus, Actinomyces, and Bacterionema species. Licorice powder, ammoniated 
glycyrrhizin, and monoammonium glycyrrhetic acid competitively reduced the metabolism 
of sucrose, glucose, and fructose, but were themselves minimally fermentable. In contrast 
to these results, it was reported that neither licorice ―juice,‖ nor glycyrrhizin inhibited the 
growth of seven Streptococcus mutans strains. In the presence of sucrose, 0.5–1% 
glycyrrhizin had no effect on growth, but significantly inhibited bacterial adherence to glass 
by nearly 100% at the highest concentration tested. Licorice juice had similar anti-
adherent properties with concentrations of 5 and 10% providing almost 100% activities. 
The buffering capacity of glycyrrhizin was not sufficient to affect the fall in pH caused by 
bacterial sucrose degradation. In an additional study evaluating the mechanism of the 
anti-adherent property of glycyrrhizin, its effect was examined on bacterial 
glucosyltransferase activity—an enzyme required in the formation of insoluble glucans 
required in plaque development. A crude preparation of S. mutans glucosyltransferase 
was significantly inhibited by glycyrrhizin in a concentration-dependent manner. The 
authors concluded that inhibition of bacterial glucosyltransferase activity may be a 
mechanism by which glycyrrhizin inhibits oral bacterial adherence, but that additional 
enzyme systems may also be affected (Isbrucker et Burdock, 2006). According to Asl et 
Hosseinzadeh (2008), glycyrrhizol A and 6,8-diisoprenyl-5,7-4´-trihydroxyisoflavone from 
the root of G. uralensis exhibited potent antibacterial activity against Streptococcus 
mutans with minimum inhibitory concentrations of 1 and 2 µg/mL, respectively.  
 
Antiviral activities 
The threat to global public health by pandemics of viral diseases like those induced by 
influenza and HIV viruses requires the urgent evaluation of herbal drugs which showed 
promise in traditional herbal medicine. The lack of effective drugs against influenza virus 
and the increasing problem with multiresistance in HIV infection makes Glycyrrhiza sp.-
derived compounds important candidates for drug development. The data reviewed 
showed that several constituents of licorice roots have a potential as effective alternatives 
in combating a wide variety of respiratory, hepatic and systemic viral diseases by general 
immune modulatory and membrane effects, as well as specific effects on enzyme activity 
and expression related to selected viruses (Fiore et al., 2008). Glycyrrhizin and 
polysaccharides of licorice can inhibit proliferation of viruses, especially multiplication of 
hepatitis virus, because they can directly inhibit nucleocapsid, induce formation of 
interferon and enhance the activity of natural killer lymphocytes (Ganzhong et al., 2003e). 
In vitro antiviral effects of licorice were observed for viruses causing respiratory tract 
infections like influenza virus and the severe acute respiratory syndrome (SARS) corona 
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virus, the hepatitis B virus and Epstein Barr virus (Fiore et al., 2005), human 
immunodeficiency virus (HIV) (Anonymous, 2005; Fiore et al., 2005; Isbrucker et Burdock, 
2006), encephalitis causing viruses like Herpes simplex virus and Japanese encephalitis 
virus (Fiore et al., 2005). Glycyrrhizin has also been shown to inhibit viral replication and 
infectivity of Herpes zoster, Varicella zoster, and CMV (Anonymous, 2005). In another 
study glycyrrhizic acid induced apoptosis of primary effusion lymphoma (PEL) cells that 
were transformed by Kaposi sarcoma-associated herpesvirus and terminated latent 
infection in B lymphocytes (Asl et Hosseinzadeh, 2008). 
The first report of an antiviral property of licorice constituents dates to the year 1979. 
Following screening investigations of plant extracts, it was found  that glycyrrhizic acid, 
had antiviral activity inhibiting the growth and cytopathic effect of several DNA and RNA 
viruses, such as vaccinia (Fiore et al., 2008; Isbrucker et Burdock, 2006; Newall et al., 
1996b), herpes simplex (Fiore et al., 2008; Newall et al., 1996b), Newcastle disease 
(Fiore et al., 2008; Isbrucker et Burdock, 2006; Newall et al., 1996b) and vesicular 
stomatitis viruses in vitro (Fiore et al., 2008; Isbrucker et Burdock, 2006; Newall et al., 
1996b). In vitro studies have demonstrated that glycyrrhizin is effective at inhibiting the 
growth of a host of viruses under culture conditions including pathogenic flaviviruses, 
alphaviruses. In vivo and human studies tend to agree with the anti-viral efficacy of 
glycyrrhizin, but the mechanism of action may be more complex and promote an immune 
response (Isbrucker et Burdock, 2006).  
 
Effects of glycyrrhizin on hepatitis viruses 
Hepatitis A 
It has been reported that licorice inhibits growth and cytopathology of many unrelated 
DNA and RNA viruses, while not affecting cell activity or cellular replication. Hepatitis A 
virus (HAV) causes acute hepatitis, a major public health concern in numerous countries. 
In vitro research with glycyrrhizin and a human hepatoma cell line has demonstrated 
glycyrrhizin completely suppresses the expression of the HAV antigen. In comparison to 
ribavirin, glycyrrhizin proved to be 10 times more potent at reducing infectivity of HAV, as 
measured by reduction in viral titres. Glycyrrhizin also exhibited five-fold greater cell 
selectivity than ribavirin in that it was less cytotoxic to the hepatoma cells (Anonymous, 
2005). Another study referred a complete concentration-dependent inhibition of the 
expression of the hepatitis A virus (HAV) antigen and HAV infectivity by glycyrrhizin in the 
human hepatoma cell line PLC/PRF/5. The mechanism of this antiviral effect was the 
inhibition of the penetration and endocytosis in liver cells. Proposed mechanisms were the 
induction of a decrease in the negative charge on the cell surface and/or a decrease of 
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membrane fluidity (Fiore et al., 2008). These results indicate glycyrrhizin may be a 
potential therapeutic adjunct in fighting HAV infections (Anonymous, 2005). 
 
Hepatitis B and C 
Clinical studies on the efficacy of glycyrrhizin in the treatment of hepatitis B have generally 
shown favorable outcomes with the treatment normalizing elevated serum transaminases 
and improving liver function (Fiore et al., 2008; Isbrucker et Burdock, 2006), with 
occasional complete recovery from hepatitis (Fiore et al., 2008). In randomized controlled 
trials, glycyrrhizin, usually administered intravenously, induced a significant reduction of 
serum liver enzymes and caused an improvement in liver histology in comparison with 
placebo (Asl et Hosseinzadeh, 2008; Fiore et al., 2008). In hepatitis B the virustatic effect 
could depend on inhibition of the intrahepatic transport and sialylation of the hepatitis B-
virus (HBV) surface antigen (HBsAg) observed in vitro. In isolated rat hepatocytes 
glycyrrhizin suppressed the release of transaminase in the presence of either anti-liver cell 
membrane antibody or phospholipase A2. The results indicated that the treatment of liver 
cells with antibody activates phospholipase A2 in cell membranes leading to disintegration 
of the cell membrane and cell death, which resulted in the release of transaminases. 
Glycyrrhizin, suppressing the increase in phospholipase A2 activity, inhibited the release of 
transaminases, which demonstrated its anticytolytic effect. In vitro experiments 
demonstrated that glycyrrhizin suppresses the secretion of hepatitis B surface antigen 
(HBsAg) by inhibiting the intracellular transport of HBsAg at the trans-Golgi area after O-
linked glycosylation and before sialylation. Glycyrrhizin, as an immunomodulatory agent, 
given intravenously in combination with lamivudine was also useful in the treatment of 
subacute hepatitis due to hepatitis B (Fiore et al., 2008). The antiviral proposed 
mechanisms include glycyrrhizin´s action on nuclear factor K B, inhibition of tumor 
necrosis factor (TNF), induction of endogenous interferon production, and suppression of 
hepatitis B surface antigen (HBsAg) secretion (Verma et Thuluvath, 2007).  
Glycyrrhizin (GL) is metabolized into 18-β-glycyrrhetinic acid (GA) and 18-β-glycyrrhetinic 
acid-3-O-β-D-glucuronide (GAMA) by β-D-glucuronidase in the liver and intestines (Fig. 
64) (Asl et Hosseinzadeh, 2008; Wang et al., 2007). 
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Fig. 62. Metabolism of glycyrrhizin catalyzed by β-D-glucuronidase in human liver and intestines (adapted from Wang et al., 
2007). 
 
Structure-bioactivity relationship studies indicate that GA is the most active ingredient 
against platelet aggregation, tumor cell lines, rotavirus infection and growth of 
Helicobacter pylori, followed by GAMA and GL. Thus, GA is a better hepatoprotective 
drug than GAMA or GL (Wang et al., 2007). It has been suggested that GL binds to 
hepatocytes (Fiore et al., 2008; Wang et al., 2007) to modify the expression of HBV 
(hepatitis B virus)-related antigens (Anonymous, 2009; Fiore et al., 2008; Wang et al., 
2007) and suppress sialylation of HBV-surface antigen (HbsAg) (Fiore et al., 2008; Wang 
et al., 2007). This also applies to its hydrolytic metabolites (GAMA, GA) (Wang et al., 
2007). 
Among the most recent studies, the effect of a formulation (Stronger Neo-Minophagen C, 
SNMC) containing 40 mg glycyrrhizin (2mg/ml), administered by injection to patients with 
chronic viral hepatitis should be mentioned (Fiore et al., 2008; Asl et Hosseinzadeh, 
2008). In Japan, SNMC is a commonly prescribed glycyrrhizin solution administered 
intravenously for the treatment of chronic hepatitis B and C (Anonymous, 2005; Asl et 
Hosseinzadeh, 2008; Isbrucker et Burdock, 2006). The formulation was evaluated at 
different doses and frequency of administration, and the overall short-term therapeutic 
response consisted of a dose-dependent effect suppressing alanine aminotransferase 
(ALT) levels in patients with chronic viral hepatitis. SNMC, although without specific 
activity against hepatitis virus, showed an antiinflammatory effect and was able to improve 
the clinical condition of patients with liver disease at various stages. Daily intravenous 
administration of 100 and 40 mL of the glycyrrhizincontaining preparation SNMC for 4 
weeks was a safe and efficacious treatment in lowering or normalizing ALT levels in 
patients with chronic hepatitis B.  Intravenous administration for 1 year of glycyrrhizinic 
acid in patients with chronic viral hepatitis B was able to produce a positive effect on the 
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evolution of the disease, with a 30%–40% success rate, comparable to the results 
obtained with interferon (IFN) (Fiore et al., 2008). On the basis of clinical and histological 
markers, it was concluded that SNMC can suppress liver necrosis and inflammation in 
patients with chronic hepatitis C, suggesting that a long-term treatment with the product 
might be useful in preventing liver cirrhosis and hepatocellular carcinoma (Asl et 
Hosseinzadeh, 2008; Fiore et al., 2008). In several clinical trials, SNMC has been shown 
to significantly lower aspartate transaminase (AST), alanine transaminase (ALT), and 
gamma-glutamyltransferase (GGT) concentrations, while simultaneously ameliorating 
histologic evidence of necrosis and inflammatory lesions in the liver (Isbrucker et Burdock, 
2006; Anonymous, 2005). In a double-blind, randomized, placebo-controlled trial 
investigating IV infusions of SNMC, short-term efficacy of licorice was confirmed with 
regard to ALT levels. The study showed the need for daily IV administration of SNMC, 
which may be impractical for patients. The study also demonstrated that after cessation of 
therapy the ALT-decreasing effect of licorice disappeared, suggesting the need for long-
term administration (Anonymous, 2005). The European experience with SNMC in the 
treatment of hepatitis has also shown good results, equivalent to those produced with 
interferon treatment. However, in a doubleblind, randomized, placebo-controlled trial 
involving 57 patients with hepatitis C, the i.v. administration of 80–240mg glycyrrhizin/day, 
3 days per week for 4 weeks improved serum alanine aminotransferase, but had no effect 
on hepatitis C RNA levels (Isbrucker et Burdock, 2006).  
In a recent study in chronic HBV patients, SNMC at 2 doses (40 and 100 mL for 4 weeks 
followed by oral glycyrrhizin for 4 more weeks) resulted in normalization of ALT levels in 
more than 50% in both groups, although details on HBV DNA levels were lacking. SNMC 
also is being used increasingly in patients with chronic hepatitis C (CHC). Two studies 
with glycyrrhizin in 226 patients with CHC, although well designed, were disappointing 
because viral clearance was not achieved in any of the patients. In other study (n =170), 
the patients received either ursodesoxycholic acid plus intravenous glycyrrhizin (200 mg 3 
times/wk) or glycyrrhizin alone, and those on combination therapy showed a better 
improvement (AST, 23% vs 9%; ALT, 33% vs 10%) and normalization (AST, 54% vs 22%; 
ALT, 32% vs 18%) of liver enzyme levels. In another large, retrospective, nonrandomized 
Japanese study with a 15-year follow-up period, it was observed significantly lower (P 
=.03) prevalence of cirrhosis (21% vs 35%) and HCC (hepatocellular carcinoma) (12% vs 
25%) in those treated with SNMC. However, 10% developed hypokalemia and 3% 
developed hypertension. Furthermore, limited information was provided on viral loads and 
follow-up biopsy results, and variable doses of glycyrrhizin were used (200 mg 2–7 
days/wk). These clinical trials showed that the beneficial effects of glycyrrhizin were 
largely biochemical (improvement in liver enzyme levels), but side effects (fluid retention, 
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hypokalemia) were seen in up to 20%.  Based on current evidence, the use of this drug 
cannot be recommended to patients with liver disease (Verma et Thuluvath, 2007). 
Natural killer (NK) cell activity is known to play an important role in the elimination of virus-
infected cells during chronic hepatitis. NK cell activity is also elevated in response to γ-
interferon and interleukin-2. Due to the prior reports on elevation of γ-interferon by 
glycyrrhizin investigated NK cell activity among control subjects and patients with chronic 
liver diseases following the intravenous administration of 80–200mg glycyrrhizin/day 
(duration unknown). Glycyrrhizin administration was found to have no effect on NK cell 
activity and no further data was reported (Isbrucker et Burdock, 2006). 
Preliminary evidence suggests that isolated constituents of licorice may be effective for 
treating hepatitis B and C. Glycyrrhizin- and glycyrrhizic acid-containing intravenous 
preparations show activity against hepatitis B and hepatitis C in humans, but the trials are 
too small to draw any definitive conclusions (Anonymous, 2009).  
 
Oral Lichen Planus 
Patients with chronic hepatitis C often experience oral lichen planus, an inflammatory 
disease characterized by lymphocytic hyperkeratosis of the oral mucosa. It is rarely cured 
and effective treatments are limited. In an open clinical trial, 17 hepatitis C-positive 
patients with oral lichen planus were given either routine dental care or 40 mL IV 
glycyrrhizin daily for one month. Among nine patients taking glycyrrhizin, six (66.7%) 
noted improved clinical symptoms, such as decreased redness, fewer white papules, and 
less erosion of the mucosa. In the non-glycyrrhizin group of eight patients, only one 
(14.3%) reported any improvement (Anonymous, 2005). 
 
Antiretrovirus effects 
Glycyrrhizin achieved a dose-dependent inhibition of the replication of human 
immunomoduficiency virus type 1 (HIV-1) in Mot-4 cells within the concentration range of 
0.075 to 0.6 mmol. Within this concentration range, glycyrrhizin also effected a dose-
dependent reduction in the protein kinase D activity of Mot-4 cells. Glycyrrhizin sulfate 
completely inhibited HIV-induced plaque formation in Mot-4 cells at a concentration of 1 
mg.ml-1, the 50% inhibitory dose was 0.055 mg.ml-1. Glycyrrhizin was foud to be an 
effectient inhibitor for reverse transcriptase. The effect of glycyrrhizin sulfate was 4 times 
stronger than that of glycyrrhizin in molar terms (Shen et al., 2007). Glycyrrhizin inhibited 
the cytopathic effect and the virus-specific antigen expression in HIV-infected MT-4 cells. 
Furthermore glycyrrhizin inhibited giant cell formation caused by HIV-infection in Molt-4 
cells, which are sensitive to HIV and fuse to giant cells after infection, providing a 
parameter for determining the cytopathic effect of HIV. Glycyrrhizin sulphate was found to 
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both inhibit cell-free viral infection and cell to cell infection. Some of these effects may be 
due to its ability to reduce membrane fluidity. Reduced membrane fluidity by glycyrrhizin 
could explain how it can inhibit cell-to-cell fusion by suppression of the formation of 
virological synapses. It was found that HIV-1 reverse transcriptase (rRT) functioned as an 
effective phosphate acceptor for recombinant human casein kinase II (rhCK-II) in vitro; 
this phosphorylation was inhibited by the glycyrrhetinic acid derivative, quercetin and a 
high dose (100 µg) of glycyrrhizin. RNA-Dependent DNA-polymerase (RDDP) activity was 
stimulated by about 2.5-fold after full phosphorylation of rRT by rhCK-II. Recent 
investigations have evaluated the effect of glycyrrhizin on HIV replication in cultures of 
peripheral blood mononuclear cells (PBMC) from HIV-infected patients. In 31% of the 
samples, glycyrrhizin inhibited more than 90% of HIV replication, including a non-
syncytium-inducing variant of HIV (NSI-HIV). Glycyrrhizin induced the production of CC 
chemokine ligand (CCL) 4 and CCL5 in a dose-dependent manner, suggesting that the 
drug possesses the potential to inhibit NSI-HIV by stimulating the production of beta-
chemokines which compete with the chemokine receptor mediated infection of cells by 
HIV. Among a variety of natural products described as anti-HIV agents, glycyrrhizin was 
found to have a mechanism of action which may at least in part be attributed to 
interference with virus–cell binding. More recently, an increasing quantity of data 
suggested that the antiviral effects of glycyrrhizin are linked to the induction of 
endogenous interferon gamma. Further, glycyrrhizin affects other cellular signalling 
pathways such as protein kinase II, casein kinase II and transcription factors such as 
activator protein1 and nuclear factor κB (Fiore et al., 2008). 
Two coumarins of G. glabra, glycocoumarin and licopyranocoumarin, were able to inhibit 
giant cell formation in HIV-infected cell cultures whithout any cytotoxicity. Also, it was also 
shown that lichochalcone A had anti-HIV activity (Asl et Hosseinzadeh, 2008). 
Effects on herpesviridae 
Studies show licorice and its constituents, specifically glycyrrhizin, have antiviral activity 
against Herpes simplex and are capable of irreversibly inactivating the virus (Anonymous, 
2005). Following this landmark study glycyrrhizin was evaluated for any in vitro antiviral 
action against varicella-zoster virus. In human embryonic fibroblast cells inoculated with 
five strains of the virus, glycyrrhizin produced an inhibitory effect on viral proliferation with 
an IC50 (inhibitory concentration reducing activity to 50% of controls) of 0.71 mM. The 
selectivity index, defined as the ratio of IC50 for host-cell DNA synthesis to IC50 for virus 
replication, was estimated to be 30 (this value is not as high as for the most commonly 
used antiviral drugs, the selectivity index for acyclovir is close to 600). Pretreatment of 
cells with the drug 24h before inoculation was able to inhibit replication of the virus. 
Incubation of the virus for 30 min with a concentration of 2.4 mM glycyrrhizin was effective 
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in inactivating more than 99% of the virus particles, and glycyrrhizin demonstrated an 
additive effect with other conventional antiviral drugs such as acyclovir, and also with 
human β-interferon. In studies demonstrating the inhibition of HSV-1 by glycyrrhizic acid in 
vitro a synergism of the inhibitory effect with the endogenous antiviral substance 
lactoferrin was found (Fiore et al., 2008). 
In a clinical trial of 31 patients with severely painful herpes zoster lesions, 12 patients 
were given 20 mg IV glycyrrhizin on six separate occasions. The remaining 19 patients 
received zoster immune gamma-globulin, recombinant β-interferon, or acyclovir. 
Glycyrrhizin ranked next to acyclovir for pain resolution at the end of one month 
(Anonymous, 2005). 
A case report demonstrated a two-% topical glycyrrhizic acid cream (carbenoxolone 
sodium) applied six times daily in 12 patients with acute oral herpetic (Herpes simplex) 
infections resolved pain and dysphagia within 24-48 hours of beginning use. Moreover, 
the accompanying ulceration and lymphadenopathy gradually healed within 24-72 hours 
(Anonymous, 2005). 
Recently, it has been demonstrated that a treatment with glycyrrhizic acid of cells latently 
infected with Kaposi sarcoma-associated herpesvirus (KSHV) is able to reduce the 
synthesis of a viral latency protein and to induce apoptosis of infected cells. This finding 
suggests that glycyrrhizic acid may be the key to find a novel way to interrupt latency in 
infected cells (Fiore et al., 2008). 
 
Effects in murine herpes encephalitis 
Glycyrrhizin has also been demonstrated as effective in the treatment of herpes simplex-
induced encephalitis in mice. Animals were administered 50 µg glycyrrhizin/g i.p., on the 
third, fourth and fifth days following viral inoculation. The survival rate of among treated 
mice was 82% and only 38% in untreated animals. The mean virus yield per brain 
hemisphere in glycyrrhizin treated animals was approximately half that of control 
(Isbrucker et Burdock, 2006). In another study, intraperitoneal administration of 
glycyrrhizin increased the survival rate of the animals by about 2.5 times, and the viral 
replication in the brain was reduced to 45.6% of the control (Fiore et al., 2008). 
 
Licorice and influenza virus 
New strategies for the cure of influenza are needed, since conventional antiviral agents, 
such as amantadine and ribavirin, are not very effective and have toxic side effects (Fiore 
et al., 2008). Recently, olseltamivir and zanamivir were added to the available panel of 
antivirals, especially with regard to the H1N1 virus.  
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Glycyrrhizic acid has been shown to inhibit the recovery of hemagglutinins from influenza 
virus-infected embryonated hen eggs. The substance did not affect viral viability nor 
impair hemagglutinating activity of the virions, but was able to affect the growth of viruses 
in embryonic tissues, particularly at the late viral replication steps. A recent study was 
conducted using Glycyrrhiza uralensis ethanol extract in a culture of A549 human 
bronchial epithelial cells infected with influenza virus H1N1. The extract produced an 
inhibitory effect on the production of RANTES, the potent chemotactic cytokine for 
monocytes, basophils and T cells, typically detected in nasal secretions of patients with 
upper respiratory tract infection, and involved in the epithelial cell-mediated inflammatory 
process. The licorice extract was evaluated at concentrations in the range 20–200 μg/mL; 
at a maximal concentration, a 97.0 ± 1.8% inhibition in RANTES production was, 
suggesting that compounds derived from Glycyrrhiza spp. may be beneficial for the 
treatment of inflammatory processes related to viral infection (Fiore et al., 2008). 
BALB/c mice infected with influenza virus A2 (H2N2) were unable to survive 10 times the 
mean lethal dose (LD50) of virus. However, a complete survival was observed when these 
animals were treated with 10 mg glycyrrhizin/kg, i.p., on the day prior to, the day after, and 
on the fourth day after infection. This same dosing regimen conferred 70% survival in 
mice infected with 50 times the viral LD50. This response was demonstrated to be dose-
dependent with improved survival in animals administered greater than 2.5mg 
glycyrrhizin/kg. Although the lung viral titers were decreased in glycyrrhizin-treated 
animals, in vitro assays demonstrated that this compound did not inhibit viral replication in 
cell cultures. This suggested that the anti-viral mechanism of glycyrrhizin was indirect, and 
possibly stimulated endogenous viral defense mechanisms. In examining this theory, the 
authors reported that the transplanting of splenic T-cells from glycyrrhizin-treated mice 
conferred resistance to infected mice that had not been treated with glycyrrhizin. The 
transplanting of other splenic cell subsets did not improve the survival of infected mice, 
indicating that glycyrrhizin was a specific inhibitor of the cell-mediated immunological 
response. The administration of gamma-interferon monoclonal antibody to infected mice 
blocked the anti-viral activity of glycyrrhizin treatment (Isbrucker et Burdock, 2006). These 
results confirm that the anti-viral activity of glycyrrhizin is due to its stimulating of gamma -
interferon production by T-cells (Fiore et al., 2008; Isbrucker et Burdock, 2006). 
When mice were treated intraperitoneally with 10 mg of glycyrrhizin/kg body weight 1 day 
before exposure to 10 LD50 (lethal dose killing 50% of animals) of the influenza virus A2 
and 1 and 4 days after the infection, all of the animals survived over the experimental 
period of 21 days. Conversely, the mean survival time in control mice was 10.5 days, and 
there were no survivors. The grade of pulmonary consolidation and the virus titers in the 
lung tissues of infected mice treated with glycyrrhizin were significantly lower than those in 
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the lung tissues of infected mice treated with saline. An interesting finding was that when 
splenic T cells from glycyrrhizin-treated mice were transferred to mice exposed to 
influenza virus, all the recipients survived, while no survivor was seen in recipient mice 
inoculated with native T cells, or with splenic B cells and macrophages from 
glycyrrhizintreated mice. The administration of glycyrrhizin to infected mice in combination 
with anti-gamma interferon monoclonal antibody did not produce any antiviral effect. Other 
previously reported studies indicated that in mice glycyrrhizin and glycyrrhetinic acid were 
able to induce the production of interferon, suggesting this as a possible mechanism of  
action against viral infection (Fiore et al., 2008). 
 
Licorice and Severe Acute Respiratory Syndrome (SARS) related coronavirus 
A new coronavirus has been identified in patients with SARS, and the disease has drawn 
enormous attention and caused fear worldwide since early 2003 (Fiore et al., 2008). 
Although the disease is now under control, the possibility of a return of the pathology has 
stimulated the search for a remedy (Cinatl et al., 2003; Fiore et al., 2008). Several studies 
have been reported, but a specific treatment for SARS has not yet been established. 
Various pharmacological treatments have been suggested, such as steroids, ribavirin, 
interferon and also glycyrrhizin (Fiore et al., 2008). Preliminary evidence suggests that 
glycyrrhizin may inhibit the growth of the coronavirus, which is associated with SARS. The 
exact mechanism of the antiviral effect of glycyrrhizin is not known (Anonymous, 2009; 
Cinatl et al., 2003; Fiore et al., 2008). 
Glycyrrhizin inhibits SARS-associated coronavirus (SARS-CoV) replication in Vero cells 
with a selectivity index of 67. In addition to inhibition of virus replication, glycyrrhizin is 
able to inhibit adsorption and penetration of the virus during the early steps of the 
replicative cycle. The activity of glycyrrhizin is lower when added during the adsorption 
period than after virus adsorption (EC50 is 600 mg/L vs 2400 mg/L, respectively). 
Glycyrrhizin has been found to be most effective when given both during and after the 
adsorption period (Fiore et al., 2008). Glycyrrhizin affects cellular signalling pathways 
such as protein kinase C; casein kinase II; and transcription factors such as activator 
protein 1 and nuclear factor KB. Furthermore, glycyrrhizin and its aglycone metabolite 18-
β-glycyrrhetinic acid upregulate expression of inducible nitrous oxide synthase and 
production of nitrous oxide in macrophages (Cinatl et al., 2003). Studies show that 
glycyrrhizin induces nitrous oxide synthase in Vero cells and that virus replication is 
inhibited when a nitrous oxide donor (DETA Nonoate) is added to the culture medium 
(Cinatl et al., 2003; Fiore et al., 2008). Since glycyrrhizin was shown to be able to inhibit 
SARS-CoV replication in vitro, the activity of several glycyrrhizic acid derivatives was 
evaluated.  The introduction of 2-acetamido-beta-D-glucopyranosylamine into the 
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glycoside chain of glycyrrhizin produced a 10-fold increase of the anti-SARS-CoV activity. 
Other compounds, such as amides and conjugates of glycyrrhizin with two amino acid 
residues presented up to 70-fold increased activity against the virus; however, the 
cytotoxicity increased as well in those derivatives, resulting in a decreased selectivity 
index (Fiore et al., 2008). 
 
Effects on Cytomegalovirus  
Cytomegalovirus (CMV) is the most common cause of congenital and perinatal viral 
infections throughout the world. It manifests with profound liver dysfunction and poor 
weight gain (Anonymous, 2005). Investigation of the effects of glycyrrhizin on CMV 
infection of human monocytic and human embryonic lung cell lines showed that it inhibited 
viral antigen expression (Fiore et al., 2008). In a series of studies, both oral and IV 
preparations of licorice (SNMC) were administered to infants with CMV. Liver dysfunction 
and weight gain improved in nearly all cases compared to groups without treatment 
(Anonymous, 2005). 
 
Effects on other viruses 
Glycyrrhizin was tested in vitro for antiviral activities against several pathogenic 
flaviviruses involved in diseases such as dengue, Japanese encephalitis, mammalian tick-
borne encephalitis and yellow fever. Glycyrrhizin was found to be able to inhibit the 
replication of flaviviruses at high non-cytotoxic concentrations (Fiore et al., 2008). The 
target for glycyrrhizin action against the vesicular stomatitis virus (VSV) has been 
identified as enzyme kinase P, which is essential for the early stages of viral replication. 
Glycyrrhizin at low doses was found to selectively inhibit protein phosphorylation by 
kinase P, without any significant effect on other kinases. It has been reported that this 
direct binding of glycyrrhizin to the virus-associated kinase results in its inactivation and a 
reduction of viral infectivity (Fiore et al., 2008).  In Hela cell culture, Radix Glycyrrhizae 
was found to be a inhibitor of respiratory syncytial virus (RSV) (Dong et al., 2004; Shen et 
al., 2007). An effect of glycyrrhizic acid was also reported against Epstein-Barr virus 
(EBV), which produces infectious mononucleosis. The inhibition of EBV replication in vitro 
is dose-dependent. It has been suggested that the drug interferes with an early step of 
EBV replication, possibly penetration, without any effect on viral adsorption, or inactivation 
(Fiore et al., 2008). Glycyrrhizin was also effective against varicella-zoster virus (VZV) 
replication when human embryonic fibroblast (HEF) cells were treated 24 h before the 
inoculation (Shen et al., 2007). 
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Antiprotozoal activities 
Chinese licorice roots were found to potentially inhibit the growth of Plasmodium 
falciparum and Leishmania donovani in in vitro studies. Chalcones such as licochalcone A 
from Chinese licorice roots are known to possess antiplasmodial activity. Also, chalcones 
have a potent antileishmanial activity and might be developed into a new class of 
antileishmanial drugs. It was found that chalcones, such as lichochalcone A, alter the 
ultrastructure of the parasite mitochondria and inhibit their function by selectively inhibiting 
fumarate reductase in the respiratory chain of the parasite (Asl et Hosseinzadeh, 2008). 
Antioxidative activites 
The constituents of G. inflata, licochalcone A, B, C, D and echinatin, were effective in 
preventing microsomal lipid peroxidation induced by Fe (III)-ADP/NADPH and 
lincochalcone B, D showed potent antioxidative and superoxide scavenging activities. 
Furthermore, the isoflavone derivatives of G. glabra such as glabridin inhibited lipid 
peroxidation in rat liver microsomes and protected mitochondrial functions from oxidative 
stresses (Asl et Hosseinzadeh, 2008). Glabridin has also been reported to possess 
antioxidant properties (Cui et al., 2008). Moreover, glabridin was a potent antioxidant 
toward LDL oxidation in in vitro and in vivo studies (Asl et Hosseinzadeh, 2008; Fiore et 
al., 2005). The consumption of licorice or glabridin by atherosclerotic apolipoprotein E-
deficient (Eо) mice caused a significant reduction not only in their LDL oxidation (Asl et 
Hosseinzadeh, 2008; Fiore et al., 2005), but also in the development of atherosclerotic 
lesions. It seems that glabridin may possess this property by two mechanisms: first it 
binds to the LDL and substantially protects its oxidation. The hydroxyl groups on the B 
ring of glabridin were found to be most important for its antioxidative properties. Second, it 
accumulates in cells such as macrophages, causing a reduction of cellular oxidative 
stress by reducing cellular glutathione. In addition, other constituents of G. glabra such as 
isoflavones hispaglabridin A, hispaglabridin B and 4´-O-methylglabridin, the two 
chalcones, isoprenylchalcone derivative and isoliquiritigenin were antioxidants against 
LDL oxidation (Asl et Hosseinzadeh, 2008). 
G. glabra extracts showed great antioxidant and free radical scavenging activities in 
topical formulations and may be used in topical formulations in order to protect the skin 
against damage caused by free radical and reactive oxygen species (Asl et 
Hosseinzadeh, 2008). 
Certain licorice constituents possess significant antioxidant and hepatoprotective 
properties. Glycyrrhizin and glabridin inhibit the generation of reactive oxygen species 
(ROS) by neutrophils at the site of inflammation. In vitro studies have demonstrated 
licorice isoflavones, hispaglabridin A and B, inhibit Fe3+-induced mitochondrial lipid 
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peroxidation in rat liver cells (Anonymous, 2005). Hispaglabridin A, especially, showed a 
potent antioxidative activity against peroxidation induced by Fe-ascorbate (Asl et 
Hosseinzadeh, 2008). Other research indicates glycyrrhizin lowers lipid peroxide values in 
animal models of liver injury caused by ischemia reperfusion (Anonymous, 2005).  
 
Anticarcinogen and antitumor actions 
Licorice root has been identified by the National Cancer Institute (US) as possessing 
cancer-preventive properties (Asl et Hosseinzadeh, 2008). The effects first reported 
referring to beneficial effects on excessive tissue growth around nails, in the eye and in 
form of tumours have been confirmed in vitro by demonstrating that liquorice causes 
apoptosis. This is evident from its antineoplastic effect against melanoma and gastric 
cancer cells (Fiore et al., 2005). It was reported that the water extract of G. glabra 
effectively inhibits growth of Ehrlich ascites tumor (EAT) cells in vivo and in vitro (Sheela 
et al., 2006; Asl et Hosseinzadeh, 2008) and also acts as an inhibitor of vascular 
endothelial growth Factor (VEGF) (Sheela et al., 2006) inhibiting angiogenesis in in vivo 
assay (Asl et Hosseinzadeh, 2008; Sheela et al., 2006). Inhibition of EAT cell growth in 
vivo with corresponding reduction in cell number, body weight and ascites volume 
confirms the early findings of G. glabra as anti-neoplastic agent. Treatment with the 
soxhlet extracted solvent fractions of G. glabra on EAT-bearing mice showed that 
methanol extract and water extract induced inhibition of proliferation of tumor cells in vivo 
and in vitro. A compound licocoumarone isolated from methanolic extract of G. glabra has 
been shown to be an apoptosis-inducing component. Some results indicate that the 
methanolic extract inhibits EAT cell proliferation in vivo. This effect may probably be due 
to the presence of licocoumarone (Fig. 63) (Sheela et al., 2006). 
 
 
 
Fig. 63. Chemical structure of licocoumarone (adapted from 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=503731&loc=ec_rcs) visited 1/1/2010). 
 
 
A decrease in the cell number of EAT cells treated with G. glabra aqueous extract in vitro 
explains the strong antiproliferative effect of proteins present in the water extract of G. 
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glabra. Results show that there is inhibition of neovascularization by G. glabra extract in 
chorioallatoic membrane (CAM). Since there is inhibition of neovascularization by G. 
glabra extract, it supports our view that G. glabra extract may repress the expression of 
VEGF like factors thereby inhibiting the formation of new blood vessels and this was 
confirmed by ELISA. Results suggest that the extract from G. glabra may be a potential 
supplemental source for cancer treatment, and deserves further studies. Further work is 
ongoing to delineate the underlying mechanism and signalling cascades involved in 
targeting angiogenesis (Sheela et al., 2006). Also, the ethanol extract of G. uralensis root 
induced apoptosis and G1 cell cycle arrest in MCF-7 human breast cancer cells. On the 
other hand, there are many studies about the anticancer effects of several derivatives of 
its components both in in vivo and in vitro studies (Asl et Hosseinzadeh, 2008). 
Glycyrrhetinic acid could also trigger the proapoptotic pathway by inducing mitochondrial 
permeability transition and this property may be useful for inducing apoptosis of tumor 
cells. Recently, licochalcone E, a new retrochalcone from the roots of G. inflata, exhibited 
the most potent cytotoxic effect compared with the known antitumor agents, licochalcone 
A and isoliquiritigenin (Asl et Hosseinzadeh, 2008). Isoliquiritigenin caused great interest 
after it was found to have effects in: inhibiting proliferation of the human non-small cell 
lung cancer A549 cell line, inducing apoptosis and locking cell cycle progression in the G1 
phase, suppressing azoxymethane-induced colon carcinogenesis in ddY mice, and 
inhibiting the growth of prostate cancer. It had been suggested that isoliquiritigenin merits 
investigation as a potential cancer-chemopreventive agent in humans (Ma et al., 2005). 
Licorice appears to have anti-estrogenic and estrogenic action. Preliminary research 
indicates that licorice does not stimulate the growth of estrogen dependent breast cancer 
cells. However, the estrogenic effects of licorice might be concentration dependent. 
Glabridin, an isoflavone constituent of licorice, seems to have an estrogen receptor-
dependent growth-promoting effect at low concentrations. At higher concentrations, it 
seems to have an estrogen receptor-independent antiproliferative effect (Anonymous, 
2009). 
It was previously reported on the inhibitory effect of Glycyrrhizae radix on mouse 
endometrial carcinogenesis. Both Glycyrrhizae radix and glycyrrhizin exerted a significant 
decrease in the COX-2, IL-1 α and TNF-α mRNA expressions. Glycyrrhizin (GL) 
generated a significant decrease in the incidence of endometrial adenocarcinoma. 
Accordingly, the preventive effects of Glycyrrhizae radix may be attributable to 
glycyrrhizin, thus being related with the suppression of COX-2, IL-1α and TNF-α. Gl radix 
and GL could therefore be a promising formula for the chemoprevention of human 
endometrial cancer (Shen et al., 2007).  
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Several animal and in vitro studies indicate glycyrrhizin and its constituents possess 
anticarcinogenic activity against a variety of cancers, warranting further investigation in 
clinical trials (Anonymous, 2005). 
 
Hepatoprotective effects 
It is known in the traditional system of medicine for the licorice use in liver diseases. It is a 
major component of many antihepatotoxic polyherbal formulations. Isoflavan derivatives 
glabridin, hisplaglabridin A, hisplaglabridin B and 4‘-O-methyl glabridin have been isolated 
from G. glabra. These chemicals were reported to provide protection against oxidative 
stress. The biochemical damage produced by active oxygen species and free radicals has 
emerged as a fundamental pathway of liver injury. Despite the use of G. glabra in liver 
disorders, no systematic studies on its active oxygen scavenging properties have been 
reported. In short, CCl4-induced damage produces alteration in the antioxidant status of 
the tissues, which is manifested as an abnormal histopathology. In a recent study, G. 
glabra restored all these changes. So, it can be concluded that the herb is a potential 
antioxidant and attenuates the hepatotoxic effect of CCl4 by acting as an in vivo 
antioxidant and thereby inhibiting the initiation and promotion of lipid peroxidation or by an 
accelerated scavenging of free radicals and their products by conjugation with glutathione 
aided by glutathione-S-transferase (Ragesh et Latha, 2004). Also glycyrrhizin and 
glycyrrhetinic acid show hepatoprotective effects (Blumenthal, 2003). Glycyrrhetinic acid is 
thought to act by inhibition of the cytochrome P-450 system required for the metabolism of 
CCl4 to the highly reactive radical CCl3 (Newall et al., 1996b). In an in vitro study, 
glycyrrhizin was hepatoprotective, probably by preventing changes in cell membrane 
permeability (Asl et Hosseinzadeh, 2008). Nevertheless it was suggested that 
glycyrrhetinic acid is a better hepatoprotective drug than glycyrrhizin in vitro study (Asl et 
Hosseinzadeh, 2008), namely against CCl4- induced toxicity (Asl et Hosseinzadeh, 2008; 
Newall et al., 1996b) and retrorsine-induced liver damage, respectively, in mice and rats. 
Furthermore, in a hepatocyte model of cholestatic liver injury, glycyrrhizin exhibited pro-
apoptotic properties, whereas glycyrrhitinic acid is a potent inhibitor of bile acid-induced 
apoptosis and necrosis (Asl et Hosseinzadeh, 2008). Results of in vitro and animal (rat) 
studies supported further that glycyrrhizin inhibits lipid peroxidation, thereby protecting the 
rat hepatocytes. It was shown that glycyrrhizin inhibits immunomediated cytotoxicity 
against hepatocytes and the murine NFκB activity in the murine liver injury induced by 
CCl4-ethanol. Moreover, glycyrrhizin inhibited anti-FAS antibody-induced elevation of ALT 
in mice. Another group demonstrated that glycyrrhizin reduced ALT levels, steatosis and 
fibrosis in the mouse model of liver injury induced by CCl4 and ethanol. This experiment 
showed a concomitant reduced nuclear factor-kappa B binding (Fiore et al., 2008).   
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It was showed that liquiritigenin (LQ), an aglycone of liquiritin in G. radix, exerts 
cytoprotective effects against heavy metal-induced toxicity in vitro. This study investigated 
in vivo protective effects of LQ against acute liver injuries induced by acetaminophen 
(APAP) or APAP plus buthionine sulfoximine (BSO) (Shen et al., 2007). Licorice 
constituents also exhibit hepatoprotective activity by lowering serum liver enzyme levels 
and improving tissue pathology in hepatitis patients (Anonymous, 2005). Glycyrrhizin 
reduces the toxic action of carbon tetrachloride- and galactosamine- induced cytotoxicity 
in cultures rat hepatocytes, through its antioxidant activity. Glycyrrhizin inhibited histamine 
release from rat mast cells and prevent carbon tetrachloride-induced liver lesions and 
macrophage-mediated cytotoxicity. Glycyrrhizin protected the liver apparently through its 
membrane stabilization effects (WHO, 1999b). 
In a recent study, SNMC reduced serum level of alanine aminotransferase (ALT), albumin 
(ALB) and total bilirubin (TBIL), and attenuated hepatocyte apoptosis, leading to the 
secondary liver injury induced by lipopolysaccharide (LPS). Its related mechanisms such 
as reducing the release of NO and endothelin-1 (ET-1), restraining the formation of 
hepatic sinusoid microthrombi and microcirculation dysfunction, inhibiting immunologic 
injury caused by cytokines especially TNF-α, and suppressing the formation of endotoxin, 
may contribute to the protective effect against fulminant hepatic failure (FHF). However, in 
this study, SNMC failed to raise the albumin levels during FHF, probably due to the longer 
half life of albumin. The results suggest that SNMC can effectively attenuate hepatocyte 
apoptosis. The release of cytochrome C (Cyt-C) is a key event in the apoptosis process. 
Cyt-C has a duplex function as an initiator to activate cell apoptosis and participate in 
electron transfer. Cyt-C shifting to the cytoplasm could bring about a cascade of reactions 
of caspases, finally activate caspase-3 and result in hepatocyte apoptosis. Meanwhile, we 
speculated that SNMC inhibited the progression of hepatocyte apoptosis mainly by 
stabilizing the mitochondrial membrane and inhibiting the release of Cyt-C and 
subsequent caspase-3 activations. A study demonstrated that SNMC not only reduced 
serum aminotransferase and bilirubin, but also attenuated the hepatocyte apoptosis. 
SNMC reduced the necrotic area and increased the survival rate of mice by promoting 
hepatocyte regeneration and recovery of denatured cells, and protecting the undamaged 
cells. However, the dosages of SNMC in the treatment of FHF and the therapeutic time 
have not yet been firmly established. In summary, the results of the present study support 
SNMC treatment for FHF, but the precise mechanism should be further studied (Yang et 
al., 2007). 
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Antidepressant effects 
A recent study show that aqueous extract of G. glabra produced antidepressant-like effect 
in mice, and this effect seems most likely to be mediated through an interaction with 
adrenergic and dopaminergic systems. Glycyrrhizin inhibited monoamine oxidase, thereby 
increased the levels of monoamines like epinephrine and dopamine in brains of mice 
(Dhingra et Sharma, 2006). Glabridin inhibited serotonin reuptake. In addition, recently, 
the aqueous extract of G. glabra L. showed antidepressant activity in both the forced 
swimming test (FST) and tail suspension test (TST) in mice (Asl et Hosseinzadeh, 2008). 
It was demonstrated that two flavonoids, liquiritin and isoliquiritin, isolated from G. 
uralensis appeared to produce antidepressant-like effect in the FST and TST in mice. In 
addition, there were no differences in antidepressant-like effect between liquiritin and 
isoliquiritin. And the study suggested that the increase in 5-hydroxytryptamine and 
norepinephrine in the CNS might be one of the possible mechanisms (Zhao et al., 2008). 
 
Enhancing-memory effects 
Glycyrrhiza glabra has also been reported to enhance memory, but licorice from other 
genera has not been reported to have such an activity. The active component for this 
effect is still unknown (Cui et al., 2008). More recently, animal studies indicate aqueous 
extracts of G. glabra may have memory-enhancing activity via reversal of chemically-
induced amnesia, as measured by maze and passive avoidance testing in mice 
(Anonymous, 2005). Immunohistochemical studies suggested the existence of chronic 
inflammation in certain regions of the brain in Alzheimer´s disease patients. It has also 
been observed that elderly patients suffering from Alzheimer´s disease show reduced 
symptoms upon chronic use of anti-inflammatory drugs. Grabridin showed anti-
inflammatory activity, which would certainly help Alzheimer patients by reducing the 
inflammatory components of Alzheimer´s disease (Cui et al., 2008). Oxygen free radicals 
are implicated in the process if ageing and may be responsible for the development of 
Alzheimer´s disease in elderly persons. Oxigen-containing free radicals and other 
products of oxidative metabolism have been shown to be neurotoxic, and antioxidant-rich 
diets improved cerebellar physiology and motor learning in aged rats. Glabridin has also 
been reported to possess antioxidant properties. The neuroprotective effect of glabridin 
may be attributed to its antioxidant properties, which results in susceptible brain cells 
being exposed to less oxidative stress, in reduced brain damage and improved neuronal 
function. Thus, the combination of anticholinesterase, anti-inflammatory and antioxidant 
effects exhibited by glabridin may all be eventually responsible for its memory-enhancing 
effect (Cui et al., 2008). In addition, isoliquiritigenin showed protective effects in cerebral 
ischemia-reperfusion injury in rats. Carbenoxolone has shown anticonvulsant, sedative 
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and muscle relaxant activities in mice and in genetically epilepsy prone rats (GEPRs) (Asl 
et Hosseinzadeh, 2008). Also, it was able to suppress the generation of superoxide 
anions and hydrogen peroxide in macrophages and it also showed protective effects in 
the skeletal muscle and hippocampus against acute ischemic-reperfusion effects in rats. 
In addition it could decrease the learning performances of rats in a spatial memory task 
(Asl et Hosseinzadeh, 2008). 
Cardiovascular effects 
Licorice showed an antiplatelet aggregation effect. In other experiments, glycyrrhizin has 
been identified as a thrombin inhibitor in in vitro and in vivo studies and it was believed 
that glycyrrhizin might be used as a model for searching new antithrombotic drugs (Asl et 
Hosseinzadeh, 2008). Antiplatelet activity in vitro has been documented for a 3-
arylcoumarin derivative, GU-7, isolated from liquorice. Gu-7 was thougth to inhibit platelet 
aggregation by increasing intraplatelet cyclic AMP concentration (Newall et al., 1996b). A 
recent study reported that glycyrrhizin reduced thrombosis formation in rats in a dose-
dependent manner. The IC50 for intravenous glycyrrhizin was 75mg/kg in a stasis-induced 
model, but only 230mg/kg in an arteriovenous shunt model. Interestingly, the antithrombic 
activity was very time-dependent with an effective half life of less than 60min in both 
models. The mechanism of action did not appear to be similar to that of heparin (Isbruker 
et Burdock, 2006). Also, G. glabra accelerated the metabolism of cells in the bone marrow 
erythroid stem and increased the animal‘s resistance to stress. Isoliquiritigenin is reported 
to have a vasorelaxant effect. It could also able to decrease tube formation in vascular 
endothelial cells. Thus, the anti-angiogenic effect of licorice extract depended on the anti-
tube formation effect of isoliquiritin. On the other hand, as for the estrogen-like activities of 
glabridin in in vivo and in vitro studies, it was demonstrated that it could modulate vascular 
injury and atherogenesis. Therefore, it is suggested for the prevention of cardiovascular 
diseases in post-menopausal women (Asl et Hosseinzadeh, 2008). 
 
Immunomodulatory activities 
Several immunomodulatory activities have been attributed to glycyrrhizin and 
glycyrrhetinic acid. The same results were seen with lichochalchone A and some 
analogues which showed immunomodulatory effects. On the other hand, glycyrrhizin 
selectively activated extrathymic T cells in the liver and in human T cell lines and 
glycyrrhizic acid enhanced Fas-mediated apoptosis without alteration of caspase-3-like 
activity. Glycyrrhizin also improved the impaired resistance of thermally injured mice to 
herpes virus infection. Moreover, glycyrrhetinic acid was an inducer of type 2 antagonistic 
CD41 T cells in in vivo and in vitro studies. It improved the resistance of mice infected with 
LP-BM5 murine leukemia virus (MAIDS) mice to Candida albicans infection. Also, it 
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stimulated macrophagederived NO production, and was able to up-regulate iNOS 
expression through nuclear factor kB (NF- kB) transactivation in murine macrophages. 
Both of them could induce interferon activity and augment natural killer cell activity and in 
this study glycyrrhizin was superior to glycyrrhetinic acid in inducing interferon. It also has 
inhibitory effects on TNF-alpha-induced IL-8 production in intestinal epithelial cells. In 
addition, there are some studies on the immunomodulatory effects of polysaccharide 
fractions obtained from shoots of G. glabra and hairy roots of G. uralensis in vitro. GR-2IIa 
and GR-2IIb, two isolated acidic polysaccharides of G. uralensis, have shown 
anticomplementary activity. Also, GR-2IIc had both anticomplementary activity and 
mitogenic activity. Recently, the haemolytic activities of G. uralensis saponins (GLS) and 
its adjuvant potentials against ovalbumin (OVA) were established in mice (Asl et 
Hosseinzadeh, 2008). 
Glycyrrhizin inhibited to some extent prostaglandin E2 bio-synthesis by the activated rat 
peritoneal macrophage, whereas in the cell-free experiment glycyrrhizin and glycyrrhetinic 
acid showed little effect on the inhibition of cyclo-oxygenase. The in vitro 
immunomodulatory activities of a number of saponins and glycyrrhizic acids are 
described. Addition of these saponin preparations to mouse spleen cell cultures resulted 
in significant cell proliferation. B-cells were induced to proliferate in the presence of the 
saponin. On the other hand, glycyrrhizic acid stimulated both T- and B-lymphocytes 
equally. The selective proliferation of subtypes of lymphocytes correlated with 
restimulation responses by polyclonal mitogens. Incubation of lymphocytes in the 
presence of saponins caused effector cell generation as determined in a one-way mixed 
lymphocyte reaction. In the case of lymphocytes cultured in the presence of saponins or 
glycyrrhizic acid, the supernatants contained active soluble factors. It was demonstrated 
by the observation that glycyrrhizic acid has the most profound immunomodulatory activity 
in vitro (Shen et al., 2007). 
 
Renal effects 
Glabridin showed an antinephritis effect in the mouse glomerular disease model. Also, 
glycyrrhizin could ameliorate renal defects in gentamicininduced acute renal failure in rats. 
Also, the extract of Radix Glycyrrhyzae could protect the kidneys against peroxynitrite 
(ONOO−)-induced oxidative stress in vivo through scavenging ONOO− and/or its 
precursor NO (Asl et Hosseinzadeh, 2008). 
 
Respiratory effects 
Licorice has been used as a cough-relieving medicinal herb from ancient times. It seems 
that mucilage present in it or secretion produced under the influence of the active 
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substances covers the oral and throat mucosa soothing its irritability and relieving dry 
cough (Asl et Hosseinzadeh, 2008). Choline ester of glycyrrhetinic acid can produce a 
central antitussive effect. After oral administration of licorice, the drug may cover the 
mucosa of the throat and relieve local local inflammatory irritation to control cough and 
promote secretion of mucus from the throat and bronchi to produce an expectorant effect 
(Ganzhong et al., 2003e). The demulcent action of the drug is due primarily to glycyrrhizin. 
The antitussive and expectorant properties of the drug have also been attributed to 
glycyrrhizin, which accelerates tracheal mucus secretion (WHO, 1999b). Recently in one 
study, Radix Glycyrrhyzae produced a persistent antitussive effect in the guinea-pig, 
suggesting that liquiritin apioside, a main antitussive component, plays an important role 
in the earlier phase, while liquiritigenin and liquiritin play an important role in the late 
phase. This result is keeping with the previous antitussive effects of licorice (Asl et 
Hosseinzadeh, 2008).  
Gastrointestinal effects 
Antiulcer activity  
Licorice has been used as a demulcent and emollient for 2,000 years to promote the 
healing of ulcers by acting on the mucosal layer (Anonymous, 2005). The antiulcer activity 
of Radix Glycyrrhyzae has been demonstrated both experimentally and clinically. 
Intraperitoneal, intraduodenal, or oral administration of aqueous or alcoholic extracts of 
Radix Glycyrrhyzae reduced gastric secretions in rats, and it inhibited the formation of 
gastric ulcers induced by pyloric ligation, aspirin, and ibuprofen (Anonymous, 2009). 
Glycyrrhizin and its aglycone (glycyrrhetic acid, enoloxone) both have antiphlogistic 
activity and increase the rate of mucus secretion by the gastric mucosa (WHO, 1999b). 
Glycyrrhizinic acid seems to act by raising the local concentration of prostaglandins that 
promote mucous secretion and cell proliferation in the stomach, leading to healing of 
ulcers in experimental studies (Asl et Hosseinzadeh, 2008). In cases of acetic acid-
induced chronic gastric ulcer in rats, oral administration of glycyrrhizic acid afforded a cure 
rate of 97.7%. Glycyrrhizic acid not only decreased gastric acidity but also promoted 
healing of ulcers (Shen et al., 2007). The anti-stress ulcerogenic activity of 
deoxoglycyrrhhetol, a reducted compound of glycyrrhetinic acid, was studied by the 
experiment of restraint water immersion using mice and rats. This compound was 
administered orally to the animals. It was effective to inhibit stress-induced ulcer in mice at 
200 mg/kg. It was noted that the molecular modified compounds brought a remarkable 
enhancement of therapeutic effect (Shen et al., 2007). Glycyrrhetic acid (enoxolone) 
produced its antiulcer activity by inhibiting 15-hydroxyprostaglandin dehydrogenase and 
∆13-prostagladin reductase. Inhibition of these two enzymes stimuled an increase in the 
concentration of prostaglandins E and F2α in the stomach, which promoted the healing of 
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peptic ulcers owing to a cytoprotective effect on the gastric mucosa (WHO, 1999b). 
Glycyrrhizin (as carbenoxolone sodium) speeds healing of gastric ulcers and protects 
against aspirin-induced damage to the gastric mucosa (Anonymous, 2005). 
Carbenoxolone stimulates gastric mucus production,  enhances the rate of incorporation 
of various sugars into gastric mucosal glycoproteins, promotes mucosal cell proliferation, 
inhibits mucosal cell exfoliation, inhibits prostaglandin degradation, increases the release 
of PGE2 and reduces the formation of thromboxane B2 and regulates DNA and protein 
synthesis rates in gastric mucosa. More recently nitric oxide has been claimed to 
contribute to the anti-ulcer effect of carbenoxolone (Borrelli et Izzo, 2000). In view of the 
wide range of alternative therapies now available and of the numerous side effects, 
carbenoxolone use has been limited; indeed carbenoxolone produces effects similar to 
those of aldosterone excess (sodium retention and hypokalaemia leading to hypertension, 
oedema and cardiac failure) (Borrelli et Izzo, 2000; Newall et al., 1996b). Unfortunately, 
the side effects of licorice limit its potential to be used on a long-term basis for treatment 
of peptic ulcer disease (Anonymous, 2005).  
 
To avoid the side effects of glycyrrhizin in liquorice preparations, a glycyrrhizin-free 
fraction of liquorice extracts was studied (Borrelli et Izzo, 2000). The glycyrrhizin-free 
fraction, called FM 100 fraction, was found to be effective for gastric ulcers in rats by 
inhibiting gastric juice secretion (Borrelli et Izzo, 2000; Takagi et al., 1971). New 
isoflavonoids and chalcones from the fraction FM 100 were isolated, which could 
contribute to the anti-ulcer activity of liquorice (Borrelli et Izzo, 2000). A processed form of 
licorice, DGL (removal of the glycyrrhizin), was produced to eliminate potential adverse 
effects, including licorice-induced hypertension (Anonymous, 2005). DGL is an effective 
anti-ulcer agent (Anonymous, 2009; Borrelli et Izzo, 2000) without the fluid retention or 
electrolyte imbalance of carbenoxolone (Anonymous, 2009). DGL protected against 
gastric ulceration in rats induced by pyloric ligation and increased healing of peptic ulcer in 
patients. Moreover, DGL reduced bile acid-induced hydrogen ion back-diffusion across 
the canine gastric mucosa and diminished acute gastric mucosal damage due to aspirin or 
aspirin plus taurodeoxycholic acid (Borrelli et Izzo, 2000). Deglycyrrhizinated licorice 
formulations used in the treatment of ulcers do not suppress gastric acid release like other 
anti-ulcer medications. Rather, they promote healing by increasing mucous production 
and blood supply to the damaged stomach mucosa, thereby enhancing mucosal healing 
(Anonymous, 2005). Deglycyrrhizinated liquorice (97% of glycyrrhizin is removed) 
effectively treated stress-induced ulcers in animal models. The mechanism of antiulcer 
activity involves acceleration of mucin excretion through increasing the synthesis of 
glycoprotein at the gastric mucosa, prolonging the life of the epithelial cells, and 
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antipepsin activity (WHO, 1999b). Oral administration of deglycyrrhizinated liquorice 
(380mg, 3 times daily) to 169 patients with chronic duodenal ulcers was as effective as 
antiacid or cimetidine treatments. The results indicate that, in addition to glycyrrhitic acid, 
other unidentified constituents of Radix Glycyrrhyzae contribute to its antiulcer activity 
(WHO, 1999b). 
Helicobacter pylori infection is prevalent in individuals with peptic ulcer and is also a 
known risk factor for gastric cancer. Consequently, an in vitro study was performed to 
investigate the effects of licorice flavonoids on the growth of H. pylori. These flavonoid 
components showed promising anti-H. pylori activity against clarithromycin- and 
amoxicillin-resistant strains. As the antimicrobial property seems to be attributed to the 
flavonoid constituents of licorice, DGL preparations may provide therapeutic benefit for H. 
pylori infection (Anonymous, 2005). 
 
Spasmolytic activities 
The spasmolytic activity of Radix Glycyrrhyzae has been demonstrated in vivo (guinea-
pig, rabbit, and dog), and appears to be to the flavonoids liquiritigenin and isoliquiritigenin 
(WHO, 1999b). Liquiritigenin can produce a strong spasmolytic effect to relieve spasms of 
the intestines induced by histamine, acetylcholine and barium chloride (Ganzhong et al., 
2003e), and according to Shen et al. (2007) FM-100 and isoliquiritigenin also have this 
activities. FM-100 at the concentration of 200μg/ml exerted spasmolytic action on the 
isolated intestinal tract of the guinea pig (Shen et al., 2007). No inhibitory action on the 
smooth muscles was detected for glycyrrhizic acid and glycyrrhetic acid (Shen et al., 
2007). Recently, glycycoumarin has been isolated as an antispasmodic ingredient of 
licorice, as demonstrated by its ability to relax carbamylcholine (carbachol)-induced 
contraction of isolated mice jejunum (Nagai et al., 2006).  
Laxative activities 
Liquorice also may have mild laxative activity (Fiore et al., 2005). It is known that roots 
contain relative high fiber content (Visavadya et Narasimhasharya, 2006). 
 
Dermatological studies 
G. glabra L. has been used in herbal medicine for skin eruptions, including dermatitis, 
eczema, pruritus and cysts. Recently glycyrrhizin treatment has showed protective effects 
against UVB-irradiated human melanoma cells. Moreover, licorice extract and its active 
component, glycyrrhizic acid, has been described as effective skin whitening effects. It 
was suggested that liquiritin causes depigmentation by two mechanisms: first, via melanin 
dispersion by means of the pyran ring of its flavonoidal nucleus; second the acceleration 
of epidermal renewal. Concerning the mechanisms of glabridin on melanogenesis and 
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inflammation, it has been shown that it inhibits the tyrosinase activity of melanocytes and 
as a result, it seems that hydroquinone will be replaced by licorice extract in a new 
preparation fordermal melasma. However, in a few cases, allergic dermatitis can develop 
to oil soluble licorice extracts (Asl et Hosseinzadeh, 2008). Besides the antiproliferative 
effects shown with liquorice, new useful applications have recently been described in the 
treatment of atopic dermatitis, suggesting a potential role for the drug in 
allergic/inflammatory diseases of the skin. In addition, liquorice has been reported to be 
useful for inflammatory lesions induced by ultraviolet radiation (Fiore et al., 2005). 
 
Endocrinological effects 
Sexual hormones related activities 
Glycyrrhiza root has been shown to decrease circulating levels of testosterone in men and 
women. But it was not able to reduce salivary testosterone in men significantly. Moreover, 
it induced regular ovulation and pregnancy in infertile hyperandrogenic patients. On the 
other hand, isoliquiritigenin (ILC), glabrene and glabridin are phytoestrogens. ILC and 
glabrene can bind to the human estrogen receptor (ER) with higher affinity than glabridin. 
It was suggested that isoflavenes may serve as natural estrogen agonists in preventing 
the symptoms and diseases associated with estrogen deficiency. In some traditional 
Chinese medicine preparations, the root of G. glabra is used for treatment menopause-
related symptoms. But there are no clinical data regarding its safety or efficacy for treating 
hot flashes. Moreover, the activity of 11β-HSD-2 potently is blocked in vivo and in vitro by 
glycyrrhetinic acid by two mechanisms, direct competitive inhibition and pretranslational 
inhibition. It seems that this herb acts on the metabolism of steroids with different 
mechanisms (Asl et Hosseinzadeh, 2008). In a recent study it was  investigated the effect 
of licorice on serum testosterone in nine healthy women, ages 22-26, using a licorice 
preparation, and found total serum testosterone decreased from 27.8 (± 8.2) to 19.0 (± 
9.4) ng/dL after one month, and further decreased to 17.5 (± 6.4) ng/dL after the second 
month of therapy. This is likely due to inhibition of 17-hydroxysteroid dehydrogenase, 
indicating licorice may be of benefit in treating women with hirsutism and polycystic ovary 
syndrome (Anonymous, 2005). Licorice also decreases testosterone production in men 
who eat licorice. This is likely due to the licorice constituent, glycyrrhetinic acid, inhibiting 
the enzyme 17-hydroxysteroid dehydrogenase, which converts androstenedione to 
testosterone. Glycyrrhetinic acid also seems to inhibit 17-20 lyase which converts 17-
hydroxyprogesterone to androstenedione (Anonymous, 2009). In animal studies, the anti-
oestrogenic action documented for glycyrrhizin at relatively high concentrations has been 
associated with a blocking effect that would be caused by glycyrrhizin binding at 
oestrogen receptors. However, oestrogenic activity has also been documented for 
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liquorice and attributed to the isoflavone constituens. Liquorice exhibits an alternative 
action on oestrogen metabolism, causing inhibition if oestrogen concentrations are high 
and potentiation when concentrations are low (Newall et al., 1996b). 
 
Antidiabetic effect 
Radix Glycyrrhiza was found to exhibit markedly inhibitory effect on aldose reductase. The 
IC50 was 16.3 μg/mL. It suggests that this herb used in the control of diabetic 
complication may act through the pharmacological action of inhibiting aldose reductase. 
This herb can inhibit aldose reductase in steptozotocin-induced diabetic rats. Licorice 
markedly reduced sorbitol levels in red blood cells and without affecting blood glucose. 
When the extract of licorice was given orally at dose of 7.5g/kg/day for one week in 
diabetic rats, licorice extracts reduced sorbitol levels in white blood cell count (WBC) 
without affecting blood glucose level (Shen et al., 2007). Carbenoxolone significantly 
decreased the glucose uptake and the incorporation of glucose into triglycerides and CO2 
in rats. The effect produced by insulin on these metabolic pathways was reduced when 
adipose tissue was incubated with insulin in the presence of carbenoxolone. Nasal 
absorption of insulin in rats was enhanced by addition of sodium glycyrrhetinate, 
dipotassium glycyrrhizinate and carbenoxolone (glycyrrhetinic acid hydrogen succinate) 
disodium salt. The latter agent was effective. It suggested that the latter agent is a useful 
promoter which does not irritate the nasal mucosal membrane or degrade insulin (Shen et 
al., 2007). 
 
Hypocholesterolaemic and antioxidant effects 
Although antihyperlipilaemic and antihypertriglyceridaemic properties of Glycyrrhiza glabra 
root have been reported, no detailed reports are available on the synergistic effects of 
Glycyrrhiza glabra root on hyperlipidemia/hypercholesterolemia and oxidative stress in 
hypercholesterolaemic animal models and its role on body cholesterol metabolism 
(Visavadiya et Narasimhasharya, 2006). The cholesterol-lowering effects of Glycyrrhiza 
glabra (GG) root in hypercholesterolaemic rats is related to an increased excretion of 
cholesterol, neutral sterols, bile acid and an increase in hepatic bile acid content. In this 
context, the presence of phytosterols (2.997 gm%), saponins (3.775 gm%) and fiber (12.8 
gm%) in GG root could be important in cholesterol elimination and an increase in hepatic 
bile acid content in GG root fed hypercholesterolaemic rats. Phytosterols are reported to 
displace intestinal cholesterol and reduce cholesterol absorption from intestine. Saponins 
on the other hand, are capable of precipitating cholesterol from micelles and interfere with 
enterohepatic circulation of bile acids making it unavailable for intestinal absorption. Thus, 
the presently noted reduced cholesterol levels in hypercholesterolaemic animals 
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administered with GG root powder could be due to both phytosterol and saponin content 
of GG root. The accelerated fecal excretion of cholesterol, neutral sterol and bile acid in 
these animals could also be a response to the relatively higher fiber content of the root. 
This view is in accordance with an earlier report suggesting that the cholesterol lowering 
effect of fibers is primarily due to an increased excretion of cholesterol and bile acids. The 
significant decreases in hepatic cholesterol in HGG-I and HGG-II groups also indicate the 
possible influence of GG root fiber as dietary fibers interfere with cholesterol absorption 
and enterohepatic bile circulation and result in depletion of hepatic cholesterol pools. A 
significant decline in plasma LDL-cholesterol in these groups could be correlated with the 
fiber and saponin content of GG root as both fibers and saponins enhance the hepatic 
LDL-receptor levels, increase hepatic uptake of LDL-cholesterol and aid its catabolism to 
bile acids. Elevated levels of plasma TG have been correlated with the development 
atherosclerosis and coronary heart disease. While the hypercholesterolaemic animals 
(HC) group exhibited significantly higher TG levels, both hypercholesterolaemic animals 
administered with 5 gm% Glycyrrhiza glabra root powder (HGG-I) and 
hypercholesterolaemic animals administered with 10 gm% Glycyrrhiza glabra root powder 
(HGG-II) groups registered a significant decline of TG in plasma and hepatic tissue 
indicating the hypotriglyceridaemic effect of GG root. Both dietary fibers and saponins are 
known to lower TG by decreasing hepatic lipogenesis and inhibiting pancreatic lipase 
activity, respectively. Furthermore, the decline in VLDLcholesterol levels in HGG groups 
could be directly correlated to a decline in TG levels of these groups, as it is well 
established that VLDL particles are the main transporters of TG in plasma. Thus, a 
simultaneous decline in both TG and VLDL-cholesterol in HGG groups indicates the 
possible effect of both fiber and saponin on one hand, and on the other hand, the effect of 
phytosterol content of the root on TG metabolism through a decreased absorption of 
dietary cholesterol. An increased HMG-CoA reductase activity in both HGG-I and HGG-II 
groups compared to that of HC group appears to constitute a metabolic alteration 
occurring in hepatic tissue as a response to dietary fiber and saponin; such a 
compensatory increase in hepatic cholesterol synthesis is reported to occur when 
intestinal cholesterol absorption is impaired or when bile acid synthesis is stimulated. 
Thus, the increased HMG-CoA reductase activity in HGG-I and HGG-II groups alone, and 
not in HC, normal controls (NC), normal animals administered with 5 gm% Glycyrrhiza 
glabra root powder (NGG-I) and normal animals administered with 10 gm% Glycyrrhiza 
glabra root powder (NGG-II) groups clearly indicates the compensatory inductive effect of 
GG root on cholesterol synthesis. Presently observed high level of plasma HDL-
cholesterol in both hyper- and normo-cholesterolaemic animals administered with GG root 
powder as compared to HC and NC groups indicates its efficacy in elevating HDL-
175 
 
cholesterol levels. While dietary saponins and fibers are not known to elevate HDL-
cholesterol levels, ascorbic acid and flavonoids are reported to increase the HDL-
cholesterol concentrations. The GG root contained both ascorbic acid (0.58 gm%) and 
flavonoids (0.926 gm%) that could have contributed to an increase in HDL-cholesterol 
concentrations in both GG root powder administered to hyper- and normo-
cholesterolaemic animals. High cholesterol diet increases both LDL cholesterol levels and 
oxidative stress that results in increased oxidized-LDL levels leading to atherosclerotic 
plaque formation. Several studies suggest that naturally occurring antioxidants such as 
polyphenols, flavonoids and vitamin-C in diet may play a role as anti-atherogenic agents. 
In addition to ascorbic acid and flavonoids, the GG root also contained polyphenols (3.22 
gm%). While polyphenols and flavonoids scavenge hydroxyl and superoxide anions, 
ascorbic acid and flavonoids were shown to synergistically decrease lipid peroxidation and 
improve lipid profile. In this context, it is pertinent to note that the Glycyrrhiza root extract 
has been shown to possess antioxidant activity in vitro and glabridin, one of the major 
components of the root is reported to be a potent antioxidant that prevents LDL oxidation. 
Epidemiological studies have revealed that diets containing polyphenols and flavonoids 
also stimulated catalase and superoxide dismutase (SOD) activities and decreased 
malondialdehyde concentration. Administration of GG root powder to 
hypercholesterolaemic animals significantly decreased lipid peroxidation with a 
concomitant increase in catalase, SOD activities and ascorbic acid levels. Thus, the 
elevated levels of hepatic antioxidants in GG root powder administered animals might be 
due to the presence of polyphenols and flavonoids in the diet. Additionally, the root could 
be a potent source for ascorbic acid as it suppressed lipid peroxidation and reduced the 
levels of malondialdehyde. It was suggested that the 
hypolipidaemic/hypocholesterolaemic effect of GG root is mediated through an increased 
cholesterol turnover via higher fecal sterol excretion. The increased hepatic antioxidant 
activities in GG root powder administered animals indicate a decreased oxidative 
susceptibility in these animals. These hypolipidaemic/hypocholesterolaemic and 
antioxidant effects of GG root powder could be attributed to aforementioned 
phytoconstituents (Visavadiya et Narasimhasharya, 2006). 
 
Detoxification 
Licorice and its preparations can relieve drug intoxication and neutralize bacterial toxins 
and toxic metabolites, because glycyrrhizin can reduce the responsiveness of the 
organism to toxic substances, in the same way that corticoid hormone does, and 
promotes dissociation of toxic substances through inducing the production of drug 
metabolizing enzyme in the liver. In addition, licorice can also absorb and conjugate toxic 
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substances to relieve intoxication. Licorice preparations and glycyrhhizin can also protect 
the livers of animals from injury caused by drug poisoning (Ganzhong et al., 2003e). It has 
been discovered from experiments on mice that glycyrrhiza extract and glycyrrhizin have 
obvious antidotal effects on chloral hydrate, strychnine, urethane, cocaine, phenyl arsenic 
and mercuric bichloride. Glycyrrhizin has an antidotal effect on tetrodentoxin and 
ophoitoxin, and can relieve the lethal effects of diphitheria toxin and tetanus toxin 
(Anonymous, 2009l). 
 
Weight loss activities 
There is conflicting information about the use of licorice for weight loss. Licorice has been 
shown to reduce body fat; however accompanying fluid retention offsets any change in 
body weight (Anonymous, 2009). The consumption of licorice extract and glycyrrhetinic 
acid could decrease body fat mass in humans and a possible mechanism seems to be by 
inhibiting 11-ß-hydroxysteroid dehydrogenase at the level of fat cells (Anonymous, 2005; 
Asl et Hosseinzadeh, 2008).  
A novel flavonoid, licochalcone A possesses multiple bioactive properties including 
antibacterial, anti-parasitic, estrogenic and antitumor activities. Furthermore, it has been 
shown that licochalcone A isolated from the roots of G. uralensis reduce the lipase activity 
as a new inhibitor of pancreatic lipase as well. It can be useful in developing a functional 
food for obesity and a lead compound for the design of new antiobesity drugs. 
Licochalcone A is a non-competitive and reversible inhibitor on pancreatic lipase (Won et 
al., 2007). 
In a trial of 15 normal-weight subjects (seven males, eight females, ages 22-26), 3.5 mg of 
a commercial licorice preparation daily for two months resulted in a decrease in body fat 
mass. Plasma rennin activity and aldosterone were also suppressed. No changes in body 
mass index were noted (Anonymous, 2005). More evidence is needed to rate licorice for 
these uses (Anonymous, 2009).  
 
Other therapeutic considerations 
Reports on the usefulness of liquorice extracts on body fluid homeostasis in patients with 
Addison disease are contradictory. One study found no positive effects, while three other 
studies noted an increase in weight gain and sodium retention (WHO, 1999b). Glycyrrhizin 
is classified as a saponin compound, and this property has been tested to determine its 
interaction with cellular membranes of erythrocytes and hepatic lysosomal preparations. 
Glycyrrhizin was found to protect erythrocytes against the hemolysis induced by other 
saponin compounds including digitonin, excin, tomatin, and saponin A. The effect of 
glycyrrhizin was concentration-dependent but it was only effective at preventing hemolysis 
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at concentrations approximately 400 times greater than the hemolysin. Glycyrrhizin was 
found to be as eficacious against the sapogenins digitogenin, tomatidine, and sapogenin 
A, indicating that its mechanism of action is not the result of the inhibition of membrane 
glycosidases of erythrocytes. The possibility remains that glycyrrhizin prevents access of 
hemolysin to its receptor, or alters membrane fluidic dynamics at these high 
concentrations. To test this possibility, the effects of glycyrrhizin on the release and 
activity of acid phosphatases from hepatic lysosomal preparations were investigated. Both 
glycyrrhizin and 18β-glycyrrhetic acid attenuated acid phosphatase activity, but did not 
affect β-N-acetylglucosaminidase activity. The reduction of lysosomal acid phosphatase 
activity was due to its release from the lysosomes rather than a direct inhibition of the 
enzyme suggesting an alteration in membrane fluidity (Isbruker et Burdock, 2006).  
Industrial uses 
Commercially, licorice is added to chewing gum, chocolate candy, cigarettes, smoking 
mixtures, chewing tobacco and snuff as sweetening agents and as a depigmentation 
agent in cosmetics. Also, licorice is frequently employed to mask the taste of bitter drugs 
such as aloe, quinine and others. The surfactant property of the saponins may also 
facilitate the absorption of poorly absorbed drugs, such as the anthraquinone glycosides. 
Examples of products containing considerable amounts of glycyrrhizinic acid are: 
confectionery licorice sticks, bricks, cakes, toffee, pipes, bars, balls, tubes, pastilles and 
allsorts, chewing gum, throat pearls, licorice flavored cough mixtures, herbal cough 
mixtures, licorice tea, all types of licorice root Russian, Iranian, Chinese, Turkish, Afghan 
and unknown origin chewing tobacco, alcoholic drinks (Asl et Hosseinzadeh, 2008). 
 
Pharmacokinetics 
Glycyrrhizin has a poor oral bioavailability in both rats and humans. In rats, glycyrrhizin 
was detectable in plasma samples only after the administration of oral doses exceeding 
50mg/kg. Similarly, in humans, glycyrrhizin was detected at very low levels after a single 
oral dose in the range of 100–1600mg/kg. However, these studies showed that 
glycyrrhetic acid, the aglycone of glycyrrhizin, is readily detected in plasma following the 
ingestion of glycyrrhizin or licorice extract by rats and humans. In most species, the peak 
plasma glycyrrhetic acid levels are lower and occur later when glycyrrhizin is administered 
in licorice extract than when provided at an equivalent dose as a pure compound; 
however, the contrary seems to occur in rabbits. In rats fed glycyrrhizin (160 or 200mg/kg) 
or licorice extract with the same glycyrrhizin load, the area under the plasma curve (AUC) 
for glycyrrhetic acid was approximately 2.5 times greater for the pure compound. Licorice 
extract was also found to increase bile flow in, which could partially explain the altered 
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pharmacokinetics. The time to maximum glycyrrhetic acid plasma concentration was 10h 
for glycyrrhizin and 2h longer with licorice extract. Similar results were found in a study 
involving eight healthy adult volunteers fed 800 or 1600mg glycyrrhizin as its ammoniated 
salt or in licorice extract. The lipophilic components of licorice extract were found to 
reduce the gastric emptying rate and absorption of glycyrrhizin, but the compounds 
involved in this activity have not been identified. Interestingly, neither glycyrrhizin nor 
glycyrrhetic acid are detected in the plasma of germ-free rats fed glycyrrhizin. These data, 
along with the relatively long lag time to maximum plasma glycyrrhetic acid 
concentrations, suggest a presystemic metabolic process involving the de-glucuronidation 
of glycyrrhizin by intestinal flora prior to the absorption of glycyrrhetic acid. Indeed, 
researchers have identified various intestinal bacterial strains, including Streptococcus 
and Eubacterium sp., with specialized β-glucuronidase activity capable of glycyrrhizin 
hydrolysis. Oral bioavailability of glycyrrhetic acid following the administration of 
glycyrrhizin to rats appears to be dose limiting and may be due to limitations in either the 
uptake of glycyrrhetic acid or the hydrolysis process. Because orally administered 
glycyrrhizin is poorly absorbed, and is hydrolyzed to glycyrrhetic acid by intestinal 
bacteria, it was suggested a two-step microbial hydrolysis of glycyrrhizin first to 3-β-
monoglucuronyl-18-β-glycyrrhetic acid (3MGA) and then to glycyrrhetic acid prior to 
absorption. Interindividual differences in glycyrrhizin response, metabolism and kinetics 
are influenced, at least in part, by the intestinal microflora profile. Neither glycyrrhizin nor 
glycyrrhetic acid accumulate in tissues. However, both compounds adhere extensively to 
human and rat serum albumin, and although binding sites may be specific and non-
specific, it is a saturable process. A recent study showed that glycyrrhetic acid is 
somewhat able to cross the placental barrier and can be detected in the rat fetuses. The 
enterohepatic circulation of glycyrrhetic acid was demonstrated. In a recent study it was 
shown less than 2% of the initial dose was excreted in the urine illustrating that this is not 
considered to be a major elimination pathway. Fecal extracts of rats dosed orally with 
[3H]glycyrrhetic acid revealed the presence of only the parent compound as an 
unmodified substance indicating the complete hydrolysis of glucuronyl and sulfate 
conjugates by intestinal microflora prior to excretion in the feces. The enterohepatic 
circulation of glycyrrhetic acid has not been studied in humans, but can be expected 
because glycyrrhetic acid metabolites can be hydrolyzed by human gastrointestinal 
bacteria. Time curve data for glycyrrhetic acid also provide evidence of enterohepatic 
circulation in humans. The plasma clearance of glycyrrhizin and glycyrrhetic acid is dose 
dependent when administered to rats or humans at levels which exceed the saturation of 
serum protein binding. A recent study reported that the plasma clearance of i.v. 
glycyrrhizin was not dose dependent at doses below 120mg in healthy volunteers. The 
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plasma clearance was in the range of 38–64ml/h/kg and the volume of distribution at 
steady state (38–64ml/kg) was close to the mean serum volume for humans, 43ml/kg. 
Plasma clearance was significantly decreased in patients with chronic hepatitis C and liver 
cirrhosis. Together, these data suggest a hepatic related capacity-limited process in 
metabolism or excretion in the bile. Because of the enterohepatic recycling of glycyrrhetic 
acid and the biliary storage process of glycyrrhetic acid metabolites in the gallbladder, 
plasma glycyrrhetic acid concentrations show several peaks following the oral 
administration of either glycyrrhizin glycyrrhetic acid or licorice. In summary, the metabolic 
fate of glycyrrhizin is complex and involves several inter-dependent steps (Fig. 64). 
Following an oral administration, there is a primary metabolic step involving the enteric 
microbial metabolism of glycyrrhizin to a monoglycone and/or aglycone compound. The 
resulting 3MGA and glycyrrhetic acid are absorbed through the intestines with only a 
minimal absorption of glycyrrhizin. In humans, the hepatic metabolism and processing of 
3MGA and glycyrrhetic acid are not yet clearly defined, but it is apparent that each can 
undergo further conjugation or reduction followed by biliary excretion. Glucuronide 
compounds and metabolites excreted in the bile are likely remetabolized by the intestinal 
flora and thereby subject to enterohepatic recycling. In general, the clearance capacity for 
glycyrrhetic acid would be reduced in patients with compromised hepatic function 
(Isbrucker et Burdock, 2006). 
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Fig. 64.  Glycyrrhizin metabolism. Following ingestion glycyrrhizin is deglucuronidated by intestinal microbes either 
completely (1) or through a two-step intermediary process (2a, 2b). Glycyrrhetic acid is absorbed (3) and undergoes hepatic 
biotransformation (4) to produce 18-β-glycyrrhetyl-3-O-hydrogen sulfate (B), 18-β-glycyrrhetyl-3-O-monoglucuronide (C), or 
18-β-glycyrrhetyl-3-0-monoglucuronide (D). Glycyrrhetic acid may also undergo hepatic dehydrogenation (5) to form 3-
ketoglycyrrhetic acid (A), although this step is undocumented in humans (adapted from Isbrucker et Burdock, 2006). 
 
Adverse Reactions 
 
One of the most commonly reported side effects with licorice supplementation is 
hypertension (Anonymous, 2005; Anonymous, 2009; Asl et Hosseinzadeh, 2008; 
Blumenthal, 2003; Chan et Kritchley, 1996; Coon et Ernst, 2004; Cunha et al., 2007; Fiore 
et al., 2008; WHO, 1999b). This hypertension is caused by decreased 11β-hydroxysteroid 
hydroxygenase activity. This enzyme is responsible for the renal conversion of cortisol to 
cortisone. Thus, licorice leads to activation of renal mineralocorticoid receptors by cortisol, 
resulting in a state of apparent mineralocorticoid excess (Anonymous, 2009; Asl et 
Hosseinzadeh, 2008; Fiore et al., 2008) and suppression of the rennin angiotensin system 
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(Asl et Hosseinzadeh, 2008; Fiore et al., 2008). Patients may experience hypokalemia 
(potassium loss) (Anonymous, 2005; Anonymous, 2009; Asl et Hosseinzadeh, 2008; 
Blumenthal, 2003; Chan et Kritchley, 1996; Coon et Ernst, 2004; Cunha et al., 2007; Fiore 
et al., 2008; WHO, 1999b) and sodium retention (Anonymous, 2005; Anonymous, 2009; 
Blumenthal, 2003; Chan et Kritchley, 1996; Coon et Ernst, 2004; Cunha et al., 2007; 
WHO, 1999b), water accumulation (Blumenthal, 2003; Chan et Kritchley, 1996; Cunha et 
al., 2007; WHO, 1999b) resulting in edema (Anonymous, 2005; Anonymous, 2009; 
Blumenthal, 2003; Chan et Kritchley, 1996; WHO, 1999b). The phenomenon is known as 
―pseudoaldosteronism‖ (Anonymous, 2005; Anonymous, 2009; Blumenthal, 2003; 
Breidthardt et al., 2006; WHO, 1999b). The metabolic abnormalities caused by licorice 
can lead to electrocardiography (EKG) changes, arrhythmias, rhabdomyolysis, paralysis, 
and encephalopathy (Anonymous, 2009), headache, muscle weakness, (Anonymous, 
2009; Cunha et al., 2007b), lethargy, muscle weakness, dropped head syndrome (DHS), 
rhabdomyolysis, myoglobinuria, paralysis, encephalopathy, respiratory impairment, 
hyperparathyroidism, and acute renal failure. These effects are most likely to occur when 
30 grams or more of licorice is consumed daily for several weeks (Anonymous, 2009). In 
rare cases, myoglobinuria (Anonymous, 2005; Blumenthal, 2003; WHO, 1999b) and 
myopathy can occur (WHO, 1999b). However, some people may be more sensitive, 
especially those with hypertension, heart problems, or kidney problems (Anonymous, 
2009). The water accumulation causes swelling of the hands and feet (Blumenthal, 2003; 
WHO, 1999b) and can lead to weight gain (Blumenthal, 2003; Coon et Ernst, 2004; WHO, 
1999b). These effects are associated with prolonged use of large doses (›50g/day) of the 
drug for extended periods (›6 weeks) (Blumenthal, 2003; WHO, 1999b). Because licorice 
can decrease serum testosterone and increase 17-hydroxyprogesterone, it might cause 
decreased libido and sexual dysfunction in men (Asl et Hosseinzadeh, 2008). 
The increases in blood pressure, and cortisol to cortisone ratio are proportional to the 
amount of glycyrrhizic acid ingested (Anonymous, 2009). Generally, the onset and 
severity of symptoms depend on the dose and duration of licorice intake, as well as 
individual susceptibility. Patients with delayed gastrointestinal transit time may be more 
susceptible to these side effects, due to enterohepatic cycling and reabsorption of licorice 
metabolites. The amount of licorice ingested daily by patients with mineralocorticoid 
excess syndromes appears to vary over a wide range, from as little as 1.5 g daily to as 
much as 250g daily (Anonymous, 2005). According to Cunha et al., (2007) high doses (ca. 
50g/dia), which corresponds to about 130mg of glycyrrhizinic acid, can produce adverse 
effects. All symptoms usually disappear with discontinuation of therapy (Anonymous, 
2005; Blumenthal, 2003; Newall et al., 1996b). Glycyrrhetinic acid has a long half life, a 
large volume of distribution, and extensive enterohepatic recirculation. Therefore, it may 
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take 1-2 weeks before hypokalemia resolves. Normalization of the renin-aldosterone axis 
and blood pressure can take up to several months (Anonymous, 2009). An acceptable 
daily intake avoiding these effects has been determined as 0.2 mg/kg of glycyrrhizin (Fiore 
et al., 2008) and no adverse reactions have been associated with the drug when within 
the recommended dosage and treatment period (Blumenthal, 2003; WHO, 1999b). 
Future trials need to address the potential side effects, which have been reported with 
licorice use, particularly in elderly people with heart disease and on diuretic medication. 
Further in vitro studies working on chemically modified derivatives with greater activity and 
increased selectivity indices are required (Fiore et al., 2008). 
 
Drug interactions 
 
Antihypertensive drugs 
The aldosterone effects of licorice root may counteract the effect of antihypertensive drug 
therapy (Anonymous, 2009; Asl et Hosseinzadeh, 2008). Licorice increases blood 
pressure in a dose dependent manner (Anonymous, 2009). Because it reduces sodium 
and water excretion, the effectiveness of drugs used in the treatment of hypertension may 
be reduced (Beers, 2008a; WHO, 1999b). 
Corticosteroids 
Radix Glycyrrhizae should not be taken concurrently with corticosteroid treatment (WHO, 
1999b). Theoretically, concomitant use might potentiate the duration of activity of 
corticosteroids, e.g., hydrocortisone. Concomitant use of licorice and corticosteroids might 
also increase potassium loss and increase the risk of potassium depletion. Overuse or 
misuse of licorice can cause potassium depletion (Anonymous, 2009). Causes addictive 
and enhanced effects of these drugs (Beers, 2008a).  
Cytochrome p450 2b6 (cyp2b6) substrates 
There is preliminary evidence that licorice can inhibit the cytochrome P450 2B6 (CYP2B6) 
isoenzymes in vitro. Theoretically, licorice might increase levels of drugs metabolized by 
CYP2B6; however, as of yet, these interactions have not been reported in humans. Some 
drugs that are metabolized by CYP2B6 include ketamine, phenobarbital, orphenadrine, 
secobarbital, and dexamethasone. Use licorice cautiously or avoid in patients taking these 
drugs (Anonymous, 2009). 
Estrogens 
Theoretically, licorice might interfere with estrogen therapy due to estrogenic and anti-
estrogenic effects (Anonymous, 2009; Newall et al., 1996b). Estrogen-based oral 
contraceptives may enhance the mineralocorticoid side effects of licorice in susceptible 
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individuals. This may be due in part to estrogens reacting with mineralocorticoid receptors 
or inhibition of 11-β-hydroxysteroid dehydrogenase (Anonymous, 2005). 
Ethacrynic acid 
Theoretically, ethacrynic acid might enhance the mineralocorticoid effects of licorice by 
inhibiting the enzyme that converts cortisol to cortisone; however, bumetanide (Bumex) 
does not appear to have this effect. Theoretically, furosemide might enhance the 
mineralocorticoid effects of licorice by inhibiting the enzyme that converts cortisol to 
cortisone; however, bumetanide does not appear to have this effect (Anonymous, 2009). 
Warfarin 
Licorice seems to increase metabolism and decrease levels of warfarin in animal models. 
This is likely due to induction of cytochrome P450 2C9 (CYP2C9) metabolism by licorice 
(Anonymous, 2009). 
Aspirin 
May provide protection against aspirin-induced damage to GI mucosa (Beers, 2008a). 
Digoxin 
Herb causes hypokalemia, which predisposes to drug toxicity (Anonymous, 2009l; Beers, 
2008a). 
Insulin 
Causes hypokalemia and sodium retention (Beers, 2008a). 
Spironolactone 
Decreases effect of drug (Beers, 2008a). 
 
Interactions with Herbs & Supplements 
 
Cardiac glycoside-containing herbs 
Theoretically, the overuse or misuse of licorice can increase the risk of cardiotoxicity due 
to potassium depletion. Cardioactive herbs include digitalis, lily-of-the-valley, pheasant's 
eye, and squill (Anonymous, 2009). 
Stimulant laxative herbs 
Theoretically, concomitant overuse or misuse of licorice with stimulant laxatives can 
increase the risk of potassium depletion. Stimulant laxative herbs include aloe, alder 
buckthorn, black root, blue flag, butternut bark, colocynth, European buckthorn, fo ti, 
gamboge, gossypol, greater bindweed, jalap, manna, Mexican scammony root, rhubarb, 
senna, and yellow dock (Anonymous, 2009). 
Panax ginseng 
Some research shows that Panax ginseng appears to compliment licorice by increasing 
serum cortisol concentrations (Anonymous, 2009). 
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Interactions with Foods 
Grapefruit juice 
Theoretically, grapefruit juice and its component naringenin might enhance the 
mineralocorticoid activities of licorice, by blocking the conversion of cortisol to cortisone 
(Anonymous, 2009). 
Salt 
A high salt diet can exacerbate adverse effects of licorice such as sodium and water 
retention and hypertension (Anonymous, 2009). 
 
Interactions with Laboratory Tests 
17-hydroxyprogesterone 
Licorice can increase serum 17-hydroxyprogesterone concentrations and test results in 
healthy volunteers who consume 7 grams of licorice per day (Anonymous, 2009). 
Blood pressure 
Excessive use of licorice can cause hypertension and increase blood pressure readings 
(Anonymous, 2009). 
Potassium 
Excessive use of licorice can cause hypokalemia, reducing serum potassium levels and 
test results (Anonymous, 2009). 
Testosterone 
Licorice can decrease serum testosterone concentrations and test results in healthy 
volunteers who consume 7 grams of licorice per day (Anonymous, 2009). 
 
Contraindications and precautions 
 
Hypertension 
Radix Glycyrrhizae is contraindicated in patients with hypertension (Anonymous, 2009; 
Anonymous, 2009l; Blumenthal, 2003; Cunha et al., 2007; Cunha et al., 2007c; WHO, 
1999b) because patients with underlying essential hypertension are more sensitive to the 
inhibition of 11-beta-hydroxysteroiddehydrogenase by liquorice (Breidthardt et al., 2006) 
and the mineralocorticoid effects of licorice can increase blood pressure (Anonymous, 
2009). 
Heart disease 
The mineralocorticoid effects of licorice can induce fluid retention and worsen congestive 
heart failure .Licorice can also cause hypokalemia and increase the risk of arrhythmias 
(Anonymous, 2009). Advise patients with heart disease to avoid excessive amounts of 
licorice (Anonymous, 2009; Cunha et al., 2007b). 
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Hormone sensitive cancers/conditions 
Licorice might have estrogenic effects. Women with hormone sensitive conditions should 
avoid using licorice. Some of these conditions include breast cancer, uterine cancer, 
ovarian cancer, endometriosis, and uterine fibroids (Anonymous, 2009). 
Hypertonia 
The mineralocorticoid effects of licorice can cause hypokalemia. Licorice-induced 
hypokalemia can worsen hypertonia (Anonymous, 2009). 
Hypokalemia 
The mineralocorticoid effects of licorice can decrease potassium serum levels and 
exacerbate hypokalemia (Anonymous, 2009; Asl et Hosseinzadeh, 2008; Blumenthal, 
2003; Cunha et al., 2007c; WHO, 1999b). 
Kidney insufficiency 
The mineralocorticoid effects of licorice may worsen renal function (Anonymous, 2009; 
Anonymous, 2009l; Blumenthal, 2003; Cunha et al., 2007c; WHO, 1999b). 
Sexual dysfunction 
Theoretically, licorice might decrease libido and worsen erectile dysfunction by decreasing 
testosterone and increasing 17-hydroxyprogesterone serum concentrations (Anonymous, 
2009). 
Surgery 
Licorice might affect blood pressure. Theoretically, licorice might interfere with blood 
pressure control during and after surgical procedures. Is recommended discontinue 
licorice at least 2 weeks before elective surgical procedures (Anonymous, 2009). 
Cholestatic disorders or cirrhosis of the liver 
(Asl et Hosseinzadeh, 2008; Blumenthal, 2003; Cunha et al., 2007c; WHO, 1999b). 
Diabetes 
Licorice is contraindicated in diabetes by the Belgian Pharmaceutical Association, 
although this was not confirmed in a subsequent monograph by the WHO (Blumenthal, 
2003; WHO, 1999b). 
Pregnancy and lactation 
Radix Glycyrrhizae is not mutagenic in vitro and is not teratogenic in animal models 
(WHO, 1999b). According to Anonymous (2009) licorice has abortifacient, estrogenic, and 
steroid effects; and can cause uterine stimulation. The safety of Radix Glycyrrhizae 
preparations during pregnancy has not been established (Asl et Hosseinzadeh, 2008; 
Cunha et al., 2007c; WHO, 1999b). Stranberg et al. (2002) reported that heavy licorice 
(glycyrrhizin) consumption (≥500 mg/week) has been associated with shorter gestation 
(Anonymous, 2009l; Asl et Hosseinzadeh, 2008; Cunha et al., 2007c; WHO, 1999b). 
Heavy consumption of licorice has also been associated with an increased risk of preterm 
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birth in cross-sectional and retrospective studies (Fiore et al., 2008). ). In view of the 
oestrogenic and steroid effects associated with licorice, which may exacerbate pregnancy-
realated hypertension, excessive ingestion during pregnancy and lactation shoud be 
avoided. In addition, liquorice has exhibited a uterine stimulant activity in animal studies, 
and is traditionally reputed to be abortifacient and to affect the menstrual cycle 
(emmenagogue) (Newall et al., 1996b). According to the American Herbal Products 
Association, licorice is classified as Class 2D (not to be used during pregnancy) 
(Blumenthal, 2003). As a precautionary measure the drug should not be used during 
pregnancy (Anonymous, 2009l; Asl et Hosseinzadeh, 2008; Cunha et al., 2007c; WHO, 
1999b).  
The safety of Radix Glycyrrhizae preparations during lactation has not been established. 
As a precautionary measure the drug should not be used during lactation except on 
medical advice (Anonymous, 2009; WHO, 1999b). 
 
Posology 
Average daily dose of crude plant material, 5-15g, corresponding to 200-800mg of 
glycyrrhizin. Doses of other preparations should be calculated accordingly. Radix 
Glycyrrhizae should not be used for longer than 4-6weeks without medical advice (WHO, 
1999b). Because individual susceptibility to various licorice preparations is vast, it is 
difficult to predict a dose appropriate for all individuals. Nevertheless, a daily oral intake of 
1-10 mg of glycyrrhizin, which corresponds to 1-5 g licorice (2% glycyrrhizin), has been 
estimated to be a safe dose for most healthy adults (Anonymous, 2005). 
 
Storage 
 
Protect from light (FP, 2005).According to Chinese Pharmacopoeia (2005d) preserve in a 
ventilated and dry place, protect from moth. 
 
Regulatory Status 
Austria: Unpeeled dried root is official in the Austrian Pharmacopoeia (Blumenthal, 2003). 
Belgium: Traditional Herbal Medicine (THM) permitted for specific indications 
(Blumenthal, 2003). 
Canada: Approved active ingredient in THM products and in Homeopathic products, both 
requiring pre-marketing authorization with Drug Identification Number (DIN). Food if no 
claim statement is made (Blumenthal, 2003). 
China: Dried root and rhizome, prepared (stir-fried with honey) root and rhizome, 
alcoholic fluid extract and dry aqueous native extract, containing not less than (NLT) 
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20.0% glycyrrhetic acid, are official drugs of the Pharmacopoeia of the People´s Republic 
of China (Blumenthal, 2003). 
Europen Union: Dried unpeeled or peeled, root and stolons containing NLT 4.0% 
glycyrrhetic acid and NMT 5.0% glycyrrhetic acid are official in European Pharmacopoeia 
(Blumenthal, 2003). 
France: THM permitted for specific indications, internal or locally (mouth and throat). 
Official in French Pharmacopoeia (Blumenthal, 2003). 
Germany: Dried root or dry extract for infusion, decoction, liquid or solid dosage forms, 
are approved non-prescription drugs in the Comission E monographs. Licorice root tea is 
approved as an over-the-counter (OTC) drug in the German Standard License 
monographs. Peeled dried root containing NLT 4.0% glycyrrhetic acid and standardized 
ethanolic fluid extraing containing NLT 5.0% glycyrrhetic acid and NMT 7.0% glycyrrhetic 
acid are official in German Drug Codex supplement to German Pharmacopoeia. Standard 
ethanolic fluid containing NLT 2.0% glycyrrhetic acid and NMT 4.0% glycyrrhetic acid are 
official in German Pharmacopoeia.  
India: Dried unpeeled roots and stolons containing NLT 4.0% glycyrrhetic acid are official 
in Indian Pharmacopoeia. Dried unpeeled stolon and root are official in the Government of 
India Ayurvedic Pharmacopoeia of India. Prepared mature root /min. 4 years) is an official 
single-drug and/or component of multiple-ingredient drugs dispensed in Unani system of 
medicine. A monograph for dried roots occurs in the Indian Herbal Pharmacopoeia. 
Italy: Listed in the Italian Pharmacopoeia. 
Japan: Traditional Kampo medicine. Dried peeled or unpeeled root and stolon are official 
in the Japanese Pharmacopoeia. 
Portugal: Listed in the Portuguese Pharmacopoeia. 
Russian Federation: Official in the State Pharmacopoeia of the Union of Soviet Socialist 
Republics. 
Sweden: Classified as foodstuff. As of January 2001, no licorice products are listed in the 
Medical Products Agency (MPA) ―Authorized Natural Remedies‖. 
Switzerland: Official in the Swiss Pharmacopoeia. Licorice is an approved component of 
multi-ingredient phytomediciness listed in the Swiss Codex 2001/2 available in juice, 
syrup, tea infusion, and tincture dosage forms with positive classification (List D) by 
Interkantonale Kontrollstelle fur Heilmittel (IKS) and corresponding sales Category D with 
sale limited to pharmacies and drugstores, without prescription. 
U.K.: Herbal medicine on the General Sale List, Schedule 1 (requires full Product 
License), Table A (internal or external use). Dried unpeeled roots containing NLT 4.0% 
glycyrrhetic acid, ethanolic fluid extract, and DGL dry aqueous extract containing 0.5-2.0% 
total flavonoids, calculated as liquiritigennin, are official in the British Pharmacopoeia. 
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U.S.: Dietary supplement or food depending on label claim statement. Licorice root and 
derivatives are affirmed as Generally Recognized as Safe (GRAS) for use as flavoring 
agent or flavor enhancer in vitamin or mineral dietary supplements, herb and seasoning 
products and nonalcoholic beverages, including tea. Dried roots, rhizome and stoloms, 
powdered root, and powdered dry extract are subjects of botanical monographs in 
development for the US National Formulary. Previews of the standards developmemt 
were published in Pharmacopeial Forum (Blumenthal, 2003). 
 
7.4.1. Radix Glycyrrhizae (甘草 ) according to Traditional Chinese 
Medicine 
 
Liquorice is commonly used in Chinese herbalism, where it is considered to be one of the 
50 fundamental herbs. It is considered to be second in importance only to Ginseng 
(Anonymous, 2009l) and is almost always used in combination with other herbs 
(Blumenthal, 2003). It is included in almost all Chinese herbal formulae, where it is said to 
harmonize and direct the effects of the various ingredients (Anonymous, 2009l). 
Radix Glycyrrhizae Uralensis (Gancao or Gan Cao) is produced mainly in the Chinese 
provinces of Inner Mongolia, Shanxi, Gansu, and Xinjiang (Anonymous, 2009l; Ganzhong 
et al., 2003e; Wu, 2005c). It is collected in spring and autumn (Ganzhong et al., 2003e; 
Wu, 2005c), preferably from plants 3-4 years old (Anonymous, 2009l).  After the stem, 
fibrous roots and bark of the roots are removed (Ganzhong et al., 2003e; Yanfu, 2002e), 
is sliced and dried in sunlight (Ganzhong et al., 2003e; Wu, 2005c) (Fig.65) and it is used 
unprepared or rosted with honey (Anonymous, 2009l; CP, 2005d; Wu, 2005c; Yanfu, 
2002e). 
 
 
 
 
Fig. 65. Processed Radix Glycyrrhizae (adapted from http://www.e2121.com/fherb.html) (visited 24/11/09) 
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Zhi gan cao is Gan Cao that has been coated with honey and baked to dark brown color 
and often it is being used in tonic (Honey Fried Licorice Root). Sheng gan cao is 
untreated Gan Cao (Fig. 66) (Chu, 2008). 
 
 
 
 
 
 
Fig. 66. Zhi gan cao and Sheng gan cao (adapted from Chinese Herb Dictionary, Complementary and Alternative Healing 
University´ available at http://alternativehealing.org/chinese_herbs_dictionary.htm) (visited on 29/11/08) 
 
Radix Glycyrrhizae was earliestly recorded in Shengnong Materia Medica (Shennong 
Bencao Jing) (Shen et al., 2007). 
 
Common name 
Licorice root (Ganzhong et al., 2003e; Leite, 2005e; Liu et Tseng, 2005d; Wu, 2005c). 
Also called Asian Liquorice or Chinese Licorice (Anonymous, 2009l).  
 
Pharmaceutical name 
Radix Glycyrrhizae Uralensis (Gongwang, 2000; Wu, 2005c), Radix Glycyrrhizae 
(Anonymous, 2009o; Flaws, 1999g; Ganzhong et al., 2003e) 
 
Botanical name 
Glycyrrhiza uralensis Fisch. (Gongwang, 2000; Leite, 2005e). 
 
Pynin name 
Gan Cao (Flaws, 1999g; Gongwang, 2000; Leite, 2005e; Liu et Tseng, 2005d), Gancao 
(Greten, 2007; Yanfu, 2002e).  
 
Part used 
Dried root (Ganzhong et al., 2003e; Leite, 2005e; Wu, 2005c) or root with rhizome (Leite, 
2005e; Wu, 2005c) 
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Classification 
Supports and strengthens the fluids and buffers. Belongs to the group “Supplentia qi – XV 
a)” (Greten, 2007) i.e. ―Herbs that Tonify Qi‖ (Anonymous, 2009o; Shen et al., 2007; 
Yanfu, 2002e). 
 
Sapor &Temperature  
Sweet (Anonymous, 2009o; Anonymous, 2009l; Chu, 2008; Flaws, 1999g; Greten, 2007; 
Leite, 2005e; Liu et Tseng, 2005d; Shen et al., 2007; Wu, 2005c; Yanfu, 2002e) in smell 
and peculiarly sweet in taste. It is about five hundred times the sweetness of cane sugar 
(Chu, 2008). Mild in nature (Anonymous, 2009l; Shen et al., 2007; Yanfu, 2002e). Neutral 
(Chu, 2008; Flaws, 1999g; Greten, 2007; Leite, 2005e; Liu et Tseng, 2005d; Wu, 2005c),  
 
Orbs 
All the 12 orbs (Anonymous, 2009o; Chu, 2008; Greten, 2007; Leite, 2005e; Liu et 
Tseng, 2005d), mainly the heart, lung, spleen and stomach (Anonymous, 2009l; Chu, 
2008; Flaws, 1999g; Ganzhong et al, 2003; Gongwang, 2000; Leite, 2005e; Liu et 
Tseng, 2005d; Shen et al., 2007; Wu, 2005c; Yanfu, 2002e). 
 
Functions 
In traditional Chinese medicine, the herb is one of herbs that tonify spleen and replenish qi 
(Flaws, 1999g; Ganzhong et al., 2003e; Gongwang, 2000; Liu et Tseng, 2005d; Shen et 
al., 2007; Wu, 2005c),). Tonifys the heart and spleen (Anonymous, 2009l; Shen et al., 
2007), purges fire, remove toxins (Anonymous, 2009l; Flaws, 1999g; Ganzhong et al., 
2003e; Liu et Tseng, 2005d Shen et al., 2007) and relieves spasm to alleviate pain. Being 
sweet, mild, moist, not dry for invigoration qi, it is a typical herb with many effects of sweet 
flavor, such as tonifying the heart and spleen, moistening the lung, relieving spasm, 
clearing toxic substances (Anonymous, 2009l) and harmonizing other herbs (Anonymous, 
2009l; Shen et al., 2007). 
 
Indications  
Radix Glycyrrhizae is officially listed in the Chinese Pharmacopeia. It is used as a tonic, 
antiphlogistic, mucolytic, expectorant, and analgesic for the treatment of gastroinstinal and 
respiratory diseases (Shen et al., 2007).   
It is used to invigorate the functions of the heart and spleen (Shen et al., 2007) so it´s 
indicated for deficiency of the heart-qi and spleen-qi (Anonymous, 2009l; Yanfu, 2002e). 
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Release spasms (Anonymous, 2009l; Flaws, 1999g; Ganzhong et al., 2003e; Gongwang, 
2000; Liu et Tseng, 2005d; Shen et al., 2007; Wu, 2005c) and alleviates pain 
(Anonymous, 2009l; Flaws, 1999g; Ganzhong et al., 2003e; Gongwang, 2000; Liu et 
Tseng, 2005d; Wu, 2005c). 
Used to treat carbuncles (Ganzhong et al., 2003e; Liu et Tseng, 2005d; Shen et al., 
2007), sore throat (Ganzhong et al., 2003e; Liu et Tseng, 2005d; Shen et al., 2007; Wu, 
2005c; Yanfu, 2002e) and cellulitis (Ganzhong et al., 2003e). For sores, ulcers, and other 
skin infections (Wu, 2005c). 
As it has the action of moistening the lung (Anonymous, 2009l; Flaws, 1999g; Ganzhong 
et al., 2003e; Gongwang, 2000; Liu et Tseng, 2005d; Wu, 2005c; Yanfu, 2002e) and 
resolving phlem (Yanfu, 2002e) it is indicated for many kinds or syndromes of cough 
(Anonymous, 2009l; Flaws, 1999g; Ganzhong et al., 2003e; Gongwang, 2000; Liu et 
Tseng, 2005d; Shen et al., 2007; Wu, 2005c; Yanfu, 2002e), wheezing and dyspnea (Liu 
et Tseng, 2005d; Yanfu, 2002e). 
Relieve the side effects of drugs (Anonymous, 2009l; Ganzhong et al., 2003e; Liu et 
Tseng, 2005d; Shen et al., 2007), regulates and harmonizes the actions of various 
ingredients in a prescription (Anonymous, 2009l; Flaws, 1999g; Gongwang, 2000; Wu, 
2005c). Used for drug poisoning (Anonymous, 2009l; Ganzhong et al., 2003e; Shen et al., 
2007; Yanfu, 2002e) and food poisoning (Anonymous, 2009l; Yanfu, 2002e). Because 
licorice can moderate the side effects of many drugs, it has earned the nickname of 
Guolao (expert negotiator) (Ganzhong et al., 2003e).  
 
Chinese therapeutic actions and examples of major combinations 
 
 Used for deficiency of the spleen and stomach (Anonymous, 2009l; Flaws, 1999g; 
Shen et al., 2007) qi shortness (Flaws, 1999g), weakness (Flaws, 1999g; 
Ganzhong et al., 2003e; Wu, 2005c), poor appetite (Flaws, 1999g; Ganzhong et 
al., 2003e; Shen et al., 2007; Wu, 2005c), and loose stools (Flaws, 1999g; 
Ganzhong et al., 2003e; Shen et al., 2007; Wu, 2005c), and loose stools due to 
Spleen Deficiency (Shen et al., 2007; Wu, 2005c),  for shortness of breath 
(Ganzhong et al., 2003e; Wu, 2005c), palpitations of the heart due to weakness of 
the spleen and stomach, and deficiency of qi in the middle energizer (Ganzhong et 
al., 2003e). In this cases, it is used with Radix Ginseng (Ren Shen), Sclerotium 
Poriae Cocos (Fu Ling), and Rhizoma Atractylodis Macrocephalae (Bai Zhu) in 
―The Decoction of Four Noble Herbs‖ (Ganzhong et al., 2003e; Shen et al., 2007; 
Wu, 2005c), (Si Jun Zi Tang) (Anonymous, 2009l; Flaws, 1999g; Ganzhong et al., 
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2003e; Shen et al., 2007; Wu, 2005c), i.e. Four Gentlemen Decoction (Flaws, 
1999g)/ ―Quattuor Nobilium‖ (Greten, 2007). 
 In the case with deficiency of heart-qi manifested as palpitation, spontaneous 
sweating and knotted or slow-regular-intermittent pulse, Radix Glycyrrhizae, 
honey-fried (Zhigancao), is mainly used together with Radix Ginseng (Renshen), 
Radix Trichosantis (Maimendong), Ramulus Cinnamomi (Guizhi) and Cola Corri 
Asini (Ejiao), etc. such Zhigancao Tang (Yanfu, 2002e). 
 For qi vacuity and scanty blood, heart palpitations, spontaneous perspiration, and 
a bound or regulary intermittent pulse, Radix Glycyrrhizae is often combined with 
uncooked Radix Rehmanniae (Sheng Di), Radix Codonopsitis Pilosulae (Dang 
Shen), Tuber Ophiopogonis Japonici (Mai Dong), and Ramulus Cinnamomi 
Cassiae (Gui Zhi) as in Zhi Gan Cao Tang (Mix-fried Licorice Decoction) (Flaws, 
1999g; Ganzhong et al., 2003e).  
 In the case due to deficiency of the spleen with fatigue, poor appetite or loose 
stool, it is used with Radix Codonopsis (Dangshen), Rhizoma Atractylodis 
Macrocephalae (Baizhu), etc. such as Sijunzi Tang (Yanfu, 2002e). 
 For throat swelling and pain, it is commonly combined with Radix Platycodi 
Grandiflori (Jie Geng) as in Jie Geng Tang (Platycodon Decoction) (Anonymous, 
2009l; Flaws, 1999g; Ganzhong et al., 2003e; Yanfu, 2002e).  
 Licorice root can also be used with Honeysuckle flower and Forsythia fruit for 
carbuncles, furuncles and swellings (Shen et al., 2007).  
 For abdominal pain due to spasms of the stomach or intestines, licorice root is 
used with White peony root (Shen et al., 2007). 
 For epigastric and abdominal pains, it is used with Ramulus Cinnamoni (Guizhi), 
Radix Paeoniae Alba (Baishaoyao), and Sacharum cum Malto (Yitang), etc. such 
as Xiao Jianzhong Tang, ―The Minor Decoction for Strengthening the Middle 
Heater‖ (Ganzhong et al., 2003e; Wu, 2005c; Yanfu, 2002e). 
 For spasm and pain of limbs, used with Radix Paeoniae Alba (Baishaoyao) as 
Shaoyao Gancao Tang (Yanfu, 2002e). 
 Licorice root with Prepared aconite root and dried ginger can weaken the heating 
properties and lessen the side effects of some herbs (Shen et al., 2007). 
 For wind heat cough, Radix Glycyrrhizae can be combined with Radix Platycodi 
Grandiflori (Jie Geng), Fructus Arctii Lappae (Niu Xi), Radix Peucedani (Qian Hu), 
and Folium Mori Albi (Sang Ye) (Flaws, 1999g; Yanfu, 2002e). 
 For cough and asthma due to algor venti, it is used with Herba Ephedrae 
(Mahuang) and Semen Armeniacae Amarum (Xing Ren) in ―The Decoction of 
Three Crude Herbs‖ (San Ao Tang) (Anonymous, 2009l; Ganzhong et al., 2003e; 
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Shen et al., 2007; Wu, 2005c; Yanfu, 2002e), (Three Rough & Ready [Ingredients] 
Decoction) (Flaws, 1999g). 
 For cough and asthma due to Lung Heat, it is used with Gypsum Fibrosum (Shi 
Gao), Herba Ephedrae (Mahuang), and Semen Armeniacae Amarum (Xing Ren) 
(Flaws, 1999g; Ganzhong et al., 2003e; Wu, 2005c) as in Ma Xing Shi Gan Tang 
(Ephedra, Armeniaca, Gypsum & Licorice Decoction) (Flaws, 1999g; Ganzhong et 
al., 2003e; Yanfu, 2002e).  
 For cough due to stagnation of damp-phlegm, use with Rhizoma Pinellia (Banxia), 
Poria alba (Fuling), etc. (Yanfu, 2002e). 
 Decoction of Mulberry Leaf and Chrysanthemum (Sangju Yin), composed of 
mulberry leaf (Folium Mori, Sangye), chrysanthemum flower, ballonflower root 
(Radix Platycodi, Jiegeng) and licorice is used to treat cough of wind heat type 
(Ganzhong et al., 2003e).  
 Decoction of Poria, licorice, Schisandra (Magnoliavine fruit, Wuweizi) Dried Ginger 
and Asarum (wild ginger, Xixin) (Linggan Wuwei Jiangxin Tang) is used to treat 
cough with cold phlegm (Ganzhong et al., 2003e).  
 For poisoning due to foods and medicinal (Flaws, 1999g; Ganzhong et al., 2003e; 
Wu, 2005c; Yanfu, 2002e), used alone (Ganzhong et al., 2003e; Wu, 2005c; 
Yanfu, 2002e) or combined with Semen Phaseoli Munginis (Lu Dou) or Radix 
Ledebouriellae Divaricatae (Fang Feng) (Flaws, 1999g; Yanfu, 2002e) or 
combined with mung beans or soybeans (Ganzhong et al., 2003e). 
 Licorice can be used with apricot kernel to treat lead poisoning; with black beans 
to treat arsenic trioxide poisoning; and with talcum power to treat phosporus 
poisoning (Ganzhong et al., 2003e).  
 For sores and open sores swelling and toxins, Radix Glycyrrhizae can be 
combined with Flos Lonicerae Japonicae (Jin Yin Hua) and Fructus Forsythiae 
Suspensae (Lian Qiao) (Flaws, 1999g). 
 In Decoction of Two Old Drugs (Erchen Tang), it is used with pinellia tuber 
(Rhizoma Pinelliae, Banxia), tangerine peel (Pericarpium Citri Reticulate, Chenpi) 
and poria to treat cough with damp phlegm (Ganzhong et al., 2003e).  
 In Decotion for Relieving Dryness in the Lungs (Qingzao Jiufei Tang), it is used 
with mulberry leaf, gypsum, lilyturf root and ginseng to treat cough due to dryness 
in the lungs (Ganzhong et al., 2003e).  
 In Fairy Decoction for Cutaneous Infections (Xianfang Huoming Yin) licorice is 
combined with honey suckle flower (Flos Lonicerae, Jinynhua), snakegourd root 
(Radix Trichosanthis, Tianhuafeng) and dahurian angelica root (Radix Angelicae 
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Dahuricae) to treat sores and ulcers of the skin caused by toxic heat pathogens 
(Ganzhong et al., 2003e).  
 
Dosage and method of use 
Decoct in water and administer internally. This medicinal should be used uncooked when 
entered with clearing and draining medicinals. It should be used honey mix-fried when 
entered with supplementing and boosting medicinal (Flaws, 1999g). For clearing away 
heat and poisons it is used unprepared (Anonymous, 2009l Gongwang, 2000; Wu, 
2005c); for tonifying the Spleen and Stomach, it is honey-baked (Gongwang, 2000; Wu, 
2005c). Used stir-baked with auxiliary fluid mainly for others (Anonymous, 2009l). 
According different authors there are different recommended doses: 
 3–12 g. Up to 30 g for Addison‘s disease (Liu et Tseng, 2005d).  
 3-6 g (Flaws, 1999g).  
 3-9 g (Gongwang, 2000).  
 As the main medicinal in a formula, it can be used from 10-30g (Flaws, 1999g).  
 3-10g for licorice and 2-5ml of licorice extract. They are orally administraded t.i.d. 
(Ganzhong et al., 2003e).  
 2-10 g (Anonymous, 2009l; Wu, 2005c) or up to 10-30g is used in decoction when 
used as a dominat herb. It fits to be used crudely in the prescription for clearing or 
purging while the honey-roasted Gancao is used in the one for tonifying and 
nourishing (Yanfu, 2002e). 
 1.5-18g (Greten, 2007). 
 1.5-9g (CP, 2005d). 
 
Herb Interactions 
Gan Cao is incompatible with: 
1. Gan Sui (Radix Euphorbiae kansui), kansui root (Anonymous, 2009l; CP, 2005d; Flaws, 
1999g; Ganzhong et al., 2003e; Liu et Tseng, 2005d; Shen et al., 2007; Wu, 2005c; 
Yanfu, 2002e) 
2. Da Ji (Rx.Euphorbiae seuKnoxiae, Radix Knoxiae), knoxia root, Peking Euphorbia Root 
(Anonymous, 2009l; CP, 2005d; Flaws, 1999g; Ganzhong et al., 2003e; Gongwang, 2000; 
Liu et Tseng, 2005d; Wu, 2005c; Yanfu, 2002e). 
3. Yuan Hua (Flos Daphnis), Daphne Flower-bud (Gongwang, 2000; Liu et Tseng, 2005d; 
Wu, 2005c) 
4. Sargassum, Hai Zao (Hb. Sargassii), seaweed (Anonymous, 2009l; Ganzhong et al., 
2003e; Liu et Tseng, 2005d; Shen et al., 2007; Wu, 2005c) 
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5. Flos Genkwa (Yuan Hua), genka flower (Anonymous, 2009l; CP, 2005d; Flaws, 1999g; 
Ganzhong et al., 2003e; Shen et al., 2007; Wu, 2005c; Yanfu, 2002e) 
 
Precautions and contraindications 
Radix Glycyrrhizae is contraindicated in case of damp exuberance center fullness and 
vomiting and spitting (Flaws, 1999g; Gongwang, 2000). It is contraindicated in patients 
with dampness, stuffiness in the chest, abdominal distension, and vomiting (Gongwang, 
2000; Wu, 2005c). Enduring administration of relatively large doses easily leads to the 
arising of water swelling (Flaws, 1999g). With a sweet taste, can cause fullness and 
distention in the chest and abdomen due to excessive dampness (Gongwang, 2000), so 
it‘s contraindicated for the case with fullness of epigastric abdomen, vomiting or edema 
due to excessive dampness. And it should be avoided using for a long course and in large 
amount to prevent a case from having edema (Yanfu, 2002e). 
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8. Conclusions 
 
I conclude that Ephedrae Decoction has clinical efectivity by the meanings of Western 
approach coincident with the traditional Chinese applications. 
The effects of the contituients are compatible with its traditional description applications: 
 
 Herba Ephedrae contains ephedrine, like epinephrine, that relaxes bronchial 
muscles and is a potent bronchodilatador owing to its activation of the β-adrenoreceptors 
in the lungs. The sympathomimetic action of ephedrine leads to an increase in respiratory 
rate and pulmonary ventilation and it is used to eliminate the cough. Ephedrine promote 
the release of noradrenaline and adrenaline and inhibit the release of sensitizing 
substances as histamine, resulting in the dilation of bronchial smooth muscle, the 
contraction of intra-mucosal blood vessels of the respiratory tract, and eventually, free 
movement in the air passage. These feactures are coincident with the fact the ephedra 
acts on the pulmorary orb. Additionally, ephedra has varying degrees of inhibitory effect 
against several bacteria and virus, including various types of influenza virus. H. ephedra 
was reported to show the in vitro anti-influenza viral effects and augments the production 
of inflammatory cytokines including interleukin-6 and interleukin-1. These features are 
coincident with the Chinese therapeutic utilization of Ephedrae Decoction on respiratory 
system symptoms.  On the other hand, the most popular application of pseudoephedrine 
of Herba ephedrae is in flu medications to relieve nasal decongestion and perhaps to an 
anti-inflammatory effect. Pseudoephedrine has also a diuretic function, greater than 
ephedrine, which is also consistent with the fact that ephedra belongs to the vesical orb. 
All these features of Herba ephedrae are consistent with the Heidelberg model. 
The diaphoretic components of Herba ephedrae are the volatile compounds and alkaloids. 
The diaphoretic effect reflects the extima liberating capacity of Herba ephedrae. 
Adicionally, Herba ephedrae has saponins in is constitution. Saponins are substances that 
in aqueous solution are surfactant agents, so they are capable of foaming. The presences 
of these constituents maybe are the responsible for the foam formed in the decoction 
process. This foam is considered toxic and irritant. This is consistent with the presence of 
saponins since we must take into account that orally and in high doses, the saponins 
irritated pharyngeal mucosa and digestive tract, cause abdominal pain, vomiting and 
diarrhea and upon contact with blood are haemolytic. That´s why is indicated to remove 
the foam. According to the literature there are a lot of volatile compounds in the foam 
responsible fot the diaphoretic action. Removing the foam, the diaphoresis is reduced. 
Once again these features are coincident with the Chinese literature. 
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 As saw previously, the amygdalin compound present in Semen armeniacae 
produces a kind of antitussive and antiasthmatic effects, by stimulating the respiratory 
center reflexively.  This is perfectly coincident with the Chinese therapeutic activities 
against cough and asthma, acting on the pulmonary orb. Also the moisturizing action in 
the bowels is perfectly justified according the kernel fatty oil content, so the Chinese 
therapeutic action on the crass intestinal orb is expected.  
 
 Cinnnamon contains essential oil that can expand blood vessels, regulate blood 
circulation, and make the blood flow toward the superficial part of the body. This action 
causes diaphoresis and removal of heat, and coincides with the effects of warming and 
unbloking channels and collaterals, and dispersing heat, of Ramuli according to TCM. 
Being cinnamaldehyde the major component, this suggests that it contributes 
tremendously for the therapeutic effects of cinnamon. According to the component 
determination of the essential oils of the different parts of the plant by Shen et al. (2002) 
Ramuli has less cinnamaldehyde than the Cortex (64.57% versus 83.1%). This can 
explain why the Cortex has a stronger effect than the Ramuli, and the different uses in 
TCM. In adition to the study of Shen et al., more studies are needed to access the 
therapeutic effects of cassia and its effective ingredients. 
As for the effect of cinnamaldehyde on the CNS, it is known that its action is concentration 
dependent: the administration of low doses stimulates this system, while high doses 
cause sedation. The cinnamaldehyde accelerates the release of catecholamines, primarily 
adrenaline, from adrenergic glands into the bloodstream. So naturally, it opens the lung. 
Increases peripheral blood flow, slows heart rate, reduces blood pressure, and has 
antipyretic and hypothermic effects. Cinnamaldehyde is a circulostimulant and it 
accelerates release of catecholamines (mainly adrenaline) from the adrenal glands into 
the blood.  
Cinnamaldehyde was previously found inhibited the Mycobacterium tuberculosis and 
influenza virus effectively, and could regulate the immunological function. Also eugenol 
was identified as a major antimicrobial component of cinnamon. In addition, analgesic 
effects are attributed to: coumarin, eugenol, methyl-salicylate, p-cymene and salicylic acid 
present in cinnamon. Also expectorant, antitussive, antibronchitic and bronchorelaxant 
effects properties has been attributed to several constituents of cinnamon.  
Also 2-methoxycinnamaldehyde and cinnamaldehyde were previously found that relieved 
fever and pain and could regulate the immunological function. Recent research also 
showed that it could reduce the amount of cyclooxygenase (COX)-1, COX-2 and PGE2 
and perhaps this is the mechanism of its relieving-fever effect. In addition, analgesic 
effects are attributed to: coumarin, eugenol, methyl-salicylate, p-cymene and salicylic acid 
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present in cinnamon. All this constituents contributes to the action of Ephedrae Decoctum. 
In addition, expectorant, antitussive, antibronchitic and bronchorelaxant effects properties 
has been attributed to several constituents of cinnamon. This is persistent with the action 
on the Pulmorary orb. These features corroborate with the Chinese therapeutic usage of 
Ephedrae Decoction, according to the Heiderberg model. 
 
 Licorice and its preparations can relieve drug intoxication and neutralize bacterial 
toxins and toxic metabolites, because glycyrrhizin can reduce the responsiveness of the 
organism to toxic substances, in the same way that corticoid hormone does, and 
promotes dissociation of toxic substances through inducing the production of drug 
metabolizing enzyme in the liver. In addition, licorice can also absorb and conjugate toxic 
substances to relieve intoxication. Licorice preparations and glycyrhhizin can also protect 
the livers of animals from injury caused by drug poisoning. All this properties are 
coincident with the Chinese uses in intoxications, food poisons, and harmonizing the 
adverse effects of other plants in a complex formula. 
The antiulcer activity of Radix Glycyrrhyzae has been demonstrated both experimentally 
and clinically. Glycyrrhizin and its aglycone both have antiphlogistic activity and increase 
the rate of mucus secretion by the gastric mucosa. Glycyrrhizinic acid seems to act by 
raising the local concentration of prostaglandins that promote mucous secretion and cell 
proliferation in the stomach, leading to healing of ulcers in experimental studies. This also 
demonstrates a good effect on the stomach orb and the center. It is known that making 
stronger the center it is better for get rid of of pituita. 
The spasmolytic activity of Radix Glycyrrhyzae has been demonstrated in vivo and 
appears to be to the flavonoids liquiritigenin and isoliquiritigenin, so its Chinese utilization 
in spastic pain makes sence, acting on the phase Wood. 
Licorice has been used as a cough-relieving medicinal herb from ancient times. It seems 
that mucilage present in it or secretion produced under the influence of the active 
substances covers the oral and throat mucosa soothing its irritability and relieving dry 
cough. Choline ester of glycyrrhetinic acid can produce a central antitussive effect. After 
oral administration of licorice, the drug may cover the mucosa of the throat and relieve 
local local inflammatory irritation to control cough and promote secretion of mucus from 
the throat and bronchi to produce an expectorant effect. The demulcent action of  the drug 
is due primarily to glycyrrhizin. The antitussive and expectorant properties of the drug 
have also been attributed to glycyrrhizin, which accelerates tracheal mucus secretion. 
This is very pertinent in a formula like Ephedrae Decoctum, and licorice contributes once 
again for the anti-tussic effect. Pharmacological studies showed a marked anti-
inflammatory action by licorice. The similarity in structure of glycyrrhetic acid to the 
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structure of hormones secreted by the adrenal cortex accounts for the mineralocorticoid 
and glucocorticoid activity of glycyrrhizic acid. Licorice constituents also exhibit steroid-like 
anti-inflammatory activity, similar to the action of hydrocortisone. Also the antiallergic 
aspect of Radix Glycyrrhiza, played by glycyrrhizin, 18-β-glycyrrhetinic acid and 
liquiritigenin can be very important to treat several respiratory diseases where this 
particularity plays a crucial role. Also the anti-infeccious activity revealed by Radix 
Glycyrrhiza plays an important role in a decoction as Ephedrae Decoctum. This decoction 
is used in many situations where infectious organisms are the causing factors of the 
disease, according to the Western point of view. Radix Glycyrrihzae is a very complex 
plant and used for so many purposes. Indeed, is almost considered a panacea. This is 
conniving with the fact that the Radix Glycyrrhiza acts in the 12 orbs and is a buffering 
herb.Once again these features are coincident with the with the Chinese therapeutic 
usage of Ephedrae Decoction, according to the Heiderberg model. 
 
The Ephedra Decoction is just one example of thousands of constellations that belong to 
the rich spoil of the classic Chinese herbs. No wonder that Ephedra Decoction has been 
used for millennia. All its constituents seem out carefully combined to obtain successfully 
therapeutic results. All the properties of these plants are perfectly explicable by 
conventional Western methods, according to the tradicional use of this concoction. 
This master thesis shows that is possible to successfully translate the effects described by 
the traditional language of TCM, by the Heidelberg model, into the language of Western 
physiology. The research of this master thesis also shows that Ephedra Decoction can be 
regarded as an effective medicine against symptoms related to cough, sputum, bronchitis, 
asthma, flu and COPD, and it may therefore be recommended to treat the symptoms 
above named if these cannot be controlled by Western medicine. 
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